[
  {
    "id": 10,
    "user_query": "Name synonym of Acrokeratosis paraneoplastica.",
    "llama-2-7b-chat-hf_response": "Acrokeratosis paraneoplastica is also known as:\n* Acrokeratosis paraneoplastic syndrome\nNote: These terms are synonyms, and both refer to the same medical condition.",
    "llama-2-7b-chat-hf_fact_raw": "1. Acrokeratosis paraneoplastica is also known as Acrokeratosis paraneoplastic syndrome.",
    "llama-2-7b-chat-hf_fact": [
      "Acrokeratosis paraneoplastica is also known as Acrokeratosis paraneoplastic syndrome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 47,
    "user_query": "Is Weaver syndrome similar to Sotos?",
    "llama-2-7b-chat-hf_response": "Weaver syndrome and Sotos syndrome are both rare genetic disorders that are characterized by overgrowth and developmental delays, but they have some differences in their clinical features and genetic causes.\nSimilarities:\n* Both Weaver syndrome and Sotos syndrome are caused by mutations in genes that are involved in cell growth and division.\n* Both disorders result in overgrowth and developmental delays, with children typically reaching milestones later than their peers.\n* Both disorders can also cause intellectual disability, although the severity of this condition can vary widely between individuals.\nDifferences:\n* Genetic cause: Weaver syndrome is caused by mutations in the SMC1 gene, while Sotos syndrome is caused by mutations in the NSD1 gene.\n* Age of onset: Weaver syndrome typically becomes apparent at birth or in early childhood, while Sotos syndrome can be diagnosed at any age but is usually apparent by the time a child is 2-3 years old.\n* Physical features: While both disorders can cause overgrowth and developmental delays, the physical features of Weaver syndrome are more variable and can include a range of skeletal, cardiovascular, and other abnormalities. Sotos syndrome typically has more consistent physical features, including a distinctive facial appearance, short stature, and heart defects.\n* Intellectual disability: While both disorders can cause intellectual disability, Sotos syndrome is often more severe and can result in significant cognitive impairment.\nIn summary, while Weaver syndrome and Sotos syndrome share some similarities, they are distinct genetic disorders with different genetic causes, age of onset, physical features, and severity of intellectual disability.",
    "llama-2-7b-chat-hf_fact_raw": "1. Weaver syndrome and Sotos syndrome are both rare genetic disorders characterized by overgrowth and developmental delays.\n2. Mutations in the SMC1 gene cause Weaver syndrome.\n3. Mutations in the NSD1 gene cause Sotos syndrome.\n4. Weaver syndrome typically becomes apparent at birth or in early childhood.\n5. The physical features of Sotos syndrome include a distinctive facial appearance, short stature, and heart defects.",
    "llama-2-7b-chat-hf_fact": [
      "Weaver syndrome and Sotos syndrome are both rare genetic disorders characterized by overgrowth and developmental delays.",
      "Mutations in the SMC1 gene cause Weaver syndrome.",
      "Mutations in the NSD1 gene cause Sotos syndrome.",
      "Weaver syndrome typically becomes apparent at birth or in early childhood.",
      "The physical features of Sotos syndrome include a distinctive facial appearance, short stature, and heart defects."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Mutations in the EZH2 gene, not the SMC1 gene, cause Weaver syndrome.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The physical features of Sotos syndrome include a distinctive facial appearance, overgrowth (tall stature), and may include heart defects, but short stature is not characteristic of Sotos syndrome.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 81,
    "user_query": "List the releases of JASPAR database",
    "llama-2-7b-chat-hf_response": "The JASPAR (Joint Annotation and Scanning Project for Assessment of Regulatory Elements) database is a collection of transcription factor binding site (TFBS) matrices that predict the presence and strength of TFBSs in the human genome. Here are the releases of the JASPAR database:\n1. JASPAR Release 1.0 (2002): This was the first release of the JASPAR database, which contained TFBS matrices for 10 transcription factors and covered approximately 20% of the human genome.\n2. JASPAR Release 2.0 (2004): This release added TFBS matrices for an additional 10 transcription factors, bringing the total number of TFs to 20. The coverage of the genome was also increased to approximately 40%.\n3. JASPAR Release 3.0 (2007): This release included TFBS matrices for 30 transcription factors and covered the entire human genome.\n4. JASPAR Release 4.0 (2010): This release added new features such as improved TFBS prediction and the ability to download matrices in a variety of formats.\n5. JASPAR Release 5.0 (2013): This release included TFBS matrices for 40 transcription factors and improved prediction algorithms.\n6. JASPAR Release 6.0 (2016): This release added new features such as the ability to predict TFBSs in non-coding regions and improved prediction algorithms.\n7. JASPAR Release 7.0 (2019): This release included TFBS matrices for 50 transcription factors and improved prediction algorithms.\n8. JASPAR Release 8.0 (2022): This is the latest release of the JASPAR database, which includes TFBS matrices for 60 transcription factors and improved prediction algorithms.\nPlease note that these releases are not the only ones available, and the database is constantly being updated with new data and improved methods.",
    "llama-2-7b-chat-hf_fact_raw": "1. JASPAR Release 1.0 was launched in 2002 with TFBS matrices for 10 transcription factors.\n2. The coverage of the human genome in JASPAR Release 2.0, released in 2004, was approximately 40%.\n3. JASPAR Release 3.0 from 2007 included TFBS matrices for 30 transcription factors and covered the entire human genome.\n4. The JASPAR database received a new feature update with Release 4.0 in 2010, which allowed the downloading of matrices in various formats.\n5. JASPAR Release 8.0 was released in 2022 and includes TFBS matrices for 60 transcription factors.",
    "llama-2-7b-chat-hf_fact": [
      "JASPAR Release 1.0 was launched in 2002 with TFBS matrices for 10 transcription factors.",
      "The coverage of the human genome in JASPAR Release 2.0, released in 2004, was approximately 40%.",
      "JASPAR Release 3.0 from 2007 included TFBS matrices for 30 transcription factors and covered the entire human genome.",
      "The JASPAR database received a new feature update with Release 4.0 in 2010, which allowed the downloading of matrices in various formats.",
      "JASPAR Release 8.0 was released in 2022 and includes TFBS matrices for 60 transcription factors."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: JASPAR Release 1.0 was launched in 2004 with TFBS matrices for 123 transcription factors.\n2. UNKNOWN: There is no specific information available on the coverage of the human genome in JASPAR Release 2.0.\n3. FALSE [correction]: JASPAR Release 3.0 from 2006 included TFBS matrices for about 100 transcription factors; there is no clear information regarding the human genome coverage or the statement might be inaccurate.\n4. TRUE: The JASPAR database has indeed improved with various feature updates over time, including the ability to download matrices in various formats.\n5. FALSE [correction]: JASPAR Release 8.0 does not exist; the most recent release at the time of my last update (2023) was JASPAR 2022, which actually includes TFBS matrices for several hundred transcription factors.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 99,
    "user_query": "What is the function of the viral KP4 protein?",
    "llama-2-7b-chat-hf_response": "The KP4 protein is a protein encoded by the KP4 gene of the poxvirus. The KP4 protein is a key regulator of the poxvirus life cycle and plays a crucial role in the replication and pathogenesis of the virus. The KP4 protein has several functions, including:\n1. Inhibition of interferon signaling: The KP4 protein can inhibit the production of interferon, a protein that plays a crucial role in the immune response to viral infections. By inhibiting interferon signaling, the KP4 protein can prevent the host immune system from mounting a response to the virus.\n2. Activation of cellular signaling pathways: The KP4 protein can activate various cellular signaling pathways, including the PI3K/Akt and MAPK pathways, which can promote cell survival and proliferation.\n3. Regulation of gene expression: The KP4 protein can regulate the expression of viral genes, including the gene encoding the viral protein P30, which is involved in the replication of the virus.\n4. Inhibition of apoptosis: The KP4 protein can inhibit the induction of apoptosis, or programmed cell death, in infected cells. This can allow the virus to persist in the host for longer periods of time.\nOverall, the KP4 protein plays a critical role in the replication and pathogenesis of poxviruses, and its functions are essential for the virus to establish a productive infection in the host.",
    "llama-2-7b-chat-hf_fact_raw": "1. The KP4 protein is encoded by the KP4 gene of the poxvirus.\n2. The KP4 protein inhibits the production of interferon, a protein that plays a crucial role in the immune response to viral infections.\n3. The KP4 protein can activate cellular signaling pathways, including the PI3K/Akt and MAPK pathways.\n4. The KP4 protein can regulate the expression of viral genes, such as the gene encoding the viral protein P30.\n5. The KP4 protein inhibits the induction of apoptosis in infected cells.",
    "llama-2-7b-chat-hf_fact": [
      "The KP4 protein is encoded by the KP4 gene of the poxvirus.",
      "The KP4 protein inhibits the production of interferon, a protein that plays a crucial role in the immune response to viral infections.",
      "The KP4 protein can activate cellular signaling pathways, including the PI3K/Akt and MAPK pathways.",
      "The KP4 protein can regulate the expression of viral genes, such as the gene encoding the viral protein P30.",
      "The KP4 protein inhibits the induction of apoptosis in infected cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The KP4 protein is a virally encoded protein from the Ustilago maydis (corn smut fungus) and not from a poxvirus.\n2. TRUE: The KP4 protein from Ustilago maydis has been reported to inhibit interferon production, which is important in antiviral defense mechanisms.\n3. UNKNOWN: The effect of KP4 on cellular signaling pathways like PI3K/Akt and MAPK is not commonly documented, and such details would require specific scientific literature to confirm.\n4. UNKNOWN: The regulatory function of the KP4 protein on specific viral gene expression, such as a gene encoding the viral protein P30, cannot be determined without additional specific context or scientific literature.\n5. UNKNOWN: The impact of the KP4 protein on the induction of apoptosis in infected cells is also not commonly documented and requires specific research evidence to confirm its accuracy.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 124,
    "user_query": "Is DITPA a thyroid hormone analog utilized in experimental and clinical studies",
    "llama-2-7b-chat-hf_response": "Yes, DITPA (N-[4-(2-chloroethyl)-N-ethyl-2,3-bis(trifluoromethyl)pyridinium chloride) is a synthetic thyroid hormone analog that has been utilized in both experimental and clinical studies. It is a potent inhibitor of thyroid hormone synthesis and action, and has been used to investigate the role of thyroid hormones in various physiological processes, including metabolism, growth, and development. DITPA has also been used as a therapeutic agent in the treatment of certain thyroid disorders, such as thyroid cancer and Graves' disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. DITPA is a synthetic thyroid hormone analog.\n2. It has been utilized in experimental and clinical studies.\n3. DITPA is an inhibitor of thyroid hormone synthesis and action.\n4. It has been used to study the role of thyroid hormones in metabolism, growth, and development.\n5. DITPA has been used as a therapeutic agent in the treatment of thyroid disorders like thyroid cancer and Graves' disease.",
    "llama-2-7b-chat-hf_fact": [
      "DITPA is a synthetic thyroid hormone analog.",
      "It has been utilized in experimental and clinical studies.",
      "DITPA is an inhibitor of thyroid hormone synthesis and action.",
      "It has been used to study the role of thyroid hormones in metabolism, growth, and development.",
      "DITPA has been used as a therapeutic agent in the treatment of thyroid disorders like thyroid cancer and Graves' disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: DITPA is not an inhibitor of thyroid hormone synthesis and action; rather, it mimics the effects of thyroid hormones.\n4. TRUE\n5. FALSE [correction]: DITPA is not commonly used as a therapeutic agent in the treatment of thyroid disorders like thyroid cancer and Graves' disease; standard treatments include other thyroid hormone analogs and medications.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 144,
    "user_query": "What is the COUGER tool?",
    "llama-2-7b-chat-hf_response": "COUGER (Comprehensive Update of Genetic Information) is a tool used in bioinformatics and computational biology to predict the functional impact of non-synonymous single nucleotide variants (nsSNVs) in the human genome. It uses a machine learning approach to analyze the structural and evolutionary context of the variant, as well as the protein structure and function, to predict the possible effects of the variant on protein function and disease risk. COUGER is a comprehensive tool that integrates multiple types of data, including protein structure, protein-protein interactions, and gene expression data, to provide a more accurate prediction of the functional impact of nsSNVs.",
    "llama-2-7b-chat-hf_fact_raw": "1. COUGER stands for Comprehensive Update of Genetic Information.\n2. COUGER is used to predict the functional impact of non-synonymous single nucleotide variants in the human genome.\n3. The tool utilizes a machine learning approach for analysis.\n4. COUGER integrates data such as protein structure, protein-protein interactions, and gene expression data.\n5. It is designed to predict effects of variants on protein function and disease risk.",
    "llama-2-7b-chat-hf_fact": [
      "COUGER stands for Comprehensive Update of Genetic Information.",
      "COUGER is used to predict the functional impact of non-synonymous single nucleotide variants in the human genome.",
      "The tool utilizes a machine learning approach for analysis.",
      "COUGER integrates data such as protein structure, protein-protein interactions, and gene expression data.",
      "It is designed to predict effects of variants on protein function and disease risk."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: COUGER does not stand for Comprehensive Update of Genetic Information. To my knowledge, COUGER is not a recognized acronym for a genetic tool; perhaps the statement refers to another tool or is misspelled.\n2. UNKNOWN: Without the correct identification of COUGER, it's uncertain whether it is used to predict the functional impact of non-synonymous single nucleotide variants in the human genome.\n3. UNKNOWN: Since COUGER's function is unclear due to question 1, it is unknown whether it uses a machine learning approach.\n4. UNKNOWN: The integration of data such as protein structure, protein-protein interactions, and gene expression is not verifiable without the proper identification of what COUGER is.\n5. UNKNOWN: It is not possible to confirm if COUGER is designed to predict effects of variants on protein function and disease risk without accurate information about the tool.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 145,
    "user_query": "Are there drugs for Tick-borne Encephalitis?",
    "llama-2-7b-chat-hf_response": "Yes, there are drugs available for the treatment of tick-borne encephalitis (TBE). The most commonly used drugs are:\n1. Antiviral medications: Oseltamivir (Tamiflu), Zanamivir (Relenza), and Peramivir (Rapivab) are the most commonly used antiviral medications for treating TBE. These medications can help reduce the severity and duration of symptoms, and may also help prevent complications.\n2. Corticosteroids: Corticosteroids, such as prednisone, may be prescribed to reduce inflammation in the brain and other parts of the body. They can help reduce symptoms such as headache, fever, and muscle weakness.\n3. Immunoglobulins: Immunoglobulins, such as intravenous immunoglobulin (IVIG), may be given to help boost the body's immune system and reduce the severity of TBE.\n4. Supportive care: Supportive care, such as rest, hydration, and pain management, is important for managing symptoms and preventing complications.\nIt's important to note that the best treatment approach for TBE may vary depending on the severity and location of the infection, as well as the individual patient's medical history and overall health. In some cases, a combination of these treatments may be used. It's important to consult a healthcare professional for proper diagnosis and treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. Oseltamivir (Tamiflu), Zanamivir (Relenza), and Peramivir (Rapivab) are antiviral medications used to treat tick-borne encephalitis (TBE).\n2. Corticosteroids like prednisone are prescribed to reduce inflammation in the brain and other parts of the body for TBE patients.\n3. Intravenous immunoglobulin (IVIG) is used as an immunoglobulin treatment to help boost the immune system against TBE.\n4. Supportive care is utilized in managing symptoms and preventing complications in tick-borne encephalitis patients.\n\nNote: While these statements are presented as facts within the context, it should be noted that the effectiveness and recommendation of specific treatments for tick-borne encephalitis can vary, and new evidence could change current understanding. Always refer to the latest guidelines and consult a medical professional for the most accurate information.",
    "llama-2-7b-chat-hf_fact": [
      "Oseltamivir (Tamiflu), Zanamivir (Relenza), and Peramivir (Rapivab) are antiviral medications used to treat tick-borne encephalitis (TBE).",
      "Corticosteroids like prednisone are prescribed to reduce inflammation in the brain and other parts of the body for TBE patients.",
      "Intravenous immunoglobulin (IVIG) is used as an immunoglobulin treatment to help boost the immune system against TBE.",
      "Supportive care is utilized in managing symptoms and preventing complications in tick-borne encephalitis patients.",
      "te: While these statements are presented as facts within the context, it should be noted that the effectiveness and recommendation of specific treatments for tick-borne encephalitis can vary, and new evidence could change current understanding. Always refer to the latest guidelines and consult a medical professional for the most accurate information."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Oseltamivir (Tamiflu), Zanamivir (Relenza), and Peramivir (Rapivab) are antiviral medications commonly used to treat influenza, not tick-borne encephalitis (TBE).\n2. UNKNOWN: While corticosteroids like prednisone can be prescribed to reduce inflammation, it is not clear from this statement whether they are specifically used for TBE without further context or medical guidelines supporting their use for this condition.\n3. UNKNOWN: Intravenous immunoglobulin (IVIG) is used for various conditions to boost the immune system, but whether it is used specifically for TBE would require more specific information or reference to medical guidelines.\n4. TRUE: Supportive care is commonly utilized in managing symptoms and preventing complications in patients with many infectious diseases, including tick-borne encephalitis.\n5. This is not a statement but a note of caution and therefore does not require a true or false assessment. \n\nNote: The information provided in my responses is indicative of general practices and knowledge as of my last update and should not be considered medical advice. For clinical decision-making and treatment recommendations, always refer to updated medical resources and consult a healthcare professional.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 151,
    "user_query": "Which genome browser database for DNA shape annotations is available?",
    "llama-2-7b-chat-hf_response": "There are several genome browsers and databases available for DNA shape annotations, including:\n1. ChromHMM: ChromHMM is a genome-scale model of chromatin structure and epigenetic marks, which provides DNA shape annotations for various organisms.\n2. HiC-Pro: HiC-Pro is a database of chromosome conformation capture (Hi-C) data, which provides information on the three-dimensional structure of chromosomes and the interactions between different regions.\n3. 4D-Nucleosome: 4D-Nucleosome is a database of nucleosome positioning and dynamics in different cell types and states, which provides information on the three-dimensional organization of nucleosomes and their interactions with other chromatin structures.\n4. ENCODE: The Encyclopedia of DNA Elements (ENCODE) project is a comprehensive database of chromatin modification profiles and functional genomics data, which provides information on the epigenetic marks and their functional implications.\n5. Roadmap Epigenomics: Roadmap Epigenomics is a database of epigenetic profiles and genomic annotations for various organisms, which provides information on the spatial and temporal patterns of epigenetic marks and their functional implications.\n6. Chromatin Atlas: Chromatin Atlas is a database of chromatin structure and epigenetic marks in various organisms, which provides information on the three-dimensional organization of chromatin and its interactions with other chromatin structures.\n7. H3K27ac ChIP-seq Peaks: H3K27ac ChIP-seq Peaks is a database of histone H3 lysine 27 acetylation (H3K27ac) ChIP-seq peaks in various organisms, which provides information on the genomic locations of H3K27ac peaks and their functional implications.\n8. H3K4me3 ChIP-seq Peaks: H3K4me3 ChIP-seq Peaks is a database of histone H3 lysine 4 methylation (H3K4me3) ChIP-seq peaks in various organisms, which provides information on the genomic locations of H3K4me3 peaks and their functional implications.\n9. H3K27me3 ChIP-seq Peaks:",
    "llama-2-7b-chat-hf_fact_raw": "1. ChromHMM provides DNA shape annotations for various organisms.\n2. HiC-Pro is a database that includes information on the three-dimensional structure of chromosomes and their interactions.\n3. 4D-Nucleosome provides information on nucleosome positioning and dynamics in different cell types and states.\n4. The ENCODE project offers a comprehensive database of chromatin modification profiles and functional genomics data.\n5. Roadmap Epigenomics provides epigenetic profiles and genomic annotations for various organisms.",
    "llama-2-7b-chat-hf_fact": [
      "ChromHMM provides DNA shape annotations for various organisms.",
      "HiC-Pro is a database that includes information on the three-dimensional structure of chromosomes and their interactions.",
      "4D-Nucleosome provides information on nucleosome positioning and dynamics in different cell types and states.",
      "The ENCODE project offers a comprehensive database of chromatin modification profiles and functional genomics data.",
      "Roadmap Epigenomics provides epigenetic profiles and genomic annotations for various organisms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: ChromHMM is a computational tool that uses chromatin state data to segment the genome and infer the genome-wide chromatin state annotation, not specifically \"DNA shape annotations.\"\n2. FALSE [correction]: HiC-Pro is not a database but a software suite designed to process high-throughput chromosome conformation capture data (Hi-C data), which includes information on the three-dimensional structure of chromosomes and their interactions.\n3. UNKNOWN: Without further context or a well-known source, it is difficult to verify the existence or purpose of \"4D-Nucleosome.\" There are tools and databases for studying nucleosome positioning, but whether \"4D-Nucleosome\" is accurate as described cannot be confirmed.\n4. TRUE: The ENCODE (Encyclopedia of DNA Elements) project does indeed offer a comprehensive database that includes information on chromatin modifications and functional genomics data.\n5. TRUE: The Roadmap Epigenomics project provides an extensive collection of epigenomic data, including histone modification patterns, DNA methylation, chromatin accessibility, and more, for a variety of cell types and states.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 174,
    "user_query": "Which syndromes are associated with mutations in the EZH2 gene?",
    "llama-2-7b-chat-hf_response": "The EZH2 gene has been associated with several syndromes, including:\n1. Beckwith-Wiedemann syndrome (BWS): This is a genetic disorder that affects the development of various organs and tissues, including the brain, kidneys, and pancreas.\n2. Silver-Russell syndrome (SRS): This is a rare genetic disorder that affects growth and development, and is characterized by short stature, delayed speech and cognitive development, and distinctive facial features.\n3. Lyon syndrome: This is a rare genetic disorder that affects the development of various organs and tissues, including the brain, kidneys, and pancreas.\n4. Hutchinson-Gilford progeria syndrome (HGPS): This is a rare genetic disorder that causes accelerated aging in children, resulting in a shortened lifespan.\n5. Langer syndrome: This is a rare genetic disorder that affects the development of various organs and tissues, including the brain, kidneys, and pancreas.\nThese syndromes are caused by mutations in the EZH2 gene, which can lead to abnormalities in the regulation of gene expression and the development of various tissues and organs.",
    "llama-2-7b-chat-hf_fact_raw": "1. Beckwith-Wiedemann syndrome (BWS) is associated with mutations in the EZH2 gene.\n2. Silver-Russell syndrome (SRS) is associated with mutations in the EZH2 gene.\n3. Lyon syndrome is associated with mutations in the EZH2 gene.\n4. Hutchinson-Gilford progeria syndrome (HGPS) is associated with mutations in the EZH2 gene.\n5. Langer syndrome is associated with mutations in the EZH2 gene.",
    "llama-2-7b-chat-hf_fact": [
      "Beckwith-Wiedemann syndrome (BWS) is associated with mutations in the EZH2 gene.",
      "Silver-Russell syndrome (SRS) is associated with mutations in the EZH2 gene.",
      "Lyon syndrome is associated with mutations in the EZH2 gene.",
      "Hutchinson-Gilford progeria syndrome (HGPS) is associated with mutations in the EZH2 gene.",
      "Langer syndrome is associated with mutations in the EZH2 gene."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Beckwith-Wiedemann syndrome (BWS) is mainly associated with changes on chromosome 11 in the region involving the genes CDKN1C, IGF2, H19, and KCNQ1OT1. It is not typically associated with mutations in the EZH2 gene.\n\n2. FALSE [correction]: Silver-Russell syndrome (SRS) is primarily associated with genetic changes involving chromosome 7 or chromosome 11. The duplication of the maternal allele of the 11p15 region or loss of methylation at this region can be a cause, but it is not typically associated with mutations in the EZH2 gene.\n\n3. UNKNOWN: Lyon syndrome is not a well-established medical condition or term in the context of genetics. Without additional context, it's unclear what syndrome is being referred to here; therefore, the association with the EZH2 gene cannot be determined.\n\n4. FALSE [correction]: Hutchinson-Gilford progeria syndrome (HGPS) is associated with a point mutation in the LMNA gene, which results in the production of an abnormal version of the lamin A protein.\n\n5. UNKNOWN: Langer syndrome is not a recognized medical condition. There is a Langer-Giedion syndrome, which is associated with changes to the EXT1 and TRPS1 genes, and there are various other syndromes with \"Langer\" in the name, but without further clarification, it is not possible to determine the correctness of the statement regarding the EZH2 gene.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 193,
    "user_query": "List human proteins that are subject to a dimer-to-tetramer transition.",
    "llama-2-7b-chat-hf_response": "There are several human proteins that are known to undergo a dimer-to-tetramer transition, including:\n1. p53: The tumor suppressor protein p53 undergoes a dimer-to-tetramer transition in response to DNA damage, leading to the activation of its transcriptional activity.\n2. Myc: The Myc transcription factor also undergoes a dimer-to-tetramer transition, which is important for its ability to regulate gene expression.\n3. E2F1: The E2F transcription factor E2F1 undergoes a dimer-to-tetramer transition in response to growth factors and nutrient availability, leading to the activation of cell cycle progression.\n4. c-Jun: The transcription factor c-Jun undergoes a dimer-to-tetramer transition in response to growth factors and stress, leading to the activation of gene expression.\n5. c-Myc: The transcription factor c-Myc undergoes a dimer-to-tetramer transition in response to growth factors and nutrient availability, leading to the activation of gene expression.\n6. Max: The transcription factor Max undergoes a dimer-to-tetramer transition in response to growth factors and nutrient availability, leading to the activation of gene expression.\n7. Myb: The transcription factor Myb undergoes a dimer-to-tetramer transition in response to growth factors and nutrient availability, leading to the activation of gene expression.\n8. GATA-1: The transcription factor GATA-1 undergoes a dimer-to-tetramer transition in response to growth factors and nutrient availability, leading to the activation of gene expression.\n9. NF-κB: The transcription factor NF-κB undergoes a dimer-to-tetramer transition in response to growth factors and inflammatory signals, leading to the activation of gene expression.\n10. STAT3: The transcription factor STAT3 undergoes a dimer-to-tetramer transition in response to growth factors and inflammatory signals, leading to the activation of gene expression.\nIt's worth not",
    "llama-2-7b-chat-hf_fact_raw": "1. The tumor suppressor protein p53 undergoes a dimer-to-tetramer transition in response to DNA damage.\n2. The Myc transcription factor undergoes a dimer-to-tetramer transition important for its gene expression regulation.\n3. The transcription factor E2F1 undergoes a dimer-to-tetramer transition in response to growth factors and nutrient availability.\n4. The transcription factor c-Jun undergoes a dimer-to-tetramer transition in response to growth factors and stress.\n5. The transcription factor NF-κB undergoes a dimer-to-tetramer transition in response to growth factors and inflammatory signals.",
    "llama-2-7b-chat-hf_fact": [
      "The tumor suppressor protein p53 undergoes a dimer-to-tetramer transition in response to DNA damage.",
      "The Myc transcription factor undergoes a dimer-to-tetramer transition important for its gene expression regulation.",
      "The transcription factor E2F1 undergoes a dimer-to-tetramer transition in response to growth factors and nutrient availability.",
      "The transcription factor c-Jun undergoes a dimer-to-tetramer transition in response to growth factors and stress.",
      "The transcription factor NF-κB undergoes a dimer-to-tetramer transition in response to growth factors and inflammatory signals."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The tumor suppressor protein p53 can indeed form tetramers through its oligomerization domain, and this tetramerization is critical for its role in response to DNA damage.\n2. FALSE [correction]: The Myc transcription factor does not undergo a dimer-to-tetramer transition; rather, it forms heterodimers with Max to bind DNA and regulate gene expression.\n3. UNKNOWN: The status of E2F1 undergoing a dimer-to-tetramer transition in response to growth factors and nutrient availability is not widely established or characterized in the literature, making this statement difficult to verify.\n4. FALSE [correction]: The transcription factor c-Jun, part of the AP-1 complex, forms dimers with other proteins such as c-Fos, but it is not commonly described as undergoing a dimer-to-tetramer transition in response to growth factors and stress.\n5. FALSE [correction]: The transcription factor NF-κB is known to form dimers that translocate to the nucleus in response to various stimuli, such as growth factors and inflammatory signals, but it does not form tetramers as part of this process.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "false",
      "false"
    ]
  },
  {
    "id": 210,
    "user_query": "Which protein has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein?",
    "llama-2-7b-chat-hf_response": "One protein that has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein is BCL-2 (B-cell lymphoma 2).",
    "llama-2-7b-chat-hf_fact_raw": "1. BCL-2 interacts with phospholamban (PLN).\n2. BCL-2 is an anti-apoptotic protein.",
    "llama-2-7b-chat-hf_fact": [
      "BCL-2 interacts with phospholamban (PLN).",
      "BCL-2 is an anti-apoptotic protein."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true"
    ]
  },
  {
    "id": 218,
    "user_query": "Has vitamin D has been shown to reduce incidence of falls in older people in clinical trials?",
    "llama-2-7b-chat-hf_response": "Yes, several clinical trials have shown that vitamin D supplementation can reduce the incidence of falls in older people. Here are some examples:\n1. A 2013 Cochrane review of 15 randomized controlled trials found that vitamin D supplementation was associated with a significant reduction in the risk of falls in older adults (1).\n2. A 2014 meta-analysis of 11 randomized controlled trials found that vitamin D supplementation reduced the risk of falls by 23% in older adults (2).\n3. A 2017 randomized controlled trial found that vitamin D supplementation reduced the incidence of falls in older adults with a history of falls (3).\n4. A 2019 systematic review and meta-analysis of 23 randomized controlled trials found that vitamin D supplementation was associated with a reduced risk of falls in older adults, with a pooled relative risk reduction of 23% (4).\nOverall, the evidence suggests that vitamin D supplementation may be effective in reducing the incidence of falls in older people, although the exact mechanisms by which this occurs are not fully understood. However, it is thought that vitamin D may play a role in maintaining muscle strength and function, as well as in the regulation of neuromuscular transmission and balance.",
    "llama-2-7b-chat-hf_fact_raw": "1. A 2013 Cochrane review of 15 randomized controlled trials found that vitamin D supplementation was associated with a significant reduction in the risk of falls in older adults.\n2. A 2014 meta-analysis of 11 randomized controlled trials indicated that vitamin D supplementation reduced the risk of falls by 23% in older adults.\n3. A 2017 randomized controlled trial reported that vitamin D supplementation reduced the incidence of falls in older adults with a history of falls.\n4. A 2019 systematic review and meta-analysis of 23 randomized controlled trials suggested a reduced risk of falls in older adults due to vitamin D supplementation, with a pooled relative risk reduction of 23%.",
    "llama-2-7b-chat-hf_fact": [
      "A 2013 Cochrane review of 15 randomized controlled trials found that vitamin D supplementation was associated with a significant reduction in the risk of falls in older adults.",
      "A 2014 meta-analysis of 11 randomized controlled trials indicated that vitamin D supplementation reduced the risk of falls by 23% in older adults.",
      "A 2017 randomized controlled trial reported that vitamin D supplementation reduced the incidence of falls in older adults with a history of falls.",
      "A 2019 systematic review and meta-analysis of 23 randomized controlled trials suggested a reduced risk of falls in older adults due to vitamin D supplementation, with a pooled relative risk reduction of 23%."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: A 2014 meta-analysis indicated that vitamin D supplementation was associated with a significant reduction in the risk of falls in older adults, but there is no specification that the risk reduction was exactly 23% without a proper citation.\n3. UNKNOWN (Without specifics regarding the trial's findings, it is difficult to determine the veracity of the statement)\n4. UNKNOWN (Again, without a proper citation, the specific figures mentioned in the statement cannot be verified for accuracy)",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 222,
    "user_query": "Is there any association between Jarid2 and miR-155 in Th17 cells?",
    "llama-2-7b-chat-hf_response": "Yes, there is an association between Jarid2 and miR-155 in Th17 cells. Jarid2 (Jumonji-ATF-interacting protein 2) is a histone-modifying enzyme that regulates chromatin structure and gene expression, and miR-155 (microRNA-155) is a small non-coding RNA that plays a critical role in the regulation of Th17 cell differentiation and inflammation. Studies have shown that Jarid2 and miR-155 interact in Th17 cells, with Jarid2 promoting the expression of miR-155 and miR-155 in turn regulating the expression of genes involved in Th17 cell differentiation and function.",
    "llama-2-7b-chat-hf_fact_raw": "1. Jarid2 is a histone-modifying enzyme that regulates chromatin structure and gene expression.\n2. miR-155 is a non-coding RNA that plays a role in the regulation of Th17 cell differentiation and inflammation.\n3. There is an interaction between Jarid2 and miR-155 in Th17 cells.\n4. Jarid2 promotes the expression of miR-155.\n5. miR-155 regulates the expression of genes involved in Th17 cell differentiation and function.",
    "llama-2-7b-chat-hf_fact": [
      "Jarid2 is a histone-modifying enzyme that regulates chromatin structure and gene expression.",
      "miR-155 is a non-coding RNA that plays a role in the regulation of Th17 cell differentiation and inflammation.",
      "There is an interaction between Jarid2 and miR-155 in Th17 cells.",
      "Jarid2 promotes the expression of miR-155.",
      "miR-155 regulates the expression of genes involved in Th17 cell differentiation and function."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Jarid2 is not a histone-modifying enzyme itself, but it is a component of the Polycomb Repressive Complex 2 (PRC2) which regulates chromatin structure and gene expression.\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 224,
    "user_query": "How many genes does the human hoxD cluster contain?",
    "llama-2-7b-chat-hf_response": "The human HoxD cluster contains 9 genes: Hoxd-1 to Hoxd-9.",
    "llama-2-7b-chat-hf_fact_raw": "1. The human HoxD cluster contains 9 genes.",
    "llama-2-7b-chat-hf_fact": [
      "The human HoxD cluster contains 9 genes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The human HoxD gene cluster contains 9 genes relevant to limb formation but there are a few additional genes in the cluster, making the total more than 9. The HoxD cluster is usually described as containing 11 genes (HOXD1-HOXD13), with the exclusion of HOXD11 as it is considered a pseudogene.",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 268,
    "user_query": "List phosphorylation consensus motifs for Casein Kinase 1 (CK1)?",
    "llama-2-7b-chat-hf_response": "Casein Kinase 1 (CK1) is a serine/threonine kinase that phosphorylates a variety of substrates in cells. The consensus motifs for phosphorylation by CK1 are:\n1. Ser/Thr-Pro-X-X-Ser/Thr (where X is any amino acid)\nThis motif is found in the activation loops of many CK1 substrates and is important for their phosphorylation and activity.\n2. Ser/Thr-X-X-Ser/Thr (where X is any amino acid)\nThis motif is found in the regulatory regions of CK1 substrates and is important for their phosphorylation and inhibition by CK1.\n3. Ser/Thr-Gly-X-X-Ser/Thr (where X is any amino acid)\nThis motif is found in the substrate sequences of CK1 and is important for their phosphorylation and activity.\n4. Ser/Thr-Pro-X-X-Ser/Thr-Pro (where X is any amino acid)\nThis motif is found in the substrate sequences of CK1 and is important for their phosphorylation and activity.\n5. Ser/Thr-X-X-Ser/Thr-X (where X is any amino acid)\nThis motif is found in the substrate sequences of CK1 and is important for their phosphorylation and activity.\nIt's worth noting that these consensus motifs are not exclusive to CK1 and other kinases can also phosphorylate these sites, but these are the most common consensus motifs found in CK1 substrates.",
    "llama-2-7b-chat-hf_fact_raw": "1. CK1 is a serine/threonine kinase.\n2. The consensus phosphorylation motif for CK1 includes Ser/Thr-Pro-X-X-Ser/Thr, where X is any amino acid.\n3. Another consensus motif recognizable by CK1 is Ser/Thr-X-X-Ser/Thr, where X is any amino acid.\n4. The motif Ser/Thr-Gly-X-X-Ser/Thr, where X is any amino acid, is associated with CK1 substrate phosphorylation.\n5. CK1 substrate sequences feature the phosphorylation motif Ser/Thr-Pro-X-X-Ser/Thr-Pro, where X is any amino acid.",
    "llama-2-7b-chat-hf_fact": [
      "CK1 is a serine/threonine kinase.",
      "The consensus phosphorylation motif for CK1 includes Ser/Thr-Pro-X-X-Ser/Thr, where X is any amino acid.",
      "Another consensus motif recognizable by CK1 is Ser/Thr-X-X-Ser/Thr, where X is any amino acid.",
      "The motif Ser/Thr-Gly-X-X-Ser/Thr, where X is any amino acid, is associated with CK1 substrate phosphorylation.",
      "CK1 substrate sequences feature the phosphorylation motif Ser/Thr-Pro-X-X-Ser/Thr-Pro, where X is any amino acid."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The consensus phosphorylation motif for CK1 is often reported as Ser/Thr-X-X-Ser/Thr, where X can be any amino acid, not Ser/Thr-Pro-X-X-Ser/Thr.\n3. TRUE\n4. UNKNOWN: The motif Ser/Thr-Gly-X-X-Ser/Thr is not a commonly recognized or well-characterized consensus motif for CK1, and without specific context or source, it is unclear whether this is associated with CK1.\n5. FALSE [correction]: CK1 substrate sequences often feature the phosphorylation motif Ser/Thr-X-X-Ser/Thr, where X is any amino acid. The motif provided, Ser/Thr-Pro-X-X-Ser/Thr-Pro, does not accurately represent the recognized consensus motif for CK1.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 305,
    "user_query": "Which are the different proteins/isoforms encoded but the ASPH (aspartate beta-hydroxylase) gene in humans?",
    "llama-2-7b-chat-hf_response": "The ASPH (aspartate beta-hydroxylase) gene in humans encodes multiple isoforms of the ASPH protein, including:\n1. ASPH1: The full-length form of the ASPH protein, which is the most well-studied isoform.\n2. ASPH2: A shorter isoform that lacks the N-terminal region of the protein.\n3. ASPH3: A splice variant that is produced through alternative splicing and contains a distinct C-terminal region.\n4. ASPH4: A variant that is produced through a mutation in the ASPH gene and has been associated with certain diseases, including cancer.\n5. ASPH5: A form of the protein that is produced through a post-translational modification, such as phosphorylation.\nThese isoforms of ASPH have different functions and are involved in various cellular processes, including cell signaling, cytoskeleton organization, and regulation of gene expression.",
    "llama-2-7b-chat-hf_fact_raw": "1. The ASPH gene in humans encodes multiple isoforms of the ASPH protein.\n2. ASPH1 is the full-length form of the ASPH protein.\n3. ASPH2 is an isoform that lacks the N-terminal region of the protein.\n4. ASPH3 is a splice variant with a distinct C-terminal region.\n5. ASPH4 is a variant associated with certain diseases, including cancer.",
    "llama-2-7b-chat-hf_fact": [
      "The ASPH gene in humans encodes multiple isoforms of the ASPH protein.",
      "ASPH1 is the full-length form of the ASPH protein.",
      "ASPH2 is an isoform that lacks the N-terminal region of the protein.",
      "ASPH3 is a splice variant with a distinct C-terminal region.",
      "ASPH4 is a variant associated with certain diseases, including cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statement that the ASPH gene encodes multiple isoforms of the ASPH protein is true, as many genes can encode different protein isoforms through a process called alternative splicing. However, without specific scientific literature references or a detailed context regarding the nomenclature (ASPH1, ASPH2, ASPH3, ASPH4), the remaining statements about the specific isoforms and their attributes, as well as any disease associations, cannot be reliably confirmed or corrected. Therefore, they are marked as UNKNOWN.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 330,
    "user_query": "When was empagliflozin FDA approved?",
    "llama-2-7b-chat-hf_response": "Empagliflozin was FDA approved in 2014. It was approved on June 28, 2014, by the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes.",
    "llama-2-7b-chat-hf_fact_raw": "1. Empagliflozin was FDA approved in the year 2014.\n2. The U.S. Food and Drug Administration (FDA) approved empagliflozin specifically on June 28, 2014.\n3. The approval was for the treatment of type 2 diabetes.",
    "llama-2-7b-chat-hf_fact": [
      "Empagliflozin was FDA approved in the year 2014.",
      "The U.S. Food and Drug Administration (FDA) approved empagliflozin specifically on June 28, 2014.",
      "The approval was for the treatment of type 2 diabetes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The U.S. Food and Drug Administration (FDA) approved empagliflozin on August 1, 2014.\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 350,
    "user_query": "What are the results of loss of the protein Lon1 in the plant Arabidopsis?",
    "llama-2-7b-chat-hf_response": "Loss of the protein Lon1 in the plant Arabidopsis thaliana has been shown to have several effects on plant development and physiology. Some of the key results include:\n1. Delayed growth and reduced stem elongation: Lon1-deficient plants are smaller and have delayed growth compared to wild-type plants.\n2. Altered leaf morphology: Lon1-deficient leaves are thicker and have a smaller blade size compared to wild-type leaves.\n3. Reduced flowering: Lon1-deficient plants produce fewer flowers and have a reduced fertility compared to wild-type plants.\n4. Increased sensitivity to abiotic stress: Lon1-deficient plants are more sensitive to abiotic stressors such as drought and high temperature.\n5. Altered root architecture: Lon1-deficient roots are shorter and have a reduced number of lateral roots compared to wild-type roots.\n6. Reduced tolerance to oxidative stress: Lon1-deficient plants have reduced tolerance to oxidative stress, as evidenced by increased sensitivity to the oxidative stress-inducing agent, H2O2.\n7. Altered hormone regulation: Lon1-deficient plants have altered levels of various hormones, including ABA, ethylene, and cytokinin, which can affect plant growth and development.\n8. Changes in gene expression: Lon1-deficient plants have altered expression of various genes involved in various cellular processes, including DNA repair, stress response, and cell division.\nThese results demonstrate that Lon1 plays a critical role in regulating various aspects of plant growth and development, and that its loss can have significant effects on plant physiology and stress tolerance.",
    "llama-2-7b-chat-hf_fact_raw": "1. Lon1-deficient Arabidopsis thaliana plants exhibit delayed growth and reduced stem elongation compared to wild-type plants.\n2. Leaves of Lon1-deficient Arabidopsis thaliana plants are thicker and have a smaller blade size than those of wild-type plants.\n3. Lon1-deficient Arabidopsis thaliana plants produce fewer flowers and have reduced fertility compared to wild-type plants.\n4. Lon1-deficient Arabidopsis thaliana plants have increased sensitivity to abiotic stressors like drought and high temperature.\n5. The root architecture of Lon1-deficient Arabidopsis thaliana plants is characterized by shorter roots and a reduced number of lateral roots in comparison to wild-type plants.",
    "llama-2-7b-chat-hf_fact": [
      "Lon1-deficient Arabidopsis thaliana plants exhibit delayed growth and reduced stem elongation compared to wild-type plants.",
      "Leaves of Lon1-deficient Arabidopsis thaliana plants are thicker and have a smaller blade size than those of wild-type plants.",
      "Lon1-deficient Arabidopsis thaliana plants produce fewer flowers and have reduced fertility compared to wild-type plants.",
      "Lon1-deficient Arabidopsis thaliana plants have increased sensitivity to abiotic stressors like drought and high temperature.",
      "The root architecture of Lon1-deficient Arabidopsis thaliana plants is characterized by shorter roots and a reduced number of lateral roots in comparison to wild-type plants."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Lon1-deficient Arabidopsis thaliana plants have been reported to show delayed growth and reduced stem elongation compared to the wild-type, as the Lon1 gene is involved in various plant developmental processes.\n\n2. UNKNOWN: Without specific research reference, it's difficult to determine if Lon1-deficiency leads to changes in leaf thickness and blade size. Although Lon1 has a role in plant architecture and phenotype, the specific effect on leaf characteristics would require more information or a cited source.\n\n3. UNKNOWN: The fertility and flowering ability of Lon1-deficient Arabidopsis thaliana plants would depend on the specific function of the Lon1 gene. A deficiency could potentially affect many developmental aspects, but without a direct reference, the impact on fertility and flower production remains uncertain.\n\n4. UNKNOWN: While it is plausible that a gene like Lon1 could affect plant responsiveness to abiotic stress, without direct evidence or specific studies detailing the role of Lon1 in stress response, the effect of its deficiency on sensitivity to drought and high temperature is indeterminate.\n\n5. UNKNOWN: Root architecture can be influenced by various genetic factors, and although Lon1 could conceivably affect root growth, the precise role of Lon1-deficiency on root length and lateral root formation is not specified here and thus cannot be accurately assessed.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 409,
    "user_query": "Does a linker histone exist in the yeast genome?",
    "llama-2-7b-chat-hf_response": "Yes, a linker histone called H3K56ac exists in the yeast genome. H3K56ac is a histone modification that plays a role in the regulation of chromatin structure and gene expression, particularly in the context of transcriptional elongation. In yeast, H3K56ac is known to be involved in the regulation of various cellular processes, including cell cycle progression, DNA repair, and stress response.",
    "llama-2-7b-chat-hf_fact_raw": "1. A linker histone called H3K56ac exists in the yeast genome.\n2. H3K56ac is a histone modification that is involved in regulating chromatin structure and gene expression.\n3. In the yeast genome, H3K56ac plays a role in transcriptional elongation.\n4. The regulation of cell cycle progression in yeast involves H3K56ac.\n5. H3K56ac is involved in DNA repair and stress response in yeast.",
    "llama-2-7b-chat-hf_fact": [
      "A linker histone called H3K56ac exists in the yeast genome.",
      "H3K56ac is a histone modification that is involved in regulating chromatin structure and gene expression.",
      "In the yeast genome, H3K56ac plays a role in transcriptional elongation.",
      "The regulation of cell cycle progression in yeast involves H3K56ac.",
      "H3K56ac is involved in DNA repair and stress response in yeast."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The linker histone referred to as H3K56ac is a misnomer; H3K56ac denotes the acetylation at lysine 56 on histone H3 rather than a histone itself.\n2. TRUE\n3. TRUE: H3K56ac can play a role in transcriptional elongation, although this is context-dependent and may vary.\n4. TRUE: The acetylation of histone H3 on lysine 56 has been implicated in the regulation of cell cycle progression in yeast.\n5. TRUE: H3K56 acetylation is involved in DNA repair processes and can be modulated in response to stress in yeast.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 418,
    "user_query": "Is there evidence that tomato juice lowers cholesterol levels?",
    "llama-2-7b-chat-hf_response": "Yes, there is some evidence to suggest that tomato juice may help lower cholesterol levels.\nTomato juice contains a compound called lycopene, which has been shown to have cholesterol-lowering effects. Lycopene is a powerful antioxidant that can help reduce inflammation and improve cardiovascular health.\nSeveral studies have investigated the potential of tomato juice to lower cholesterol levels. A 2011 study published in the Journal of Nutrition found that drinking tomato juice for 12 weeks significantly reduced total cholesterol and LDL (bad) cholesterol levels in healthy adults. Another study published in the Journal of Agricultural and Food Chemistry in 2015 found that lycopene from tomato juice reduced cholesterol levels in mice fed a high-cholesterol diet.\nIt's thought that the lycopene in tomato juice may help lower cholesterol levels by reducing the absorption of dietary cholesterol in the gut, as well as by inhibiting the production of cholesterol in the liver. Additionally, lycopene may help improve the function of the LDL (bad) cholesterol receptor, which can help remove excess cholesterol from the bloodstream.\nWhile these findings are promising, it's important to note that the evidence for the cholesterol-lowering effects of tomato juice is still emerging and more research is needed to fully understand its potential benefits. Additionally, it's important to remember that tomato juice is just one part of a healthy diet and lifestyle, and it's not a substitute for other cholesterol-lowering strategies, such as a balanced diet, regular exercise, and medication if necessary.",
    "llama-2-7b-chat-hf_fact_raw": "1. Lycopene, found in tomato juice, has been shown to have cholesterol-lowering effects.\n2. A study published in the Journal of Nutrition in 2011 found that drinking tomato juice for 12 weeks significantly reduced total cholesterol and LDL cholesterol levels in healthy adults.\n3. A study published in the Journal of Agricultural and Food Chemistry in 2015 demonstrated that lycopene from tomato juice reduced cholesterol levels in mice fed a high-cholesterol diet.\n4. Lycopene is suggested to lower cholesterol levels by reducing the absorption of dietary cholesterol in the gut and inhibiting the production of cholesterol in the liver.\n5. Lycopene may also improve the function of the LDL cholesterol receptor, aiding in the removal of excess cholesterol from the bloodstream.",
    "llama-2-7b-chat-hf_fact": [
      "Lycopene, found in tomato juice, has been shown to have cholesterol-lowering effects.",
      "A study published in the Journal of Nutrition in 2011 found that drinking tomato juice for 12 weeks significantly reduced total cholesterol and LDL cholesterol levels in healthy adults.",
      "A study published in the Journal of Agricultural and Food Chemistry in 2015 demonstrated that lycopene from tomato juice reduced cholesterol levels in mice fed a high-cholesterol diet.",
      "Lycopene is suggested to lower cholesterol levels by reducing the absorption of dietary cholesterol in the gut and inhibiting the production of cholesterol in the liver.",
      "Lycopene may also improve the function of the LDL cholesterol receptor, aiding in the removal of excess cholesterol from the bloodstream."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Lycopene, an antioxidant found in tomatoes and tomato products, has indeed been associated with cholesterol-lowering effects in some studies.\n2. TRUE: There have been studies such as this that have shown drinking tomato juice can have beneficial effects on cholesterol levels.\n3. TRUE: Similar research has been conducted with animals, and studies like the one mentioned have demonstrated that lycopene could reduce cholesterol levels in certain contexts, such as with mice on a high-cholesterol diet.\n4. TRUE: These are two purported mechanisms by which lycopene may influence cholesterol metabolism.\n5. TRUE: This statement aligns with some scientific hypotheses and findings regarding the function of lycopene in relation to LDL cholesterol receptors and cholesterol metabolism. However, it's important to note that while there is scientific evidence supporting these effects, more research may be necessary to fully understand the mechanisms and effects across diverse populations.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 472,
    "user_query": "How do Hsp70 and Hsp110 affect mRNA stability?",
    "llama-2-7b-chat-hf_response": "Hsp70 and Hsp110 are molecular chaperones that play a role in regulating mRNA stability by interacting with the 3' untranslated region (UTR) of target mRNAs and modulating their stability.\nHsp70:\n* Hsp70 binds to the 3' UTR of target mRNAs and protects them from degradation by the 5' to 3' exonuclease activity of the ribosome.\n* Hsp70 can also induce a conformational change in the 3' UTR that inhibits the activity of the ribosome, leading to increased mRNA stability.\n* Hsp70 can also regulate mRNA stability by modulating the activity of other proteins involved in mRNA degradation, such as the E3 ubiquitin ligase complex.\nHsp110:\n* Hsp110 also binds to the 3' UTR of target mRNAs and protects them from degradation by the ribosome.\n* Hsp110 can induce a conformational change in the 3' UTR that inhibits the activity of the ribosome, leading to increased mRNA stability.\n* Hsp110 can also regulate mRNA stability by modulating the activity of other proteins involved in mRNA degradation, such as the E3 ubiquitin ligase complex.\nIn summary, both Hsp70 and Hsp110 regulate mRNA stability by interacting with the 3' UTR of target mRNAs and modulating the activity of the ribosome and other proteins involved in mRNA degradation.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hsp70 and Hsp110 are molecular chaperones involved in regulating mRNA stability.\n2. Hsp70 binds to the 3' untranslated region of target mRNAs and protects them from degradation by ribosomal 5' to 3' exonuclease activity.\n3. Hsp70 can induce conformational changes that inhibit the ribosome's activity leading to increased mRNA stability.\n4. Hsp110 binds to the 3' untranslated region of target mRNAs, protecting them from degradation by the ribosome.\n5. Both Hsp70 and Hsp110 can regulate mRNA stability by modulating the activity of proteins involved in mRNA degradation, such as the E3 ubiquitin ligase complex.",
    "llama-2-7b-chat-hf_fact": [
      "Hsp70 and Hsp110 are molecular chaperones involved in regulating mRNA stability.",
      "Hsp70 binds to the 3' untranslated region of target mRNAs and protects them from degradation by ribosomal 5' to 3' exonuclease activity.",
      "Hsp70 can induce conformational changes that inhibit the ribosome's activity leading to increased mRNA stability.",
      "Hsp110 binds to the 3' untranslated region of target mRNAs, protecting them from degradation by the ribosome.",
      "Both Hsp70 and Hsp110 can regulate mRNA stability by modulating the activity of proteins involved in mRNA degradation, such as the E3 ubiquitin ligase complex."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Hsp70 and Hsp110 are molecular chaperones involved in protein folding and preventing the aggregation of misfolded proteins, not directly in regulating mRNA stability.\n2. FALSE [correction]: Hsp70 does not typically bind to the 3' untranslated region of mRNAs to protect them from degradation. Instead, its primary function is related to protein folding.\n3. UNKNOWN: The statement attributes a specific function to Hsp70 regarding mRNA stability by affecting ribosome activity, which is generally not a recognized role of Hsp70. The role of Hsp70 in mRNA regulation is not well established, and the statement is not a common characterization of Hsp70 function.\n4. FALSE [correction]: Hsp110, like Hsp70, is mainly known for its roles in protein folding and stabilizing proteins, not for binding to the 3' untranslated regions of mRNAs and protecting them from degradation by the ribosome.\n5. FALSE [correction]: Hsp70 and Hsp110 are primarily known for their roles in protein homeostasis. While there is evidence suggesting that molecular chaperones can indirectly influence mRNA stability, this statement is overly specific in detailing a mechanism involving the E3 ubiquitin ligase complex, which is not a well-established function of Hsp70 and Hsp110.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "false",
      "false"
    ]
  },
  {
    "id": 481,
    "user_query": "Which deiodinases are present in skeletal  muscle?",
    "llama-2-7b-chat-hf_response": "There are two deiodinases present in skeletal muscle:\n1. Deiodinase type 1 (D1): found primarily in the brain and other organs, but also expressed in skeletal muscle, where it plays a role in regulating muscle mass and function.\n2. Deiodinase type 2 (D2): primarily expressed in skeletal muscle, where it is responsible for the conversion of T4 to T3, the active form of the hormone, which plays a crucial role in regulating muscle metabolism and growth.",
    "llama-2-7b-chat-hf_fact_raw": "1. Deiodinase type 1 (D1) is expressed in skeletal muscle and plays a role in regulating muscle mass and function.\n2. Deiodinase type 2 (D2) is primarily expressed in skeletal muscle and is responsible for converting T4 to T3.\n3. T3 is the active form of the thyroid hormone that regulates muscle metabolism and growth.",
    "llama-2-7b-chat-hf_fact": [
      "Deiodinase type 1 (D1) is expressed in skeletal muscle and plays a role in regulating muscle mass and function.",
      "Deiodinase type 2 (D2) is primarily expressed in skeletal muscle and is responsible for converting T4 to T3.",
      "T3 is the active form of the thyroid hormone that regulates muscle metabolism and growth."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Deiodinase type 1 (D1) is not primarily expressed in skeletal muscle. It is present in various tissues, including liver and kidney, and is involved in the conversion of T4 to T3 as well as reverse T3 (rT3) to T2.\n2. FALSE [correction]: Deiodinase type 2 (D2) is primarily expressed in the brain, pituitary, and brown adipose tissue, and it converts T4 to active T3 predominantly in those tissues. It is not primarily expressed in skeletal muscle.\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 534,
    "user_query": "List inflammatory caspase proteins?",
    "llama-2-7b-chat-hf_response": "Caspase proteins are a family of enzymes that play a central role in the inflammatory response. Here are some of the inflammatory caspase proteins:\n1. Caspase-1 (also known as interleukin-1β converting enzyme, or ICE): This caspase is involved in the processing and activation of pro-inflammatory cytokines such as interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α).\n2. Caspase-3: This caspase is involved in the cleavage of a variety of inflammatory proteins, including the pro-inflammatory cytokines IL-1β and TNF-α, as well as the anti-inflammatory cytokine interleukin-10 (IL-10).\n3. Caspase-6: This caspase is involved in the processing and activation of pro-inflammatory cytokines such as IL-1β and TNF-α.\n4. Caspase-7: This caspase is involved in the cleavage of a variety of inflammatory proteins, including the pro-inflammatory cytokines IL-1β and TNF-α, as well as the anti-inflammatory cytokine IL-10.\n5. Caspase-8: This caspase is involved in the processing and activation of pro-inflammatory cytokines such as Fas ligand (FasL) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).\n6. Caspase-9: This caspase is involved in the cleavage of a variety of inflammatory proteins, including the pro-inflammatory cytokines IL-1β and TNF-α, as well as the anti-inflammatory cytokine IL-10.\n7. Caspase-12: This caspase is involved in the processing and activation of pro-inflammatory cytokines such as IL-1β and TNF-α.\n8. Caspase-13: This caspase is involved in the cleavage of a",
    "llama-2-7b-chat-hf_fact_raw": "1. Caspase-1 is involved in the processing and activation of pro-inflammatory cytokines such as interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α).\n2. Caspase-3 is involved in the cleavage of various inflammatory proteins, including IL-1β, TNF-α, and interleukin-10 (IL-10).\n3. Caspase-6 is involved in the processing and activation of pro-inflammatory cytokines such as IL-1β and TNF-α.\n4. Caspase-8 is involved in the processing and activation of pro-inflammatory cytokines such as Fas ligand (FasL) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).\n5. Caspase-12 is involved in the processing and activation of pro-inflammatory cytokines such as IL-1β and TNF-α.",
    "llama-2-7b-chat-hf_fact": [
      "Caspase-1 is involved in the processing and activation of pro-inflammatory cytokines such as interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α).",
      "Caspase-3 is involved in the cleavage of various inflammatory proteins, including IL-1β, TNF-α, and interleukin-10 (IL-10).",
      "Caspase-6 is involved in the processing and activation of pro-inflammatory cytokines such as IL-1β and TNF-α.",
      "Caspase-8 is involved in the processing and activation of pro-inflammatory cytokines such as Fas ligand (FasL) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).",
      "Caspase-12 is involved in the processing and activation of pro-inflammatory cytokines such as IL-1β and TNF-α."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Caspase-3 is primarily involved in the execution phase of apoptosis, not the cleavage of inflammatory proteins.\n3. FALSE [correction]: Caspase-6 is primarily involved in apoptosis and has not been shown to process or activate pro-inflammatory cytokines such as IL-1β and TNF-α.\n4. TRUE\n5. FALSE [correction]: Caspase-12 is involved in the modulation of inflammation and innate immunity, but its role is mostly linked to the attenuation of the inflammatory response, not the processing and activation of IL-1β and TNF-α.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 579,
    "user_query": "Is there any link between the aurora B kinase and the polycomb protein ring1B?",
    "llama-2-7b-chat-hf_response": "Yes, there is a link between Aurora B kinase and the polycomb protein Ring1B. Ring1B is a member of the polycomb repressive complex 2 (PRC2) and is involved in the regulation of gene expression, particularly during cell division. Aurora B kinase, on the other hand, is a serine/threonine kinase that plays a critical role in the proper separation of chromosomes during mitosis and meiosis.\nStudies have shown that Ring1B and Aurora B kinase interact and coordinate their functions during mitosis. Ring1B is phosphorylated by Aurora B kinase, which leads to its activation and the subsequent regulation of chromatin remodeling and gene expression. In addition, Ring1B has been shown to regulate the localization and activity of Aurora B kinase, providing a negative feedback loop that helps to ensure proper chromosome segregation.\nIn summary, there is a functional link between Aurora B kinase and the polycomb protein Ring1B, with each protein playing a critical role in the regulation of chromatin dynamics and gene expression during cell division.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ring1B is a member of the polycomb repressive complex 2 (PRC2).\n2. Ring1B is involved in the regulation of gene expression during cell division.\n3. Aurora B kinase is a serine/threonine kinase important in chromosome separation during mitosis and meiosis.\n4. Studies have indicated that Ring1B is phosphorylated by Aurora B kinase.\n5. The phosphorylation of Ring1B by Aurora B kinase leads to its activation and impacts chromatin remodeling and gene expression.",
    "llama-2-7b-chat-hf_fact": [
      "Ring1B is a member of the polycomb repressive complex 2 (PRC2).",
      "Ring1B is involved in the regulation of gene expression during cell division.",
      "Aurora B kinase is a serine/threonine kinase important in chromosome separation during mitosis and meiosis.",
      "Studies have indicated that Ring1B is phosphorylated by Aurora B kinase.",
      "The phosphorylation of Ring1B by Aurora B kinase leads to its activation and impacts chromatin remodeling and gene expression."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Ring1B is a member of the polycomb repressive complex 1 (PRC1), not PRC2.\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 597,
    "user_query": "What are the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates?",
    "llama-2-7b-chat-hf_response": "Non-canonical sequence motifs are alterations in the splice site sequences that can disrupt the normal splicing process. In vertebrates, the most frequent non-canonical sequence motifs at the donor and acceptor splice sites are:\nDonor splice sites:\n* GU-rich sequences (GU4-7)\n* GU-rich clusters (2-4 GU bases in a row)\n* GA-rich sequences (GA4-7)\n* GA-rich clusters (2-4 GA bases in a row)\n* AG-rich sequences (AG4-7)\n* AG-rich clusters (2-4 AG bases in a row)\n* A-rich sequences (A4-7)\n* A-rich clusters (2-4 A bases in a row)\n* T-rich sequences (T4-7)\n* T-rich clusters (2-4 T bases in a row)\n* GT-rich sequences (GT4-7)\n* GT-rich clusters (2-4 GT bases in a row)\nAcceptor splice sites:\n* GU-rich sequences (GU4-7)\n* GU-rich clusters (2-4 GU bases in a row)\n* GA-rich sequences (GA4-7)\n* GA-rich clusters (2-4 GA bases in a row)\n* AG-rich sequences (AG4-7)\n* AG-rich clusters (2-4 AG bases in a row)\n* A-rich sequences (A4-7)\n* A-rich clusters (2-4 A bases in a row)\n* T-rich sequences (T4-7)\n* T-rich clusters (2-4 T bases in a row)\n* GT-rich sequences (GT4-7)\n* GT-rich clusters (2-4 GT bases in a row)\nIt's worth noting that the frequency of these non-canonical motifs can vary depending on the tissue and cell type, and some of these motifs may also be found in other organisms.",
    "llama-2-7b-chat-hf_fact_raw": "1. Non-canonical sequence motifs are alterations in splice site sequences that can affect normal splicing.\n2. GU-rich sequences ranging from GU4-7 are among the most frequent non-canonical motifs at donor splice sites in vertebrates.\n3. GA-rich sequences ranging from GA4-7 are among the most frequent non-canonical motifs at donor splice sites in vertebrates.\n4. A-rich sequences and T-rich sequences, both ranging from 4 to 7 consecutive bases, are common non-canonical motifs at donor splice sites in vertebrates.\n5. The frequency of non-canonical motifs at splice sites can vary depending on tissue and cell type.",
    "llama-2-7b-chat-hf_fact": [
      "Non-canonical sequence motifs are alterations in splice site sequences that can affect normal splicing.",
      "GU-rich sequences ranging from GU4-7 are among the most frequent non-canonical motifs at donor splice sites in vertebrates.",
      "GA-rich sequences ranging from GA4-7 are among the most frequent non-canonical motifs at donor splice sites in vertebrates.",
      "A-rich sequences and T-rich sequences, both ranging from 4 to 7 consecutive bases, are common non-canonical motifs at donor splice sites in vertebrates.",
      "The frequency of non-canonical motifs at splice sites can vary depending on tissue and cell type."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The most common non-canonical motif at donor splice sites is actually a GC-rich sequence, particularly GCAG/GTAG.\n3. FALSE [correction]: While GA sequences can be involved in splicing regulation, they are not characterized as the most frequent non-canonical motifs at donor splice sites in vertebrates. The most frequent non-canonical motif at donor splice sites is GC-rich.\n4. UNKNOWN (There is not enough context to verify if A-rich or T-rich sequences in the range of 4 to 7 consecutive bases are common as non-canonical motifs at donor splice sites in vertebrates, as it can depend on various factors including the specific gene and organism being studied. More specific information is needed.)\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 629,
    "user_query": "Which event results in the acetylation of S6K1?",
    "llama-2-7b-chat-hf_response": "S6K1 (S6 kinase 1) is acetylated in response to activation of the PI3K (phosphoinositide 3-kinase) signaling pathway. Specifically, the phosphatidylinositol 3,4,5-trisphosphate (PIP3) produced downstream of PI3K activation binds to and recruits S6K1 to the plasma membrane, where it is acetylated by the histone acetyltransferase (HAT) complex p300/CBP-associated factor (PCAF).",
    "llama-2-7b-chat-hf_fact_raw": "1. S6K1 (S6 kinase 1) is acetylated in response to activation of the PI3K (phosphoinositide 3-kinase) signaling pathway.\n2. The production of phosphatidylinositol 3,4,5-trisphosphate (PIP3) occurs downstream of PI3K activation.\n3. S6K1 is recruited to the plasma membrane after the production of PIP3.\n4. S6K1 is acetylated by the histone acetyltransferase (HAT) complex known as p300/CBP-associated factor (PCAF).",
    "llama-2-7b-chat-hf_fact": [
      "S6K1 (S6 kinase 1) is acetylated in response to activation of the PI3K (phosphoinositide 3-kinase) signaling pathway.",
      "The production of phosphatidylinositol 3,4,5-trisphosphate (PIP3) occurs downstream of PI3K activation.",
      "S6K1 is recruited to the plasma membrane after the production of PIP3.",
      "S6K1 is acetylated by the histone acetyltransferase (HAT) complex known as p300/CBP-associated factor (PCAF)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n\nThe accuracy of these statements is dependent on current scientific knowledge and consensus. As of my knowledge cutoff in 2023, it is known that the PI3K signaling pathway can lead to various post-translational modifications of proteins, including acetylation, although the specific acetylation of S6K1 in response to this signaling pathway may be subject to ongoing research. PIP3 production is a well-established downstream event of PI3K activation and is known to recruit various signaling proteins to the plasma membrane. Without specific literature references regarding the acetylation of S6K1 by the PCAF complex, the truth of statement 4 cannot be determined and is therefore listed as UNKNOWN.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 632,
    "user_query": "What is the cause of episodic ataxia type 6?",
    "llama-2-7b-chat-hf_response": "Episodic ataxia type 6 (EA6) is a rare genetic disorder that is caused by mutations in the CACNA1A gene. This gene encodes a subunit of a calcium channel that is important for the transmission of calcium signals in neurons. Mutations in the CACNA1A gene lead to a loss of function of the calcium channel, resulting in the episodic ataxia symptoms.",
    "llama-2-7b-chat-hf_fact_raw": "1. Episodic ataxia type 6 (EA6) is a rare genetic disorder.\n2. EA6 is caused by mutations in the CACNA1A gene.\n3. The CACNA1A gene encodes a subunit of a calcium channel.\n4. This calcium channel is important for the transmission of calcium signals in neurons.\n5. Mutations in the CACNA1A gene can lead to a loss of function of the calcium channel.",
    "llama-2-7b-chat-hf_fact": [
      "Episodic ataxia type 6 (EA6) is a rare genetic disorder.",
      "EA6 is caused by mutations in the CACNA1A gene.",
      "The CACNA1A gene encodes a subunit of a calcium channel.",
      "This calcium channel is important for the transmission of calcium signals in neurons.",
      "Mutations in the CACNA1A gene can lead to a loss of function of the calcium channel."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 646,
    "user_query": "Are chromomethylases present in animal genomes?",
    "llama-2-7b-chat-hf_response": "Yes, chromomethylases are present in animal genomes. Chromomethylases are enzymes that modify chromatin structure by adding methyl groups to specific histone residues, and they play important roles in regulating chromatin dynamics and gene expression in both prokaryotes and eukaryotes.\nIn animals, chromomethylases have been identified as playing a role in a variety of processes, including:\n1. Epigenetic regulation of gene expression: Chromomethylases can modify histone H3 and H4 residues, leading to changes in chromatin structure and accessibility to transcription factors, and thereby affecting gene expression.\n2. Chromosome stability: Chromomethylases can help maintain chromosome stability by preventing the formation of chromatin structures that could lead to chromosomal abnormalities.\n3. Cell fate determination: Chromomethylases have been implicated in the regulation of cell fate determination, particularly in the context of stem cell differentiation.\n4. Cancer: Chromomethylases have been implicated in cancer development and progression, as alterations in their expression or activity can lead to changes in chromatin structure and gene expression that contribute to tumorigenesis.\nOverall, chromomethylases are an important class of enzymes that play a complex and multifaceted role in animal cell biology, and their dysregulation can have significant consequences for cellular function and health.",
    "llama-2-7b-chat-hf_fact_raw": "1. Chromomethylases are present in animal genomes.\n2. These enzymes add methyl groups to specific histone residues.\n3. Chromomethylases are involved in the epigenetic regulation of gene expression by modifying histone H3 and H4 residues.\n4. Chromomethylases contribute to maintaining chromosome stability.\n5. Alterations in the expression or activity of chromomethylases can be implicated in cancer development and progression.",
    "llama-2-7b-chat-hf_fact": [
      "Chromomethylases are present in animal genomes.",
      "These enzymes add methyl groups to specific histone residues.",
      "Chromomethylases are involved in the epigenetic regulation of gene expression by modifying histone H3 and H4 residues.",
      "Chromomethylases contribute to maintaining chromosome stability.",
      "Alterations in the expression or activity of chromomethylases can be implicated in cancer development and progression."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Chromomethylases are not present in animal genomes; they are typically found in plants where they methylate DNA, not histones.\n2. FALSE [correction]: Chromomethylases methylate DNA rather than histone residues. This task is performed by histone methyltransferases in animals.\n3. FALSE [correction]: Chromomethylases are involved in the epigenetic regulation of gene expression by modifying DNA in plants. Histone modification involving H3 and H4 residues is carried out by histone methyltransferases in animals.\n4. TRUE: While the statement is generally correct for plant chromomethylases as they contribute to maintaining genetic and epigenetic stability, it should be noted that in animals, the equivalent process of maintaining chromosome stability through methylation is carried out by DNA methyltransferases and histone modifiers, not chromomethylases.\n5. TRUE: Alterations in the expression or activity of DNA and histone-modifying enzymes, including those similar to plant chromomethylases, can be implicated in cancer development and progression in animals.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 650,
    "user_query": "List packages for transcription factor binding sites' (TFBS) analysis available in R/Bioconductor",
    "llama-2-7b-chat-hf_response": "There are several packages available in R/Bioconductor for the analysis of transcription factor binding sites (TFBS):\n1. ChromHMM: This package uses a hidden Markov model (HMM) to predict TFBS in DNA sequences. It can also be used to predict other types of genomic features such as gene regulatory elements.\n2. TFBSpred: This package uses a combination of machine learning algorithms and sequence motif discovery methods to predict TFBS in DNA sequences. It can also be used to predict the binding affinity of transcription factors to their target sites.\n3. TRANSFAC: This package is a comprehensive database of transcription factor binding sites and their corresponding binding sites. It can be used to predict TFBS in new DNA sequences or to identify potential binding sites in a given sequence.\n4. RSAT: This package uses a statistical approach to predict TFBS in DNA sequences. It can also be used to predict the binding affinity of transcription factors to their target sites.\n5. GREAT: This package uses a combination of machine learning algorithms and sequence motif discovery methods to predict TFBS in DNA sequences. It can also be used to predict the binding affinity of transcription factors to their target sites.\n6. DeepSEA: This package uses deep learning methods to predict TFBS in DNA sequences. It can also be used to predict the binding affinity of transcription factors to their target sites.\n7. TFBS-predict: This package uses a combination of sequence motif discovery methods and machine learning algorithms to predict TFBS in DNA sequences.\n8. TF-Predict: This package uses a combination of sequence motif discovery methods and machine learning algorithms to predict TFBS in DNA sequences.\n9. Chromatin-Motif-Predictor: This package uses a combination of sequence motif discovery methods and machine learning algorithms to predict TFBS in DNA sequences.\n10. Transcription-Factor-Predictor: This package uses a combination of sequence motif discovery methods and machine learning algorithms to predict TFBS in DNA sequences.\nIt's worth noting that these packages are constantly being updated and new packages are being developed, so it's a good idea to check the latest packages available in R/Bioconductor and the documentation for each package to see which one is",
    "llama-2-7b-chat-hf_fact_raw": "1. ChromHMM is an R/Bioconductor package that uses a hidden Markov model to predict transcription factor binding sites (TFBS) in DNA sequences.\n2. TFBSpred is an R/Bioconductor package that combines machine learning algorithms and sequence motif discovery methods for the prediction of TFBS.\n3. TRANSFAC is an R/Bioconductor package that includes a database of transcription factor binding sites and their corresponding binding sites.\n4. RSAT is an R/Bioconductor package that uses statistical approaches to predict TFBS in DNA sequences.\n5. DeepSEA is an R/Bioconductor package that applies deep learning methods to predict TFBS in DNA sequences.",
    "llama-2-7b-chat-hf_fact": [
      "ChromHMM is an R/Bioconductor package that uses a hidden Markov model to predict transcription factor binding sites (TFBS) in DNA sequences.",
      "TFBSpred is an R/Bioconductor package that combines machine learning algorithms and sequence motif discovery methods for the prediction of TFBS.",
      "TRANSFAC is an R/Bioconductor package that includes a database of transcription factor binding sites and their corresponding binding sites.",
      "RSAT is an R/Bioconductor package that uses statistical approaches to predict TFBS in DNA sequences.",
      "DeepSEA is an R/Bioconductor package that applies deep learning methods to predict TFBS in DNA sequences."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: ChromHMM is not an R/Bioconductor package. It is a computational tool that uses hidden Markov models to characterize the chromatin states (like enhancers, promoters, etc.) in the genome but does not specifically predict transcription factor binding sites (TFBS).\n2. UNKNOWN\n3. FALSE [correction]: TRANSFAC is not an R/Bioconductor package. TRANSFAC is a manually curated database of eukaryotic transcription factors, their genomic binding sites, and DNA-binding profiles.\n4. UNKNOWN\n5. FALSE [correction]: DeepSEA is not an R/Bioconductor package. DeepSEA is a machine learning framework that uses deep learning techniques to predict the effects of noncoding variants, including predicting transcription factor binding sites (TFBS), but it is not itself a package specifically for R/Bioconductor.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 721,
    "user_query": "List clinical trials for prevention of sarcopenia",
    "llama-2-7b-chat-hf_response": "Here are some clinical trials related to the prevention of sarcopenia:\n1. \"Exercise and Nutrition Interventions to Prevent Sarcopenia in Older Adults: A Systematic Review and Meta-Analysis\" (2019) - This study published in the Journal of the American Medical Directors Association found that exercise and nutrition interventions can help prevent sarcopenia in older adults.\n2. \"Effects of Resistance Training on Sarcopenia in Older Adults: A Systematic Review and Meta-Analysis\" (2018) - This study published in the Journal of Aging and Physical Activity found that resistance training can help prevent sarcopenia in older adults.\n3. \"The Effects of Omega-3 Fatty Acids on Sarcopenia in Older Adults: A Systematic Review\" (2018) - This study published in the Journal of the American Geriatrics Society found that omega-3 fatty acid supplementation may help prevent sarcopenia in older adults.\n4. \"Effects of Vitamin D and Omega-3 Fatty Acid Supplementation on Sarcopenia in Older Adults: A Randomized Controlled Trial\" (2017) - This study published in the Journal of the American Geriatrics Society found that vitamin D and omega-3 fatty acid supplementation may help prevent sarcopenia in older adults.\n5. \"Resistance Training and Nutrition Interventions to Prevent Sarcopenia in Older Adults: A Randomized Controlled Trial\" (2017) - This study published in the Journal of the American Geriatrics Society found that a combination of resistance training and nutrition interventions can help prevent sarcopenia in older adults.\n6. \"The Effects of Tai Chi Exercise on Sarcopenia in Older Adults: A Systematic Review and Meta-Analysis\" (2017) - This study published in the Journal of Aging and Physical Activity found that tai chi exercise can help prevent sarcopenia in older adults.\n7. \"Effects of Probiotic Supplementation on Sarcopenia in",
    "llama-2-7b-chat-hf_fact_raw": "1. A study titled \"Exercise and Nutrition Interventions to Prevent Sarcopenia in Older Adults: A Systematic Review and Meta-Analysis\" was published in the Journal of the American Medical Directors Association in 2019.\n2. The 2018 study \"Effects of Resistance Training on Sarcopenia in Older Adults: A Systematic Review and Meta-Analysis\" was published in the Journal of Aging and Physical Activity.\n3. A systematic review named \"The Effects of Omega-3 Fatty Acids on Sarcopenia in Older Adults\" was published in the Journal of the American Geriatrics Society in 2018.\n4. In 2017, a study on \"Effects of Vitamin D and Omega-3 Fatty Acid Supplementation on Sarcopenia in Older Adults\" was published in the Journal of the American Geriatrics Society.\n5. \"The Effects of Tai Chi Exercise on Sarcopenia in Older Adults: A Systematic Review and Meta-Analysis\" is a study from 2017 published in the Journal of Aging and Physical Activity.",
    "llama-2-7b-chat-hf_fact": [
      "A study titled \"Exercise and Nutrition Interventions to Prevent Sarcopenia in Older Adults: A Systematic Review and Meta-Analysis\" was published in the Journal of the American Medical Directors Association in 2019.",
      "The 2018 study \"Effects of Resistance Training on Sarcopenia in Older Adults: A Systematic Review and Meta-Analysis\" was published in the Journal of Aging and Physical Activity.",
      "A systematic review named \"The Effects of Omega-3 Fatty Acids on Sarcopenia in Older Adults\" was published in the Journal of the American Geriatrics Society in 2018.",
      "In 2017, a study on \"Effects of Vitamin D and Omega-3 Fatty Acid Supplementation on Sarcopenia in Older Adults\" was published in the Journal of the American Geriatrics Society.",
      "\"The Effects of Tai Chi Exercise on Sarcopenia in Older Adults: A Systematic Review and Meta-Analysis\" is a study from 2017 published in the Journal of Aging and Physical Activity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nReason: Without access to databases or publications to confirm specific titles and publication details, the veracity of the listed studies and their publishing journals cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 722,
    "user_query": "Which is the database of molecular recognition features in membrane proteins?",
    "llama-2-7b-chat-hf_response": "There are several databases of molecular recognition features in membrane proteins, but some of the most well-known and widely used include:\n1. The Membrane Protein Database (MPD): This database contains a collection of structurally and functionally annotated membrane proteins, including their sequences, structures, and functional information.\n2. The Protein Data Bank (PDB): This database contains a large collection of 3D structures of proteins, including membrane proteins, and their complexes with ligands and other molecules.\n3. The Membrane Protein Structural Alignment (MPSA): This database provides a collection of aligned structures of membrane proteins, allowing for the comparison of their structural features and the identification of conserved regions.\n4. The Membrane Protein Interaction Database (MPI): This database contains information on the interactions between membrane proteins and other molecules, including ligands, other proteins, and small molecules.\n5. The Membrane Protein Functional Site Database (MPFSD): This database provides information on the functional sites of membrane proteins, including their binding sites, active sites, and other functional regions.\n6. The Membrane Protein-Ligand Interaction Database (MPLID): This database contains information on the interactions between membrane proteins and their ligands, including the binding affinity and specificity of these interactions.\n7. The Membrane Protein-Protein Interaction Database (MPPI): This database provides information on the interactions between membrane proteins and other proteins, including their binding affinity and specificity.\n8. The Membrane Protein-Nucleic Acid Interaction Database (MPNA): This database contains information on the interactions between membrane proteins and nucleic acids, including their binding affinity and specificity.\n9. The Membrane Protein-Small Molecule Interaction Database (MPSMI): This database provides information on the interactions between membrane proteins and small molecules, including their binding affinity and specificity.\n10. The Membrane Protein-Drug Interaction Database (MPDI): This database contains information on the interactions between membrane proteins and drugs, including their binding affinity and specificity.\nThese databases are valuable resources for understanding the structure and function of memb",
    "llama-2-7b-chat-hf_fact_raw": "1. The Membrane Protein Database (MPD) contains structurally and functionally annotated membrane proteins, sequences, structures, and functional information.\n2. The Protein Data Bank (PDB) includes a collection of 3D structures of proteins, such as membrane proteins and complexes with ligands and other molecules.\n3. The Membrane Protein Structural Alignment (MPSA) database provides aligned structures of membrane proteins for structural feature comparison and conserved region identification.\n4. The Membrane Protein Interaction Database (MPI) contains information on interactions between membrane proteins and other molecules like ligands and small molecules.\n5. The Membrane Protein Functional Site Database (MPFSD) offers information on functional sites of membrane proteins, including binding sites and active sites.",
    "llama-2-7b-chat-hf_fact": [
      "The Membrane Protein Database (MPD) contains structurally and functionally annotated membrane proteins, sequences, structures, and functional information.",
      "The Protein Data Bank (PDB) includes a collection of 3D structures of proteins, such as membrane proteins and complexes with ligands and other molecules.",
      "The Membrane Protein Structural Alignment (MPSA) database provides aligned structures of membrane proteins for structural feature comparison and conserved region identification.",
      "The Membrane Protein Interaction Database (MPI) contains information on interactions between membrane proteins and other molecules like ligands and small molecules.",
      "The Membrane Protein Functional Site Database (MPFSD) offers information on functional sites of membrane proteins, including binding sites and active sites."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN (The statement sounds plausible, but without specific information about the MPSA database, I cannot verify its accuracy.)\n4. FALSE [correction]: There is no widely recognized database known as the Membrane Protein Interaction Database (MPI); instead, protein interactions are often found in databases like the BioGRID or IntAct.\n5. UNKNOWN (The statement sounds plausible, but without specific information about the MPFSD, I cannot verify its accuracy.)",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 745,
    "user_query": "Is rivaroxaban metabolized in kidneys?",
    "llama-2-7b-chat-hf_response": "Yes, rivaroxaban is metabolized in the kidneys. Rivaroxaban is primarily metabolized by the liver and kidneys, with the liver being the primary site of metabolism. The kidneys play a secondary role in metabolizing rivaroxaban, converting it into inactive metabolites that are then eliminated from the body.",
    "llama-2-7b-chat-hf_fact_raw": "1. Rivaroxaban is metabolized in the kidneys.\n2. The liver is the primary site of metabolism for rivaroxaban.\n3. The kidneys convert rivaroxaban into inactive metabolites.",
    "llama-2-7b-chat-hf_fact": [
      "Rivaroxaban is metabolized in the kidneys.",
      "The liver is the primary site of metabolism for rivaroxaban.",
      "The kidneys convert rivaroxaban into inactive metabolites."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Rivaroxaban is primarily metabolized in the liver.\n2. TRUE\n3. FALSE [correction]: While the kidneys do excrete rivaroxaban and its metabolites, it is the liver that is responsible for converting rivaroxaban into inactive metabolites.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 763,
    "user_query": "Which genes are regulated by TRalpha2  in the heart?",
    "llama-2-7b-chat-hf_response": "TRα2 regulates the expression of several genes in the heart, including:\n1. ANF (α-myosin heavy chain): TRα2 binds to the ANF promoter and enhances its activity, leading to increased cardiac myosin heavy chain expression and contractility.\n2. BNP (brain natriuretic peptide): TRα2 inhibits the expression of BNP, a hormone involved in cardiac remodeling and failure.\n3. CAV1 (caveolin-1): TRα2 regulates the expression of CAV1, a protein involved in cardiac ion channels and contraction.\n4. GATA4 (GATA-binding protein 4): TRα2 regulates the expression of GATA4, a transcription factor involved in cardiac development and differentiation.\n5. Mef2c (myocyte-specific enhancer factor 2C): TRα2 regulates the expression of Mef2c, a transcription factor involved in cardiac hypertrophy and adaptation.\n6. NFATc3 (nuclear factor of activated T cells 3): TRα2 regulates the expression of NFATc3, a transcription factor involved in T cell activation and cardiac hypertrophy.\n7. TNNI3 (troponin I3): TRα2 regulates the expression of TNNI3, a protein involved in cardiac contractility and relaxation.\n8. TNNT2 (troponin T2): TRα2 regulates the expression of TNNT2, a protein involved in cardiac contractility and relaxation.\nThese genes are regulated by TRα2 in the heart, and their dysregulation can lead to various cardiac diseases, including hypertension, heart failure, and arrhythmias.",
    "llama-2-7b-chat-hf_fact_raw": "1. TRα2 binds to the ANF promoter to enhance its activity in the heart.\n2. TRα2 inhibits the expression of BNP in the heart.\n3. TRα2 regulates the expression of CAV1 in the heart.\n4. TRα2 regulates the expression of GATA4 in the heart.\n5. TRα2 regulates the expression of Mef2c in the heart.",
    "llama-2-7b-chat-hf_fact": [
      "TRα2 binds to the ANF promoter to enhance its activity in the heart.",
      "TRα2 inhibits the expression of BNP in the heart.",
      "TRα2 regulates the expression of CAV1 in the heart.",
      "TRα2 regulates the expression of GATA4 in the heart.",
      "TRα2 regulates the expression of Mef2c in the heart."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nMy response is \"UNKNOWN\" for all statements as the specific effects of TRα2, or any transcription factor, on the promoters of ANF (Atrial Natriuretic Factor), BNP (B-type Natriuretic Peptide), CAV1 (Caveolin 1), GATA4 (GATA Binding Protein 4), and Mef2c (Myocyte Enhancer Factor 2C) are highly specific scientific claims that require direct evidence from scientific research. Without access to the specific studies or literature that investigates the relationship between TRα2 and these genes in the heart, it is impossible for me to confirm or correct these statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 786,
    "user_query": "List available biomedical question answering systems.",
    "llama-2-7b-chat-hf_response": "There are several biomedical question answering systems available, including:\n1. PubMed Central's \"Ask a Biologist\": This system allows users to ask questions related to biology and medicine and receive answers from a community of scientists and experts.\n2. IBM's Watson for Oncology: This system uses natural language processing and machine learning to answer questions related to cancer diagnosis and treatment.\n3. The Biomedical Informatics Research Laboratory's \"BioQA\": This system is a comprehensive biomedical question answering system that can answer questions on a wide range of topics, including genetics, proteomics, and drug discovery.\n4. The National Center for Biotechnology Information's (NCBI) \"Bookshelf\": This system provides access to a collection of biomedical books and other resources, including a question answering feature that allows users to ask and answer questions on various biomedical topics.\n5. The Biomedical Information and Technology Initiative's (BITI) \"BioQA\": This system is a web-based question answering system that can answer questions on a wide range of biomedical topics, including genetics, proteomics, and drug discovery.\n6. The University of California, San Diego's \"BioQuestions\": This system is a web-based question answering system that can answer questions on a wide range of biomedical topics, including genetics, proteomics, and drug discovery.\n7. The University of Texas Southwestern Medical Center's \"UTSW BioQA\": This system is a web-based question answering system that can answer questions on a wide range of biomedical topics, including genetics, proteomics, and drug discovery.\n8. The University of Pennsylvania's \"Penn BioQA\": This system is a web-based question answering system that can answer questions on a wide range of biomedical topics, including genetics, proteomics, and drug discovery.\n9. The University of California, Los Angeles's \"UCLA BioQA\": This system is a web-based question answering system that can answer questions on a wide range of biomedical topics, including genetics, proteomics, and drug discovery.\n10. The University of California, San Francisco's \"UCSF BioQA\": This system is a web",
    "llama-2-7b-chat-hf_fact_raw": "1. PubMed Central offers a system called \"Ask a Biologist\" which provides answers to biology and medicine related questions from experts.\n2. IBM's Watson for Oncology uses natural language processing and machine learning to respond to queries about cancer diagnosis and treatment.\n3. The Biomedical Informatics Research Laboratory has developed \"BioQA,\" a biomedical question answering system.\n4. The National Center for Biotechnology Information (NCBI) provides a question answering feature within its \"Bookshelf\" collection of biomedical resources.\n5. The University of Texas Southwestern Medical Center offers the \"UTSW BioQA,\" a web-based question answering system for a variety of biomedical topics.",
    "llama-2-7b-chat-hf_fact": [
      "PubMed Central offers a system called \"Ask a Biologist\" which provides answers to biology and medicine related questions from experts.",
      "IBM's Watson for Oncology uses natural language processing and machine learning to respond to queries about cancer diagnosis and treatment.",
      "The Biomedical Informatics Research Laboratory has developed \"BioQA,\" a biomedical question answering system.",
      "The National Center for Biotechnology Information (NCBI) provides a question answering feature within its \"Bookshelf\" collection of biomedical resources.",
      "The University of Texas Southwestern Medical Center offers the \"UTSW BioQA,\" a web-based question answering system for a variety of biomedical topics."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: PubMed Central is a free full-text archive of biomedical and life sciences journal literature, but it does not offer a system called \"Ask a Biologist.\" The \"Ask A Biologist\" service is provided by Arizona State University, not PubMed Central.\n2. TRUE\n3. UNKNOWN: Without additional context or information, it is unclear whether the Biomedical Informatics Research Laboratory has developed such a system named \"BioQA.\" \"BioQA\" could refer to general biomedical question answering systems, but the statement is too vague to determine its accuracy.\n4. FALSE [correction]: The National Center for Biotechnology Information (NCBI) provides a \"Bookshelf\" collection of biomedical books and documents, but it does not offer a question answering feature within this collection.\n5. UNKNOWN: Without more specific information, it's not possible to verify whether the University of Texas Southwestern Medical Center offers a \"UTSW BioQA\" or what the features of such a system might be. It would require research or confirmation from the institution itself.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 794,
    "user_query": "Which trancription factor activates the betalain pathway?",
    "llama-2-7b-chat-hf_response": "The transcription factor that activates the bethanechol pathway is ABSCISIC ACID INSENSITIVE 3 (ABI3).",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 883,
    "user_query": "Global quantitative phosphoproteomic analyses are emerging. List the preferred technologies for the enrichment for phosphorylated peptides?",
    "llama-2-7b-chat-hf_response": "There are several technologies that are commonly used for enriching phosphorylated peptides in global quantitative phosphoproteomic analyses. Here are some of the preferred technologies:\n1. TiO2-based enrichment: This method uses titanium dioxide (TiO2) to selectively capture phosphorylated peptides based on their negative charge. The sample is incubated with TiO2 beads, which bind to the phosphate groups on the peptides, resulting in their enrichment.\n2. IMAC (immunomagnetic bead) purification: This method uses magnetic beads coated with anti-phosphotyrosine antibodies to isolate phosphorylated peptides. The sample is incubated with the beads, which bind to the phosphorylated peptides, and then the beads are magnetically separated from the rest of the sample.\n3. RESOURCE (rapid enrichment of phosphorylated peptides using immobilized reagents): This method uses a combination of TiO2 beads and a specific reagent, such as a phosphotyrosine antibody, to enrich for phosphorylated peptides. The sample is incubated with the beads and reagent, which bind to the phosphorylated peptides, resulting in their enrichment.\n4. Blue-native PAGE (BN-PAGE): This method uses a specialized gel system that separates proteins based on their size and phosphorylation state. The sample is separated on a gel, and then the phosphorylated proteins are visualized and isolated using a specific reagent.\n5. Pro-Q Diamond: This method uses a fluorescent dye that selectively binds to phosphorylated peptides, allowing for their visualization and isolation. The sample is incubated with the dye, and then the phosphorylated peptides are isolated using a specific reagent.\n6. MALDI-TOF (matrix-assisted laser desorption/ionization time-of-flight) mass spectrometry: This method uses a combination of a matrix and a laser to ionize and detect phosph",
    "llama-2-7b-chat-hf_fact_raw": "1. TiO2-based enrichment uses titanium dioxide to capture phosphorylated peptides based on their negative charge.\n2. IMAC purification uses magnetic beads coated with anti-phosphotyrosine antibodies to isolate phosphorylated peptides.\n3. RESOURCE method combines TiO2 beads and a phosphotyrosine antibody to enrich for phosphorylated peptides.\n4. Blue-native PAGE separates proteins by size and phosphorylation state, allowing for the isolation of phosphorylated proteins.\n5. Pro-Q Diamond uses a fluorescent dye that selectively binds to phosphorylated peptides for their visualization and isolation.",
    "llama-2-7b-chat-hf_fact": [
      "TiO2-based enrichment uses titanium dioxide to capture phosphorylated peptides based on their negative charge.",
      "IMAC purification uses magnetic beads coated with anti-phosphotyrosine antibodies to isolate phosphorylated peptides.",
      "RESOURCE method combines TiO2 beads and a phosphotyrosine antibody to enrich for phosphorylated peptides.",
      "Blue-native PAGE separates proteins by size and phosphorylation state, allowing for the isolation of phosphorylated proteins.",
      "Pro-Q Diamond uses a fluorescent dye that selectively binds to phosphorylated peptides for their visualization and isolation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Titanium dioxide (TiO2) is indeed used to capture phosphorylated peptides based on their affinity for metal oxides and the negative charge of the phosphate group.\n2. FALSE [correction]: IMAC (Immobilized Metal Affinity Chromatography) purification uses metal ions, such as iron or gallium, not magnetic beads coated with anti-phosphotyrosine antibodies, to isolate phosphorylated peptides. The metal ions chelated to a matrix like nitrilotriacetic acid (NTA) capture phosphorylated peptides based on their affinity for metal ions.\n3. UNKNOWN: The RESOURCE method mentioned is not a well-established or widely recognized protocol in the context of phosphoprotein and phosphopeptide enrichment. Therefore, without additional context or detail, the truth of this statement cannot be determined.\n4. FALSE [correction]: Blue-native PAGE is an electrophoresis technique that separates proteins based on their size and native state, not specifically by phosphorylation state, although it can be combined with other techniques to analyze phosphorylation.\n5. TRUE: Pro-Q Diamond is a fluorescent stain that selectively binds to phosphorylated serine, threonine, and tyrosine residues in proteins, allowing for their visualization in gels. It is used to stain proteins in gel or blot format for subsequent isolation or analysis.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 901,
    "user_query": "Which disorder is rated by Palmini classification?",
    "llama-2-7b-chat-hf_response": "Palmini classification is used to rate the severity of intellectual disability. It categorizes intellectual disability into different levels of severity, ranging from mild to severe.",
    "llama-2-7b-chat-hf_fact_raw": "1. Palmini classification is used for rating the severity of intellectual disability.\n2. Palmini classification divides intellectual disability into levels of severity.",
    "llama-2-7b-chat-hf_fact": [
      "Palmini classification is used for rating the severity of intellectual disability.",
      "Palmini classification divides intellectual disability into levels of severity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Palmini classification is used for categorizing different types of seizures, particularly focal seizures, not for rating the severity of intellectual disability.\n2. FALSE [correction]: The severity of intellectual disability is generally categorized into levels such as mild, moderate, severe, and profound, but this classification does not pertain to Palmini classification, which is related to epilepsy.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false"
    ]
  },
  {
    "id": 905,
    "user_query": "Are viruses involved in the etiology of human subacute thyroiditis?",
    "llama-2-7b-chat-hf_response": "Yes, some viruses have been implicated in the etiology of human subacute thyroiditis. Subacute thyroiditis is an inflammatory condition that affects the thyroid gland and can cause thyroid hormone imbalances. While the exact cause of subacute thyroiditis is not fully understood, some viral infections have been linked to the development of the condition.\nSome viruses that have been associated with subacute thyroiditis include:\n1. Viruses of the enterovirus genus: Enteroviruses are common viruses that can cause a range of illnesses, including subacute thyroiditis. Studies have shown that enteroviruses can infect the thyroid gland and trigger an immune response that leads to inflammation and thyroid dysfunction.\n2. Herpesviruses: Herpesviruses, such as herpes simplex virus (HSV) and human herpesvirus 6 (HHV-6), have also been linked to subacute thyroiditis. HSV has been shown to infect the thyroid gland and cause inflammation, while HHV-6 has been associated with thyroiditis in some studies.\n3. Adenoviruses: Adenoviruses are another type of virus that has been implicated in the development of subacute thyroiditis. Adenovirus infection of the thyroid gland can lead to inflammation and thyroid dysfunction.\n4. Respiratory syncytial virus (RSV): RSV is a common virus that affects the respiratory system and can cause lower respiratory tract infections. Some studies have suggested that RSV may also play a role in the development of subacute thyroiditis.\nIt's important to note that not everyone who develops subacute thyroiditis will have a viral infection, and the condition can also be caused by other factors, such as autoimmune disorders or exposure to certain medications. However, viral infections are a common trigger for subacute thyroiditis, and identifying the underlying cause of the condition can help guide treatment and management.",
    "llama-2-7b-chat-hf_fact_raw": "1. Subacute thyroiditis is an inflammatory condition that affects the thyroid gland and can cause thyroid hormone imbalances.\n2. Some viral infections have been linked to the development of subacute thyroiditis.\n3. Enteroviruses can infect the thyroid gland and may trigger an immune response leading to inflammation and thyroid dysfunction, implicating them in subacute thyroiditis.\n4. Herpes simplex virus (HSV) and human herpesvirus 6 (HHV-6) have been linked to subacute thyroiditis, with HSV shown to infect the thyroid gland and cause inflammation.\n5. Adenoviruses and Respiratory syncytial virus (RSV) have been implicated in the development of subacute thyroiditis.",
    "llama-2-7b-chat-hf_fact": [
      "Subacute thyroiditis is an inflammatory condition that affects the thyroid gland and can cause thyroid hormone imbalances.",
      "Some viral infections have been linked to the development of subacute thyroiditis.",
      "Enteroviruses can infect the thyroid gland and may trigger an immune response leading to inflammation and thyroid dysfunction, implicating them in subacute thyroiditis.",
      "Herpes simplex virus (HSV) and human herpesvirus 6 (HHV-6) have been linked to subacute thyroiditis, with HSV shown to infect the thyroid gland and cause inflammation.",
      "Adenoviruses and Respiratory syncytial virus (RSV) have been implicated in the development of subacute thyroiditis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: While enteroviruses can cause various infections, there is no strong evidence to implicate them specifically in subacute thyroiditis.\n4. FALSE [correction]: It is not well-established that HSV and HHV-6 have been linked to subacute thyroiditis; this claim lacks strong scientific support.\n5. FALSE [correction]: There is limited evidence that specifically connects adenoviruses and RSV to the development of subacute thyroiditis, and such claims would require more scientific validation.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 963,
    "user_query": "Is STAT3 involved in EIF2AK2-dependent suppression of autophagy?",
    "llama-2-7b-chat-hf_response": "Yes, STAT3 (Signal Transducer and Activator of Transcription 3) is involved in EIF2AK2-dependent suppression of autophagy. EIF2AK2 (Eukaryotic Initiation Factor 2-Associated Kinase 2) is a kinase that phosphorylates and inhibits the translation initiation factor eIF2α, leading to suppression of global protein synthesis and induction of autophagy. STAT3 is a transcription factor that regulates the expression of genes involved in various cellular processes, including autophagy. Studies have shown that STAT3 is activated downstream of EIF2AK2 and plays a role in the regulation of autophagy under conditions of cellular stress, such as during cancer development and progression.",
    "llama-2-7b-chat-hf_fact_raw": "1. STAT3 (Signal Transducer and Activator of Transcription 3) is involved in EIF2AK2-dependent suppression of autophagy.\n2. EIF2AK2 (Eukaryotic Initiation Factor 2-Associated Kinase 2) phosphorylates and inhibits the translation initiation factor eIF2α.\n3. The phosphorylation of eIF2α leads to suppression of global protein synthesis and induction of autophagy.\n4. STAT3 is a transcription factor that regulates the expression of genes involved in various cellular processes, including autophagy.\n5. Studies have shown that STAT3 is activated downstream of EIF2AK2 and regulates autophagy in conditions of cellular stress.",
    "llama-2-7b-chat-hf_fact": [
      "STAT3 (Signal Transducer and Activator of Transcription 3) is involved in EIF2AK2-dependent suppression of autophagy.",
      "EIF2AK2 (Eukaryotic Initiation Factor 2-Associated Kinase 2) phosphorylates and inhibits the translation initiation factor eIF2α.",
      "The phosphorylation of eIF2α leads to suppression of global protein synthesis and induction of autophagy.",
      "STAT3 is a transcription factor that regulates the expression of genes involved in various cellular processes, including autophagy.",
      "Studies have shown that STAT3 is activated downstream of EIF2AK2 and regulates autophagy in conditions of cellular stress."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nThe specification of EIF2AK2's role in STAT3-dependent suppression or activation of autophagy is complex and can be context-dependent. A detailed review of the biomedical literature would be necessary to confirm the accuracy of statement 1. Similarly, for statement 5, whether STAT3 is activated downstream of EIF2AK2 and how it regulates autophagy could require specific evidence from scientific studies, which is not provided in the current context.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 973,
    "user_query": "Describe what is the usage of the Theatre software tool for genomic analysis.",
    "llama-2-7b-chat-hf_response": "Theatre is a software tool used for genomic analysis, particularly for the analysis of genomic variation data. It is designed to be used in conjunction with the BAM (Binary Alignment/Map) format, which is a common format for storing genomic sequencing data.\nTheatre can be used for a variety of genomic analysis tasks, including:\n1. Genome assembly: Theatre can be used to assemble genomes from DNA sequencing data, by aligning the sequencing reads to a reference genome and reconstructing the original DNA sequence.\n2. Variant calling: Theatre can be used to identify genetic variants (such as single nucleotide polymorphisms, insertions, deletions, and copy number variations) in a genome by aligning the sequencing reads to the reference genome and identifying differences between the two.\n3. Genome mapping: Theatre can be used to map sequencing reads to a reference genome, allowing researchers to identify which regions of the genome are covered by the sequencing data.\n4. Transcriptome analysis: Theatre can be used to analyze the transcriptome (the set of RNA molecules present in a cell or organism) by aligning RNA-seq reads to a reference genome or transcriptome.\n5. Epigenomics analysis: Theatre can be used to analyze epigenetic marks (such as DNA methylation and histone modifications) by aligning sequencing reads to a reference genome and identifying differences in the epigenetic marks between different regions of the genome.\n6. Methylation analysis: Theatre can be used to analyze DNA methylation patterns in a genome by aligning sequencing reads to a reference genome and identifying differences in methylation levels between different regions of the genome.\n7. ChIP-seq analysis: Theatre can be used to analyze ChIP-seq data (which is used to identify protein-DNA interactions) by aligning sequencing reads to a reference genome and identifying regions of the genome where a particular protein is bound.\n8. Genome-wide association studies (GWAS): Theatre can be used to identify genetic variants associated with a particular disease or trait by analyzing genome-wide variation data.\nOverall, Theatre is a powerful tool for genomic analysis, allowing researchers to align sequencing reads to a reference genome",
    "llama-2-7b-chat-hf_fact_raw": "1. Theatre is a software tool used for genomic analysis, particularly for the analysis of genomic variation data.\n2. Theatre is designed to work with BAM (Binary Alignment/Map) format, which is a common format for storing genomic sequencing data.\n3. Theatre can assemble genomes from DNA sequencing data by aligning sequencing reads to a reference genome.\n4. Theatre can be used to call variants, which includes identifying single nucleotide polymorphisms, insertions, deletions, and copy number variations.\n5. Theatre can perform epigenomics analysis by identifying differences in epigenetic marks such as DNA methylation and histone modifications.",
    "llama-2-7b-chat-hf_fact": [
      "Theatre is a software tool used for genomic analysis, particularly for the analysis of genomic variation data.",
      "Theatre is designed to work with BAM (Binary Alignment/Map) format, which is a common format for storing genomic sequencing data.",
      "Theatre can assemble genomes from DNA sequencing data by aligning sequencing reads to a reference genome.",
      "Theatre can be used to call variants, which includes identifying single nucleotide polymorphisms, insertions, deletions, and copy number variations.",
      "Theatre can perform epigenomics analysis by identifying differences in epigenetic marks such as DNA methylation and histone modifications."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The statement is too vague to be corrected accurately without specific knowledge about a software tool named \"Theatre\". If \"Theatre\" is a hypothetical or a proprietary tool not widely recognized in the genomic community, it's impossible to validate this claim. In general, common software tools used for genomic analysis include names like Galaxy, IGV, GATK, and others.\n2. UNKNOWN: The use of BAM format is common in genomic analysis software, but without specific knowledge of \"Theatre,\" it's impossible to confirm if it supports this format.\n3. UNKNOWN: Assembling genomes from DNA sequencing data is a common feature of genomic analysis software. However, without specific information about \"Theatre,\" it cannot be confirmed if it has this capability.\n4. UNKNOWN: Calling variants, including detecting single nucleotide polymorphisms (SNPs), insertions, deletions (indels), and copy number variations (CNVs), is a typical function in genomic analysis tools. Without concrete information about \"Theatre,\" the capability cannot be confirmed.\n5. UNKNOWN: Epigenomics analysis is a specialized area within genomics, and some tools have this capability. However, without more information on \"Theatre,\" whether it can perform such analysis is indeterminable.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 997,
    "user_query": "Which  is the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences",
    "llama-2-7b-chat-hf_response": "The execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences depends on the length of the sequences and the type of comparison being made.\nFor the basic Smith-Waterman algorithm, the time complexity is O(n^2), where n is the length of the shorter sequence. This is because the algorithm needs to compare each element of the shorter sequence with every element of the longer sequence, resulting in a total of n^2 comparisons.\nHowever, there are several variations of the Smith-Waterman algorithm that have different time complexities:\n* The Needleman-Wunsch algorithm, which is a variation of the Smith-Waterman algorithm that uses a different scoring function, has a time complexity of O(n log n).\n* The global Smith-Waterman algorithm, which is a variation of the Smith-Waterman algorithm that uses a global alignment strategy, has a time complexity of O(n^3).\n* The parallel Smith-Waterman algorithm, which is a variation of the Smith-Waterman algorithm that uses parallel processing to speed up the computation, has a time complexity of O(n^2 parallel operations).\nIt's worth noting that these time complexities are approximate and can vary depending on the specific implementation and the input sequences.",
    "llama-2-7b-chat-hf_fact_raw": "1. The basic Smith-Waterman algorithm has a time complexity of O(n^2), where n is the length of the shorter sequence.\n2. The Needleman-Wunsch algorithm, a variation of the Smith-Waterman algorithm, has a time complexity of O(n log n).\n3. The global Smith-Waterman algorithm has a time complexity of O(n^3).\n4. The parallel Smith-Waterman algorithm has a time complexity of O(n^2 parallel operations).\n5. The execution time (complexity) for the Smith-Waterman algorithm depends on the length of the sequences and the type of comparison being made.",
    "llama-2-7b-chat-hf_fact": [
      "The basic Smith-Waterman algorithm has a time complexity of O(n^2), where n is the length of the shorter sequence.",
      "The Needleman-Wunsch algorithm, a variation of the Smith-Waterman algorithm, has a time complexity of O(n log n).",
      "The global Smith-Waterman algorithm has a time complexity of O(n^3).",
      "The parallel Smith-Waterman algorithm has a time complexity of O(n^2 parallel operations).",
      "The execution time (complexity) for the Smith-Waterman algorithm depends on the length of the sequences and the type of comparison being made."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The Needleman-Wunsch algorithm, like the basic Smith-Waterman algorithm, also has a time complexity of O(n^2), where n is the length of the sequences being aligned.\n3. FALSE [correction]: There is no \"global Smith-Waterman algorithm.\" The Smith-Waterman algorithm is used for local sequence alignment, whereas the global alignment equivalent is the Needleman-Wunsch algorithm.\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1004,
    "user_query": "Which SLC family is FLVCR1 a member of?",
    "llama-2-7b-chat-hf_response": "FLVCR1 is a member of the solute carrier (SLC) family of transmembrane transporters. Specifically, it is a member of the SLC12A family, which is also known as the hydroxyl-carboxylate carrier family.",
    "llama-2-7b-chat-hf_fact_raw": "1. FLVCR1 is a member of the solute carrier (SLC) family of transmembrane transporters.\n2. FLVCR1 belongs to the SLC12A family.\n3. The SLC12A family is also known as the hydroxyl-carboxylate carrier family.",
    "llama-2-7b-chat-hf_fact": [
      "FLVCR1 is a member of the solute carrier (SLC) family of transmembrane transporters.",
      "FLVCR1 belongs to the SLC12A family.",
      "The SLC12A family is also known as the hydroxyl-carboxylate carrier family."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: FLVCR1 belongs to the SLC19 family, not the SLC12A family.\n3. FALSE [correction]: The SLC12A family is also known as the cation-chloride cotransporter family, not the hydroxyl-carboxylate carrier family.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 1047,
    "user_query": "List GATA-1 interacting partners as discovered with the help of the biotinylation tagging approach.",
    "llama-2-7b-chat-hf_response": "GATA-1 is a transcription factor that plays a crucial role in regulating gene expression in hematopoietic cells. The biotinylation tagging approach has been used to identify GATA-1 interacting partners. Some of the known interacting partners of GATA-1 include:\n1. BCL-6: GATA-1 and BCL-6 are transcription factors that are important for the regulation of immune cell differentiation and function. They interact directly and cooperatively regulate the expression of multiple genes involved in these processes.\n2. CBX3: CBX3 is a chromodomain-containing protein that is involved in the regulation of gene expression, particularly in the context of hematopoiesis. GATA-1 and CBX3 interact directly and cooperatively regulate the expression of genes involved in erythropoiesis.\n3. KAT2A: KAT2A is a histone acetyltransferase that is involved in the regulation of chromatin structure and gene expression. GATA-1 and KAT2A interact directly and cooperatively regulate the expression of genes involved in hematopoiesis.\n4. PPARγ: PPARγ is a nuclear receptor that is involved in the regulation of glucose metabolism and adipocyte differentiation. GATA-1 and PPARγ interact indirectly, with GATA-1 regulating the expression of genes involved in glucose metabolism and PPARγ regulating the expression of genes involved in adipocyte differentiation.\n5. TFAP2A: TFAP2A is a transcription factor that is involved in the regulation of gene expression in various cell types, including hematopoietic cells. GATA-1 and TFAP2A interact directly and cooperatively regulate the expression of genes involved in hematopoiesis.\n6. TFAP2C: TFAP2C is a transcription factor that is involved in the regulation of gene expression in various cell types, including hematopoietic cells. GATA-1 and TFAP2C interact directly and cooperatively regulate the expression of genes involved in hematopoiesis.\n7. TAL1: TAL1 is a trans",
    "llama-2-7b-chat-hf_fact_raw": "1. BCL-6 is an interacting partner of GATA-1 and they are both important for the regulation of immune cell differentiation and function.\n2. CBX3 interacts directly with GATA-1 and cooperatively regulates the expression of genes involved in erythropoiesis.\n3. KAT2A is a histone acetyltransferase that interacts directly with GATA-1 and is involved in the regulation of genes involved in hematopoiesis.\n4. GATA-1 and PPARγ interact indirectly with GATA-1 regulating genes involved in glucose metabolism and PPARγ in adipocyte differentiation.\n5. TFAP2A is a transcription factor that interacts directly with GATA-1 and is involved in the cooperative regulation of gene expression in hematopoietic cells.",
    "llama-2-7b-chat-hf_fact": [
      "BCL-6 is an interacting partner of GATA-1 and they are both important for the regulation of immune cell differentiation and function.",
      "CBX3 interacts directly with GATA-1 and cooperatively regulates the expression of genes involved in erythropoiesis.",
      "KAT2A is a histone acetyltransferase that interacts directly with GATA-1 and is involved in the regulation of genes involved in hematopoiesis.",
      "GATA-1 and PPARγ interact indirectly with GATA-1 regulating genes involved in glucose metabolism and PPARγ in adipocyte differentiation.",
      "TFAP2A is a transcription factor that interacts directly with GATA-1 and is involved in the cooperative regulation of gene expression in hematopoietic cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: BCL-6 is not reported as an interacting partner of GATA-1. BCL-6 is a transcriptional repressor that plays a role in immune cell differentiation, but it is not commonly known to interact with GATA-1, which is a transcription factor important in the differentiation of erythroid cells.\n\n2. UNKNOWN: The interaction between CBX3 and GATA-1 and their cooperative regulation of erythropoiesis is not widely established in the literature as of the knowledge cutoff date. Thus, without specific evidence, the veracity of this statement cannot be determined.\n\n3. TRUE: KAT2A, also known as GCN5, is a histone acetyltransferase that can interact with GATA-1. It's involved in the regulation of genes during hematopoiesis, particularly in the context of erythropoiesis.\n\n4. FALSE [correction]: This statement is not entirely accurate because it contains contradictory information. It says \"GATA-1 and PPARγ interact indirectly with GATA-1,\" which doesn't make sense as GATA-1 cannot interact with itself. PPARγ is involved in adipocyte differentiation, but whether it interacts directly or indirectly with GATA-1 is not well-established.\n\n5. UNKNOWN: TFAP2A, or transcription factor AP-2 alpha, is a transcription factor that has roles in development and differentiation but its direct interaction with GATA-1 in hematopoietic cells and cooperative regulation of gene expression is not well-documented in the literature. Without specific evidence, the accuracy of this statement remains unknown.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1072,
    "user_query": "What is the outcome of TAF10 interacting with the GATA1 transcription factor?",
    "llama-2-7b-chat-hf_response": "TAF10 (TATA-binding protein-associated factor 10) interacts with the GATA1 (GATA-binding protein 1) transcription factor to regulate the expression of genes involved in erythroid cell development. The interaction between TAF10 and GATA1 leads to the recruitment of RNA polymerase II to the promoter region of target genes, which are involved in the final stages of erythropoiesis, including the synthesis of hemoglobin and other erythrocyte-specific proteins. This outcome is crucial for the proper differentiation and maturation of red blood cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. TAF10 (TATA-binding protein-associated factor 10) interacts with GATA1 (GATA-binding protein 1) transcription factor.\n2. The interaction between TAF10 and GATA1 regulates gene expression involved in erythroid cell development.\n3. This interaction leads to the recruitment of RNA polymerase II to the promoter region of target genes.\n4. The target genes affected by the TAF10-GATA1 interaction are involved in the final stages of erythropoiesis.\n5. The outcome of the TAF10-GATA1 interaction includes the synthesis of hemoglobin and other erythrocyte-specific proteins.",
    "llama-2-7b-chat-hf_fact": [
      "TAF10 (TATA-binding protein-associated factor 10) interacts with GATA1 (GATA-binding protein 1) transcription factor.",
      "The interaction between TAF10 and GATA1 regulates gene expression involved in erythroid cell development.",
      "This interaction leads to the recruitment of RNA polymerase II to the promoter region of target genes.",
      "The target genes affected by the TAF10-GATA1 interaction are involved in the final stages of erythropoiesis.",
      "The outcome of the TAF10-GATA1 interaction includes the synthesis of hemoglobin and other erythrocyte-specific proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: TAF10 does interact with various transcription factors, including GATA1 according to scientific literature.\n2. TRUE: This interaction is known to regulate gene expression in erythroid cells, which are involved in the development of red blood cells.\n3. TRUE: Recruitment of RNA polymerase II to the promoter region of genes is a common mechanism by which transcription factors like GATA1 regulate gene expression.\n4. UNKNOWN: Without specific references, it's difficult to determine the exact target genes affected by the TAF10-GATA1 interaction or the stages of erythropoiesis they are involved in.\n5. TRUE: The stated outcome is consistent with the roles of GATA1 and its associated factors in regulating the expression of genes involved in erythrocyte differentiation and function, which includes the synthesis of hemoglobin and other erythrocyte-specific proteins.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1082,
    "user_query": "Are there any Decision support systems for chronic pain management ?",
    "llama-2-7b-chat-hf_response": "Yes, there are several decision support systems (DSS) available for chronic pain management. These systems are designed to help healthcare providers make informed decisions about the management of chronic pain, taking into account the patient's individual needs and medical history. Some of the key features of these systems include:\n1. Clinical decision support systems (CDSSs): These systems use algorithms and clinical guidelines to provide healthcare providers with recommendations for pain management based on the patient's medical history and current symptoms.\n2. Patient-facing decision support systems (PDSs): These systems provide patients with information and tools to help them make informed decisions about their pain management, such as pain assessment tools, treatment options, and pain management strategies.\n3. Telemedicine and remote monitoring systems: These systems allow healthcare providers to remotely monitor patients with chronic pain and provide real-time feedback and support.\n4. Artificial intelligence (AI) and machine learning (ML) systems: These systems use machine learning algorithms to analyze large datasets and provide personalized recommendations for pain management based on the patient's individual characteristics and treatment history.\n5. Integrated pain management platforms: These platforms bring together various tools and resources for chronic pain management, such as CDSSs, PDSs, and telemedicine systems, into a single, integrated system.\nSome examples of decision support systems for chronic pain management include:\n1. The Chronic Pain Management Decision Support System (CPMDSS): This system provides healthcare providers with evidence-based recommendations for pain management based on the patient's medical history and current symptoms.\n2. The Pain Management Collaborative (PMC): This system provides healthcare providers with a framework for multidisciplinary pain management, including clinical guidelines, treatment protocols, and quality improvement initiatives.\n3. The American Pain Society's Pain Management Consultation Tool (PMC-T): This system provides healthcare providers with a structured framework for pain management consultations, including assessment tools, treatment recommendations, and follow-up strategies.\n4. The National Pain Management Collaboratory's (NPMC) Pain Management Decision Support System (PMDSS): This system provides healthcare providers with evidence-",
    "llama-2-7b-chat-hf_fact_raw": "1. Decision support systems (DSS) are available for chronic pain management to assist healthcare providers.\n2. Clinical decision support systems (CDSSs) use algorithms and guidelines to offer recommendations for pain management based on patient's medical history and symptoms.\n3. Patient-facing decision support systems (PDSs) provide information and tools for patients to make decisions about their pain management.\n4. Telemedicine and remote monitoring systems allow healthcare providers to monitor patients with chronic pain remotely.\n5. Integrated pain management platforms combine various resources, such as CDSSs, PDSs, and telemedicine systems, into a single system.",
    "llama-2-7b-chat-hf_fact": [
      "Decision support systems (DSS) are available for chronic pain management to assist healthcare providers.",
      "Clinical decision support systems (CDSSs) use algorithms and guidelines to offer recommendations for pain management based on patient's medical history and symptoms.",
      "Patient-facing decision support systems (PDSs) provide information and tools for patients to make decisions about their pain management.",
      "Telemedicine and remote monitoring systems allow healthcare providers to monitor patients with chronic pain remotely.",
      "Integrated pain management platforms combine various resources, such as CDSSs, PDSs, and telemedicine systems, into a single system."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1149,
    "user_query": "Which is the subcellular localization of the protein angiogenin?",
    "llama-2-7b-chat-hf_response": "Angiogenin is a protein that is localized primarily in the cytoplasm and nucleus of cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. Angiogenin is a protein.\n2. Angiogenin is primarily localized in the cytoplasm of cells.\n3. Angiogenin is also found in the nucleus of cells.",
    "llama-2-7b-chat-hf_fact": [
      "Angiogenin is a protein.",
      "Angiogenin is primarily localized in the cytoplasm of cells.",
      "Angiogenin is also found in the nucleus of cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n\nAngiogenin is indeed a protein that is known to be involved in the process of angiogenesis. It is primarily localized in the cytoplasm of cells but is also known to translocate to the nucleus under certain cellular conditions.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1161,
    "user_query": "How does ranolazine affect kinase signaling activation in the heart?",
    "llama-2-7b-chat-hf_response": "Ranolazine is a drug that has been shown to inhibit the activation of kinase signaling pathways in the heart, particularly the Akt/PKB signaling pathway. Ranolazine works by blocking the activity of the enzyme ATP-dependent phosphate translocator (ANT), which is involved in the transport of phosphate groups from the cytosol to the membrane. This inhibition of ANT activity reduces the activation of Akt/PKB signaling pathway, which is involved in cell survival and metabolism. By inhibiting the activation of Akt/PKB signaling pathway, ranolazine can reduce the proliferation of cardiac cells and inhibit the development of heart failure.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ranolazine inhibits the activation of kinase signaling pathways in the heart.\n2. The Akt/PKB signaling pathway is one of the pathways affected by ranolazine.\n3. Ranolazine blocks the activity of the enzyme ATP-dependent phosphate translocator (ANT).\n4. ANT is involved in the transport of phosphate groups from the cytosol to the membrane.\n5. Inhibition of the Akt/PKB signaling pathway by ranolazine can reduce the proliferation of cardiac cells.",
    "llama-2-7b-chat-hf_fact": [
      "Ranolazine inhibits the activation of kinase signaling pathways in the heart.",
      "The Akt/PKB signaling pathway is one of the pathways affected by ranolazine.",
      "Ranolazine blocks the activity of the enzyme ATP-dependent phosphate translocator (ANT).",
      "ANT is involved in the transport of phosphate groups from the cytosol to the membrane.",
      "Inhibition of the Akt/PKB signaling pathway by ranolazine can reduce the proliferation of cardiac cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Ranolazine is primarily known for inhibiting the late sodium current (INa) in the heart, not for the activation of kinase signaling pathways.\n2. UNKNOWN: While ranolazine mainly affects the late sodium current, any direct effect on the Akt/PKB signaling pathway is not well-established and would require specific academic references to confirm.\n3. FALSE [correction]: Ranolazine inhibits the late sodium current (INa); it is not primarily known to block the activity of ATP-dependent phosphate translocators (ANT).\n4. FALSE [correction]: ANT (Adenine Nucleotide Translocator) is involved in the transport of ADP into the mitochondria and ATP out of the mitochondria, not specifically phosphate groups from the cytosol to the membrane.\n5. UNKNOWN: Without specific evidence or references, it is uncertain how the inhibition of Akt/PKB signaling pathway by ranolazine affects the proliferation of cardiac cells, or even if ranolazine directly inhibits this pathway.\n",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1225,
    "user_query": "Is the regulation of Vsr endonuclease independent of the growth phase of bacteria?",
    "llama-2-7b-chat-hf_response": "No, the regulation of Vsr endonuclease is not entirely independent of the growth phase of bacteria. While Vsr is induced in response to DNA damage and is active in both log and stationary phases of growth, the level of Vsr induction and activity can vary depending on the growth phase. For example, one study found that Vsr expression is higher in the stationary phase than in the log phase of growth, suggesting that the enzyme may play a role in the resolution of DNA damage that accumulates during cellular stress in the stationary phase.",
    "llama-2-7b-chat-hf_fact_raw": "1. The regulation of Vsr endonuclease is influenced by the growth phase of bacteria.\n2. Vsr endonuclease is induced in response to DNA damage.\n3. Vsr endonuclease is active in both log and stationary phases of bacterial growth.\n4. The induction and activity level of Vsr endonuclease can vary depending on the bacterial growth phase.\n5. A study found that Vsr expression is higher in the stationary phase than in the log phase.",
    "llama-2-7b-chat-hf_fact": [
      "The regulation of Vsr endonuclease is influenced by the growth phase of bacteria.",
      "Vsr endonuclease is induced in response to DNA damage.",
      "Vsr endonuclease is active in both log and stationary phases of bacterial growth.",
      "The induction and activity level of Vsr endonuclease can vary depending on the bacterial growth phase.",
      "A study found that Vsr expression is higher in the stationary phase than in the log phase."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nWithout a specific study to reference, it is impossible to confirm the accuracy of statement 5.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1233,
    "user_query": "What are the computational tools for the prediction of beta-barrel transmembrane proteins?",
    "llama-2-7b-chat-hf_response": "There are several computational tools available for the prediction of beta-barrel transmembrane proteins. Some of the commonly used tools include:\n1. TMHMM: A widely used tool for predicting the structure and function of transmembrane proteins. It uses a combination of sequence analysis and structure-based methods to predict the transmembrane helices and the orientation of the protein in the membrane.\n2. SignalP: A tool for predicting the presence and location of signal peptides in a protein sequence. Signal peptides are the regions of a protein that direct its transport across the membrane, and the prediction of these regions can help identify beta-barrel transmembrane proteins.\n3. PredictProtein: A tool that uses a combination of sequence analysis and machine learning algorithms to predict the structure and function of a protein. It can predict the transmembrane helices and the orientation of the protein in the membrane, as well as other features such as the presence of signal peptides and the location of the active site.\n4. TMGMM: A tool that uses a combination of sequence analysis and structure-based methods to predict the transmembrane helices and the orientation of the protein in the membrane. It also predicts the presence of potential membrane-spanning segments and the location of the active site.\n5. PHD: A tool that uses a combination of sequence analysis and machine learning algorithms to predict the structure and function of a protein. It can predict the transmembrane helices and the orientation of the protein in the membrane, as well as other features such as the presence of signal peptides and the location of the active site.\n6. BepiPred: A tool that uses a combination of sequence analysis and structure-based methods to predict the transmembrane helices and the orientation of the protein in the membrane. It also predicts the presence of potential membrane-spanning segments and the location of the active site.\n7. TMPro: A tool that uses a combination of sequence analysis and machine learning algorithms to predict the structure and function of a protein. It can predict the transmembrane helices and the orientation of the protein in the membrane, as well as other features such as the presence of signal peptides and the location of the active site.\n8. SOSUI: A tool that uses a combination of sequence analysis and structure-",
    "llama-2-7b-chat-hf_fact_raw": "1. TMHMM is a tool used for predicting the structure and function of transmembrane proteins.\n2. SignalP predicts the presence and location of signal peptides in protein sequences.\n3. PredictProtein uses machine learning algorithms and sequence analysis to predict protein structure and function.\n4. PHD uses machine learning algorithms and sequence analysis to predict protein structure and function, including transmembrane helices.\n5. BepiPred predicts transmembrane helices and the orientation of the protein in the membrane.",
    "llama-2-7b-chat-hf_fact": [
      "TMHMM is a tool used for predicting the structure and function of transmembrane proteins.",
      "SignalP predicts the presence and location of signal peptides in protein sequences.",
      "PredictProtein uses machine learning algorithms and sequence analysis to predict protein structure and function.",
      "PHD uses machine learning algorithms and sequence analysis to predict protein structure and function, including transmembrane helices.",
      "BepiPred predicts transmembrane helices and the orientation of the protein in the membrane."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: BepiPred predicts the location of linear B-cell epitopes in proteins, not transmembrane helices and the orientation of the protein in the membrane.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1251,
    "user_query": "Galassi classification is used for which disorder?",
    "llama-2-7b-chat-hf_response": "Galassi classification is used to classify individuals with intellectual disability (ID) based on the severity of their cognitive and adaptive functioning deficits. It is used to determine the level of support and services an individual may require to live independently or with minimal support. The Galassi classification system includes three categories:\n1. Mild ID: Individuals with mild ID have cognitive and adaptive functioning deficits that do not significantly impact their daily functioning.\n2. Moderate ID: Individuals with moderate ID have cognitive and adaptive functioning deficits that impact their daily functioning, but they are able to perform most tasks with some support.\n3. Severe ID: Individuals with severe ID have significant cognitive and adaptive functioning deficits that significantly impact their daily functioning and require extensive support and accommodations to live independently.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Galassi classification is used to classify individuals with intellectual disability (ID).\n2. The Galassi classification uses severity of cognitive and adaptive functioning deficits as a basis for categorizing ID.\n3. The classification includes three categories: Mild ID, Moderate ID, and Severe ID.\n4. Individuals with Mild ID do not have deficits that significantly impact their daily functioning.\n5. Individuals with Severe ID have significant deficits that require extensive support and accommodations to live independently.",
    "llama-2-7b-chat-hf_fact": [
      "The Galassi classification is used to classify individuals with intellectual disability (ID).",
      "The Galassi classification uses severity of cognitive and adaptive functioning deficits as a basis for categorizing ID.",
      "The classification includes three categories: Mild ID, Moderate ID, and Severe ID.",
      "Individuals with Mild ID do not have deficits that significantly impact their daily functioning.",
      "Individuals with Severe ID have significant deficits that require extensive support and accommodations to live independently."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Galassi classification is not used to classify individuals with intellectual disability. The classification systems typically used for intellectual disability are based on severity, but the Galassi classification pertains to meniscal cysts in the knee.\n2. FALSE [correction]: Since the Galassi classification is not for intellectual disability, it does not use severity of cognitive and adaptive functioning deficits for categorization. The DSM-5 and ICD systems are used for this purpose in classifying intellectual disability.\n3. FALSE [correction]: The classification for intellectual disability often includes more than three categories (Mild, Moderate, Severe, and Profound). As mentioned before, the Galassi classification is not applicable here.\n4. FALSE [correction]: Individuals with Mild ID typically have some deficits in intellectual and adaptive functioning that can impact their daily functioning but with the right supports, they can usually live independently or with minimal support. However, to what extent these deficits impact daily functioning can vary greatly from person to person.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 1304,
    "user_query": "List common features of Shapiro syndrome",
    "llama-2-7b-chat-hf_response": "Shapiro syndrome, also known as Shapiro-Omenn syndrome, is a rare genetic disorder that affects the development of the eyes, ears, and other organs. Here are some common features of Shapiro syndrome:\n1. Congenital cataracts: Most individuals with Shapiro syndrome are born with cataracts, which are cloudy areas in the lens of the eye that can impair vision.\n2. Microphthalmia: People with Shapiro syndrome typically have small eyes, which can lead to vision problems.\n3. Anophthalmia: In some cases, individuals with Shapiro syndrome may be born without one or both eyes.\n4. Hearing loss: Shapiro syndrome can cause hearing loss, which can range from mild to severe.\n5. Cerebellar hypoplasia: The cerebellum is the part of the brain that coordinates movement and balance. In Shapiro syndrome, the cerebellum may be smaller than usual, which can lead to coordination problems and movement disorders.\n6. Intellectual disability: Individuals with Shapiro syndrome may have mild to moderate intellectual disability.\n7. Distinctive facial features: People with Shapiro syndrome may have distinctive facial features, including a small head, narrow eyes, and a short nose.\n8. Skeletal abnormalities: Shapiro syndrome can cause various skeletal abnormalities, including short stature, joint deformities, and extra or missing ribs.\n9. Heart defects: Some individuals with Shapiro syndrome may have heart defects, such as ventricular septal defect or atrial septal defect.\n10. Other abnormalities: Shapiro syndrome can also cause various other abnormalities, including kidney problems, gastrointestinal issues, and developmental delays.\nIt's important to note that the severity and specific features of Shapiro syndrome can vary widely between individuals, and some people may have a milder or more severe form of the disorder. A diagnosis of Shapiro syndrome is typically made through a combination of clinical evaluation, genetic testing, and imaging studies.",
    "llama-2-7b-chat-hf_fact_raw": "1. Shapiro syndrome, also known as Shapiro-Omenn syndrome, is a rare genetic disorder.\n2. Most individuals with Shapiro syndrome are born with congenital cataracts.\n3. People with Shapiro syndrome typically have microphthalmia, which means they have small eyes.\n4. Shapiro syndrome can lead to different degrees of hearing loss.\n5. Individuals with Shapiro syndrome can have cerebellar hypoplasia, leading to coordination problems and movement disorders.",
    "llama-2-7b-chat-hf_fact": [
      "Shapiro syndrome, also known as Shapiro-Omenn syndrome, is a rare genetic disorder.",
      "Most individuals with Shapiro syndrome are born with congenital cataracts.",
      "People with Shapiro syndrome typically have microphthalmia, which means they have small eyes.",
      "Shapiro syndrome can lead to different degrees of hearing loss.",
      "Individuals with Shapiro syndrome can have cerebellar hypoplasia, leading to coordination problems and movement disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Shapiro syndrome is a rare neurological condition characterized by recurrent episodes of hypothermia, hyperhidrosis, and agenesis of the corpus callosum, not to be confused with Shapiro-Omenn syndrome, which is a different condition.\n2. UNKNOWN: The hallmark features of Shapiro syndrome do not typically include congenital cataracts; this is not a commonly recognized feature of the syndrome.\n3. UNKNOWN: Microphthalmia is not usually associated with Shapiro syndrome; rather, it is a different condition affecting eye size.\n4. UNKNOWN: Hearing loss is not a typical feature described in Shapiro syndrome.\n5. TRUE: Individuals with Shapiro syndrome can have cerebellar hypoplasia, which can lead to coordination problems and movement disorders.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1320,
    "user_query": "Which disease is linked to mutations within BRAG1?",
    "llama-2-7b-chat-hf_response": "BRAG1 (BRAG-1-related gene 1) is linked to several diseases, including:\n1. Brag1 syndrome: A rare genetic disorder characterized by growth retardation, intellectual disability, and facial dysmorphism.\n2. Cerebral cavernous malformations (CCMs): Mutations in BRAG1 have been identified as a cause of some forms of CCMs, which are abnormalities in the brain that can cause seizures, stroke-like episodes, and other neurological problems.\n3. Neurofibromatosis type 1 (NF1): BRAG1 mutations have been identified in some cases of NF1, a genetic disorder that can cause various symptoms including benign tumors on the skin, optic nerve gliomas, and other neurological problems.",
    "llama-2-7b-chat-hf_fact_raw": "1. BRAG1 mutations are linked to Brag1 syndrome, which is characterized by growth retardation, intellectual disability, and facial dysmorphism.\n2. Mutations in BRAG1 have been identified as a cause of cerebral cavernous malformations (CCMs).\n3. Some forms of cerebral cavernous malformations can lead to seizures, stroke-like episodes, and other neurological problems.\n4. BRAG1 mutations have been found in some cases of neurofibromatosis type 1 (NF1).\n5. Neurofibromatosis type 1 (NF1) can cause benign tumors on the skin, optic nerve gliomas, and other neurological issues.",
    "llama-2-7b-chat-hf_fact": [
      "BRAG1 mutations are linked to Brag1 syndrome, which is characterized by growth retardation, intellectual disability, and facial dysmorphism.",
      "Mutations in BRAG1 have been identified as a cause of cerebral cavernous malformations (CCMs).",
      "Some forms of cerebral cavernous malformations can lead to seizures, stroke-like episodes, and other neurological problems.",
      "BRAG1 mutations have been found in some cases of neurofibromatosis type 1 (NF1).",
      "Neurofibromatosis type 1 (NF1) can cause benign tumors on the skin, optic nerve gliomas, and other neurological issues."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: Mutations in the CCM genes (CCM1, CCM2, and CCM3/PDCD10) have been identified as a cause of cerebral cavernous malformations (CCMs), not BRAG1.\n3. TRUE\n4. FALSE [correction]: BRAG1 mutations have not been commonly associated with neurofibromatosis type 1 (NF1). NF1 is typically caused by mutations in the NF1 gene.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1362,
    "user_query": "Which protein is the main inhibitor of protein phosphatase 1 (PP1)?",
    "llama-2-7b-chat-hf_response": "The main inhibitor of protein phosphatase 1 (PP1) is called PP1-specific inhibitor 1 (PIN1).",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 1374,
    "user_query": "Which mechanisms underlie adaptive mutagenesis (stationary-phase mutagenesis) in Bacillus subtilis?",
    "llama-2-7b-chat-hf_response": "Adaptive mutagenesis, also known as stationary-phase mutagenesis, in Bacillus subtilis involves the increased mutation rate of the bacterial genome during stationary phase, which is characterized by limited nutrient availability and high stress levels. The underlying mechanisms include:\n1. DNA damage response: The increased mutation rate during stationary phase may be due to the activation of the DNA damage response, which involves the repair of DNA damage through mutagenic processes such as base excision repair and mutL mutS homologous recombination.\n2. Reactive oxygen species (ROS) production: Stationary-phase bacteria produce high levels of ROS, which can directly damage DNA and lead to mutations.\n3. Mismatch repair deficiency: The stationary-phase mutator phenotype is often associated with mutations in genes involved in mismatch repair, such as mutS and mutL.\n4. Telomere shortening: Telomeres, the repetitive DNA sequences that cap the ends of chromosomes, shorten during stationary phase. This can lead to the activation of the SOS response, which can result in mutations.\n5. Transcriptional interference: During stationary phase, the expression of certain genes can interfere with the transcription of other genes, leading to mutations.\n6. Epigenetic changes: Stationary-phase bacteria may experience epigenetic changes, such as alterations in DNA methylation or histone modification, which can affect gene expression and lead to mutations.\n7. Genome instability: Stationary-phase bacteria may have a higher genome instability due to the accumulation of mutations in genes involved in DNA repair and maintenance, leading to a higher mutation rate.\n8. Error-prone DNA repair: Stationary-phase bacteria may use error-prone DNA repair pathways, such as nucleotide excision repair, which can lead to mutations.\n9. Chromosomal rearrangements: Stationary-phase bacteria may undergo chromosomal rearrangements, such as chromosome fragmentation or chromosome loss, which can lead to mutations.\n10. Horizontal gene transfer: Stationary-phase bacteria may undergo horizontal gene transfer",
    "llama-2-7b-chat-hf_fact_raw": "1. Adaptive mutagenesis in Bacillus subtilis is associated with an increased mutation rate of the bacterial genome during the stationary phase.\n2. The DNA damage response in Bacillus subtilis includes mutagenic processes such as base excision repair and mutL mutS homologous recombination.\n3. During the stationary phase, Bacillus subtilis bacteria produce high levels of reactive oxygen species (ROS) which can damage DNA and lead to mutations.\n4. Mutations in genes involved in mismatch repair, such as mutS and mutL, are associated with the stationary-phase mutator phenotype in Bacillus subtilis.\n5. Genome instability in Bacillus subtilis during the stationary phase may be higher due to the accumulation of mutations in genes related to DNA repair and maintenance.",
    "llama-2-7b-chat-hf_fact": [
      "Adaptive mutagenesis in Bacillus subtilis is associated with an increased mutation rate of the bacterial genome during the stationary phase.",
      "The DNA damage response in Bacillus subtilis includes mutagenic processes such as base excision repair and mutL mutS homologous recombination.",
      "During the stationary phase, Bacillus subtilis bacteria produce high levels of reactive oxygen species (ROS) which can damage DNA and lead to mutations.",
      "Mutations in genes involved in mismatch repair, such as mutS and mutL, are associated with the stationary-phase mutator phenotype in Bacillus subtilis.",
      "Genome instability in Bacillus subtilis during the stationary phase may be higher due to the accumulation of mutations in genes related to DNA repair and maintenance."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Adaptive mutagenesis in Bacillus subtilis is known to occur during stressful conditions such as the stationary phase, which is associated with increased mutation rates.\n2. FALSE [correction]: The DNA damage response in Bacillus subtilis includes repair processes such as base excision repair and mismatch repair, which utilize proteins like MutS and MutL, but do not involve mutL mutS homologous recombination. Homologous recombination involves different sets of proteins.\n3. TRUE: During the stationary phase, bacteria including Bacillus subtilis can produce higher levels of reactive oxygen species, which can lead to DNA damage and potentially result in mutations.\n4. TRUE: Mutations in mismatch repair genes like mutS and mutL can lead to a mutator phenotype, which is characteristic of an increased mutation rate that can occur during the stationary phase.\n5. TRUE: Genome instability may indeed be higher during the stationary phase due to the potential accumulation of mutations, especially if the mutations affect genes related to DNA repair and maintenance.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1399,
    "user_query": "What causes erucism?",
    "llama-2-7b-chat-hf_response": "Erucism, also known as erucismatosis or eruptions of the skin, can be caused by a variety of factors, including:\n1. Allergies: Eruptions on the skin can be triggered by allergies to certain substances, such as plants, medications, or insect bites.\n2. Infections: Bacterial, fungal, or viral infections can cause eruptions on the skin.\n3. Autoimmune disorders: Conditions such as psoriasis, eczema, and lupus can cause eruptions on the skin.\n4. Genetic disorders: Certain genetic disorders, such as x-linked epidermolysis bullosa, can cause eruptions on the skin.\n5. Hormonal changes: Hormonal changes, such as those that occur during pregnancy or menopause, can cause eruptions on the skin.\n6. Medications: Certain medications, such as antibiotics, nonsteroidal anti-inflammatory drugs (NSAIDs), and blood pressure medications, can cause eruptions on the skin as a side effect.\n7. Environmental factors: Exposure to sunlight, wind, and cold weather can cause eruptions on the skin.\n8. Nutritional deficiencies: Deficiencies in certain nutrients, such as vitamin B12 or zinc, can cause eruptions on the skin.\n9. Skin injuries: Injuries to the skin, such as burns or cuts, can cause eruptions on the skin.\n10. Cancer: In rare cases, eruptions on the skin can be a symptom of skin cancer, such as melanoma.\nIt's important to note that this is not an exhaustive list and there may be other causes of erucism not mentioned here. If you are experiencing eruptions on your skin, it's important to see a dermatologist to determine the underlying cause and receive proper treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. Eruptions on the skin caused by erucism can be triggered by allergies to substances like plants, medications, or insect bites.\n2. Bacterial, fungal, or viral infections can cause eruptions on the skin, according to the concept of erucism.\n3. Autoimmune disorders such as psoriasis, eczema, and lupus can lead to skin eruptions in erucism.\n4. Certain genetic disorders, like x-linked epidermolysis bullosa, are mentioned as potential causes of eruptions on the skin in erucism.\n5. Hormonal changes, such as those during pregnancy or menopause, can be a cause of skin eruptions in erucism.",
    "llama-2-7b-chat-hf_fact": [
      "Eruptions on the skin caused by erucism can be triggered by allergies to substances like plants, medications, or insect bites.",
      "Bacterial, fungal, or viral infections can cause eruptions on the skin, according to the concept of erucism.",
      "Autoimmune disorders such as psoriasis, eczema, and lupus can lead to skin eruptions in erucism.",
      "Certain genetic disorders, like x-linked epidermolysis bullosa, are mentioned as potential causes of eruptions on the skin in erucism.",
      "Hormonal changes, such as those during pregnancy or menopause, can be a cause of skin eruptions in erucism."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Erucism is specifically caused by contact with caterpillar hairs or bristles. Bacterial, fungal, or viral infections can cause skin eruptions, but they are not related to erucism.\n3. FALSE [correction]: While autoimmune disorders like psoriasis, eczema, and lupus can cause skin eruptions, they are not the causes of erucism. Erucism is a reaction to caterpillar hairs or bristles.\n4. FALSE [correction]: Genetic disorders like x-linked epidermolysis bullosa can cause skin issues, but they are not associated with erucism. Erucism occurs due to contact with caterpillar hairs or bristles.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1413,
    "user_query": "What are the indications for hydrochlorothiazide?",
    "llama-2-7b-chat-hf_response": "Hydrochlorothiazide is a diuretic medication that is commonly used to treat a variety of conditions, including:\n1. Hypertension (high blood pressure): Hydrochlorothiazide is used to treat mild to moderate hypertension, as it helps to reduce blood pressure by increasing urine production.\n2. Heart failure: Hydrochlorothiazide can help to reduce fluid buildup in the body, which can occur in heart failure patients.\n3. Edema (swelling): Hydrochlorothiazide is used to treat edema (swelling) caused by fluid buildup in the body, which can occur in conditions such as liver disease, kidney disease, or cancer.\n4. Nephrotic syndrome: Hydrochlorothiazide can help to reduce proteinuria (excess protein in the urine) in patients with nephrotic syndrome.\n5. Diabetes insipidus: Hydrochlorothiazide can help to treat diabetes insipidus, a condition that causes the body to produce too much urine.\n6. Urinary tract infections: Hydrochlorothiazide can help to treat urinary tract infections by increasing urine production and flushing out bacteria from the urinary tract.\n7. Cystitis: Hydrochlorothiazide can help to treat cystitis, a bladder infection caused by bacteria.\n8. Overactive bladder: Hydrochlorothiazide can help to treat overactive bladder, a condition characterized by sudden, intense need to urinate, and urgency to urinate.\nIt is important to note that hydrochlorothiazide can have side effects, such as electrolyte imbalances, and it may interact with other medications. Therefore, it is important to use hydrochlorothiazide only as directed by a healthcare professional.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hydrochlorothiazide is used to treat mild to moderate hypertension by increasing urine production.\n2. It is used to reduce fluid buildup in patients with heart failure.\n3. Hydrochlorothiazide is utilized to treat edema caused by fluid buildup in the body due to conditions such as liver disease, kidney disease, or cancer.\n4. It can help to reduce proteinuria in patients with nephrotic syndrome.\n5. Hydrochlorothiazide is used in the treatment of diabetes insipidus, a condition that causes the body to produce too much urine.",
    "llama-2-7b-chat-hf_fact": [
      "Hydrochlorothiazide is used to treat mild to moderate hypertension by increasing urine production.",
      "It is used to reduce fluid buildup in patients with heart failure.",
      "Hydrochlorothiazide is utilized to treat edema caused by fluid buildup in the body due to conditions such as liver disease, kidney disease, or cancer.",
      "It can help to reduce proteinuria in patients with nephrotic syndrome.",
      "Hydrochlorothiazide is used in the treatment of diabetes insipidus, a condition that causes the body to produce too much urine."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Hydrochlorothiazide is not typically used in the treatment of diabetes insipidus; instead, other medications such as thiazide diuretics are used for this condition.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1447,
    "user_query": "Has silicon been used in treatment of  incontinence ?",
    "llama-2-7b-chat-hf_response": "Yes, silicon has been used in the treatment of urinary incontinence. Silicon-based materials, such as silicon gel or silicon foam, have been used to create implantable devices that can help strengthen the muscles in the pelvic floor, which can help improve bladder control and reduce the risk of incontinence. These devices are typically used in cases of stress urinary incontinence, which is the most common type of incontinence in women.\nSilicon-based devices work by providing support to the urethral sphincter, the muscle that controls the flow of urine. By providing this support, the devices can help improve the function of the urethral sphincter and reduce the risk of incontinence. These devices are typically implanted through a minimally invasive surgical procedure and can be effective in improving bladder control and reducing the risk of incontinence in women.\nIt is important to note that silicon-based devices are not suitable for everyone and the decision to undergo this type of treatment should be made in consultation with a healthcare provider. Additionally, there may be other treatment options available, such as physical therapy or medication, that may be more appropriate for some individuals.",
    "llama-2-7b-chat-hf_fact_raw": "1. Silicon has been used in the treatment of urinary incontinence.\n2. Silicon-based materials like gel or foam have been utilized to create implantable devices for strengthening pelvic floor muscles.\n3. These silicon-based devices are primarily used in cases of stress urinary incontinence.\n4. The devices support the urethral sphincter to improve bladder control and reduce the risk of incontinence.\n5. The implantation of these silicon-based devices is typically done through a minimally invasive surgical procedure.",
    "llama-2-7b-chat-hf_fact": [
      "Silicon has been used in the treatment of urinary incontinence.",
      "Silicon-based materials like gel or foam have been utilized to create implantable devices for strengthening pelvic floor muscles.",
      "These silicon-based devices are primarily used in cases of stress urinary incontinence.",
      "The devices support the urethral sphincter to improve bladder control and reduce the risk of incontinence.",
      "The implantation of these silicon-based devices is typically done through a minimally invasive surgical procedure."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Silicone, not silicon, has been used in the treatment of urinary incontinence. Silicon is a chemical element, while silicone is a polymer used in various medical applications.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1454,
    "user_query": "What is the association between moon cycle and rupture risk of intracranial aneurysms?",
    "llama-2-7b-chat-hf_response": "There is a controversial association between the moon cycle and the risk of rupture of intracranial aneurysms. Some studies have suggested that the incidence of aneurysm rupture may increase during the full moon, while others have found no correlation. The exact mechanism behind this association is not fully understood, but it is thought that changes in blood pressure and cerebral vasospasm may play a role. However, the evidence is mixed and more research is needed to confirm or refute this association.",
    "llama-2-7b-chat-hf_fact_raw": "1. Some studies have suggested an increased incidence of aneurysm rupture during the full moon.\n2. Other studies have found no correlation between the moon cycle and the risk of rupture of intracranial aneurysms.\n3. It is hypothesized that changes in blood pressure and cerebral vasospasm may play a role in the association between moon cycle and aneurysm rupture.\n4. The exact mechanism behind the association between the moon cycle and aneurysm rupture risk is not fully understood.\n5. There is a need for more research to confirm or refute the association between the moon cycle and the rupture risk of intracranial aneurysms.",
    "llama-2-7b-chat-hf_fact": [
      "Some studies have suggested an increased incidence of aneurysm rupture during the full moon.",
      "Other studies have found no correlation between the moon cycle and the risk of rupture of intracranial aneurysms.",
      "It is hypothesized that changes in blood pressure and cerebral vasospasm may play a role in the association between moon cycle and aneurysm rupture.",
      "The exact mechanism behind the association between the moon cycle and aneurysm rupture risk is not fully understood.",
      "There is a need for more research to confirm or refute the association between the moon cycle and the rupture risk of intracranial aneurysms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nWithout specific studies to reference for statement 1, it is not possible to confirm the validity of the claim, thus it remains \"UNKNOWN\". Statements 2, 3, 4, and 5 are broadly consistent with the nature of scientific inquiry into complex medical phenomena, where different studies might yield varying results, hypotheses are generated to explain observations, mechanisms behind those hypotheses may be elusive, and further research is often called to resolve uncertainties.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1477,
    "user_query": "Does HuR protein regulate the splicing process?",
    "llama-2-7b-chat-hf_response": "Yes, the HuR protein (also known as ELAVL1) regulates the splicing process by binding to specific pre-mRNAs and modulating their splicing patterns. HuR is a member of the ELAVL (ELAV-like RNA-binding) family of proteins, which are involved in the regulation of mRNA metabolism, including splicing, transport, and stability.\nHuR recognizes and binds to specific introns and exons in pre-mRNAs, particularly those containing a conserved sequence motif called the ELAVL-binding element (EBE). By binding to these sequences, HuR can either enhance or suppress the splicing of specific exons, leading to changes in the final mRNA product.\nHuR has been implicated in the regulation of a wide range of genes involved in various cellular processes, including cell proliferation, differentiation, and survival. Dysregulation of HuR has been implicated in various diseases, including cancer and neurodegenerative disorders, highlighting its potential as a therapeutic target for these conditions.",
    "llama-2-7b-chat-hf_fact_raw": "1. The HuR protein, known as ELAVL1, is involved in regulating the splicing process of pre-mRNAs.\n2. HuR is a member of the ELAVL family of proteins, which play a role in mRNA metabolism.\n3. HuR recognizes and binds to specific introns and exons in pre-mRNAs that contain the ELAVL-binding element.\n4. The binding of HuR to pre-mRNAs can either enhance or suppress the splicing of specific exons.\n5. Dysregulation of HuR has been implicated in various diseases, including cancer and neurodegenerative disorders.",
    "llama-2-7b-chat-hf_fact": [
      "The HuR protein, known as ELAVL1, is involved in regulating the splicing process of pre-mRNAs.",
      "HuR is a member of the ELAVL family of proteins, which play a role in mRNA metabolism.",
      "HuR recognizes and binds to specific introns and exons in pre-mRNAs that contain the ELAVL-binding element.",
      "The binding of HuR to pre-mRNAs can either enhance or suppress the splicing of specific exons.",
      "Dysregulation of HuR has been implicated in various diseases, including cancer and neurodegenerative disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The HuR protein, known as ELAVL1, is involved in stabilizing and regulating the translation of mRNAs, not specifically in the splicing process of pre-mRNAs.\n2. TRUE\n3. FALSE [correction]: HuR recognizes and binds to specific RNA sequences or motifs typically found in the 3'-UTR (untranslated region) of mRNAs rather than introns and exons.\n4. FALSE [correction]: The primary role of HuR is the stabilization and regulation of mRNA, not the enhancement or suppression of splicing of specific exons.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 1492,
    "user_query": "Describe the known functions for the prothymosin alpha c-terminal peptide?",
    "llama-2-7b-chat-hf_response": "Prothymosin alpha (ProT) is a protein that plays a crucial role in the regulation of various cellular processes, including cell proliferation, differentiation, and survival. The c-terminal peptide of ProT, also known as ProT-CT, has been shown to have a number of distinct functions:\n1. Cell cycle regulation: ProT-CT can inhibit the progression of cells through the G1/S phase transition of the cell cycle and induce cell cycle arrest in G2/M phase.\n2. Apoptosis: ProT-CT can induce apoptosis (programmed cell death) in response to various stimuli, including oxidative stress and DNA damage.\n3. Anti-inflammatory effects: ProT-CT has been shown to inhibit the production of pro-inflammatory cytokines and chemokines, such as TNF-alpha and IL-8, in response to inflammatory stimuli.\n4. Neuroprotection: ProT-CT has been shown to protect against neurodegeneration in various animal models of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.\n5. Cardiovascular protection: ProT-CT has been shown to protect against cardiovascular damage in various animal models of cardiovascular disease, including hypertension and atherosclerosis.\n6. Anti-cancer effects: ProT-CT has been shown to inhibit the growth and survival of various types of cancer cells, including breast, lung, and colon cancer cells.\nOverall, the c-terminal peptide of ProT has a wide range of biological activities that are involved in the regulation of various cellular processes, and it has potential as a therapeutic agent for the treatment of various diseases, including cancer, neurodegenerative diseases, and cardiovascular disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. The c-terminal peptide of prothymosin alpha (ProT-CT) can inhibit the progression of cells through the G1/S phase transition and induce cell cycle arrest in G2/M phase.\n2. ProT-CT can induce apoptosis in response to various stimuli including oxidative stress and DNA damage.\n3. ProT-CT has been shown to inhibit the production of pro-inflammatory cytokines and chemokines, such as TNF-alpha and IL-8.\n4. ProT-CT has been noted for its neuroprotective effects in animal models of neurodegenerative diseases like Alzheimer's and Parkinson's disease.\n5. ProT-CT provides cardiovascular protection in various animal models of cardiovascular diseases, including hypertension and atherosclerosis.",
    "llama-2-7b-chat-hf_fact": [
      "The c-terminal peptide of prothymosin alpha (ProT-CT) can inhibit the progression of cells through the G1/S phase transition and induce cell cycle arrest in G2/M phase.",
      "ProT-CT can induce apoptosis in response to various stimuli including oxidative stress and DNA damage.",
      "ProT-CT has been shown to inhibit the production of pro-inflammatory cytokines and chemokines, such as TNF-alpha and IL-8.",
      "ProT-CT has been noted for its neuroprotective effects in animal models of neurodegenerative diseases like Alzheimer's and Parkinson's disease.",
      "ProT-CT provides cardiovascular protection in various animal models of cardiovascular diseases, including hypertension and atherosclerosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout access to specific scientific studies or literature on the c-terminal peptide of prothymosin alpha (ProT-CT), I am unable to confirm the accuracy of these statements. They relate to specific biochemical functions and effects that would need to be supported by experimental evidence, which is outside the scope of my current knowledge database. For accurate verification, one should consult the relevant scientific research publications.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1516,
    "user_query": "Which peptide plays a pivotal role in human cystatin C fibrillization?",
    "llama-2-7b-chat-hf_response": "The peptide that plays a pivotal role in human cystatin C fibrillization is the N-terminal peptide (residues 1-13) of human cystatin C.",
    "llama-2-7b-chat-hf_fact_raw": "1. The N-terminal peptide of human cystatin C consists of residues 1-13.\n2. The N-terminal peptide of human cystatin C plays a pivotal role in its fibrillization.",
    "llama-2-7b-chat-hf_fact": [
      "The N-terminal peptide of human cystatin C consists of residues 1-13.",
      "The N-terminal peptide of human cystatin C plays a pivotal role in its fibrillization."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 1574,
    "user_query": "Does the concentration of protein HIF-1α increase after the administration of the cytoprotective prodrug\"amifostine\" (ethyol) ?",
    "llama-2-7b-chat-hf_response": "Yes, the concentration of protein HIF-1α (hypoxia-inducible factor-1 alpha) increases after the administration of the cytoprotective prodrug ethyol (amifostine). HIF-1α is a transcription factor that plays a critical role in response to hypoxia and is involved in the regulation of various cellular processes, including cell survival, angiogenesis, and glucose metabolism. Ethyol is a prodrug that is converted to the active compound ethylene diamine (EDA), which has been shown to activate the PI3K/Akt signaling pathway, leading to the increase in HIF-1α protein levels.",
    "llama-2-7b-chat-hf_fact_raw": "1. The concentration of protein HIF-1α increases after the administration of the cytoprotective prodrug ethyol (amifostine).\n2. HIF-1α is involved in the regulation of cellular processes such as cell survival, angiogenesis, and glucose metabolism.\n3. Ethyol (amifostine) is a prodrug converted to the active compound ethylene diamine (EDA).\n4. Ethylene diamine (EDA) activates the PI3K/Akt signaling pathway.\n5. Activation of the PI3K/Akt signaling pathway leads to an increase in HIF-1α protein levels.",
    "llama-2-7b-chat-hf_fact": [
      "The concentration of protein HIF-1α increases after the administration of the cytoprotective prodrug ethyol (amifostine).",
      "HIF-1α is involved in the regulation of cellular processes such as cell survival, angiogenesis, and glucose metabolism.",
      "Ethyol (amifostine) is a prodrug converted to the active compound ethylene diamine (EDA).",
      "Ethylene diamine (EDA) activates the PI3K/Akt signaling pathway.",
      "Activation of the PI3K/Akt signaling pathway leads to an increase in HIF-1α protein levels."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. FALSE [correction]: Ethyol (amifostine) is a prodrug that is dephosphorylated to the active compound WR-1065.\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1588,
    "user_query": "Which histone marks are deposited by Set7?",
    "llama-2-7b-chat-hf_response": "Set7 is a histone methyltransferase that deposits histone 3 lysine 4 trimethylation (H3K4me3) marks on histone proteins.",
    "llama-2-7b-chat-hf_fact_raw": "1. Set7 is a histone methyltransferase.\n2. Set7 deposits histone 3 lysine 4 trimethylation (H3K4me3) marks on histone proteins.",
    "llama-2-7b-chat-hf_fact": [
      "Set7 is a histone methyltransferase.",
      "Set7 deposits histone 3 lysine 4 trimethylation (H3K4me3) marks on histone proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Set7 (also known as Set7/9) primarily deposits histone 3 lysine 4 monomethylation (H3K4me1) marks on histone proteins, not trimethylation (H3K4me3).",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false"
    ]
  },
  {
    "id": 1620,
    "user_query": "How many disulfide bridges has the protein hepcidin got?",
    "llama-2-7b-chat-hf_response": "The protein hepcidin has 4 disulfide bridges.",
    "llama-2-7b-chat-hf_fact_raw": "1. The protein hepcidin has 4 disulfide bridges.",
    "llama-2-7b-chat-hf_fact": [
      "The protein hepcidin has 4 disulfide bridges."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 1643,
    "user_query": "What is the localization of the protein encoded by the gene DNAJC11?",
    "llama-2-7b-chat-hf_response": "The protein encoded by the gene DNAJC11 is a cytoplasmic protein.",
    "llama-2-7b-chat-hf_fact_raw": "1. The protein encoded by the gene DNAJC11 is localized in the cytoplasm.",
    "llama-2-7b-chat-hf_fact": [
      "The protein encoded by the gene DNAJC11 is localized in the cytoplasm."
    ],
    "llama-2-7b-chat-hf_judge_raw": "UNKNOWN\n\nWithout specific scientific reference or context verifying the subcellular localization of the protein encoded by the gene DNAJC11, it is not possible to determine the accuracy of the statement. Localization can often be determined by experimental studies such as immunofluorescence or biochemical fractionation, but without such data, the localization of a given protein cannot be assumed.",
    "llama-2-7b-chat-hf_judge": [
      "unknown"
    ]
  },
  {
    "id": 1655,
    "user_query": "Are ultraconserved elements depleted among copy number variants (CNVs)?",
    "llama-2-7b-chat-hf_response": "Yes, ultraconserved elements (UCEs) are depleted among copy number variants (CNVs). UCEs are sequences that are highly conserved across species and are thought to be important for regulating gene expression. CNVs, on the other hand, are genomic regions that contain extra or missing copies of DNA sequences, which can lead to changes in gene expression and other genomic effects.\nStudies have shown that UCEs are enriched in the regions of the genome that are not affected by CNVs, while CNVs are more likely to occur in regions that are less conserved and have lower UCE content. This suggests that UCEs may play a role in protecting against the disruption of gene expression caused by CNVs.\nAdditionally, a study published in the journal Nature in 2015 found that UCEs are more likely to be located in regions of the genome that are in close proximity to genes, and that these regions are also more likely to be affected by CNVs. This suggests that UCEs may play a role in protecting against the disruption of gene expression caused by CNVs by acting as a buffer zone around genes.\nIn summary, UCEs are depleted among CNVs, and this depletion may be due to the fact that UCEs are more likely to be located in regions of the genome that are in close proximity to genes, which are more likely to be affected by CNVs.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ultraconserved elements (UCEs) are highly conserved across different species.\n2. UCEs are thought to be important for regulating gene expression.\n3. Copy number variants (CNVs) are genomic regions with extra or missing copies of DNA sequences.\n4. Studies indicate that UCEs are enriched in genomic regions not affected by CNVs, while CNVs tend to occur more in less conserved regions with lower UCE content.\n5. A study published in the journal Nature in 2015 reported that UCEs tend to be near genes and that these regions are more likely to be affected by CNVs.",
    "llama-2-7b-chat-hf_fact": [
      "Ultraconserved elements (UCEs) are highly conserved across different species.",
      "UCEs are thought to be important for regulating gene expression.",
      "Copy number variants (CNVs) are genomic regions with extra or missing copies of DNA sequences.",
      "Studies indicate that UCEs are enriched in genomic regions not affected by CNVs, while CNVs tend to occur more in less conserved regions with lower UCE content.",
      "A study published in the journal Nature in 2015 reported that UCEs tend to be near genes and that these regions are more likely to be affected by CNVs."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: While it is true that UCEs tend to be near genes, they are typically found in regions that are less likely to be affected by CNVs, not more. This statement is contradictory to the general understanding of UCEs and CNVs as indicated in statement 4. Studies suggest that CNVs are less common in regions with high UCE content, hence UCE regions are less likely to be impacted by CNVs, contrary to what the statement claims.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1665,
    "user_query": "Which is the substrate of the haspin kinase during mitosis?",
    "llama-2-7b-chat-hf_response": "Has2 (Haspin) is a kinase that plays a crucial role in regulating the progression of mitosis by phosphorylating and inhibiting the activity of the separin protein. The substrate of Has2 (Haspin) during mitosis is separin.",
    "llama-2-7b-chat-hf_fact_raw": "1. Haspin kinase regulates the progression of mitosis.\n2. Haspin kinase phosphorylates and inhibits the activity of the separin protein.\n3. The substrate of Haspin kinase during mitosis is separin.",
    "llama-2-7b-chat-hf_fact": [
      "Haspin kinase regulates the progression of mitosis.",
      "Haspin kinase phosphorylates and inhibits the activity of the separin protein.",
      "The substrate of Haspin kinase during mitosis is separin."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Haspin kinase does not phosphorylate and inhibit the activity of the separin protein. Instead, Haspin kinase is known to phosphorylate histone H3 on Thr3 (H3T3ph) during mitosis, which promotes the proper attachment of the chromosomal passenger complex (CPC) to chromosomes.\n3. FALSE [correction]: The substrate of Haspin kinase during mitosis is not separin, but rather histone H3 at threonine 3 (Thr3).",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 1696,
    "user_query": "What is the mechanism of viroid replication?",
    "llama-2-7b-chat-hf_response": "Viroids are small, single-stranded RNA molecules that replicate through a mechanism that is distinct from other RNA viruses. They do not have a protein coat or a host cell machinery to replicate, but instead, they replicate through a process called \"rolling circle replication\".\nDuring rolling circle replication, the viroid RNA acts as both the template and the replication intermediate. The RNA molecule is circularized, and the replication machinery unwinds the RNA and synthesizes a new complementary strand. This process results in the production of multiple copies of the original RNA molecule, which can then go on to infect other cells.\nIn addition to rolling circle replication, some viroids have been shown to use a process called \"RNA-dependent RNA polymerase-mediated replication\" to replicate their genome. This process involves the use of an RNA-dependent RNA polymerase enzyme to synthesize a new complementary strand of RNA from the template RNA.\nOverall, the mechanisms of viroid replication are complex and not fully understood, and further research is needed to elucidate the details of this process.",
    "llama-2-7b-chat-hf_fact_raw": "1. Viroids are small, single-stranded RNA molecules.\n2. Viroids do not have a protein coat for replication.\n3. Viroids utilize a replication process known as \"rolling circle replication\".\n4. In rolling circle replication, the viroid RNA circularizes and serves as both the template and the replication intermediate.\n5. Some viroids also use \"RNA-dependent RNA polymerase-mediated replication\" for replication.",
    "llama-2-7b-chat-hf_fact": [
      "Viroids are small, single-stranded RNA molecules.",
      "Viroids do not have a protein coat for replication.",
      "Viroids utilize a replication process known as \"rolling circle replication\".",
      "In rolling circle replication, the viroid RNA circularizes and serves as both the template and the replication intermediate.",
      "Some viroids also use \"RNA-dependent RNA polymerase-mediated replication\" for replication."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Viroids are known to hijack the host cell's RNA polymerase II for replication, not an RNA-dependent RNA polymerase.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1723,
    "user_query": "Does fibronectin constitute a serum biomarker for Duchenne muscular dystrophy?",
    "llama-2-7b-chat-hf_response": "Yes, fibronectin has been identified as a potential serum biomarker for Duchenne muscular dystrophy (DMD). Studies have shown that levels of fibronectin in the bloodstream are significantly lower in individuals with DMD compared to healthy controls, and this reduction can be detected as early as 6 months of age. This decrease in fibronectin levels may serve as an early diagnostic marker for DMD and could potentially be used in conjunction with other biomarkers to improve the accuracy of diagnosis. Additionally, fibronectin levels have been shown to be associated with disease progression and muscle strength in DMD, making it a useful marker for monitoring disease severity and treatment response.",
    "llama-2-7b-chat-hf_fact_raw": "1. Fibronectin has been identified as a potential serum biomarker for Duchenne muscular dystrophy (DMD).\n2. Studies indicate that fibronectin levels are significantly lower in individuals with DMD compared to healthy controls.\n3. The reduction in fibronectin levels can be detected in individuals as early as 6 months of age.\n4. Fibronectin levels are associated with disease progression and muscle strength in DMD patients.\n5. Fibronectin may be used alongside other biomarkers to improve the accuracy of DMD diagnosis.",
    "llama-2-7b-chat-hf_fact": [
      "Fibronectin has been identified as a potential serum biomarker for Duchenne muscular dystrophy (DMD).",
      "Studies indicate that fibronectin levels are significantly lower in individuals with DMD compared to healthy controls.",
      "The reduction in fibronectin levels can be detected in individuals as early as 6 months of age.",
      "Fibronectin levels are associated with disease progression and muscle strength in DMD patients.",
      "Fibronectin may be used alongside other biomarkers to improve the accuracy of DMD diagnosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Studies indicate that fibronectin levels are significantly higher in individuals with DMD compared to healthy controls.\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 1763,
    "user_query": "Data from which major epigenome projects are contained in the DeepBlue epigenomic data server?",
    "llama-2-7b-chat-hf_response": "DeepBlue is an epigenomic data server that contains data from several major epigenome projects, including:\n1. The ENCODE ( Encyclopedia of DNA Elements) project: This project aims to create a comprehensive catalog of all the functional elements in the human genome.\n2. The Roadmap Epigenomics Project: This project is focused on understanding the epigenetic changes that occur during development and disease, and has generated epigenetic data for multiple tissues and cell types.\n3. The Human Epigenome Project: This project aims to generate comprehensive epigenetic profiles for all human tissues and cells, and has generated data for over 100 different tissues and cell types.\n4. The Mouse Epigenome Project: This project aims to generate a comprehensive epigenetic map of the mouse genome, and has generated data for multiple tissues and cell types.\n5. The Epigenomics of Disease Project: This project aims to understand the epigenetic changes that occur in disease, and has generated epigenetic data for a variety of diseases, including cancer, diabetes, and neurological disorders.\nThese projects have generated a vast amount of epigenetic data, including DNA methylation, histone modification, and chromatin structure data, among others. The data from these projects are contained in the DeepBlue epigenomic data server and are available for analysis and integration with other datasets.",
    "llama-2-7b-chat-hf_fact_raw": "1. DeepBlue is an epigenomic data server that contains data from the ENCODE (Encyclopedia of DNA Elements) project.\n2. The Roadmap Epigenomics Project, which focuses on epigenetic changes related to development and disease, has contributed data to DeepBlue.\n3. Data from the Human Epigenome Project, which has created epigenetic profiles for over 100 different human tissues and cell types, are included in DeepBlue.\n4. The Mouse Epigenome Project, aiming to map the mouse genome epigenetically, has provided data for DeepBlue.\n5. DeepBlue contains epigenetic data from the Epigenomics of Disease Project, which studies epigenetic changes in diseases such as cancer, diabetes, and neurological disorders.",
    "llama-2-7b-chat-hf_fact": [
      "DeepBlue is an epigenomic data server that contains data from the ENCODE (Encyclopedia of DNA Elements) project.",
      "The Roadmap Epigenomics Project, which focuses on epigenetic changes related to development and disease, has contributed data to DeepBlue.",
      "Data from the Human Epigenome Project, which has created epigenetic profiles for over 100 different human tissues and cell types, are included in DeepBlue.",
      "The Mouse Epigenome Project, aiming to map the mouse genome epigenetically, has provided data for DeepBlue.",
      "DeepBlue contains epigenetic data from the Epigenomics of Disease Project, which studies epigenetic changes in diseases such as cancer, diabetes, and neurological disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The Human Epigenome Project is distinct and separate from DeepBlue. DeepBlue may contain data on various human tissues and cell types, but there is no \"Human Epigenome Project\" that fits the description given. Commonly recognized are initiatives such as the International Human Epigenome Consortium (IHEC) which supports multiple human epigenome projects.\n4. UNKNOWN\n5. UNKNOWN\n\nFor statements 4 and 5, without specific references to the existence and contributions of a \"Mouse Epigenome Project\" and the \"Epigenomics of Disease Project,\" it is difficult to confirm their status without more context or information. These may not be formal project names or might not be directly associated with DeepBlue.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1792,
    "user_query": "Which tool employs self organizing maps for analyzing synonymous codon usage?",
    "llama-2-7b-chat-hf_response": "The tool that employs self-organizing maps (SOM) for analyzing synonymous codon usage is called \"CodonUsage\".",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 1793,
    "user_query": "What is MINDY-1?",
    "llama-2-7b-chat-hf_response": "MINDY-1 (Microtubule-Associated Protein 1 Light Chain 1, also known as EB1) is a protein that plays a crucial role in the regulation of microtubule dynamics and cellular behavior, particularly in the context of cancer. It is a plus-end tracking protein that binds to the plus ends of microtubules and regulates their stability and dynamics. MINDY-1 has been shown to be overexpressed in various types of cancer, and its overexpression has been linked to cancer progression and poor prognosis. Inhibition of MINDY-1 has been proposed as a potential therapeutic strategy for cancer treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. MINDY-1 is also known as Microtubule-Associated Protein 1 Light Chain 1 and EB1.\n2. MINDY-1 plays a role in regulating microtubule dynamics and cellular behavior.\n3. It is a plus-end tracking protein that binds to the plus ends of microtubules.\n4. MINDY-1 has been found to be overexpressed in various types of cancer.\n5. Inhibition of MINDY-1 has been suggested as a potential therapeutic strategy for cancer treatment.",
    "llama-2-7b-chat-hf_fact": [
      "MINDY-1 is also known as Microtubule-Associated Protein 1 Light Chain 1 and EB1.",
      "MINDY-1 plays a role in regulating microtubule dynamics and cellular behavior.",
      "It is a plus-end tracking protein that binds to the plus ends of microtubules.",
      "MINDY-1 has been found to be overexpressed in various types of cancer.",
      "Inhibition of MINDY-1 has been suggested as a potential therapeutic strategy for cancer treatment."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: MINDY-1 refers to a family of deubiquitinating enzymes and not Microtubule-Associated Protein 1 Light Chain 1 (which is MAP1LC3) or EB1. \n2. UNKNOWN: The role of MINDY-1 has not been specified, and without proper context, it cannot be assumed it relates to microtubule dynamics and cellular behavior unless there is specific evidence connecting it to these functions.\n3. FALSE [correction]: EB1 is a microtubule plus-end tracking protein (+TIP) that binds to the growing plus ends of microtubules, but MINDY-1 is not this protein.\n4. UNKNOWN: Without specific context, it's unclear if MINDY-1 is overexpressed in various types of cancer. More information is needed to confirm or refute this statement.\n5. UNKNOWN: While inhibition of certain proteins and enzymes has been explored as a therapeutic strategy for cancer, without more context it's unclear if MINDY-1 inhibition has been suggested or proven as a viable strategy.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1810,
    "user_query": "Which software package is available for the analysis of conserved genomic loci?",
    "llama-2-7b-chat-hf_response": "There are several software packages available for the analysis of conserved genomic loci, including:\n1. MACS (Multiple Alignment of Conserved Sequences): This package uses a Hidden Markov Model (HMM) to identify conserved regions in multiple alignments of genomic sequences.\n2. MEME (Motif Explorer): This package uses a position-specific scoring matrix (PSSM) to identify conserved motifs in a multiple alignment of genomic sequences.\n3. HMMER: This package uses a HMM to identify conserved regions in a multiple alignment of genomic sequences.\n4. GERP (Genomic Expectation-Maximization for Repeats Prediction): This package uses a probabilistic model to identify conserved regions in a multiple alignment of genomic sequences.\n5. RepeatMasker: This package uses a combination of sequence similarity and genomic context to identify repetitive elements in a genome, including conserved regions.\n6. Prodigal: This package uses a Bayesian approach to identify conserved regions in a multiple alignment of genomic sequences.\n7. MUSCLE (Multiple Sequence Comparison by Log-Expectation): This package uses a multiple sequence alignment method to identify conserved regions in a multiple alignment of genomic sequences.\n8. RAxML (Raxml): This package uses a maximum likelihood approach to identify conserved regions in a multiple alignment of genomic sequences.\n9. BEAST (Bayesian Evolutionary Analysis by Sampling Trees): This package uses a Bayesian approach to identify conserved regions in a multiple alignment of genomic sequences.\n10. PhyloBayes (Phylogenetic Bayesian Analysis): This package uses a Bayesian approach to identify conserved regions in a multiple alignment of genomic sequences, and also infer the phylogenetic relationships among the sequences.\nIt's worth noting that the choice of software package will depend on the specific requirements and goals of the analysis, as well as the complexity and size of the dataset.",
    "llama-2-7b-chat-hf_fact_raw": "1. MACS (Multiple Alignment of Conserved Sequences) identifies conserved regions using a Hidden Markov Model.\n2. MEME (Motif Explorer) identifies conserved motifs using a position-specific scoring matrix.\n3. HMMER uses a Hidden Markov Model to identify conserved regions in multiple alignments.\n4. GERP (Genomic Expectation-Maximization for Repeats Prediction) uses a probabilistic model to identify conserved regions in alignments.\n5. RepeatMasker identifies repetitive elements in a genome, including conserved regions, through sequence similarity and genomic context.",
    "llama-2-7b-chat-hf_fact": [
      "MACS (Multiple Alignment of Conserved Sequences) identifies conserved regions using a Hidden Markov Model.",
      "MEME (Motif Explorer) identifies conserved motifs using a position-specific scoring matrix.",
      "HMMER uses a Hidden Markov Model to identify conserved regions in multiple alignments.",
      "GERP (Genomic Expectation-Maximization for Repeats Prediction) uses a probabilistic model to identify conserved regions in alignments.",
      "RepeatMasker identifies repetitive elements in a genome, including conserved regions, through sequence similarity and genomic context."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: MACS (Multiple Alignment of Conserved Sequences) is actually a software used to find peaks (regions of interest) in ChIP-seq data, not specifically for identifying conserved regions using a Hidden Markov Model. The name MACS does not stand for \"Multiple Alignment of Conserved Sequences\"; it actually stands for Model-based Analysis of ChIP-Seq.\n\n2. FALSE [correction]: MEME (Multiple EM for Motif Elicitation) is a tool that identifies conserved motifs in a dataset of sequences, but it does not specifically use a position-specific scoring matrix (PSSM). It identifies motifs by searching for repeated, ungapped sequence patterns that can be described by a probabilistic model known as a profile. However, the motifs identified by MEME can be represented as PSSMs.\n\n3. TRUE: HMMER does use a Hidden Markov Model to identify conserved regions in multiple sequences (multiple alignments). HMMER is designed to discover and align homologous protein or nucleotide sequences using probabilistic models.\n\n4. FALSE [correction]: GERP (Genomic Evolutionary Rate Profiling) does not stand for \"Genomic Expectation-Maximization for Repeats Prediction.\" GERP is actually used to identify conserved elements in multiple alignments by comparing the observed evolutionary rates across species with expected rates to identify regions under constraint.\n\n5. FALSE [correction]: RepeatMasker primarily identifies and masks repetitive elements in genomic sequences. While it does involve conserved regions to some extent, since some repetitive elements can be conserved, it is not specifically used to identify conserved regions. RepeatMasker uses sequence databases like Repbase and matches them to the genome to identify repeats, not through genomic context.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 1860,
    "user_query": "Please list 3 diseases associated with the PIEZO2 gene.",
    "llama-2-7b-chat-hf_response": "The PIEZO2 gene has been associated with several diseases, including:\n1. Hypertension: Mutations in the PIEZO2 gene have been found to be associated with essential hypertension, a condition characterized by high blood pressure that can increase the risk of heart disease, stroke, and other cardiovascular problems.\n2. Nephropathy: PIEZO2 mutations have also been linked to certain forms of kidney disease, including nephropathy, which is damage to the kidneys that can lead to kidney failure.\n3. Hearing loss: Some studies have suggested that PIEZO2 mutations may be associated with hearing loss, particularly in the high-frequency range.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutations in the PIEZO2 gene have been associated with essential hypertension.\n2. PIEZO2 mutations have been linked to certain forms of kidney disease, including nephropathy.\n3. Studies have suggested that PIEZO2 mutations may be associated with hearing loss.",
    "llama-2-7b-chat-hf_fact": [
      "Mutations in the PIEZO2 gene have been associated with essential hypertension.",
      "PIEZO2 mutations have been linked to certain forms of kidney disease, including nephropathy.",
      "Studies have suggested that PIEZO2 mutations may be associated with hearing loss."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Mutations in the PIEZO2 gene have not been specifically associated with essential hypertension; they have been studied for their role in mechanosensation and related diseases.\n2. UNKNOWN: As of my last update, there were no widely recognized studies linking PIEZO2 mutations directly to kidney disease. However, this is a field of ongoing research, so it may require a check on the latest scientific literature.\n3. UNKNOWN: The role of PIEZO2 mutations in hearing loss is not widely reported as of my last update. PIEZO2 is more commonly associated with mechanosensory functions, but whether it has a direct link to hearing loss would need to be verified with current research data.\n",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1867,
    "user_query": "What is promoted by ERAP1-ERAP2 dimerization?",
    "llama-2-7b-chat-hf_response": "ERAP1-ERAP2 dimerization promotes the degradation of endogenous retroviral elements (ERVs) and other RNA substrates.",
    "llama-2-7b-chat-hf_fact_raw": "1. ERAP1-ERAP2 dimerization promotes the degradation of endogenous retroviral elements (ERVs).\n2. ERAP1-ERAP2 dimerization also promotes the degradation of other RNA substrates.",
    "llama-2-7b-chat-hf_fact": [
      "ERAP1-ERAP2 dimerization promotes the degradation of endogenous retroviral elements (ERVs).",
      "ERAP1-ERAP2 dimerization also promotes the degradation of other RNA substrates."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n\nExplanation:\nWithout specific scientific context or a source to verify these statements, the role of ERAP1-ERAP2 in the degradation of ERVs and other RNA substrates cannot be determined as true or false. ERAP (Endoplasmic Reticulum Aminopeptidase) enzymes are known to be involved in protein processing, but their specific activities on different substrates such as endogenous retroviral elements and other RNA substrates would require specialized knowledge in immunology and molecular biology, as well as specific research findings to confirm.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1890,
    "user_query": "What is the function of R-spondin 1 and noggin in non-damaged gallbladders?",
    "llama-2-7b-chat-hf_response": "R-spondin 1 and Noggin are two proteins that play important roles in the regulation of stem cell maintenance and differentiation in non-damaged gallbladders.\nR-spondin 1 is a secreted protein that functions as a ligand for the Wnt receptor ROR2, promoting the proliferation and maintenance of stem cells in the gallbladder. It also regulates the expression of genes involved in cell adhesion and migration.\nNoggin, on the other hand, is a secreted protein that inhibits the Wnt signaling pathway by binding to and neutralizing Wnt proteins. In non-damaged gallbladders, Noggin regulates the balance between Wnt signaling and the maintenance of stem cell self-renewal, ensuring the proper differentiation of gallbladder cells.\nTogether, R-spondin 1 and Noggin help maintain the stem cell pool in the gallbladder, ensuring the proper functioning of the organ and preventing aberrant cell growth and differentiation.",
    "llama-2-7b-chat-hf_fact_raw": "1. R-spondin 1 functions as a ligand for the Wnt receptor ROR2 in the gallbladder.\n2. R-spondin 1 promotes the proliferation and maintenance of stem cells in non-damaged gallbladders.\n3. Noggin is a protein that inhibits the Wnt signaling pathway in non-damaged gallbladders.\n4. Noggin regulates the balance between Wnt signaling and maintenance of stem cell self-renewal in non-damaged gallbladders.\n5. Together, R-spondin 1 and Noggin help maintain the stem cell pool in non-damaged gallbladders to ensure proper organ functioning.",
    "llama-2-7b-chat-hf_fact": [
      "R-spondin 1 functions as a ligand for the Wnt receptor ROR2 in the gallbladder.",
      "R-spondin 1 promotes the proliferation and maintenance of stem cells in non-damaged gallbladders.",
      "Noggin is a protein that inhibits the Wnt signaling pathway in non-damaged gallbladders.",
      "Noggin regulates the balance between Wnt signaling and maintenance of stem cell self-renewal in non-damaged gallbladders.",
      "Together, R-spondin 1 and Noggin help maintain the stem cell pool in non-damaged gallbladders to ensure proper organ functioning."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. FALSE [correction]: Noggin is a protein known to inhibit the BMP (bone morphogenetic protein) signaling pathway, not the Wnt signaling pathway. \n4. FALSE [correction]: Since Noggin inhibits the BMP pathway and not the Wnt pathway, the statement about regulating the balance between Wnt signaling and stem cell self-renewal is incorrect based on the provided context.\n5. UNKNOWN\n\nThe response to statements 1, 2, and 5 is \"UNKNOWN\" because the function of R-spondin 1 and its interaction with Wnt receptor ROR2, as well as its role in stem cell maintenance in the gallbladder, are very specific and require particular biological knowledge or context that was not provided.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1937,
    "user_query": "Does NADPH oxidase 5 require any subunit for function?",
    "llama-2-7b-chat-hf_response": "Yes, NADPH oxidase 5 (NOX5) requires at least two subunits, p47phox and p67phox, to function properly. These subunits work together to generate reactive oxygen species (ROS) in the cell.",
    "llama-2-7b-chat-hf_fact_raw": "1. NADPH oxidase 5 (NOX5) requires subunits to function properly.\n2. The subunits p47phox and p67phox are required for the proper functioning of NOX5.\n3. NOX5 generates reactive oxygen species (ROS) in the cell.",
    "llama-2-7b-chat-hf_fact": [
      "NADPH oxidase 5 (NOX5) requires subunits to function properly.",
      "The subunits p47phox and p67phox are required for the proper functioning of NOX5.",
      "NOX5 generates reactive oxygen species (ROS) in the cell."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: NOX5 does not require p47phox and p67phox subunits for its function. Unlike other NOX family members, NOX5 is calcium-dependent and functions independently of these subunits.\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1944,
    "user_query": "What is the connection between furin and hepcidin?",
    "llama-2-7b-chat-hf_response": "Furin and hepcidin are connected in the regulation of iron metabolism. Furin is a protease that processes several iron-responsive proteins, including hepcidin, a hormone that regulates iron absorption and recycling in the body. Furin cleaves hepcidin to activate its biological activity, leading to decreased iron absorption and increased iron recycling, thereby maintaining iron homeostasis in the body.",
    "llama-2-7b-chat-hf_fact_raw": "1. Furin is a protease involved in the processing of several iron-responsive proteins.\n2. Hepcidin is a hormone that regulates iron absorption and recycling in the body.\n3. Furin activates the biological activity of hepcidin by cleaving it.\n4. The activation of hepcidin by furin leads to decreased iron absorption in the body.\n5. Increased iron recycling is a result of hepcidin activation by furin, contributing to iron homeostasis in the body.",
    "llama-2-7b-chat-hf_fact": [
      "Furin is a protease involved in the processing of several iron-responsive proteins.",
      "Hepcidin is a hormone that regulates iron absorption and recycling in the body.",
      "Furin activates the biological activity of hepcidin by cleaving it.",
      "The activation of hepcidin by furin leads to decreased iron absorption in the body.",
      "Increased iron recycling is a result of hepcidin activation by furin, contributing to iron homeostasis in the body."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Furin is a protease involved in the processing of several precursor proteins, not specifically \"iron-responsive proteins\".\n2. TRUE\n3. FALSE [correction]: Hepcidin is produced in an active form and does not require cleavage by furin to activate its biological activity.\n4. TRUE\n5. FALSE [correction]: Increased iron recycling is not a direct result of hepcidin activation by furin. Hepcidin itself leads to decreased iron absorption and promotes iron storage, but furin's activation of hepcidin is not accurate as stated in the third point.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 1956,
    "user_query": "Which is the largest metabolic gene cluster in yeast?",
    "llama-2-7b-chat-hf_response": "The largest metabolic gene cluster in yeast is the glycolysis-gluconeogenesis pathway, which consists of 13 genes.",
    "llama-2-7b-chat-hf_fact_raw": "1. The largest metabolic gene cluster in yeast is related to the glycolysis-gluconeogenesis pathway.\n2. The glycolysis-gluconeogenesis pathway in yeast consists of 13 genes.",
    "llama-2-7b-chat-hf_fact": [
      "The largest metabolic gene cluster in yeast is related to the glycolysis-gluconeogenesis pathway.",
      "The glycolysis-gluconeogenesis pathway in yeast consists of 13 genes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN (The statement provides a specific claim, but without reference to the source passage or additional scientific data, it's not possible to confirm the accuracy of the gene cluster size in relation to metabolic pathways in yeast.)\n2. FALSE [correction]: The core glycolysis pathway typically includes 10 enzymes, which would correspond to at least 10 genes, but this may vary as there are different isozymes for some of the glycolytic enzymes in yeast like Saccharomyces cerevisiae. As for gluconeogenesis, some enzymes are shared with glycolysis, but additional distinct enzymes are involved. The exact gene count would also depend on the specific organism and genome annotation. The statement of 13 genes seems to amalgamate both pathways without distinguishing between shared and unique components.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false"
    ]
  },
  {
    "id": 1967,
    "user_query": "What is the role of LIMT lncRNA?",
    "llama-2-7b-chat-hf_response": "LIMT (Long Non-Coding RNA in Myeloid Lineage Transcription) is a long non-coding RNA (lncRNA) that plays a critical role in the regulation of myeloid cell differentiation and function. It is specifically expressed in myeloid cells, including granulocytes, monocytes, and macrophages, and has been shown to play a key role in the following processes:\n1. Myeloid cell differentiation: LIMT lncRNA regulates the expression of genes involved in myeloid cell differentiation, including the transcription factors PU.1 and GATA2.\n2. Immune response: LIMT lncRNA modulates the immune response by regulating the expression of genes involved in the production of cytokines and chemokines, such as TNF-alpha and CXCL10.\n3. Inflammation: LIMT lncRNA has been shown to regulate the production of pro-inflammatory cytokines, such as IL-6 and IL-8, in response to inflammatory stimuli.\n4. Cancer: LIMT lncRNA has been implicated in the development and progression of myeloid malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).\nOverall, the role of LIMT lncRNA is to regulate the expression of genes involved in myeloid cell differentiation, immune response, inflammation, and cancer, and its dysregulation has been implicated in a variety of diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. LIMT lncRNA is involved in the regulation of myeloid cell differentiation and function.\n2. It regulates the expression of genes involved in myeloid cell differentiation, including transcription factors PU.1 and GATA2.\n3. LIMT lncRNA modulates the immune response by regulating genes involved in cytokine and chemokine production, such as TNF-alpha and CXCL10.\n4. LIMT lncRNA regulates the production of pro-inflammatory cytokines like IL-6 and IL-8 in response to inflammatory stimuli.\n5. It has been implicated in the development and progression of myeloid malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).",
    "llama-2-7b-chat-hf_fact": [
      "LIMT lncRNA is involved in the regulation of myeloid cell differentiation and function.",
      "It regulates the expression of genes involved in myeloid cell differentiation, including transcription factors PU.1 and GATA2.",
      "LIMT lncRNA modulates the immune response by regulating genes involved in cytokine and chemokine production, such as TNF-alpha and CXCL10.",
      "LIMT lncRNA regulates the production of pro-inflammatory cytokines like IL-6 and IL-8 in response to inflammatory stimuli.",
      "It has been implicated in the development and progression of myeloid malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nAll the statements are consistent with known functions of some long non-coding RNAs (lncRNAs) in the regulation of myeloid cell differentiation and functions. LncRNAs are known to play key roles in gene regulation, immune response, and have been implicated in various diseases, including malignancies such as AML and MDS. Without specific references to contradict these statements, they appear to be true based on current scientific understanding. However, please note that the specifics can vary, and without a specific reference to \"LIMT lncRNA,\" these responses assume that \"LIMT lncRNA\" shares these properties that are common to lncRNAs involved in myeloid cell regulation.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1984,
    "user_query": "Which R / bioconductor package is used for performing SNP enrichment analysis?",
    "llama-2-7b-chat-hf_response": "There are several R packages and bioconductor packages that can be used for performing SNP (single nucleotide polymorphism) enrichment analysis. Some of the commonly used packages are:\n1. \"SNPs\" package: This package provides a comprehensive set of functions for SNP analysis, including enrichment analysis.\n2. \"MAS5\" package: This package is a widely used tool for SNP enrichment analysis and can be used to identify overrepresented SNPs in a set of genes.\n3. \"GSEA\" package: This package is a popular tool for gene set enrichment analysis, which can be used to identify overrepresented gene sets in a set of SNPs.\n4. \"ENSA\" package: This package provides a comprehensive set of functions for SNP enrichment analysis, including gene set enrichment analysis.\n5. \"SNPEnrich\" package: This package provides a simple and efficient way to perform SNP enrichment analysis using a variety of methods.\n6. \"SNPsifter\" package: This package provides a comprehensive set of functions for SNP analysis, including enrichment analysis.\n7. \"GenomicRanges\" package: This package provides a comprehensive set of functions for genomic range analysis, which can be used to identify overrepresented SNPs in a set of genes.\n8. \"GSEA2\" package: This package is a updated version of the popular GSEA package and provides improved performance and functionality for SNP enrichment analysis.\n9. \"SNPEnricher\" package: This package provides a comprehensive set of functions for SNP enrichment analysis, including gene set enrichment analysis.\n10. \"Genome-Wide Association Study\" (GWAS) package: This package provides a comprehensive set of functions for performing GWAS, which can be used to identify SNPs associated with a trait or disease.\nIt's worth noting that the choice of package will depend on the specific requirements of the analysis and the type of data being analyzed.",
    "llama-2-7b-chat-hf_fact_raw": "1. The \"SNPs\" package in R provides functions for SNP analysis, including enrichment analysis.\n2. The \"MAS5\" package is used for SNP enrichment analysis to identify overrepresented SNPs in a set of genes.\n3. \"GSEA\" is an R package used for gene set enrichment analysis to identify overrepresented gene sets in a set of SNPs.\n4. The \"ENSA\" package provides functions for SNP enrichment analysis, including gene set enrichment analysis.\n5. The \"GenomicRanges\" package is used for genomic range analysis, which can help in identifying overrepresented SNPs in a set of genes.",
    "llama-2-7b-chat-hf_fact": [
      "The \"SNPs\" package in R provides functions for SNP analysis, including enrichment analysis.",
      "The \"MAS5\" package is used for SNP enrichment analysis to identify overrepresented SNPs in a set of genes.",
      "\"GSEA\" is an R package used for gene set enrichment analysis to identify overrepresented gene sets in a set of SNPs.",
      "The \"ENSA\" package provides functions for SNP enrichment analysis, including gene set enrichment analysis.",
      "The \"GenomicRanges\" package is used for genomic range analysis, which can help in identifying overrepresented SNPs in a set of genes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The existence of an R package specifically named \"SNPs\" providing functions for SNP analysis, including enrichment analysis, cannot be verified without further context or an official source confirming its features. The term \"SNP\" is commonly associated with single nucleotide polymorphisms, and there are R packages for SNP analysis, but whether \"SNPs\" is a package with the described capabilities is not clear.\n\n2. FALSE [correction]: The \"MAS5\" algorithm is actually associated with microarray data analysis, specifically for gene expression, not for SNP enrichment analysis. It stands for \"MicroArray Suite 5.0\" and is used to process Affymetrix microarray data.\n\n3. FALSE [correction]: \"GSEA\" stands for Gene Set Enrichment Analysis, which is a method for interpreting gene expression data. The goal of GSEA is to determine whether an a priori defined set of genes shows statistically significant, concordant differences between two biological states. It is not typically used for analyzing sets of SNPs as part of its core functionality.\n\n4. UNKNOWN: The \"ENSA\" package is not a well-known package in bioinformatics. Without additional context, it is not possible to confirm the existence of this package or what its functions are. There are many packages available for enrichment analysis, but without specific information, the existence and features of an \"ENSA\" package cannot be verified.\n\n5. TRUE: The \"GenomicRanges\" package is indeed used for representing and manipulating genomic ranges and annotations in R. It is part of the Bioconductor project and is designed to work with range-based queries, which could aid in identifying overrepresented features, like SNPs, in a set of genes.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2015,
    "user_query": "Which are the key players on radial glial specification to ependymal cells?",
    "llama-2-7b-chat-hf_response": "Radial glial cells are intermediate progenitors that give rise to ependymal cells in the developing brain. The key players involved in radial glial specification to ependymal cells include:\n1. Notch signaling: Notch is a critical regulator of radial glial cell fate and differentiation. Notch signaling promotes the maintenance of radial glial cells and their specification to ependymal cells.\n2. Wnt/β-catenin signaling: Wnt/β-catenin signaling also plays a crucial role in radial glial cell fate determination and differentiation. Wnt/β-catenin signaling promotes the transition of radial glial cells to ependymal cells.\n3. Shh signaling: Shh signaling is also involved in the regulation of radial glial cell fate and differentiation. Shh signaling promotes the maintenance of radial glial cells and their specification to ependymal cells.\n4. BMP signaling: BMP signaling can also regulate radial glial cell fate and differentiation, promoting the transition of radial glial cells to ependymal cells.\n5. FGF signaling: FGF signaling can also play a role in radial glial cell fate determination and differentiation, promoting the transition of radial glial cells to ependymal cells.\nThese signaling pathways work together to regulate the specification of radial glial cells to ependymal cells during brain development.",
    "llama-2-7b-chat-hf_fact_raw": "1. Notch signaling is a critical regulator of radial glial cell fate and differentiation, promoting their maintenance and specification to ependymal cells.\n2. Wnt/β-catenin signaling plays a crucial role in radial glial cell fate determination and differentiation, promoting the transition of radial glial cells to ependymal cells.\n3. Shh signaling is involved in the regulation of radial glial cell fate and differentiation, promoting the maintenance of radial glial cells and their specification to ependymal cells.\n4. BMP signaling can regulate radial glial cell fate and differentiation, promoting the transition of radial glial cells to ependymal cells.\n5. FGF signaling can play a role in radial glial cell fate determination and differentiation, promoting the transition of radial glial cells to ependymal cells.",
    "llama-2-7b-chat-hf_fact": [
      "Notch signaling is a critical regulator of radial glial cell fate and differentiation, promoting their maintenance and specification to ependymal cells.",
      "Wnt/β-catenin signaling plays a crucial role in radial glial cell fate determination and differentiation, promoting the transition of radial glial cells to ependymal cells.",
      "Shh signaling is involved in the regulation of radial glial cell fate and differentiation, promoting the maintenance of radial glial cells and their specification to ependymal cells.",
      "BMP signaling can regulate radial glial cell fate and differentiation, promoting the transition of radial glial cells to ependymal cells.",
      "FGF signaling can play a role in radial glial cell fate determination and differentiation, promoting the transition of radial glial cells to ependymal cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Wnt/β-catenin signaling plays a role in the regulation of radial glial cell fate but it is generally not associated with promoting the transition to ependymal cells. Instead, it influences the proliferation and neurogenesis of radial glial cells.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2065,
    "user_query": "How are triple negative gliomas characterized?",
    "llama-2-7b-chat-hf_response": "Triple negative gliomas are a type of glioma, which is a type of brain cancer, that are characterized by the lack of expression of certain proteins that are typically used as markers for glioma diagnosis and prognosis. These proteins include:\n* Tumor suppressor proteins, such as p53 and PTEN\n* Markers of glial cell lineage, such as GFAP and A2B5\n* Receptors and signaling proteins, such as EGFR and PDGFR\nThe absence of these proteins makes it difficult to classify triple negative gliomas into more specific subtypes, such as glioblastoma, astrocytoma, or oligodendroglioma, which are typically defined by their molecular and histological features. Triple negative gliomas are often aggressive and have a poor prognosis, with a five-year survival rate of around 20-30%.",
    "llama-2-7b-chat-hf_fact_raw": "1. Triple negative gliomas lack expression of certain proteins that are normally used as markers for glioma diagnosis and prognosis.\n2. The proteins not expressed in triple negative gliomas include tumor suppressor proteins such as p53 and PTEN.\n3. Triple negative gliomas do not express markers of glial cell lineage like GFAP and A2B5.\n4. Receptors and signaling proteins such as EGFR and PDGFR are not expressed in triple negative gliomas.\n5. Triple negative gliomas have a five-year survival rate of approximately 20-30%.",
    "llama-2-7b-chat-hf_fact": [
      "Triple negative gliomas lack expression of certain proteins that are normally used as markers for glioma diagnosis and prognosis.",
      "The proteins not expressed in triple negative gliomas include tumor suppressor proteins such as p53 and PTEN.",
      "Triple negative gliomas do not express markers of glial cell lineage like GFAP and A2B5.",
      "Receptors and signaling proteins such as EGFR and PDGFR are not expressed in triple negative gliomas.",
      "Triple negative gliomas have a five-year survival rate of approximately 20-30%."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: While triple negative gliomas lack expression of certain markers, tumor suppressor proteins like p53 and PTEN are not normally among the markers used to define triple negative status in gliomas. Instead, these proteins are often mutated or altered in various types of cancers, including gliomas, but not specifically used to define triple negative gliomas.\n3. TRUE\n4. UNKNOWN: Without more context, it is unclear whether EGFR and PDGFR are not expressed in triple negative gliomas as the term \"triple negative\" typically refers to the lack of expression of specific markers, which can vary based on the type of cancer.\n5. UNKNOWN: The survival rate for triple negative gliomas can vary widely and is influenced by various factors, including but not limited to, patient age, tumor location, and the aggressiveness of the tumor. Without specific data or references, it is not possible to confirm this survival rate.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2069,
    "user_query": "What is TOPAZ1?",
    "llama-2-7b-chat-hf_response": "TOPAZ1 (Topoisomerase 2-associated protein 1) is a protein that plays a role in regulating the activity of topoisomerase II, an enzyme that relaxes supercoiled DNA. TOPAZ1 is a histone chaperone that interacts with topoisomerase II and helps to recruit it to specific genomic regions, where it can perform its enzymatic functions. TOPAZ1 is involved in various cellular processes, including DNA replication, repair, and transcription, and it has been implicated in various diseases, including cancer and neurodegenerative disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. TOPAZ1 stands for Topoisomerase 2-associated protein 1.\n2. TOPAZ1 plays a role in regulating the activity of the enzyme topoisomerase II.\n3. Topoisomerase II is an enzyme that relaxes supercoiled DNA.\n4. TOPAZ1 acts as a histone chaperone that interacts with topoisomerase II.\n5. TOPAZ1 has been implicated in diseases such as cancer and neurodegenerative disorders.",
    "llama-2-7b-chat-hf_fact": [
      "TOPAZ1 stands for Topoisomerase 2-associated protein 1.",
      "TOPAZ1 plays a role in regulating the activity of the enzyme topoisomerase II.",
      "Topoisomerase II is an enzyme that relaxes supercoiled DNA.",
      "TOPAZ1 acts as a histone chaperone that interacts with topoisomerase II.",
      "TOPAZ1 has been implicated in diseases such as cancer and neurodegenerative disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: TOPAZ1 stands for Topoisomerase II-associated protein 1.\n2. UNKNOWN\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nThe correction in statement 1 is based on the common nomenclature for protein naming. The other statements regarding functions, interactions, and disease implications of TOPAZ1 cannot be verified without a specific passage or scientific literature providing that information.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2075,
    "user_query": "Which gene controls the expression of GATA-1 isoforms?",
    "llama-2-7b-chat-hf_response": "The gene that controls the expression of GATA-1 isoforms is the GATA-1 gene itself. GATA-1 is a transcription factor that is involved in the regulation of gene expression during hematopoiesis, and it has multiple isoforms that are produced through alternative splicing. The expression of these isoforms is controlled by the GATA-1 gene, which contains different exons that are spliced together to produce the different isoforms.",
    "llama-2-7b-chat-hf_fact_raw": "1. The GATA-1 gene controls the expression of its own isoforms.\n2. GATA-1 is a transcription factor involved in the regulation of gene expression during hematopoiesis.\n3. GATA-1 has multiple isoforms.\n4. These isoforms are produced through alternative splicing.\n5. The GATA-1 gene contains different exons that are spliced together to produce the different isoforms.",
    "llama-2-7b-chat-hf_fact": [
      "The GATA-1 gene controls the expression of its own isoforms.",
      "GATA-1 is a transcription factor involved in the regulation of gene expression during hematopoiesis.",
      "GATA-1 has multiple isoforms.",
      "These isoforms are produced through alternative splicing.",
      "The GATA-1 gene contains different exons that are spliced together to produce the different isoforms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2076,
    "user_query": "What is MIRA-seq?",
    "llama-2-7b-chat-hf_response": "MIRA-seq is a genomic technique used to study the regulation of gene expression at the level of RNA molecules. MIRA (Microarray for In situ RNA Analysis) is a method that allows for the analysis of RNA molecules in their native context within cells and tissues, without the need for RNA isolation or purification.\nIn MIRA-seq, cells or tissues are fixed and embedded in a matrix, and then probed with a microarray containing thousands of known RNA sequences. The array is then scanned to detect the presence and abundance of specific RNA molecules in the sample. This allows researchers to identify and quantify the expression of specific RNA transcripts in different cells or tissues, and to study the regulation of gene expression at the level of RNA molecules.\nMIRA-seq has several advantages over other methods for studying RNA expression, including its high sensitivity and resolution, its ability to detect rare or novel transcripts, and its ability to study RNA expression in a spatially-resolved manner. It has been used to study a wide range of biological processes, including development, cell differentiation, and disease progression.",
    "llama-2-7b-chat-hf_fact_raw": "1. MIRA-seq is a genomic technique used to study the regulation of gene expression at the RNA level.\n2. MIRA (Microarray for In situ RNA Analysis) enables analysis of RNA molecules within their native context in cells and tissues.\n3. MIRA-seq involves fixing and embedding cells or tissues in a matrix, then probing with a microarray.\n4. MIRA-seq's array detects the presence and abundance of specific RNA molecules in the sample.\n5. MIRA-seq has been used in research to study development, cell differentiation, and disease progression.",
    "llama-2-7b-chat-hf_fact": [
      "MIRA-seq is a genomic technique used to study the regulation of gene expression at the RNA level.",
      "MIRA (Microarray for In situ RNA Analysis) enables analysis of RNA molecules within their native context in cells and tissues.",
      "MIRA-seq involves fixing and embedding cells or tissues in a matrix, then probing with a microarray.",
      "MIRA-seq's array detects the presence and abundance of specific RNA molecules in the sample.",
      "MIRA-seq has been used in research to study development, cell differentiation, and disease progression."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: MIRA-seq, or \"Methylated-CpG Island Recovery Assay sequencing,\" is a genomic technique used to study DNA methylation patterns at the epigenetic level, not RNA expression.\n2. FALSE [correction]: The statement likely confuses MIRA with other methods used for in situ RNA analysis, like fluorescent in situ hybridization (FISH). MIRA does not specifically analyze RNA molecules within cells and tissues.\n3. FALSE [correction]: Since MIRA-seq is related to studying DNA methylation, it does not involve fixing and embedding cells or tissues for RNA probing with a microarray as stated. Instead, it involves bisulfite treatment and PCR to analyze methylation states.\n4. FALSE [correction]: Since MIRA-seq is not related to RNA analysis, the statement about an array detecting the presence and abundance of specific RNA molecules is incorrect. MIRA-seq uses sequencing, usually next-generation sequencing, to determine the methylation state of CpG islands.\n5. UNKNOWN\n\nNote: MIRA-seq as described in statement 1 is used for DNA methylation analysis, and statements 2, 3, and 4 seem to confuse this technique with RNA analysis technologies. The use of MIRA-seq in specific areas of research may be true, but without specific reference to how it has been applied (considering it is for DNA methylation studies), this statement's accuracy cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2108,
    "user_query": "What is the indication of ARCALYST?",
    "llama-2-7b-chat-hf_response": "ARCALYST (rilonacept) is a prescription medication used to treat a rare genetic disorder called cryopyrin-associated periodic syndrome (CAPS) in adults and children aged 12 years and older. It is also used to treat a related disorder called pyogenic sterile arthritis (PSA) in adults and children aged 12 years and older. CAPS and PSA are caused by a deficiency of the enzyme NLRC4, which is involved in the regulation of inflammation. By replacing the missing enzyme, ARCALYST helps to reduce the symptoms of these disorders, which can include recurring fever, joint pain, and swelling.",
    "llama-2-7b-chat-hf_fact_raw": "1. ARCALYST (rilonacept) is used to treat cryopyrin-associated periodic syndrome (CAPS) in adults and children aged 12 and older.\n2. ARCALYST is also used to treat pyogenic sterile arthritis (PSA) in adults and children aged 12 years and older.\n3. CAPS and PSA are caused by a deficiency of the enzyme NLRC4.\n4. ARCALYST works by replacing the missing NLRC4 enzyme, which is involved in the regulation of inflammation.\n5. Symptoms of CAPS and PSA can include recurring fever, joint pain, and swelling.",
    "llama-2-7b-chat-hf_fact": [
      "ARCALYST (rilonacept) is used to treat cryopyrin-associated periodic syndrome (CAPS) in adults and children aged 12 and older.",
      "ARCALYST is also used to treat pyogenic sterile arthritis (PSA) in adults and children aged 12 years and older.",
      "CAPS and PSA are caused by a deficiency of the enzyme NLRC4.",
      "ARCALYST works by replacing the missing NLRC4 enzyme, which is involved in the regulation of inflammation.",
      "Symptoms of CAPS and PSA can include recurring fever, joint pain, and swelling."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: ARCALYST (rilonacept) is currently not approved for the treatment of pyogenic sterile arthritis (PSA). It is commonly used to treat CAPS and other conditions related to uncontrolled inflammation.\n3. FALSE [correction]: CAPS is caused by mutations in the NLRP3 gene, which leads to the overproduction of a protein called interleukin-1β (IL-1β), causing inflammation. PSA is an entirely different condition and not specifically related to deficiencies in the enzyme NLRC4.\n4. FALSE [correction]: ARCALYST does not replace the missing NLRC4 enzyme because NLRC4 deficiency isn't the issue in CAPS. Instead, ARCALYST is an interleukin-1 blocker that binds to and inactivates interleukin-1, a protein involved in the inflammatory response.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 2170,
    "user_query": "List the human acrocentric chromosomes that are involved in Robertsonian translocation.",
    "llama-2-7b-chat-hf_response": "Robertsonian translocations involve the exchange of a segment of chromosomal material between two acrocentric chromosomes, which are characterized by their terminal centromere. The following are the human acrocentric chromosomes that can be involved in Robertsonian translocations:\n1. Chromosome 13\n2. Chromosome 14\n3. Chromosome 15\n4. Chromosome 21\nRobertsonian translocations involving these chromosomes can result in a variety of genetic disorders, including Down syndrome (trisomy 21), Turner syndrome (monosomy 45, X), and Klinefelter syndrome (XXY).",
    "llama-2-7b-chat-hf_fact_raw": "1. Robertsonian translocations involve the exchange of chromosomal material between two acrocentric chromosomes.\n2. Acrocentric chromosomes are characterized by their terminal centromere.\n3. Human acrocentric chromosomes that can be involved in Robertsonian translocations include chromosome 13, chromosome 14, chromosome 15, and chromosome 21.\n4. Robertsonian translocations can result in genetic disorders such as Down syndrome (trisomy 21).",
    "llama-2-7b-chat-hf_fact": [
      "Robertsonian translocations involve the exchange of chromosomal material between two acrocentric chromosomes.",
      "Acrocentric chromosomes are characterized by their terminal centromere.",
      "Human acrocentric chromosomes that can be involved in Robertsonian translocations include chromosome 13, chromosome 14, chromosome 15, and chromosome 21.",
      "Robertsonian translocations can result in genetic disorders such as Down syndrome (trisomy 21)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Acrocentric chromosomes are characterized by their centromere being close to one end, creating a long arm and a very short (often not visible) other arm.\n3. FALSE [correction]: Human acrocentric chromosomes that can be involved in Robertsonian translocations include chromosome 13, chromosome 14, chromosome 15, chromosome 21, and chromosome 22.\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 2237,
    "user_query": "Which R package could be used for the identification of pediatric brain tumors?",
    "llama-2-7b-chat-hf_response": "The R package \"survival\" could be used for the identification of pediatric brain tumors. This package provides functions for survival analysis, which can be used to analyze the time-to-event data (e.g. time to disease progression or death) in medical datasets, including those related to brain tumors.\nSome of the key functions in the \"survival\" package that could be used for identifying pediatric brain tumors include:\n* \"surv\": This function estimates the survival function, which describes the probability of surviving beyond a certain time point, given the time of diagnosis or other covariates.\n* \"failure\": This function estimates the failure time, which is the time of death or failure (e.g. disease progression) for a patient.\n* \"coxph\": This function fits a Cox proportional hazards model, which is a commonly used statistical model for survival analysis. The model estimates the effect of covariates on the hazard rate (i.e. the rate at which the event occurs over time), while controlling for other variables in the model.\n* \"rpart\": This function fits a recursive partitioning model, which is a type of decision tree that can be used to identify subgroups of patients with different survival outcomes.\nBy using these functions, researchers could analyze the time-to-event data for pediatric brain tumors and identify subgroups of patients with different survival outcomes, which could help inform personalized treatment strategies.",
    "llama-2-7b-chat-hf_fact_raw": "1. The R package \"survival\" provides functions for survival analysis.\n2. The \"survival\" package includes a function called \"surv\" that estimates the survival function describing the probability of surviving past a certain time point.\n3. The \"survival\" package has a function named \"failure\" that estimates the failure time for a patient.\n4. The \"coxph\" function in the \"survival\" package fits a Cox proportional hazards model for survival analysis.\n5. The \"rpart\" function in the \"survival\" package fits a recursive partitioning model, which can aid in identifying subgroups of patients with different survival outcomes.",
    "llama-2-7b-chat-hf_fact": [
      "The R package \"survival\" provides functions for survival analysis.",
      "The \"survival\" package includes a function called \"surv\" that estimates the survival function describing the probability of surviving past a certain time point.",
      "The \"survival\" package has a function named \"failure\" that estimates the failure time for a patient.",
      "The \"coxph\" function in the \"survival\" package fits a Cox proportional hazards model for survival analysis.",
      "The \"rpart\" function in the \"survival\" package fits a recursive partitioning model, which can aid in identifying subgroups of patients with different survival outcomes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The \"survival\" package does not have a function named \"failure\". The function that estimates survival times is \"Surv\", which creates a survival object.\n4. TRUE\n5. FALSE [correction]: The \"rpart\" function is not part of the \"survival\" package. It is part of the \"rpart\" package that fits recursive partitioning models, which can, among other things, be used for survival analysis.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 2246,
    "user_query": "Is NEMO a zinc finger protein?",
    "llama-2-7b-chat-hf_response": "No, NEMO (NF-κB essential modulator) is not a zinc finger protein. NEMO is a protein that plays a crucial role in the regulation of NF-κB (nuclear factor kappa B), a transcription factor that regulates inflammation and immune responses. While NEMO does contain some zinc finger-like domains, it is not primarily a zinc finger protein.",
    "llama-2-7b-chat-hf_fact_raw": "1. NEMO stands for NF-κB essential modulator.\n2. NEMO is not classified as a zinc finger protein.\n3. NEMO plays a crucial role in the regulation of NF-κB, a transcription factor.\n4. NF-κB is involved in regulating inflammation and immune responses.\n5. NEMO contains some zinc finger-like domains.",
    "llama-2-7b-chat-hf_fact": [
      "NEMO stands for NF-κB essential modulator.",
      "NEMO is not classified as a zinc finger protein.",
      "NEMO plays a crucial role in the regulation of NF-κB, a transcription factor.",
      "NF-κB is involved in regulating inflammation and immune responses.",
      "NEMO contains some zinc finger-like domains."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: NEMO does not contain zinc finger-like domains; it interacts with components of the NF-κB pathway through other types of domains and motifs.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2247,
    "user_query": "Does TFIIS affect nucleosome positioning?",
    "llama-2-7b-chat-hf_response": "Yes, TFIIS (Transcription Factor IIS) can affect nucleosome positioning. TFIIS is a transcription factor that plays a role in the initiation of transcription in eukaryotic cells, and it has been shown to interact with nucleosomes and influence their positioning on the DNA. TFIIS can bind to the nucleosomal DNA and help to displace the histone H3 lysine 9 dimethyl (H3K9me2) mark, which is typically associated with compacted chromatin and transcriptional repression. By displacing this mark, TFIIS can help to recruit RNA polymerase to the promoter region and facilitate the initiation of transcription.",
    "llama-2-7b-chat-hf_fact_raw": "1. TFIIS (Transcription Factor IIS) can affect nucleosome positioning.\n2. TFIIS plays a role in the initiation of transcription in eukaryotic cells.\n3. TFIIS has been shown to interact with nucleosomes and influence their positioning on DNA.\n4. TFIIS can bind to nucleosomal DNA and help to displace the histone H3 lysine 9 dimethyl (H3K9me2) mark.\n5. Displacement of the H3K9me2 mark by TFIIS can help to recruit RNA polymerase to the promoter region.",
    "llama-2-7b-chat-hf_fact": [
      "TFIIS (Transcription Factor IIS) can affect nucleosome positioning.",
      "TFIIS plays a role in the initiation of transcription in eukaryotic cells.",
      "TFIIS has been shown to interact with nucleosomes and influence their positioning on DNA.",
      "TFIIS can bind to nucleosomal DNA and help to displace the histone H3 lysine 9 dimethyl (H3K9me2) mark.",
      "Displacement of the H3K9me2 mark by TFIIS can help to recruit RNA polymerase to the promoter region."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: TFIIS has been shown to affect nucleosome positioning through interaction with RNA polymerase II, which can in turn influence the accessibility of the DNA for transcription.\n2. TRUE: TFIIS plays a role in the elongation phase of transcription in eukaryotic cells by stimulating the transcriptional activity of RNA polymerase II.\n3. TRUE: There is evidence that TFIIS interacts with nucleosomes, which can affect their positioning on DNA and potentially facilitate transcriptional processes.\n4. UNKNOWN: Without specific evidence regarding TFIIS's role in displacing the H3K9me2 mark, this statement cannot be verified as true or false with the information provided.\n5. UNKNOWN: This statement makes a specific claim about the mechanism of TFIIS—facilitating recruitment of RNA polymerase by displacing a histone mark. However, without additional context or evidence for this mechanism, it's difficult to determine the accuracy of the statement.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2262,
    "user_query": "Do origins of replication close to yeast centromeres fire early or late?",
    "llama-2-7b-chat-hf_response": "Origins of replication near yeast centromeres typically fire late in the cell cycle.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2268,
    "user_query": "Which are the properties of mammalian GA-sequences?",
    "llama-2-7b-chat-hf_response": "Mammalian GA-sequences are characterized by the following properties:\n1. Long-range orientation: Mammalian GA-sequences are typically long-range oriented, meaning that they are oriented in the opposite direction to the major groove of the DNA molecule.\n2. High GC content: Mammalian GA-sequences have a high GC content (greater than 50%), which is higher than the average GC content of most other types of DNA sequences.\n3. High stability: Mammalian GA-sequences are highly stable and resistant to degradation, due to the presence of guanine and cytosine bases.\n4. Low melting temperature: The Tm (melting temperature) of mammalian GA-sequences is typically low, indicating that they are less stable and more prone to denaturation than other types of DNA sequences.\n5. High affinity for DNA-binding proteins: Mammalian GA-sequences have a high affinity for DNA-binding proteins, such as transcription factors and regulatory proteins, which can bind to these sequences and regulate gene expression.\n6. Important role in regulation of gene expression: Mammalian GA-sequences play an important role in the regulation of gene expression, particularly in the context of cellular differentiation and development.\n7. Widely distributed in mammalian genomes: Mammalian GA-sequences are found throughout the mammalian genome, and are particularly enriched in regions of the genome that are involved in regulation of gene expression.\n8. High degree of sequence variability: There is a high degree of sequence variability among mammalian GA-sequences, which allows for the creation of a diverse range of functional motifs and binding sites.\n9. Regulation of chromatin structure: Mammalian GA-sequences can also regulate chromatin structure, by influencing the positioning and organization of histone-modifying enzymes and other chromatin-associated proteins.\n10. Involvement in disease: Mammalian GA-sequences have been implicated in a number of diseases, including cancer and neurological disorders, although the exact mechanisms by which they contribute",
    "llama-2-7b-chat-hf_fact_raw": "1. Mammalian GA-sequences are typically long-range oriented, meaning they are oriented in the opposite direction to the major groove of the DNA molecule.\n2. Mammalian GA-sequences have a high GC content greater than 50%.\n3. Mammalian GA-sequences are highly stable and resistant to degradation due to the presence of guanine and cytosine bases.\n4. The melting temperature of mammalian GA-sequences is typically low.\n5. Mammalian GA-sequences have a high affinity for DNA-binding proteins and play an important role in the regulation of gene expression.",
    "llama-2-7b-chat-hf_fact": [
      "Mammalian GA-sequences are typically long-range oriented, meaning they are oriented in the opposite direction to the major groove of the DNA molecule.",
      "Mammalian GA-sequences have a high GC content greater than 50%.",
      "Mammalian GA-sequences are highly stable and resistant to degradation due to the presence of guanine and cytosine bases.",
      "The melting temperature of mammalian GA-sequences is typically low.",
      "Mammalian GA-sequences have a high affinity for DNA-binding proteins and play an important role in the regulation of gene expression."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The orientation of GA-sequences in relation to the major groove of DNA is not a common point of description, so without specific scientific context, this statement's validity is difficult to determine.\n2. FALSE [correction]: Mammalian GA-sequences are usually rich in guanine (G) and adenine (A) bases, not guanine and cytosine (GC). Therefore, they do not typically have a high GC content greater than 50%.\n3. FALSE [correction]: While guanine and cytosine bases do contribute to stability through their triple hydrogen bonding, the stability and resistance to degradation of mammalian GA-sequences are not necessarily high solely due to the presence of these bases. The stability can vary depending on sequence context and environmental conditions.\n4. UNKNOWN: Without specific thermo-dynamic data, the typical melting temperature of mammalian GA-sequences is difficult to evaluate. Melting temperature can be influenced by many factors, including GC content, sequence length, and environmental conditions.\n5. TRUE: Sequences in DNA, such as GA-rich motifs, are known to have an affinity for DNA-binding proteins and can be involved in the regulation of gene expression by serving as binding sites for transcription factors and other regulatory proteins.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2291,
    "user_query": "How many Groucho-related genes (GRG) are contained in the mouse genome?",
    "llama-2-7b-chat-hf_response": "According to the Ensembl database, there are 4 Groucho-related genes (GRG) contained in the mouse genome:\n1. Grm1 (Groucho-related gene 1)\n2. Grm2 (Groucho-related gene 2)\n3. Grm3 (Groucho-related gene 3)\n4. Grm4 (Groucho-related gene 4)\nNote: The number of GRG genes may vary depending on the source and method of annotation.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Ensembl database lists 4 Groucho-related genes (GRG) in the mouse genome.\n2. The mouse genome includes a gene named Grm1 which stands for Groucho-related gene 1.\n3. The mouse genome includes a gene named Grm2 which stands for Groucho-related gene 2.\n4. The mouse genome includes a gene named Grm3 which stands for Groucho-related gene 3.\n5. The mouse genome includes a gene named Grm4 which stands for Groucho-related gene 4.",
    "llama-2-7b-chat-hf_fact": [
      "The Ensembl database lists 4 Groucho-related genes (GRG) in the mouse genome.",
      "The mouse genome includes a gene named Grm1 which stands for Groucho-related gene 1.",
      "The mouse genome includes a gene named Grm2 which stands for Groucho-related gene 2.",
      "The mouse genome includes a gene named Grm3 which stands for Groucho-related gene 3.",
      "The mouse genome includes a gene named Grm4 which stands for Groucho-related gene 4."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The exact number of Groucho-related genes listed in the Ensembl database for the mouse genome requires verification from current Ensembl genomic data.\n2. FALSE [correction]: The Grm1 gene in the mouse genome stands for \"glutamate metabotropic receptor 1,\" not Groucho-related gene 1.\n3. FALSE [correction]: The Grm2 gene in the mouse genome stands for \"glutamate metabotropic receptor 2,\" not Groucho-related gene 2.\n4. FALSE [correction]: The Grm3 gene in the mouse genome stands for \"glutamate metabotropic receptor 3,\" not Groucho-related gene 3.\n5. FALSE [correction]: The Grm4 gene in the mouse genome stands for \"glutamate metabotropic receptor 4,\" not Groucho-related gene 4.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 2304,
    "user_query": "Which RNA polymerase II subunit carries RNA cleavage activity?",
    "llama-2-7b-chat-hf_response": "RNA polymerase II subunit RPB1 (also known as RNA polymerase II subunit B1) carries the RNA cleavage activity.",
    "llama-2-7b-chat-hf_fact_raw": "1. RNA polymerase II has a subunit that carries RNA cleavage activity.\n2. The subunit with RNA cleavage activity in RNA polymerase II is referred to as RPB1.\n3. RPB1 is also known as RNA polymerase II subunit B1.",
    "llama-2-7b-chat-hf_fact": [
      "RNA polymerase II has a subunit that carries RNA cleavage activity.",
      "The subunit with RNA cleavage activity in RNA polymerase II is referred to as RPB1.",
      "RPB1 is also known as RNA polymerase II subunit B1."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: RNA polymerase II does not have a subunit that carries RNA cleavage activity. It is responsible for transcribing mRNA. The RNA cleavage activity in eukaryotes is generally carried out by a different set of proteins, such as the CPSF complex involved in cleavage and polyadenylation.\n2. FALSE [correction]: RPB1 is not the subunit with RNA cleavage activity; it is, in fact, the largest subunit of RNA polymerase II that is part of the enzyme's core and essential for its activity. RNA cleavage is not a function of RNA polymerase II itself.\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 2321,
    "user_query": "What is the genetic basis of Ohdo syndrome?",
    "llama-2-7b-chat-hf_response": "Ohdo syndrome is caused by mutations in the PTPN11 gene, which encodes the protein tyrosine phosphatase non-receptor type 11 (PTPN11). PTPN11 is a negative regulator of the RAS/MAPK signaling pathway, which is important for cell growth and differentiation. Mutations in the PTPN11 gene lead to the loss of PTPN11 function, resulting in the activation of the RAS/MAPK pathway and the development of Ohdo syndrome.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ohdo syndrome is caused by mutations in the PTPN11 gene.\n2. The PTPN11 gene encodes the protein tyrosine phosphatase non-receptor type 11.\n3. PTPN11 functions as a negative regulator of the RAS/MAPK signaling pathway.\n4. The RAS/MAPK signaling pathway is important for cell growth and differentiation.\n5. Loss of PTPN11 function due to mutations leads to activation of the RAS/MAPK pathway, which results in the development of Ohdo syndrome.",
    "llama-2-7b-chat-hf_fact": [
      "Ohdo syndrome is caused by mutations in the PTPN11 gene.",
      "The PTPN11 gene encodes the protein tyrosine phosphatase non-receptor type 11.",
      "PTPN11 functions as a negative regulator of the RAS/MAPK signaling pathway.",
      "The RAS/MAPK signaling pathway is important for cell growth and differentiation.",
      "Loss of PTPN11 function due to mutations leads to activation of the RAS/MAPK pathway, which results in the development of Ohdo syndrome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Ohdo syndrome is typically caused by mutations in the MED12 gene, although there are other genes that have also been associated with the syndrome.\n2. TRUE\n3. FALSE [correction]: PTPN11 functions as a positive regulator of the RAS/MAPK signaling pathway.\n4. TRUE\n5. FALSE [correction]: Typically, gain-of-function mutations in PTPN11 lead to activation of the RAS/MAPK pathway; loss-of-function mutations would generally lead to the inhibition or reduction of pathway activity. However, the specific relationship between PTPN11 function and Ohdo syndrome would depend on the nature of the mutations involved and the exact pathogenic mechanisms, which might vary.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 2331,
    "user_query": "Which R/Bioconductor package has been developed for the analysis of psychiatric disease genes?",
    "llama-2-7b-chat-hf_response": "The R/Bioconductor package \"psychgene\" has been developed for the analysis of psychiatric disease genes. It provides tools for the analysis of genetic data in psychiatric disorders, including gene-level association testing, gene-gene interaction analysis, and pathway analysis.",
    "llama-2-7b-chat-hf_fact_raw": "1. The \"psychgene\" package has been developed for the analysis of psychiatric disease genes.\n2. It is an R/Bioconductor package.\n3. The package provides tools for gene-level association testing.\n4. The package includes tools for gene-gene interaction analysis.\n5. It offers pathway analysis tools for genetic data in psychiatric disorders.",
    "llama-2-7b-chat-hf_fact": [
      "The \"psychgene\" package has been developed for the analysis of psychiatric disease genes.",
      "It is an R/Bioconductor package.",
      "The package provides tools for gene-level association testing.",
      "The package includes tools for gene-gene interaction analysis.",
      "It offers pathway analysis tools for genetic data in psychiatric disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific context or additional information about the \"psychgene\" package, it is not possible to determine the veracity of these statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2360,
    "user_query": "Describe swirl sign in intracerebral hemorrhage.",
    "llama-2-7b-chat-hf_response": "The \"swirl sign\" is a clinical sign that can be observed in patients with intracerebral hemorrhage (ICH), which is a type of stroke caused by bleeding in the brain. The sign is characterized by a swirling or spiral pattern of brain tissue surrounding the site of the hemorrhage.\nThe swirl sign is typically seen on computed tomography (CT) or magnetic resonance imaging (MRI) scans of the brain, and is caused by the movement of the brain tissue due to the bleeding. The sign can be seen in the form of a spiral or wavy pattern, which can be quite distinctive and can help doctors to identify the location and extent of the hemorrhage.\nThe swirl sign is thought to occur due to the displacement of brain tissue caused by the bleeding, which can cause the tissue to move in a spiral or wavy pattern. This displacement can be caused by the direct pressure of the hemorrhage on the surrounding brain tissue, or by the movement of the blood in the brain vessels.\nThe swirl sign can be an important diagnostic clue in the evaluation of patients with ICH, as it can help doctors to identify the location and extent of the hemorrhage. However, it is not a definitive diagnostic sign, and other imaging findings, such as the location and size of the hemorrhage, the presence of edema, and the involvement of nearby structures, should also be taken into account in the diagnosis and management of ICH.",
    "llama-2-7b-chat-hf_fact_raw": "1. The \"swirl sign\" is a clinical sign observed in intracerebral hemorrhage (ICH).\n2. The swirl sign is characterized by a swirling or spiral pattern of brain tissue surrounding the site of the hemorrhage.\n3. This sign is typically seen on computed tomography (CT) scans or magnetic resonance imaging (MRI) of the brain.\n4. The swirl sign can indicate the location and extent of the hemorrhage.\n5. The swirl sign is caused by the displacement of brain tissue due to bleeding.",
    "llama-2-7b-chat-hf_fact": [
      "The \"swirl sign\" is a clinical sign observed in intracerebral hemorrhage (ICH).",
      "The swirl sign is characterized by a swirling or spiral pattern of brain tissue surrounding the site of the hemorrhage.",
      "This sign is typically seen on computed tomography (CT) scans or magnetic resonance imaging (MRI) of the brain.",
      "The swirl sign can indicate the location and extent of the hemorrhage.",
      "The swirl sign is caused by the displacement of brain tissue due to bleeding."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The swirl sign is characterized by the presence of a heterogeneous density with areas of low attenuation within a hematoma on a CT scan, which represents active bleeding within the hematoma, not a swirling or spiral pattern of brain tissue.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The swirl sign is not caused by the displacement of brain tissue but rather indicates active bleeding within the hematoma, as seen by the presence of mixed blood density within the clot on imaging.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2392,
    "user_query": "What induces Arabidopsis ROF1 expression?",
    "llama-2-7b-chat-hf_response": "Arabidopsis ROF1 (RNA polymerase II-associated factor 1) expression is induced by various environmental and developmental signals, including:\n1. Light: Light signals can induce ROF1 expression in Arabidopsis, particularly blue light.\n2. Temperature: High temperatures can also induce ROF1 expression in Arabidopsis.\n3. Water availability: ROF1 expression can be induced in response to drought stress in Arabidopsis.\n4. Hormones: ROF1 expression can be regulated by various hormones, including abscisic acid (ABA), ethylene, and cytokinin.\n5. Developmental cues: ROF1 expression can also be induced during specific stages of plant development, such as during seedling establishment or floral development.",
    "llama-2-7b-chat-hf_fact_raw": "1. Light signals, especially blue light, can induce ROF1 expression in Arabidopsis.\n2. High temperatures can induce ROF1 expression in Arabidopsis.\n3. Drought stress can induce ROF1 expression in Arabidopsis.\n4. ROF1 expression in Arabidopsis can be regulated by hormones including abscisic acid (ABA), ethylene, and cytokinin.\n5. ROF1 expression can be induced during specific developmental stages in Arabidopsis, such as during seedling establishment or floral development.",
    "llama-2-7b-chat-hf_fact": [
      "Light signals, especially blue light, can induce ROF1 expression in Arabidopsis.",
      "High temperatures can induce ROF1 expression in Arabidopsis.",
      "Drought stress can induce ROF1 expression in Arabidopsis.",
      "ROF1 expression in Arabidopsis can be regulated by hormones including abscisic acid (ABA), ethylene, and cytokinin.",
      "ROF1 expression can be induced during specific developmental stages in Arabidopsis, such as during seedling establishment or floral development."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Light signals, particularly blue light, are known to affect various plant processes and can induce gene expression in Arabidopsis.\n2. TRUE: High temperatures are a form of abiotic stress that can induce the expression of certain heat shock proteins and genes such as ROF1 in plants.\n3. TRUE: Drought stress is a type of environmental stress that can lead to the induction of various stress response genes, including ROF1, in plants like Arabidopsis.\n4. TRUE: Hormones such as abscisic acid (ABA), ethylene, and cytokinin are key regulators of plant growth and stress responses and can regulate the expression of genes like ROF1.\n5. TRUE: The expression of genes like ROF1 can indeed be induced during specific developmental stages like seedling establishment or floral development as plants adapt their growth and development to changing conditions.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2398,
    "user_query": "What protein is the most common cause of hereditary  renal amyloidosis?",
    "llama-2-7b-chat-hf_response": "The most common cause of hereditary renal amyloidosis is the protein alpha-2-macroglobulin (A2M).",
    "llama-2-7b-chat-hf_fact_raw": "1. The protein alpha-2-macroglobulin (A2M) is the most common cause of hereditary renal amyloidosis.",
    "llama-2-7b-chat-hf_fact": [
      "The protein alpha-2-macroglobulin (A2M) is the most common cause of hereditary renal amyloidosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The most common cause of hereditary renal amyloidosis is mutations in the genes encoding for proteins such as transthyretin (TTR), fibrinogen A alpha-chain, apolipoprotein A-I, and lysozyme. Alpha-2-macroglobulin is not the most common cause.",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 2407,
    "user_query": "Has the proteome of mice hippocampus been analysed?",
    "llama-2-7b-chat-hf_response": "Yes, the proteome of the mouse hippocampus has been extensively analyzed using various proteomics techniques. The hippocampus is a complex brain structure involved in memory formation, spatial navigation, and emotion regulation, and its proteome has been studied in various contexts, including development, aging, and disease.\nSome of the key findings from these studies include:\n1. Identification of novel proteins: Many proteins have been identified in the mouse hippocampus for the first time, including proteins involved in synaptic plasticity, neurotransmission, and protein degradation.\n2. Alterations in protein expression: Studies have shown that the expression of certain proteins changes in the hippocampus under different conditions, such as aging, disease, or exposure to drugs. For example, some studies have found that the expression of the synaptic plasticity protein, Arc, decreases with age, while others have found that the expression of the inflammatory protein, TNF-alpha, increases in response to stress.\n3. Protein modification: The hippocampus is rich in post-translational modifications (PTMs), such as phosphorylation and ubiquitination, which play important roles in regulating protein function. Studies have identified many PTMs in the hippocampus, including those involved in synaptic plasticity and memory formation.\n4. Protein-protein interactions: The hippocampus is a complex tissue with many proteins interacting with each other to regulate synaptic plasticity and memory formation. Studies have identified many protein-protein interactions in the hippocampus, including those involving the N-methyl-D-aspartate (NMDA) receptor, the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor, and the CaMKII (calcium/calmodulin-dependent protein kinase II) protein.\n5. Regulation of protein localization: The hippocampus is a dynamic tissue with proteins localizing to different subcellular regions to regulate synaptic plasticity and memory formation. Studies have identified many proteins that are localized to specific subcell",
    "llama-2-7b-chat-hf_fact_raw": "1. Proteomic techniques have been used to analyze the proteome of the mouse hippocampus.\n2. Proteins involved in synaptic plasticity, neurotransmission, and protein degradation have been identified in the mouse hippocampus for the first time.\n3. The expression of the synaptic plasticity protein Arc decreases with age in the mouse hippocampus.\n4. The expression of the inflammatory protein TNF-alpha increases in the mouse hippocampus in response to stress.\n5. Post-translational modifications important for synaptic plasticity and memory formation have been identified in the mouse hippocampus.",
    "llama-2-7b-chat-hf_fact": [
      "Proteomic techniques have been used to analyze the proteome of the mouse hippocampus.",
      "Proteins involved in synaptic plasticity, neurotransmission, and protein degradation have been identified in the mouse hippocampus for the first time.",
      "The expression of the synaptic plasticity protein Arc decreases with age in the mouse hippocampus.",
      "The expression of the inflammatory protein TNF-alpha increases in the mouse hippocampus in response to stress.",
      "Post-translational modifications important for synaptic plasticity and memory formation have been identified in the mouse hippocampus."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Proteins involved in synaptic plasticity, neurotransmission, and protein degradation have been identified in the mouse hippocampus, but it is unlikely that this is the first time they have been identified given the history and depth of proteomic research.\n3. TRUE (assuming research supports this statement; generally, age-related changes in protein expression such as Arc's decrease are well-documented in neuroscientific literature).\n4. TRUE (assuming research supports this statement; it is known that stress can lead to increases in pro-inflammatory cytokines like TNF-alpha).\n5. TRUE (assuming that scientific studies support this statement; post-translational modifications are a key area of study in the field of proteomics and their role in synaptic plasticity and memory formation is a significant topic of interest).",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2409,
    "user_query": "Are mouse chromosomes acrocentric?",
    "llama-2-7b-chat-hf_response": "No, mouse chromosomes are not acrocentric. Acrocentric chromosomes are a type of chromosome found in some organisms, including some bacteria and fungi, where the centromere is located near the telomere, or the end of the chromosome. In contrast, mouse chromosomes are metacentric, meaning that the centromere is located near the center of the chromosome.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mouse chromosomes are not acrocentric.\n2. Acrocentric chromosomes have the centromere located near the telomere.\n3. Acrocentric chromosomes are found in some bacteria and fungi.\n4. Mouse chromosomes are metacentric, which means their centromere is located near the center of the chromosome.",
    "llama-2-7b-chat-hf_fact": [
      "Mouse chromosomes are not acrocentric.",
      "Acrocentric chromosomes have the centromere located near the telomere.",
      "Acrocentric chromosomes are found in some bacteria and fungi.",
      "Mouse chromosomes are metacentric, which means their centromere is located near the center of the chromosome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Mouse chromosomes are acrocentric.\n2. TRUE\n3. FALSE [correction]: Acrocentric chromosomes are not typically found in bacteria and fungi as these organisms usually have circular chromosomes without a clear centromere.\n4. FALSE [correction]: While mouse chromosomes are acrocentric rather than metacentric, this statement about the definition of metacentric chromosomes is true. Metacentric chromosomes have centromeres located near the center, but this description does not apply to mouse chromosomes.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2417,
    "user_query": "Which siRNA based drug is in clinical trials for the treatment of pancreatic cancer?",
    "llama-2-7b-chat-hf_response": "One siRNA-based drug that is currently in clinical trials for the treatment of pancreatic cancer is ONC201. ONC201 is an siRNA-based drug that targets the gene PD-L1 (programmed death-ligand 1) and has shown promise in preclinical studies as a potential treatment for pancreatic cancer. It is being developed by OncoSec Medical Inc. and is currently being evaluated in Phase 1/2 clinical trials for the treatment of pancreatic cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. ONC201 is an siRNA-based drug currently in clinical trials for the treatment of pancreatic cancer.\n2. ONC201 targets the gene PD-L1, which is programmed death-ligand 1.\n3. ONC201 has shown promise in preclinical studies for the treatment of pancreatic cancer.\n4. OncoSec Medical Inc. is developing ONC201.\n5. ONC201 is currently being evaluated in Phase 1/2 clinical trials.",
    "llama-2-7b-chat-hf_fact": [
      "ONC201 is an siRNA-based drug currently in clinical trials for the treatment of pancreatic cancer.",
      "ONC201 targets the gene PD-L1, which is programmed death-ligand 1.",
      "ONC201 has shown promise in preclinical studies for the treatment of pancreatic cancer.",
      "OncoSec Medical Inc. is developing ONC201.",
      "ONC201 is currently being evaluated in Phase 1/2 clinical trials."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: ONC201 is not an siRNA-based drug; it is a small molecule that acts as a DRD2 antagonist and ClpP agonist.\n2. FALSE [correction]: ONC201 does not target PD-L1; it targets the DRD2, a dopamine receptor.\n3. TRUE\n4. FALSE [correction]: OncoSec Medical Inc. is not developing ONC201; the drug is being developed by Oncoceutics, which is now a part of Chimerix, Inc.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2419,
    "user_query": "What is the HPG pore?",
    "llama-2-7b-chat-hf_response": "The HPG (Heterochromatin Protein G) pore is a protein complex that regulates the transport of RNA polymerase II (RNAPII) and other proteins across the nuclear envelope in eukaryotic cells. It is composed of the HPG protein and its associated subunits, and it acts as a gatekeeper for RNAPII, allowing it to transcribe genes located in the nucleus while preventing it from accessing genes located in the cytoplasm. The HPG pore plays a critical role in regulating gene expression and ensuring proper cellular function.",
    "llama-2-7b-chat-hf_fact_raw": "1. The HPG pore is a protein complex that regulates the transport of RNA polymerase II and other proteins across the nuclear envelope in eukaryotic cells.\n2. The HPG pore is composed of the HPG protein and its associated subunits.\n3. It acts as a gatekeeper for RNA polymerase II, enabling transcription of genes located in the nucleus.\n4. The HPG pore prevents RNA polymerase II from accessing genes located in the cytoplasm.\n5. The HPG pore is crucial in regulating gene expression and ensuring proper cellular function.",
    "llama-2-7b-chat-hf_fact": [
      "The HPG pore is a protein complex that regulates the transport of RNA polymerase II and other proteins across the nuclear envelope in eukaryotic cells.",
      "The HPG pore is composed of the HPG protein and its associated subunits.",
      "It acts as a gatekeeper for RNA polymerase II, enabling transcription of genes located in the nucleus.",
      "The HPG pore prevents RNA polymerase II from accessing genes located in the cytoplasm.",
      "The HPG pore is crucial in regulating gene expression and ensuring proper cellular function."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The statement about the \"HPG pore\" seems to be conflating or misidentifying a known structure in eukaryotic cells, which is the nuclear pore complex (NPC). The NPC is the protein complex that regulates the transport of RNA polymerase II and other molecules across the nuclear envelope.\n2. FALSE [correction]: Since the HPG pore does not exist, this statement about its composition is incorrect. However, if we correct \"HPG pore\" to \"nuclear pore complex,\" then the NPC is indeed composed of multiple proteins, collectively termed nucleoporins.\n3. TRUE: Assuming that \"HPG pore\" is a typographical error or a misnomer for the nuclear pore complex, the statement is true with respect to the NPC's role in enabling RNA polymerase II to access genes for transcription within the nucleus.\n4. FALSE [correction]: This statement is partially incorrect. While RNA polymerase II does not access genes in the cytoplasm because transcription occurs in the nucleus, the NPC (presumably what was meant by \"HPG pore\") does not play a role in preventing access to genes in the cytoplasm as RNA polymerase II does not function in the cytoplasm.\n5. TRUE: With the assumption that \"HPG pore\" refers to the nuclear pore complex, this statement is true. The NPC is indeed crucial in regulating gene expression and ensuring proper cellular function by controlling the exchange of molecules between the nucleus and the cytoplasm.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2472,
    "user_query": "What is the 959 Nematode Genomes initiative?",
    "llama-2-7b-chat-hf_response": "The 959 Nematode Genomes initiative is a large-scale effort to sequence and analyze the genomes of 959 species of nematodes, which are a group of microscopic worms that are important model organisms in biomedical research. The initiative was launched in 2015 and is led by the University of California, Riverside, in collaboration with several other institutions and organizations.\nNematodes are found in a wide range of environments, including soil, water, and plants, and they have evolved a variety of mechanisms to survive and reproduce in these environments. As a result, they have a wide range of biological functions and processes that are of interest to researchers, including the ability to:\n* Develop resistance to pesticides and other chemicals\n* Regulate plant growth and development\n* Interact with beneficial microorganisms in the soil\n* Cause plant diseases\n* Act as vectors of plant viruses\nThe 959 Nematode Genomes initiative aims to provide a comprehensive understanding of the genetic and genomic diversity of nematodes, and how this diversity relates to their biological functions and interactions with their environments. The project involves sequencing the genomes of 959 species of nematodes using a variety of high-throughput sequencing technologies, and analyzing the resulting data to identify genes, regulatory elements, and other features of interest.\nThe initiative is expected to provide significant insights into the biology and evolution of nematodes, and to have practical applications in areas such as agriculture, biotechnology, and human health. For example, the project could lead to the development of new pest management strategies that are based on a better understanding of the biology and genetics of nematode populations, and could also provide new insights into the biology of human diseases such as filariasis, which is caused by a nematode parasite.",
    "llama-2-7b-chat-hf_fact_raw": "1. The 959 Nematode Genomes initiative aims to sequence and analyze the genomes of 959 species of nematodes.\n2. The initiative was launched in 2015.\n3. The University of California, Riverside leads the initiative in collaboration with several other institutions and organizations.\n4. Nematodes play a role in developing resistance to pesticides and affecting plant growth and development.\n5. The initiative may have practical applications in agriculture, biotechnology, and human health.",
    "llama-2-7b-chat-hf_fact": [
      "The 959 Nematode Genomes initiative aims to sequence and analyze the genomes of 959 species of nematodes.",
      "The initiative was launched in 2015.",
      "The University of California, Riverside leads the initiative in collaboration with several other institutions and organizations.",
      "Nematodes play a role in developing resistance to pesticides and affecting plant growth and development.",
      "The initiative may have practical applications in agriculture, biotechnology, and human health."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The 959 Nematode Genomes initiative, also known as the 1,000 Nematode Genomes project, was actually launched around 2011 as an outgrowth of other genome sequencing projects.\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 2557,
    "user_query": "Which R package has been developed for analyzing Non-invasive prenatal testing (NIPT) data?",
    "llama-2-7b-chat-hf_response": "There are several R packages that have been developed for analyzing Non-invasive prenatal testing (NIPT) data. Some of the popular ones include:\n1. NIPT: This package provides a set of functions for analyzing NIPT data, including the calculation of various test statistics, visualization of results, and estimation of genetic risks.\n2. Prenat: This package provides functions for analyzing NIPT data, including the calculation of test statistics, visualization of results, and estimation of genetic risks. It also includes tools for working with prenatal data more generally.\n3. PregnancyTesting: This package provides functions for analyzing NIPT data, including the calculation of test statistics, visualization of results, and estimation of genetic risks. It also includes tools for working with pregnancy-related data more generally.\n4. NIPTworkflow: This package provides a workflow for analyzing NIPT data, including functions for data cleaning, preprocessing, and visualization.\n5. PrenatalGenetics: This package provides functions for analyzing NIPT data, including the calculation of test statistics, visualization of results, and estimation of genetic risks. It also includes tools for working with prenatal data more generally, such as calculating the risk of chromosomal abnormalities.\n6. PrenatGen: This package provides functions for analyzing NIPT data, including the calculation of test statistics, visualization of results, and estimation of genetic risks. It also includes tools for working with prenatal data more generally, such as calculating the risk of chromosomal abnormalities.\nThese packages can be used to perform various analyses on NIPT data, such as calculating the risk of genetic disorders, identifying high-risk pregnancies, and detecting chromosomal abnormalities.",
    "llama-2-7b-chat-hf_fact_raw": "1. The R package \"NIPT\" provides functions for analyzing Non-invasive prenatal testing (NIPT) data, including the calculation of test statistics and the estimation of genetic risks.\n2. The R package \"Prenat\" includes tools for analyzing NIPT data and working with prenatal data more generally.\n3. The R package \"PregnancyTesting\" offers functions for analyzing NIPT data and includes tools for working with pregnancy-related data.\n4. The R package \"NIPTworkflow\" provides a workflow for data cleaning, preprocessing, and visualization in the analysis of NIPT data.\n5. The R package \"PrenatalGenetics\" includes tools for calculating the risk of chromosomal abnormalities alongside analyzing NIPT data.",
    "llama-2-7b-chat-hf_fact": [
      "The R package \"NIPT\" provides functions for analyzing Non-invasive prenatal testing (NIPT) data, including the calculation of test statistics and the estimation of genetic risks.",
      "The R package \"Prenat\" includes tools for analyzing NIPT data and working with prenatal data more generally.",
      "The R package \"PregnancyTesting\" offers functions for analyzing NIPT data and includes tools for working with pregnancy-related data.",
      "The R package \"NIPTworkflow\" provides a workflow for data cleaning, preprocessing, and visualization in the analysis of NIPT data.",
      "The R package \"PrenatalGenetics\" includes tools for calculating the risk of chromosomal abnormalities alongside analyzing NIPT data."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nExplanation: Without specific knowledge about the packages listed or access to comprehensive repositories with descriptions of various R packages such as CRAN, Bioconductor, or others, it is impossible to confirm the veracity of the statements regarding the functionalities of \"Prenat\", \"PregnancyTesting\", \"NIPTworkflow\", and \"PrenatalGenetics\". However, R is known for having an extensive range of packages for various types of bioinformatics and statistical analysis, so these packages could plausibly exist with the features described. The statement about the \"NIPT\" package is a typical description of a specialized statistical package in R, but without concrete information, it cannot be confirmed or denied for the others.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2560,
    "user_query": "Describe Achenbach’s syndrome.",
    "llama-2-7b-chat-hf_response": "Achenbach's syndrome is a rare genetic disorder characterized by a variety of physical and developmental abnormalities. The main features of the syndrome include:\n1. Short stature: Individuals with Achenbach's syndrome are short-statured, with an average height of around 4 feet (122 cm) or less.\n2. Brain abnormalities: The syndrome is associated with various brain abnormalities, including microcephaly (a small head), cerebral atrophy (reduced brain size), and abnormalities of the corpus callosum (the bundle of nerve fibers that connects the two hemispheres of the brain).\n3. Facial abnormalities: People with Achenbach's syndrome may have distinctive facial features, including a small head, narrow eyes, a short nose, and a wide mouth.\n4. Skeletal abnormalities: The syndrome can cause a range of skeletal abnormalities, including short limbs, ribcage deformities, and joint contractures (limited joint mobility).\n5. Neurological problems: Achenbach's syndrome can also cause a range of neurological problems, including seizures, intellectual disability, and problems with movement and coordination.\n6. Genetic mutations: Achenbach's syndrome is caused by mutations in the FGD1 gene, which is responsible for producing a protein involved in the development and maintenance of the nervous system.\n7. Autism-like features: Some individuals with Achenbach's syndrome may also exhibit autism-like behaviors, such as social and communication difficulties, and repetitive behaviors.\n8. Other symptoms: Other symptoms of Achenbach's syndrome can include delayed development, poor muscle tone, and vision and hearing problems.\nAchenbach's syndrome is a rare and complex disorder, and the symptoms can vary widely between individuals. The syndrome is usually diagnosed through a combination of clinical evaluation, imaging studies, and genetic testing. Treatment is focused on managing the symptoms and improving the quality of life for individuals with the syndrome.",
    "llama-2-7b-chat-hf_fact_raw": "1. Achenbach's syndrome is characterized by short stature, with individuals averaging around 4 feet (122 cm) or less in height.\n2. Brain abnormalities associated with Achenbach's syndrome include microcephaly, cerebral atrophy, and abnormalities of the corpus callosum.\n3. Facial features of individuals with Achenbach's syndrome may include a small head, narrow eyes, a short nose, and a wide mouth.\n4. Achenbach's syndrome can lead to skeletal abnormalities, such as short limbs, ribcage deformities, and joint contractures.\n5. The disorder is caused by mutations in the FGD1 gene.",
    "llama-2-7b-chat-hf_fact": [
      "Achenbach's syndrome is characterized by short stature, with individuals averaging around 4 feet (122 cm) or less in height.",
      "Brain abnormalities associated with Achenbach's syndrome include microcephaly, cerebral atrophy, and abnormalities of the corpus callosum.",
      "Facial features of individuals with Achenbach's syndrome may include a small head, narrow eyes, a short nose, and a wide mouth.",
      "Achenbach's syndrome can lead to skeletal abnormalities, such as short limbs, ribcage deformities, and joint contractures.",
      "The disorder is caused by mutations in the FGD1 gene."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Achenbach's syndrome is characterized by sudden, unexplained bruising on the hands or fingers, not short stature.\n2. UNKNOWN\n3. UNKNOWN\n4. FALSE [correction]: Achenbach's syndrome does not lead to skeletal abnormalities such as short limbs, ribcage deformities, and joint contractures. These features are not associated with Achenbach's syndrome.\n5. FALSE [correction]: Achenbach's syndrome is not caused by mutations in the FGD1 gene. It is not typically associated with genetic abnormalities and the cause is generally unknown.\n",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2581,
    "user_query": "Which algorithm is used for detection of long repeat expansions?",
    "llama-2-7b-chat-hf_response": "There are several algorithms used for the detection of long repeat expansions in genomic DNA, including:\n1. RepeatMasker: This algorithm uses a combination of sequence similarity and k-mer frequency to identify repetitive elements in a genome.\n2. GATK (Genome Analysis Toolkit): This software package includes a number of tools for repeat masking, including the \"RepeatMasker\" tool, which uses a combination of sequence similarity and k-mer frequency to identify repetitive elements in a genome.\n3. LD-Repeat: This algorithm uses a combination of sequence similarity and linkage disequilibrium (LD) to identify repetitive elements in a genome.\n4. RepeatAnalyzer: This tool uses a combination of sequence similarity and k-mer frequency to identify repetitive elements in a genome, and can also be used to predict the impact of repeat expansions on gene expression.\n5. Repetin: This algorithm uses a combination of sequence similarity and k-mer frequency to identify repetitive elements in a genome, and can also be used to predict the impact of repeat expansions on gene expression.\n6. Variance-Stabilizing Transform (VST): This algorithm uses a statistical technique called variance-stabilizing transform to identify repetitive elements in a genome.\n7. ClustalW: This algorithm uses a multiple sequence alignment tool to identify repetitive elements in a genome.\n8. HMMER: This algorithm uses a hidden Markov model (HMM) to identify repetitive elements in a genome.\n9. Prodigal: This algorithm uses a combination of sequence similarity and k-mer frequency to identify repetitive elements in a genome, and can also be used to predict the impact of repeat expansions on gene expression.\n10. RepeatScout: This algorithm uses a combination of sequence similarity and k-mer frequency to identify repetitive elements in a genome, and can also be used to predict the impact of repeat expansions on gene expression.\nIt's worth noting that the choice of algorithm will depend on the specific research question and the characteristics of the genomic data being analyzed.",
    "llama-2-7b-chat-hf_fact_raw": "1. RepeatMasker is an algorithm that identifies repetitive elements in a genome using sequence similarity and k-mer frequency.\n2. Genome Analysis Toolkit (GATK) includes tools for repeat masking, like \"RepeatMasker.\"\n3. LD-Repeat identifies repetitive elements in a genome using sequence similarity and linkage disequilibrium.\n4. RepeatAnalyzer predicts the impact of repeat expansions on gene expression besides identifying repetitive elements in a genome using sequence similarity and k-mer frequency.\n5. HMMER uses a hidden Markov model to identify repetitive elements in a genome.",
    "llama-2-7b-chat-hf_fact": [
      "RepeatMasker is an algorithm that identifies repetitive elements in a genome using sequence similarity and k-mer frequency.",
      "Genome Analysis Toolkit (GATK) includes tools for repeat masking, like \"RepeatMasker.\"",
      "LD-Repeat identifies repetitive elements in a genome using sequence similarity and linkage disequilibrium.",
      "RepeatAnalyzer predicts the impact of repeat expansions on gene expression besides identifying repetitive elements in a genome using sequence similarity and k-mer frequency.",
      "HMMER uses a hidden Markov model to identify repetitive elements in a genome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Genome Analysis Toolkit (GATK) does not include tools specifically for repeat masking like \"RepeatMasker.\" GATK is primarily used for SNP calling, variant discovery, and genotyping.\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: HMMER uses hidden Markov models to identify protein sequences that exhibit homology with known protein families, not specifically for identifying repetitive elements in a genome.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 2582,
    "user_query": "Which brain tumors does neuroligin-3 promote?",
    "llama-2-7b-chat-hf_response": "Neuroligin-3 has been shown to promote the growth and progression of certain types of brain tumors, including:\n1. Medulloblastoma: A type of pediatric brain cancer that originates in the cerebellum.\n2. Glioblastoma: The most common and aggressive type of adult brain cancer.\n3. Medullofibroma: A rare type of brain cancer that arises in the cerebellum.\nNeuroligin-3 has been shown to promote the growth and survival of cancer cells in these tumor types by modulating the PI3K/Akt signaling pathway and inhibiting the activity of the tumor suppressor protein, p53.",
    "llama-2-7b-chat-hf_fact_raw": "1. Neuroligin-3 promotes the growth and progression of medulloblastoma.\n2. Medulloblastoma is a type of pediatric brain cancer that originates in the cerebellum.\n3. Neuroligin-3 promotes the growth and progression of glioblastoma.\n4. Glioblastoma is the most common and aggressive type of adult brain cancer.\n5. Neuroligin-3 promotes the growth and progression of medullofibroma.",
    "llama-2-7b-chat-hf_fact": [
      "Neuroligin-3 promotes the growth and progression of medulloblastoma.",
      "Medulloblastoma is a type of pediatric brain cancer that originates in the cerebellum.",
      "Neuroligin-3 promotes the growth and progression of glioblastoma.",
      "Glioblastoma is the most common and aggressive type of adult brain cancer.",
      "Neuroligin-3 promotes the growth and progression of medullofibroma."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Neuroligin-3 has been shown in various studies to promote the growth and progression of medulloblastoma, a form of brain cancer.\n2. TRUE: Medulloblastoma is indeed a type of pediatric brain tumor that originates in the cerebellum or nearby regions.\n3. UNKNOWN: Without specific context or research data, the statement's accuracy regarding the effect of neuroligin-3 on glioblastoma cannot be confirmed. While neuroligin-3 has been implicated in medulloblastoma, its role in glioblastoma is not definitively established without further information.\n4. TRUE: Glioblastoma is recognized as the most common primary brain tumor in adults and is known for its aggressive nature.\n5. FALSE [correction]: The term \"medullofibroma\" does not refer to a recognized type of brain tumor. The statement may be referring to medulloblastoma, which has been mentioned earlier, or mistakenly combining it with other tumor types, such as neurofibroma or fibroma. It is unclear what the correct term should be without additional context.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "false"
    ]
  },
  {
    "id": 2586,
    "user_query": "What is the approximate size of gas vesicles?",
    "llama-2-7b-chat-hf_response": "Gas vesicles in bacteria are typically around 10-20 nanometers (nm) in diameter.",
    "llama-2-7b-chat-hf_fact_raw": "1. Gas vesicles in bacteria are typically around 10-20 nanometers in diameter.",
    "llama-2-7b-chat-hf_fact": [
      "Gas vesicles in bacteria are typically around 10-20 nanometers in diameter."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Gas vesicles in bacteria are typically around 45-200 nanometers in diameter, and about 100-600 nanometers in length.",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 2589,
    "user_query": "List BET proteins.",
    "llama-2-7b-chat-hf_response": "BET (Bromodomain and Extra-Terminal) proteins are a family of proteins that play a crucial role in regulating gene expression by modulating the structure of chromatin. Here are the four known BET proteins:\n1. BET1 (Bromodomain-Containing Protein 1)\n2. BET2 (Bromodomain-Containing Protein 2)\n3. BET3 (Bromodomain-Containing Protein 3)\n4. BET4 (Bromodomain-Containing Protein 4)\nThese proteins are characterized by a bromodomain, a protein domain that recognizes and binds to acetylated lysine residues on histone proteins, leading to changes in chromatin structure and gene expression.",
    "llama-2-7b-chat-hf_fact_raw": "1. BET proteins are a family of proteins that regulate gene expression.\n2. BET proteins modulate the structure of chromatin.\n3. The four known BET proteins are BET1, BET2, BET3, and BET4.\n4. BET proteins are characterized by a bromodomain.\n5. The bromodomain of BET proteins recognizes and binds to acetylated lysine residues on histone proteins.",
    "llama-2-7b-chat-hf_fact": [
      "BET proteins are a family of proteins that regulate gene expression.",
      "BET proteins modulate the structure of chromatin.",
      "The four known BET proteins are BET1, BET2, BET3, and BET4.",
      "BET proteins are characterized by a bromodomain.",
      "The bromodomain of BET proteins recognizes and binds to acetylated lysine residues on histone proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The four known BET proteins are BRD2, BRD3, BRD4, and BRDT.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2610,
    "user_query": "Which algorithm has been developed for prediction of protein subcellular localization using deep learning?",
    "llama-2-7b-chat-hf_response": "One algorithm that has been developed for prediction of protein subcellular localization using deep learning is the \"DeepLoc\" algorithm. DeepLoc is a deep learning-based method that uses a convolutional neural network (CNN) to predict the subcellular localization of a protein based on its amino acid sequence. The algorithm was developed by Zhang et al. in 2018 and has been shown to outperform other state-of-the-art methods for protein localization prediction.",
    "llama-2-7b-chat-hf_fact_raw": "1. The \"DeepLoc\" algorithm is developed for prediction of protein subcellular localization using deep learning.\n2. DeepLoc uses a convolutional neural network (CNN) for its predictions.\n3. The algorithm is designed to predict the subcellular localization of a protein based on its amino acid sequence.\n4. Zhang et al. developed the DeepLoc algorithm in 2018.\n5. DeepLoc has been shown to outperform other state-of-the-art methods for protein localization prediction.",
    "llama-2-7b-chat-hf_fact": [
      "The \"DeepLoc\" algorithm is developed for prediction of protein subcellular localization using deep learning.",
      "DeepLoc uses a convolutional neural network (CNN) for its predictions.",
      "The algorithm is designed to predict the subcellular localization of a protein based on its amino acid sequence.",
      "Zhang et al. developed the DeepLoc algorithm in 2018.",
      "DeepLoc has been shown to outperform other state-of-the-art methods for protein localization prediction."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Almagro Armenteros et al. developed the DeepLoc algorithm in 2017.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2634,
    "user_query": "What is MULTOVL?",
    "llama-2-7b-chat-hf_response": "MULTOVL is a protein that is involved in the regulation of mRNA splicing. It is a multivalent protein that binds to multiple sites on the pre-mRNA and regulates the splicing of specific exons.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2660,
    "user_query": "Can GDF15 be a biomarker for metformin treatment?",
    "llama-2-7b-chat-hf_response": "Yes, GDF15 (Growth Differentiation Factor 15) has been identified as a potential biomarker for metformin treatment. Studies have shown that GDF15 levels are increased in response to metformin treatment in patients with type 2 diabetes, and that high levels of GDF15 are associated with improved insulin sensitivity and glucose metabolism. Therefore, measuring GDF15 levels in the blood may be a useful way to monitor the effectiveness of metformin treatment and to identify patients who are likely to benefit from this drug.",
    "llama-2-7b-chat-hf_fact_raw": "1. GDF15 stands for Growth Differentiation Factor 15.\n2. GDF15 has been identified as a potential biomarker for metformin treatment.\n3. Studies indicate that GDF15 levels increase in response to metformin treatment in patients with type 2 diabetes.\n4. High levels of GDF15 are associated with improved insulin sensitivity and glucose metabolism.\n5. Measuring GDF15 levels in the blood may be useful in monitoring the effectiveness of metformin treatment.",
    "llama-2-7b-chat-hf_fact": [
      "GDF15 stands for Growth Differentiation Factor 15.",
      "GDF15 has been identified as a potential biomarker for metformin treatment.",
      "Studies indicate that GDF15 levels increase in response to metformin treatment in patients with type 2 diabetes.",
      "High levels of GDF15 are associated with improved insulin sensitivity and glucose metabolism.",
      "Measuring GDF15 levels in the blood may be useful in monitoring the effectiveness of metformin treatment."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE\n\nWhile statements 1, 2, 3, and 5 are true based on current scientific understanding, with GDF15 being a potential biomarker for metformin treatment and its levels increasing in response to metformin, as well as it being used to monitor treatment effectiveness, the association of high levels of GDF15 with improved insulin sensitivity and glucose metabolism can be complex. Elevated levels of GDF15 are often found in various disease states and could be a compensatory mechanism rather than a direct indicator of improved metabolic states. There's ongoing research in this area, and without specific study references, it's difficult to ascertain the direct correlation as stated in statement 4.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2664,
    "user_query": "Is recursive splicing more common in short introns?",
    "llama-2-7b-chat-hf_response": "Yes, recursive splicing is more common in short introns. Recursive splicing, also known as intron circular splicing, occurs when the same intron is spliced back into the pre-mRNA after it has been excised, resulting in the formation of a circular splicing pattern. This type of splicing is more common in short introns, as the shorter distance between the intron and the exon boundaries makes it easier for the splicing machinery to recognize and re-splice the intron.",
    "llama-2-7b-chat-hf_fact_raw": "1. Recursive splicing is more common in short introns.\n2. Recursive splicing involves the splicing of the same intron back into the pre-mRNA after excision.\n3. Recursive splicing results in the formation of a circular splicing pattern.\n4. The shorter distance between intron and exon boundaries in short introns facilitates the recognition and re-splicing by the splicing machinery.",
    "llama-2-7b-chat-hf_fact": [
      "Recursive splicing is more common in short introns.",
      "Recursive splicing involves the splicing of the same intron back into the pre-mRNA after excision.",
      "Recursive splicing results in the formation of a circular splicing pattern.",
      "The shorter distance between intron and exon boundaries in short introns facilitates the recognition and re-splicing by the splicing machinery."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Recursive splicing is more common in long introns.\n2. FALSE [correction]: Recursive splicing involves the splicing of an exon or part of an exon back into the pre-mRNA.\n3. TRUE\n4. FALSE [correction]: It's the longer distance between the boundaries in long introns that is thought to facilitate recursive splicing, as it involves a series of progressive splicing events, rather than the recognition and re-splicing because of short distance.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 2679,
    "user_query": "What is the TALE-iD method used for?",
    "llama-2-7b-chat-hf_response": "TALE-iD is a method used for identifying the functional targets of transcription factors. It stands for \"Targeted Association and Localization of Transcription Factor-binding Elements by DNA sequencing.\" The method involves using DNA sequencing to identify the specific DNA sequences that are bound by a particular transcription factor, and then using this information to predict the functional targets of the transcription factor.",
    "llama-2-7b-chat-hf_fact_raw": "1. TALE-iD is a method used for identifying the functional targets of transcription factors.\n2. TALE-iD stands for \"Targeted Association and Localization of Transcription Factor-binding Elements by DNA sequencing.\"\n3. The method involves DNA sequencing to identify specific DNA sequences bound by a particular transcription factor.",
    "llama-2-7b-chat-hf_fact": [
      "TALE-iD is a method used for identifying the functional targets of transcription factors.",
      "TALE-iD stands for \"Targeted Association and Localization of Transcription Factor-binding Elements by DNA sequencing.\"",
      "The method involves DNA sequencing to identify specific DNA sequences bound by a particular transcription factor."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: TALE-iD stands for \"Transcription factor Affinity prediction by LExical analysis and information theory with Discrimination of non-targets.\"\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2747,
    "user_query": "Which Lisp framework has been developed for image processing?",
    "llama-2-7b-chat-hf_response": "There are several Lisp frameworks that have been developed for image processing, including:\n1. CL-Image: CL-Image is a Lisp image processing library that provides a variety of image processing functions, including filtering, resizing, and thresholding. It is written in Common Lisp and is designed to be easy to use and integrate into existing Lisp applications.\n2. ImageTk: ImageTk is a Lisp interface to the Tk image processing toolkit. It provides a set of functions for loading, manipulating, and saving images, as well as a number of image processing operations, such as filtering and resizing.\n3. Lisp-Image: Lisp-Image is a Lisp library for image processing that provides a simple and easy-to-use interface for loading, manipulating, and saving images. It includes a number of image processing functions, including filtering, resizing, and thresholding.\n4. Lisp-Image-Pro: Lisp-Image-Pro is a Lisp library for image processing that provides a comprehensive set of image processing functions, including filtering, resizing, and thresholding. It also includes a number of advanced features, such as support for multiple image formats and the ability to perform image registration.\n5. Image-Lisp: Image-Lisp is a Lisp library for image processing that provides a simple and easy-to-use interface for loading, manipulating, and saving images. It includes a number of image processing functions, including filtering, resizing, and thresholding, as well as support for multiple image formats.\nIt's worth noting that these are just a few examples of Lisp frameworks for image processing, and there may be others available depending on your specific needs and requirements.",
    "llama-2-7b-chat-hf_fact_raw": "1. CL-Image is a Lisp image processing library that offers functions such as filtering, resizing, and thresholding.\n2. ImageTk is a Lisp interface to the Tk image processing toolkit, with functions for loading, manipulating, and saving images.\n3. Lisp-Image is a Lisp library that provides an interface for loading, manipulating, and saving images along with processing functions like filtering and resizing.\n4. Lisp-Image-Pro is a Lisp library for image processing that includes advanced features such as support for multiple image formats and image registration capabilities.\n5. Image-Lisp is a Lisp library that supports image processing functions and multiple image formats.",
    "llama-2-7b-chat-hf_fact": [
      "CL-Image is a Lisp image processing library that offers functions such as filtering, resizing, and thresholding.",
      "ImageTk is a Lisp interface to the Tk image processing toolkit, with functions for loading, manipulating, and saving images.",
      "Lisp-Image is a Lisp library that provides an interface for loading, manipulating, and saving images along with processing functions like filtering and resizing.",
      "Lisp-Image-Pro is a Lisp library for image processing that includes advanced features such as support for multiple image formats and image registration capabilities.",
      "Image-Lisp is a Lisp library that supports image processing functions and multiple image formats."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without specific knowledge about a library called \"CL-Image\", it is not possible to determine the truthfulness of this statement.\n2. FALSE [correction]: ImageTk is not a Lisp interface. It is actually a Python library that acts as an interface to the Tk toolkit, which can be used for loading and manipulating images in a graphical user interface.\n3. UNKNOWN: The existence and capabilities of a Lisp library named \"Lisp-Image\" cannot be verified without additional information.\n4. UNKNOWN: As with the previous statements, the details about \"Lisp-Image-Pro\" cannot be confirmed without more context or information about this specific Lisp library.\n5. UNKNOWN: The \"Image-Lisp\" Lisp library and its support for image processing functions and multiple image formats cannot be verified as true or false without further context or documentation.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2759,
    "user_query": "How many genes in S. cerevisiae are the result of an ancient whole genome duplication?",
    "llama-2-7b-chat-hf_response": "The yeast species Saccharomyces cerevisiae (baker's yeast) underwent a whole genome duplication (WGD) event about 1,000 million years ago, resulting in the duplication of approximately 80% of its genes. This means that about 600-700 genes in the S. cerevisiae genome are the result of this ancient WGD event.",
    "llama-2-7b-chat-hf_fact_raw": "1. Saccharomyces cerevisiae (baker's yeast) underwent a whole genome duplication event around 1,000 million years ago.\n2. Approximately 80% of the genes in Saccharomyces cerevisiae were duplicated as a result of the whole genome duplication event.\n3. About 600-700 genes in the S. cerevisiae genome are the result of the ancient whole genome duplication event.",
    "llama-2-7b-chat-hf_fact": [
      "Saccharomyces cerevisiae (baker's yeast) underwent a whole genome duplication event around 1,000 million years ago.",
      "Approximately 80% of the genes in Saccharomyces cerevisiae were duplicated as a result of the whole genome duplication event.",
      "About 600-700 genes in the S. cerevisiae genome are the result of the ancient whole genome duplication event."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The whole genome duplication event in Saccharomyces cerevisiae occurred approximately 100 million years ago, not 1,000 million years ago.\n2. TRUE\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2763,
    "user_query": "Which complex is bound by estrogen-related receptor β (Esrrb)?",
    "llama-2-7b-chat-hf_response": "Estrogen-related receptor β (Esrrb) binds to the nucleosome.",
    "llama-2-7b-chat-hf_fact_raw": "1. Estrogen-related receptor β (Esrrb) binds to the nucleosome.",
    "llama-2-7b-chat-hf_fact": [
      "Estrogen-related receptor β (Esrrb) binds to the nucleosome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n\n[Explanation]: Without specific context or a clear source, the interaction of Estrogen-related receptor β (Esrrb) with the nucleosome is not universally established information that can be readily classified as true or false. Detailed scientific research and evidence would be required to verify such a statement.",
    "llama-2-7b-chat-hf_judge": [
      "unknown"
    ]
  },
  {
    "id": 2842,
    "user_query": "What is the role of ZCCHC17?",
    "llama-2-7b-chat-hf_response": "ZCCHC17 is a zinc finger CCHC-type histone triad-containing protein that plays a role in the regulation of chromatin structure and gene expression. It is involved in the modulation of transcriptional elongation and the maintenance of genome stability, and has been implicated in various cellular processes, including cell proliferation, differentiation, and survival.",
    "llama-2-7b-chat-hf_fact_raw": "1. ZCCHC17 is a zinc finger CCHC-type histone triad-containing protein.\n2. ZCCHC17 plays a role in the regulation of chromatin structure and gene expression.\n3. ZCCHC17 is involved in the modulation of transcriptional elongation.\n4. ZCCHC17 helps in the maintenance of genome stability.\n5. ZCCHC17 has been implicated in cellular processes such as cell proliferation, differentiation, and survival.",
    "llama-2-7b-chat-hf_fact": [
      "ZCCHC17 is a zinc finger CCHC-type histone triad-containing protein.",
      "ZCCHC17 plays a role in the regulation of chromatin structure and gene expression.",
      "ZCCHC17 is involved in the modulation of transcriptional elongation.",
      "ZCCHC17 helps in the maintenance of genome stability.",
      "ZCCHC17 has been implicated in cellular processes such as cell proliferation, differentiation, and survival."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nZCCHC17, also known as zinc finger CCHC domain-containing protein 17, is associated with various cellular processes that involve chromatin structure, gene expression, transcriptional elongation, and genome stability, which may indirectly affect cell proliferation, differentiation, and survival. However, it's important to note that the functions and roles of many proteins can be complex and context-dependent, and the specific mechanisms by which ZCCHC17 influences these processes might require more detailed explanations based on the latest scientific research.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2861,
    "user_query": "Which proteins form the nuclear pore basket in human cells?",
    "llama-2-7b-chat-hf_response": "The nuclear pore basket in human cells is composed of several proteins, including:\n1. Nucleoporin 1 (Nup1)\n2. Nucleoporin 2 (Nup2)\n3. Nucleoporin 3 (Nup3)\n4. Nucleoporin 4 (Nup4)\n5. Nucleoporin 5 (Nup5)\n6. Nucleoporin 6 (Nup6)\n7. Nucleoporin 7 (Nup7)\n8. Nucleoporin 8 (Nup8)\n9. Nucleoporin 9 (Nup9)\n10. Nucleoporin 10 (Nup10)\nThese proteins work together to form the nuclear pore complex (NPC), which is a large protein structure that spans the nuclear envelope and regulates the transport of molecules between the nucleus and the cytoplasm.",
    "llama-2-7b-chat-hf_fact_raw": "1. The nuclear pore basket in human cells is composed of proteins known as nucleoporins.\n2. Proteins such as Nucleoporin 1 (Nup1), Nucleoporin 2 (Nup2), and Nucleoporin 3 (Nup3) are part of the nuclear pore basket.\n3. The nuclear pore complex (NPC) is a structure that spans the nuclear envelope in human cells.\n4. The NPC regulates the transport of molecules between the nucleus and the cytoplasm.\n5. The answer lists ten proteins (Nup1 to Nup10) as components of the nuclear pore basket.",
    "llama-2-7b-chat-hf_fact": [
      "The nuclear pore basket in human cells is composed of proteins known as nucleoporins.",
      "Proteins such as Nucleoporin 1 (Nup1), Nucleoporin 2 (Nup2), and Nucleoporin 3 (Nup3) are part of the nuclear pore basket.",
      "The nuclear pore complex (NPC) is a structure that spans the nuclear envelope in human cells.",
      "The NPC regulates the transport of molecules between the nucleus and the cytoplasm.",
      "The answer lists ten proteins (Nup1 to Nup10) as components of the nuclear pore basket."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: While nucleoporins are indeed proteins that compose the nuclear pore basket, they are not typically designated by such simplified names as Nup1, Nup2, or Nup3. Nucleoporins are numerous and have more complex names; these specific names do not correspond to known nucleoporins.\n3. TRUE\n4. TRUE\n5. UNKNOWN [clarification]: Without the provided answer list, we cannot determine the validity of this statement. Nucleoporins are numerous, and while there are several known nucleoporins, the specific naming as \"Nup1 to Nup10\" does not reflect the standard nomenclature of nuclear pore complex proteins.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2919,
    "user_query": "What type of topoisomerase inhibitor is gepotidacin?",
    "llama-2-7b-chat-hf_response": "Gepotidacin is a topoisomerase II inhibitor. Specifically, it is a topoisomerase II alpha (Topo IIα) inhibitor.",
    "llama-2-7b-chat-hf_fact_raw": "1. Gepotidacin is a topoisomerase II inhibitor.\n2. Gepotidacin specifically inhibits topoisomerase II alpha (Topo IIα).",
    "llama-2-7b-chat-hf_fact": [
      "Gepotidacin is a topoisomerase II inhibitor.",
      "Gepotidacin specifically inhibits topoisomerase II alpha (Topo IIα)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Gepotidacin is a topoisomerase inhibitor, but it specifically targets bacterial type II topoisomerases, DNA gyrase, and topoisomerase IV, not human topoisomerase II.\n2. FALSE [correction]: Gepotidacin does not specifically inhibit topoisomerase II alpha (Topo IIα), as Topo IIα is a human enzyme. Gepotidacin is an antibiotic that targets bacterial topoisomerases.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false"
    ]
  },
  {
    "id": 2943,
    "user_query": "Describe Canvas SPW",
    "llama-2-7b-chat-hf_response": "Canvas SPW (Spatially-Aware Processing Workflow) is a computational framework designed to enable the efficient and scalable processing of large-scale spatial data, such as those generated by satellite imagery, LiDAR (Light Detection and Ranging), and other remote sensing technologies. Canvas SPW is specifically tailored to handle the unique challenges associated with processing and analyzing large-scale spatial data, including:\n1. Data heterogeneity: Canvas SPW can handle a wide range of spatial data formats and sources, including multi-modal data (e.g., image, LiDAR, and GIS data).\n2. Data complexity: Canvas SPW can efficiently process large-scale spatial data sets with complex geometry, such as those found in 3D city models, terrain models, and other geospatial data.\n3. Data distribution: Canvas SPW is designed to scale to large-scale distributed computing environments, allowing it to handle very large data sets that would be too large for a single machine or local cluster.\n4. Data quality: Canvas SPW provides a range of tools and techniques for data quality assessment and improvement, including data cleaning, filtering, and feature extraction.\n5. Data integration: Canvas SPW can integrate data from multiple sources and formats, enabling the creation of comprehensive and accurate spatial data sets.\n6. Data visualization: Canvas SPW includes a range of visualization tools for exploring and analyzing spatial data, including 2D and 3D visualization, and support for virtual reality (VR) and augmented reality (AR) applications.\n7. Data analytics: Canvas SPW provides a range of analytics tools for analyzing spatial data, including spatial statistics, machine learning, and data mining.\n8. Data sharing: Canvas SPW supports data sharing and collaboration, enabling researchers and practitioners to share and access spatial data sets and workflows.\nSome of the key features of Canvas SPW include:\n* A modular architecture that allows users to define and execute complex workflows.\n* Support for a wide range of spatial data formats and sources.\n* Efficient data processing and analysis tools, including spatial statistics, machine learning, and data mining.\n* A range of visualization tools for exploring and analyzing spatial data.\n* Support for",
    "llama-2-7b-chat-hf_fact_raw": "1. Canvas SPW is a computational framework designed to efficiently process large-scale spatial data, such as satellite imagery and LiDAR.\n2. Canvas SPW can handle a wide range of spatial data formats and sources, including multi-modal data.\n3. Designed to scale to large-scale distributed computing environments, Canvas SPW can manage data sets too large for a single machine or local cluster.\n4. Canvas SPW includes tools for data quality assessment and improvement, like data cleaning, filtering, and feature extraction.\n5. It can integrate data from multiple sources and formats to create comprehensive spatial data sets.",
    "llama-2-7b-chat-hf_fact": [
      "Canvas SPW is a computational framework designed to efficiently process large-scale spatial data, such as satellite imagery and LiDAR.",
      "Canvas SPW can handle a wide range of spatial data formats and sources, including multi-modal data.",
      "Designed to scale to large-scale distributed computing environments, Canvas SPW can manage data sets too large for a single machine or local cluster.",
      "Canvas SPW includes tools for data quality assessment and improvement, like data cleaning, filtering, and feature extraction.",
      "It can integrate data from multiple sources and formats to create comprehensive spatial data sets."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nAll five statements regarding \"Canvas SPW\" involve specific details about a computational framework that are not common knowledge and would require additional context or reference to verify their accuracy. Since no external information is provided about \"Canvas SPW\" and it is not a widely recognized framework as of my knowledge cutoff in early 2023, it's impossible to determine the truthfulness of these statements without further information.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2960,
    "user_query": "List STING agonists.",
    "llama-2-7b-chat-hf_response": "STING (STimulator of Interferon Genes) is a protein that plays a crucial role in the innate immune response to viral infections. STING agonists are molecules that activate STING and trigger the production of interferon, a potent antiviral molecule. Here are some examples of STING agonists:\n1. Poly (I:C): Poly (I:C) is a synthetic analog of viral double-stranded RNA that activates STING and induces the production of interferon.\n2. CpG DNA: CpG DNA is a type of DNA found in the genomes of bacteria and viruses that contains the dinucleotide CpG. CpG DNA activates STING and induces the production of interferon.\n3. DNA-based vaccines: Some DNA-based vaccines, such as the HPV vaccine, have been shown to activate STING and induce the production of interferon.\n4. Small molecule agonists: Small molecule agonists of STING, such as GSK872, have been developed as potential therapeutics for the treatment of a variety of diseases, including cancer and viral infections.\n5. Peptide agonists: Some peptide molecules, such as STING-activating peptide (SAP), have been shown to activate STING and induce the production of interferon.\n6. Viral mimics: Some viral mimics, such as the Toll-like receptor (TLR) agonist, poly (I:C), have been shown to activate STING and induce the production of interferon.\n7. Imidazolediones: Imidazolediones, such as imidazole-4-acetamide (I4A), are small molecules that activate STING and induce the production of interferon.\n8. Quinacrine: Quinacrine is a small molecule that activates STING and induces the production of interferon.\nThese are just a few examples of STING agonists, and there are likely many more molecules that can activate",
    "llama-2-7b-chat-hf_fact_raw": "1. Poly (I:C) is a synthetic analog of viral double-stranded RNA that can activate STING.\n2. CpG DNA, present in bacteria and viruses, contains the dinucleotide CpG and can activate STING.\n3. Some DNA-based vaccines, such as the HPV vaccine, have been shown to activate STING.\n4. Small molecule agonists like GSK872 have been developed to potentially treat diseases, including cancer and viral infections, through STING activation.\n5. Peptide molecules, such as STING-activating peptide (SAP), can activate STING.",
    "llama-2-7b-chat-hf_fact": [
      "Poly (I:C) is a synthetic analog of viral double-stranded RNA that can activate STING.",
      "CpG DNA, present in bacteria and viruses, contains the dinucleotide CpG and can activate STING.",
      "Some DNA-based vaccines, such as the HPV vaccine, have been shown to activate STING.",
      "Small molecule agonists like GSK872 have been developed to potentially treat diseases, including cancer and viral infections, through STING activation.",
      "Peptide molecules, such as STING-activating peptide (SAP), can activate STING."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Poly (I:C) is a synthetic analog of viral double-stranded RNA that can activate immune responses but it primarily activates TLR3 and other receptors, not STING (Stimulator of Interferon Genes).\n2. FALSE [correction]: CpG DNA does contain the dinucleotide CpG and is known to activate the TLR9 pathway but not STING. Activation of STING is typically triggered by the presence of cytosolic DNA, not the specific CpG motif.\n3. UNKNOWN: While some DNA-based vaccines might activate immune pathways, including those involving the STING pathway, the statement is vague, and specific evidence of the HPV vaccine activating STING is not provided.\n4. TRUE: Small molecule agonists like GSK872 are being developed to target STING pathways. These agonists can potently trigger STING activation and are being investigated for use in treating diseases like cancer.\n5. FALSE [correction]: Peptide molecules, such as STING-activating peptide (SAP), can be designed to enhance STING pathway activation, but the acronym should correctly be STAPs (STING-Associated Peptides), not SAP, to avoid confusion with other types of SAP molecules that might not be involved in STING activation.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "true",
      "false"
    ]
  },
  {
    "id": 2964,
    "user_query": "Describe SLIC-CAGE",
    "llama-2-7b-chat-hf_response": "SLIC-CAGE (Slicing-based Chromatin Accessibility Genome Engineering) is a genome engineering technology that allows for the precise modification of chromatin structure and accessibility. It is based on the CRISPR-Cas13 system, which is a type of RNA-guided DNA endonuclease that can be programmed to recognize specific DNA sequences and cleave them.\nIn the SLIC-CAGE system, the CRISPR-Cas13 enzyme is used to introduce specific double-strand breaks (DSBs) in the genome at desired locations. These DSBs can then be repaired by the cell's own repair machinery, leading to the creation of specific chromatin modifications.\nThe SLIC-CAGE system takes advantage of the fact that the repair of DSBs can result in the formation of chromatin loops, which are higher-order chromatin structures that can bring distant regulatory elements into close proximity to their target genes. By targeting the CRISPR-Cas13 enzyme to specific regulatory regions of the genome, the SLIC-CAGE system can create specific chromatin modifications that can alter gene expression levels or chromatin structure.\nThe SLIC-CAGE system has a number of potential applications in gene therapy, including the treatment of genetic diseases caused by chromatin mutations, and the modification of gene expression levels in cancer cells. It is a relatively new technology, and further research is needed to fully understand its mechanisms and potential uses.",
    "llama-2-7b-chat-hf_fact_raw": "1. SLIC-CAGE is a genome engineering technology used to modify chromatin structure and accessibility.\n2. SLIC-CAGE is based on the CRISPR-Cas13 system, a type of RNA-guided DNA endonuclease.\n3. The CRISPR-Cas13 enzyme in SLIC-CAGE is designed to introduce double-strand breaks (DSBs) at specific locations in the genome.\n4. The introduction of DSBs by SLIC-CAGE can result in the formation of chromatin loops.\n5. SLIC-CAGE has potential applications in gene therapy and the modification of gene expression levels in cancer cells.",
    "llama-2-7b-chat-hf_fact": [
      "SLIC-CAGE is a genome engineering technology used to modify chromatin structure and accessibility.",
      "SLIC-CAGE is based on the CRISPR-Cas13 system, a type of RNA-guided DNA endonuclease.",
      "The CRISPR-Cas13 enzyme in SLIC-CAGE is designed to introduce double-strand breaks (DSBs) at specific locations in the genome.",
      "The introduction of DSBs by SLIC-CAGE can result in the formation of chromatin loops.",
      "SLIC-CAGE has potential applications in gene therapy and the modification of gene expression levels in cancer cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: SLIC-CAGE is related to the CRISPR-Cas9 system, not the CRISPR-Cas13 system. CRISPR-Cas13 is an RNA-targeting system, while CRISPR-Cas9 targets DNA.\n3. FALSE [correction]: SLIC-CAGE uses a dead Cas9 (dCas9) fused with effector domains to modulate chromatin structure without introducing double-strand breaks (DSBs) as Cas9's nuclease activity is inactive in dCas9.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2978,
    "user_query": "What are the roles of LEM-3?",
    "llama-2-7b-chat-hf_response": "LEM-3 is a protein that plays several roles in the cell, including:\n1. Chromatin remodeling: LEM-3 is a member of the LEM (lin-11, emerin, and muf1) protein family, which are involved in the remodeling of chromatin structure.\n2. Nuclear envelope maintenance: LEM-3 is also involved in the maintenance of the nuclear envelope, which is the membrane that surrounds the nucleus in eukaryotic cells.\n3. Cell cycle regulation: LEM-3 has been shown to play a role in the regulation of the cell cycle, particularly in the G2/M phase transition.\n4. Apoptosis: LEM-3 has been implicated in the regulation of programmed cell death (apoptosis), particularly in the context of cancer.\n5. Nuclear localization: LEM-3 is localized to the nucleus in most cell types, where it plays a role in the regulation of various nuclear processes.",
    "llama-2-7b-chat-hf_fact_raw": "1. LEM-3 is a member of the LEM protein family involved in chromatin remodeling.\n2. LEM-3 is involved in the maintenance of the nuclear envelope in eukaryotic cells.\n3. LEM-3 plays a role in cell cycle regulation, specifically in the G2/M phase transition.\n4. LEM-3 is implicated in the regulation of programmed cell death (apoptosis).\n5. LEM-3 is localized to the nucleus in most cell types where it regulates various nuclear processes.",
    "llama-2-7b-chat-hf_fact": [
      "LEM-3 is a member of the LEM protein family involved in chromatin remodeling.",
      "LEM-3 is involved in the maintenance of the nuclear envelope in eukaryotic cells.",
      "LEM-3 plays a role in cell cycle regulation, specifically in the G2/M phase transition.",
      "LEM-3 is implicated in the regulation of programmed cell death (apoptosis).",
      "LEM-3 is localized to the nucleus in most cell types where it regulates various nuclear processes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN \n5. TRUE\n\nWhile statements 1, 2, 3, and 5 about LEM-3 are consistent with known roles of LEM-domain proteins in chromatin organization, nuclear integrity, cell cycle regulation, and nuclear functions, the claim about LEM-3's specific involvement in apoptosis is less certain without additional context or specific scientific references. LEM-domain proteins are indeed linked to various nuclear processes, but whether LEM-3 in particular regulates apoptosis directly or is more generally associated with it would require more detailed information.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2992,
    "user_query": "List the releases of tmVar",
    "llama-2-7b-chat-hf_response": "As a helpful assistant, I'm happy to provide you with the releases of the tmVar package in R:\n1.0.0 (2018-06-01) - The first release of tmVar, which introduces the basic functionality for variable transformation.\n1.2.0 (2018-12-01) - The second release of tmVar, which adds new methods for transforming variables, including the ability to transform variables with multiple dimensions.\n1.3.0 (2019-06-01) - The third release of tmVar, which introduces a new method for transforming variables with complex structures, such as matrices and data frames.\n1.4.0 (2020-02-01) - The fourth release of tmVar, which adds new functionality for working with time series data and improves the performance of the package.\n1.5.0 (2020-06-01) - The fifth release of tmVar, which introduces a new method for transforming variables using a Bayesian approach and improves the documentation of the package.\nNote that these are the major releases of the tmVar package, and there may be minor releases with bug fixes and other improvements in between.",
    "llama-2-7b-chat-hf_fact_raw": "1. tmVar version 1.0.0 was released on 2018-06-01, introducing basic functionality for variable transformation.\n2. tmVar version 1.2.0 was released on 2018-12-01, adding methods for transforming variables with multiple dimensions.\n3. tmVar version 1.3.0 was released on 2019-06-01, with a new method for transforming variables with complex structures like matrices and data frames.\n4. tmVar version 1.4.0 was released on 2020-02-01, adding functionality for working with time series data and enhancing performance.\n5. tmVar version 1.5.0 was released on 2020-06-01, introducing a Bayesian approach for variable transformation and improved documentation.",
    "llama-2-7b-chat-hf_fact": [
      "tmVar version 1.0.0 was released on 2018-06-01, introducing basic functionality for variable transformation.",
      "tmVar version 1.2.0 was released on 2018-12-01, adding methods for transforming variables with multiple dimensions.",
      "tmVar version 1.3.0 was released on 2019-06-01, with a new method for transforming variables with complex structures like matrices and data frames.",
      "tmVar version 1.4.0 was released on 2020-02-01, adding functionality for working with time series data and enhancing performance.",
      "tmVar version 1.5.0 was released on 2020-06-01, introducing a Bayesian approach for variable transformation and improved documentation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "UNKNOWN\n\nWithout specific knowledge about the release dates and features of the versions of a software package named \"tmVar,\" it is not possible to verify the truth of these statements. They are not common historical or general knowledge, and unless provided with the accurate information regarding the \"tmVar\" software, determining the truth or providing corrections for these statements is not feasible. If \"tmVar\" is a hypothetical or fictional software, the statements cannot be verified without additional context.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3018,
    "user_query": "Which is the database of somatic mutations in normal cells?",
    "llama-2-7b-chat-hf_response": "There is no single database of somatic mutations in normal cells. Somatic mutations are mutations that occur in non-reproductive cells in a tissue or organism, and they can occur in both cancerous and non-cancerous cells.\nHowever, there are several databases that contain information on somatic mutations in various types of cells, including:\n1. The Cancer Genome Atlas (TCGA): TCGA is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI) that aims to catalogue the genomic changes in various types of cancer. The database contains RNA sequencing data, DNA mutation data, and clinical information for thousands of cancer samples.\n2. The ExAC (Exome Aggregation Consortium) database: The ExAC database is a collection of exome sequencing data from over 60,000 individuals, including both cancerous and non-cancerous samples. The database contains information on somatic mutations in exons, as well as information on the frequency and distribution of these mutations in the general population.\n3. The COSMIC (Catalogue of Somatic Mutations in Cancer) database: COSMIC is a comprehensive database of somatic mutations found in various types of cancer. The database contains information on both point mutations and structural variations, as well as information on the frequency and distribution of these mutations in different cancer types.\n4. The MutSig database: MutSig is a database of somatic mutations found in cancer genomes, including both exonic and non-exonic mutations. The database contains information on the frequency and distribution of these mutations in different cancer types, as well as information on their potential functional impact.\n5. The Cancer Mutation Hotspot Database (CMHD): CMHD is a database of somatic mutations found in cancer genomes, including both point mutations and structural variations. The database contains information on the frequency and distribution of these mutations in different cancer types, as well as information on their potential functional impact.\nThese are just a few examples of the many databases that contain information on somatic mutations in normal cells. Each database has its own specific focus and scope, and they may contain different types of data and different levels of detail.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Cancer Genome Atlas (TCGA) is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI).\n2. The ExAC (Exome Aggregation Consortium) database contains exome sequencing data from over 60,000 individuals.\n3. The COSMIC (Catalogue of Somatic Mutations in Cancer) database is a comprehensive database of somatic mutations found in various types of cancer.\n4. The MutSig database includes somatic mutations found in cancer genomes and contains information on their frequency and distribution.\n5. The Cancer Mutation Hotspot Database (CMHD) contains information on somatic mutations in cancer genomes, including their frequency and distribution.",
    "llama-2-7b-chat-hf_fact": [
      "The Cancer Genome Atlas (TCGA) is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI).",
      "The ExAC (Exome Aggregation Consortium) database contains exome sequencing data from over 60,000 individuals.",
      "The COSMIC (Catalogue of Somatic Mutations in Cancer) database is a comprehensive database of somatic mutations found in various types of cancer.",
      "The MutSig database includes somatic mutations found in cancer genomes and contains information on their frequency and distribution.",
      "The Cancer Mutation Hotspot Database (CMHD) contains information on somatic mutations in cancer genomes, including their frequency and distribution."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The ExAC (Exome Aggregation Consortium) database contains exome sequencing data from over 60,000 unrelated individuals.\n3. TRUE\n4. UNKNOWN (The statement seems plausible, but without additional information on the MutSig database's contents, it is difficult to confirm the accuracy. MutSig is actually a suite of tools used to identify significantly mutated genes and not a database.)\n5. UNKNOWN (There is no widely recognized database by this exact name—the Cancer Hotspot database is a tool that includes information on mutation hotspots in cancer genes. However, without more context on whether CMHD is referring to a specific resource, the statement's accuracy cannot be verified.)",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3037,
    "user_query": "Are there graph kernel libraries available implemented in JAVA?",
    "llama-2-7b-chat-hf_response": "Yes, there are several graph kernel libraries available that have been implemented in Java. Here are some examples:\n1. JGraphT: JGraphT is a Java library for creating and manipulating graphs. It provides a simple API for creating graphs, adding vertices and edges, and performing graph operations such as traversals and shortest paths.\n2. GraphBLAS: GraphBLAS is a high-performance graph processing library that provides a set of linear algebra operations for graphs. It includes a Java implementation of the GraphBLAS library, which can be used to perform graph computations on large graphs.\n3. Weave: Weave is a Java library for graph processing that provides a simple API for creating and manipulating graphs. It includes a number of graph algorithms and data structures, including graphs, trees, and hierarchical graphs.\n4. GraphCrunch: GraphCrunch is a Java library for graph processing that provides a simple API for creating and manipulating graphs. It includes a number of graph algorithms and data structures, including graphs, trees, and hierarchical graphs.\n5. GraphXR: GraphXR is a Java library for graph processing that provides a simple API for creating and manipulating graphs. It includes a number of graph algorithms and data structures, including graphs, trees, and hierarchical graphs.\n6. JGraph: JGraph is a Java library for creating and manipulating graphs. It provides a simple API for creating graphs, adding vertices and edges, and performing graph operations such as traversals and shortest paths.\n7. GraphMol: GraphMol is a Java library for molecular graph algorithms. It provides a simple API for creating and manipulating molecular graphs, and includes a number of algorithms for working with molecular graphs.\n8. JGraphT-Ext: JGraphT-Ext is an extension of the JGraphT library that provides additional functionality for working with large graphs. It includes a number of algorithms for working with large graphs, including graph partitioning and graph clustering.\nThese are just a few examples of the many graph kernel libraries available in Java. Each library has its own strengths and weaknesses, and the best library for a particular application will depend on the specific requirements of the project.",
    "llama-2-7b-chat-hf_fact_raw": "1. JGraphT is a Java library for creating and manipulating graphs.\n2. GraphBLAS includes a Java implementation of the library for graph computations.\n3. Weave is a Java library for graph processing that includes various graph algorithms and data structures.\n4. GraphCrunch is a Java library that provides APIs for creating and manipulating graphs, including certain graph algorithms and data structures.\n5. GraphMol is a Java library for molecular graph algorithms.",
    "llama-2-7b-chat-hf_fact": [
      "JGraphT is a Java library for creating and manipulating graphs.",
      "GraphBLAS includes a Java implementation of the library for graph computations.",
      "Weave is a Java library for graph processing that includes various graph algorithms and data structures.",
      "GraphCrunch is a Java library that provides APIs for creating and manipulating graphs, including certain graph algorithms and data structures.",
      "GraphMol is a Java library for molecular graph algorithms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: GraphBLAS is not specifically a Java library, but a building block specification for graph algorithms, mainly intended for high-performance computing. Implementations of GraphBLAS may exist in multiple languages but are not exclusive to Java.\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: RDKit is a popular toolkit that includes the GraphMol module for molecular graph algorithms, but it is primarily implemented in C++ and Python, not Java.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3045,
    "user_query": "List the four advances integrated into the SHERLOCKv2 platform.",
    "llama-2-7b-chat-hf_response": "The SHERLOCKv2 platform integrates four advances in molecular diagnostics:\n1. CRISPR-Cas12a: SHERLOCKv2 uses CRISPR-Cas12a as the nucleic acid sensing component, which is a type of RNA-guided endonuclease that can detect specific RNA sequences with high sensitivity and specificity.\n2. Multiplexing: SHERLOCKv2 allows for the simultaneous detection of multiple targets by using different guide RNAs (gRNAs) that are designed to recognize different target RNAs. This enables the detection of multiple pathogens or biomarkers in a single reaction.\n3. Reporter genes: SHERLOCKv2 uses a reporter gene, such as luciferase or GFP, to indicate the presence of the target RNA. This allows for the detection of the target RNA to be visualized and quantified in a simple and efficient manner.\n4. Digital PCR: SHERLOCKv2 uses digital PCR (dPCR) to quantify the amount of the target RNA in the sample. dPCR is a highly accurate and sensitive method for quantifying nucleic acid sequences, and it allows for the detection of very low levels of target RNA in a sample.",
    "llama-2-7b-chat-hf_fact_raw": "1. SHERLOCKv2 uses CRISPR-Cas12a as its nucleic acid sensing component.\n2. SHERLOCKv2 is capable of multiplexing, allowing simultaneous detection of multiple targets.\n3. The platform uses reporter genes like luciferase or GFP to indicate the presence of the target RNA.\n4. SHERLOCKv2 employs digital PCR to quantify the amount of target RNA in a sample.",
    "llama-2-7b-chat-hf_fact": [
      "SHERLOCKv2 uses CRISPR-Cas12a as its nucleic acid sensing component.",
      "SHERLOCKv2 is capable of multiplexing, allowing simultaneous detection of multiple targets.",
      "The platform uses reporter genes like luciferase or GFP to indicate the presence of the target RNA.",
      "SHERLOCKv2 employs digital PCR to quantify the amount of target RNA in a sample."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: SHERLOCKv2 does not employ digital PCR to quantify the amount of target RNA in a sample; instead, it uses collateral cleavage of a reporter molecule to indicate the presence of the target RNA, which can be quantitative or semi-quantitative but is based on isothermal amplification and not digital PCR.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3078,
    "user_query": "Describe the bartender algorithm",
    "llama-2-7b-chat-hf_response": "The Bartender algorithm is a machine learning algorithm used for feature selection and dimensionality reduction in datasets. It was introduced by Tanaka et al. in 2008. The algorithm is designed to identify the most informative features in a dataset and to reduce the dimensionality of the data while preserving the information content of the original features.\nThe Bartender algorithm works by treating the feature selection problem as a optimization problem. The objective function is defined as the log-likelihood of the training data given the selected features, and the algorithm minimizes this function using an iterative algorithm. The algorithm starts with an initial set of features and iteratively adds or removes features until the optimal set of features is obtained.\nThe key steps of the Bartender algorithm are:\n1. Initialize the set of features: The algorithm starts with an initial set of features, which may be all the features in the dataset.\n2. Calculate the log-likelihood: The algorithm calculates the log-likelihood of the training data given the current set of features.\n3. Evaluate the features: The algorithm evaluates each feature in the current set based on its information content, which is measured using the Shannon entropy.\n4. Select the most informative features: The algorithm selects the top-ranked features based on their information content and adds them to the set of selected features.\n5. Repeat steps 2-4: The algorithm repeats steps 2-4 until a stopping criterion is reached, such as a maximum number of iterations or a minimum level of improvement in the log-likelihood.\n6. Output the selected features: The final selected features are output, which can be used for further analysis or modeling.\nThe Bartender algorithm has several advantages over other feature selection algorithms, including:\n* It can handle high-dimensional datasets: The algorithm can handle datasets with a large number of features, making it useful for datasets with a large number of potential features.\n* It can identify non-linear relationships: The algorithm can identify non-linear relationships between the features and the target variable, which can lead to better performance in machine learning tasks.\n* It can handle missing values: The algorithm can handle missing values in the dataset, which can be a common problem in many machine learning tasks.\n* It is easy to implement: The algorithm is relatively simple to implement, and the computational cost is low, making it a good choice for large datasets.\nHowever",
    "llama-2-7b-chat-hf_fact_raw": "1. The Bartender algorithm was introduced by Tanaka et al. in 2008.\n2. It is used for feature selection and dimensionality reduction in datasets.\n3. The algorithm treats the feature selection problem as an optimization problem with the objective function defined as the log-likelihood of the training data given the selected features.\n4. The Bartender algorithm starts with an initial set of features, iteratively adding or removing features until the optimal set is obtained.\n5. The algorithm can handle high-dimensional datasets, identify non-linear relationships, manage missing values, and is relatively easy to implement.",
    "llama-2-7b-chat-hf_fact": [
      "The Bartender algorithm was introduced by Tanaka et al. in 2008.",
      "It is used for feature selection and dimensionality reduction in datasets.",
      "The algorithm treats the feature selection problem as an optimization problem with the objective function defined as the log-likelihood of the training data given the selected features.",
      "The Bartender algorithm starts with an initial set of features, iteratively adding or removing features until the optimal set is obtained.",
      "The algorithm can handle high-dimensional datasets, identify non-linear relationships, manage missing values, and is relatively easy to implement."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nGiven the information provided, it is not possible to verify the specifics of the Bartender algorithm, such as its introduction by Tanaka et al. in 2008, the details of its methodology, or the characteristics of its performance without more data or context. While statement 2 is generally consistent with the goals of feature selection and dimensionality reduction algorithms, the details given in statements 1, 3, 4, and 5 are too specific to confirm without additional references or expert knowledge on that particular algorithm.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3100,
    "user_query": "Which web-based pedigree editors are available?",
    "llama-2-7b-chat-hf_response": "There are several web-based pedigree editors available, including:\n1. Pedigree Online: This is a popular web-based platform for creating and managing family trees. It offers features such as personalized profiles, ancestry charts, and collaboration tools.\n2. MyHeritage: This platform allows users to build and share their family trees, as well as access historical records and genealogy resources.\n3. FamilySearch: This is a free genealogy website that provides access to historical records and allows users to create and share their family trees.\n4. GenoPro: This is a professional genealogy software that allows users to create and publish their family trees online. It offers features such as customizable templates, multimedia integration, and collaboration tools.\n5. Legacy Family Tree: This is a popular genealogy software that offers a web-based platform for creating and sharing family trees. It includes features such as source citations, historical records access, and collaboration tools.\n6. Family Tree Maker: This is a genealogy software that offers a web-based platform for creating and sharing family trees. It includes features such as source citations, historical records access, and collaboration tools.\n7. We Relate: This is a collaborative genealogy platform that allows users to create and share their family trees, as well as connect with other researchers and share information.\n8. WikiTree: This is a free genealogy website that allows users to create and share their family trees, as well as collaborate with other researchers.\n9. Family Tree Builder: This is a free online genealogy platform that allows users to create and share their family trees, as well as access historical records and genealogy resources.\n10. Gramps: This is a free, open-source genealogy software that offers a web-based platform for creating and sharing family trees. It includes features such as customizable templates, multimedia integration, and collaboration tools.",
    "llama-2-7b-chat-hf_fact_raw": "1. Pedigree Online is a web-based platform for creating and managing family trees, with features such as personalized profiles and ancestry charts.\n2. MyHeritage allows users to build and share their family trees, as well as access historical records and genealogy resources.\n3. FamilySearch is a free website that provides access to historical records and allows users to create and share family trees.\n4. GenoPro is a professional genealogy software with a web-based platform for creating and publishing family trees online.\n5. WikiTree is a free genealogy website that enables users to create, share family trees, and collaborate with other researchers.",
    "llama-2-7b-chat-hf_fact": [
      "Pedigree Online is a web-based platform for creating and managing family trees, with features such as personalized profiles and ancestry charts.",
      "MyHeritage allows users to build and share their family trees, as well as access historical records and genealogy resources.",
      "FamilySearch is a free website that provides access to historical records and allows users to create and share family trees.",
      "GenoPro is a professional genealogy software with a web-based platform for creating and publishing family trees online.",
      "WikiTree is a free genealogy website that enables users to create, share family trees, and collaborate with other researchers."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: There is no widely recognized web-based platform named \"Pedigree Online\" fitting this description and the name itself appears generic. There might be confusion with other existing genealogy websites or software, but without more specific information, the truthfulness of the statement cannot be determined.\n2. TRUE: MyHeritage is indeed a platform that allows users to build and share their family trees and access historical records and genealogy resources.\n3. TRUE: FamilySearch is a free genealogy website that is provided by The Church of Jesus Christ of Latter-day Saints. It offers access to historical records and tools to create and share family trees.\n4. FALSE [correction]: GenoPro is a genealogy software that users download and install on their computers for creating family trees. While it offers some services online, such as GenoProX allowing for collaboration and publishing online, the main GenoPro software is primarily a desktop application, not a web-based platform.\n5. TRUE: WikiTree is a free community-based genealogy website that allows users to create, share family trees, and work together with other genealogy researchers.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3107,
    "user_query": "Which curated databases exist for spider-venom toxins?",
    "llama-2-7b-chat-hf_response": "There are several curated databases available for spider-venom toxins, including:\n1. The Spider Toxin Database (STD): This database contains information on the structures, functions, and evolution of spider-venom toxins, including their mechanisms of action, pharmacological properties, and potential therapeutic applications.\n2. The Toxinology Database (ToxinDB): This database contains a comprehensive collection of toxins from various sources, including spiders, snakes, and scorpions. It includes information on the toxin structures, functions, and pharmacological properties, as well as their potential uses in medicine and biotechnology.\n3. The Venom-Toxin Database (ViTox): This database focuses specifically on venom-derived toxins, including spider-venom toxins. It contains information on the toxin structures, functions, and pharmacological properties, as well as their potential therapeutic applications and the species of origin.\n4. The Natural Products Database (NPDB): This database contains information on natural products, including spider-venom toxins, and their structures, functions, and pharmacological properties. It also includes information on the sources of these compounds and their potential therapeutic applications.\n5. The Toxinology Resource (ToxinologyR): This database provides a comprehensive collection of toxins, including spider-venom toxins, and their structural and functional information. It also includes tools for analyzing and predicting the properties of toxins, as well as a database of toxin-binding proteins.\nThese databases are valuable resources for researchers studying spider-venom toxins and their potential therapeutic applications, as they provide a centralized location for accessing and analyzing information on these compounds.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Spider Toxin Database (STD) contains information on the structures, functions, evolution, mechanisms of action, pharmacological properties, and potential therapeutic applications of spider-venom toxins.\n2. The Toxinology Database (ToxinDB) includes toxins from sources such as spiders, snakes, and scorpions, and contains information on toxin structures, functions, pharmacological properties, and potential medical and biotechnological uses.\n3. The Venom-Toxin Database (ViTox) focuses on venom-derived toxins, including spider-venom toxins, and provides information about toxin structures, functions, pharmacological properties, therapeutic applications, and the species of origin.\n4. The Natural Products Database (NPDB) includes information on natural products such as spider-venom toxins, detailing their structures, functions, pharmacological properties, sources, and potential therapeutic applications.\n5. The Toxinology Resource (ToxinologyR) offers a comprehensive collection of toxins, including spider-venom toxins, structural and functional information, tools for analysis and prediction of toxin properties, and a database of toxin-binding proteins.",
    "llama-2-7b-chat-hf_fact": [
      "The Spider Toxin Database (STD) contains information on the structures, functions, evolution, mechanisms of action, pharmacological properties, and potential therapeutic applications of spider-venom toxins.",
      "The Toxinology Database (ToxinDB) includes toxins from sources such as spiders, snakes, and scorpions, and contains information on toxin structures, functions, pharmacological properties, and potential medical and biotechnological uses.",
      "The Venom-Toxin Database (ViTox) focuses on venom-derived toxins, including spider-venom toxins, and provides information about toxin structures, functions, pharmacological properties, therapeutic applications, and the species of origin.",
      "The Natural Products Database (NPDB) includes information on natural products such as spider-venom toxins, detailing their structures, functions, pharmacological properties, sources, and potential therapeutic applications.",
      "The Toxinology Resource (ToxinologyR) offers a comprehensive collection of toxins, including spider-venom toxins, structural and functional information, tools for analysis and prediction of toxin properties, and a database of toxin-binding proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information about the content and real existence of databases named \"Venom-Toxin Database (ViTox),\" \"Natural Products Database (NPDB),\" and \"Toxinology Resource (ToxinologyR),\" it is impossible to verify the accuracy of statements 3, 4, and 5. Therefore the truthfulness of these statements remains unknown.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3111,
    "user_query": "Does Axitinib prolong survival of Pancreatic Cancer patients?",
    "llama-2-7b-chat-hf_response": "Yes, Axitinib has been shown to prolong survival in patients with pancreatic cancer. In a phase III clinical trial known as the ALTERA study, Axitinib was compared to gemcitabine in patients with metastatic pancreatic cancer who had progressed after previous treatment. The results of the study, published in the New England Journal of Medicine in 2018, showed that Axitinib significantly improved overall survival compared to gemcitabine, with a median overall survival of 11.3 months in the Axitinib arm versus 9.2 months in the gemcitabine arm.",
    "llama-2-7b-chat-hf_fact_raw": "1. Axitinib has been shown to prolong survival in patients with pancreatic cancer.\n2. The ALTERA study was a phase III clinical trial.\n3. The ALTERA study compared Axitinib to gemcitabine in patients with metastatic pancreatic cancer who had progressed after previous treatment.\n4. The results of the ALTERA study were published in the New England Journal of Medicine in 2018.\n5. In the ALTERA study, the median overall survival was 11.3 months in the Axitinib arm versus 9.2 months in the gemcitabine arm.",
    "llama-2-7b-chat-hf_fact": [
      "Axitinib has been shown to prolong survival in patients with pancreatic cancer.",
      "The ALTERA study was a phase III clinical trial.",
      "The ALTERA study compared Axitinib to gemcitabine in patients with metastatic pancreatic cancer who had progressed after previous treatment.",
      "The results of the ALTERA study were published in the New England Journal of Medicine in 2018.",
      "In the ALTERA study, the median overall survival was 11.3 months in the Axitinib arm versus 9.2 months in the gemcitabine arm."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information about the clinical trials or studies pertaining to Axitinib and the ALTERA study, it is not possible to confirm the validity of the statements provided. Information about medical studies and the results of clinical trials, such as patient population, study design (phase I, II, III, etc.), comparative drugs, and outcomes, would be required to accurately assess these statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3113,
    "user_query": "Through which protein interaction does MLP regulate F-actin dynamics?",
    "llama-2-7b-chat-hf_response": "MLP (Myosin Light Chain Phosphatase) regulates F-actin dynamics through its interaction with F-actin and other proteins, including the actin-binding protein cofilin. MLP dephosphorylates and inactivates cofilin, which leads to the depolymerization of F-actin filaments and the regulation of cellular processes such as cell migration, cell spreading, and cell signaling.",
    "llama-2-7b-chat-hf_fact_raw": "1. MLP regulates F-actin dynamics through its interaction with F-actin.\n2. MLP also interacts with the actin-binding protein cofilin.\n3. MLP dephosphorylates and inactivates cofilin.\n4. The inactivation of cofilin leads to the depolymerization of F-actin filaments.\n5. Regulation of F-actin dynamics by MLP affects cellular processes such as cell migration, cell spreading, and cell signaling.",
    "llama-2-7b-chat-hf_fact": [
      "MLP regulates F-actin dynamics through its interaction with F-actin.",
      "MLP also interacts with the actin-binding protein cofilin.",
      "MLP dephosphorylates and inactivates cofilin.",
      "The inactivation of cofilin leads to the depolymerization of F-actin filaments.",
      "Regulation of F-actin dynamics by MLP affects cellular processes such as cell migration, cell spreading, and cell signaling."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: MLP does not directly dephosphorylate cofilin; it can interact with proteins that regulate cofilin, but dephosphorylation and inactivation of cofilin are typically functions of phosphatases like slingshot.\n4. FALSE [correction]: The inactivation of cofilin (by phosphorylation) actually stabilizes F-actin filaments, preventing their depolymerization. Active cofilin (dephosphorylated) binds to actin filaments and promotes their disassembly.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 3125,
    "user_query": "How many pseudokinases are there in the human kinome?",
    "llama-2-7b-chat-hf_response": "Pseudokinases are proteins that have some characteristics of kinases but lack catalytic activity. The exact number of pseudokinases in the human kinome is not well established, as there is ongoing research and debate on their classification and definition. However, it is generally estimated that there are around 10-20 pseudokinases in the human kinome. These pseudokinases are often involved in various cellular processes, including cell signaling, cytoskeleton organization, and regulation of protein activity.",
    "llama-2-7b-chat-hf_fact_raw": "1. Pseudokinases are proteins that share some characteristics of kinases but lack catalytic activity.\n2. The exact number of pseudokinases in the human kinome is not well established.\n3. Estimates suggest that there are around 10-20 pseudokinases in the human kinome.\n4. Pseudokinases are involved in various cellular processes including cell signaling and cytoskeleton organization.\n5. Pseudokinases play a role in the regulation of protein activity.",
    "llama-2-7b-chat-hf_fact": [
      "Pseudokinases are proteins that share some characteristics of kinases but lack catalytic activity.",
      "The exact number of pseudokinases in the human kinome is not well established.",
      "Estimates suggest that there are around 10-20 pseudokinases in the human kinome.",
      "Pseudokinases are involved in various cellular processes including cell signaling and cytoskeleton organization.",
      "Pseudokinases play a role in the regulation of protein activity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Estimates suggest that there are over 50 pseudokinases in the human kinome.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3139,
    "user_query": "List 3 apoE mimetics.",
    "llama-2-7b-chat-hf_response": "ApoE mimetics are compounds that mimic the structure and function of apolipoprotein E (apoE), a protein involved in lipid metabolism and cholesterol transport. Here are three examples of apoE mimetics:\n1. ApoE-mimetic peptides: These are short peptides that mimic the structure of apoE and have been shown to have cholesterol-lowering and anti-inflammatory effects. Examples include peptides such as Gly-Ser-Thr-Ser-Leu-Gly-Gly-Gly (GSTSLEGG) and Gly-Ser-Thr-Ser-Leu-Gly-Gly-Ala (GSTSLELA).\n2. Small molecule apoE mimetics: These are synthetic compounds that mimic the structure of apoE and have been shown to have cholesterol-lowering and anti-inflammatory effects. Examples include compounds such as GW3965 and GW4869.\n3. ApoE-mimetic nanoparticles: These are nanoparticles that are designed to mimic the structure of apoE and have been shown to have cholesterol-lowering and anti-inflammatory effects. Examples include nanoparticles such as liposomes and polymer-based nanoparticles.",
    "llama-2-7b-chat-hf_fact_raw": "1. ApoE-mimetic peptides are designed to mimic the structure of apolipoprotein E (apoE) and have cholesterol-lowering and anti-inflammatory effects.\n2. Peptides such as Gly-Ser-Thr-Ser-Leu-Gly-Gly-Gly (GSTSLEGG) and Gly-Ser-Thr-Ser-Leu-Gly-Gly-Ala (GSTSLELA) are examples of apoE-mimetic peptides.\n3. Small molecule apoE mimetics like GW3965 and GW4869 are synthetic compounds created to imitate apoE's structure and possess cholesterol-lowering and anti-inflammatory properties.\n4. ApoE-mimetic nanoparticles, including liposomes and polymer-based nanoparticles, are engineered to replicate the structure of apoE and demonstrate cholesterol-lowering and anti-inflammatory effects.",
    "llama-2-7b-chat-hf_fact": [
      "ApoE-mimetic peptides are designed to mimic the structure of apolipoprotein E (apoE) and have cholesterol-lowering and anti-inflammatory effects.",
      "Peptides such as Gly-Ser-Thr-Ser-Leu-Gly-Gly-Gly (GSTSLEGG) and Gly-Ser-Thr-Ser-Leu-Gly-Gly-Ala (GSTSLELA) are examples of apoE-mimetic peptides.",
      "Small molecule apoE mimetics like GW3965 and GW4869 are synthetic compounds created to imitate apoE's structure and possess cholesterol-lowering and anti-inflammatory properties.",
      "ApoE-mimetic nanoparticles, including liposomes and polymer-based nanoparticles, are engineered to replicate the structure of apoE and demonstrate cholesterol-lowering and anti-inflammatory effects."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. FALSE [correction]: GW3965 and GW4869 are not typically referenced as \"small molecule apoE mimetics.\" Instead, GW3965 is a liver X receptor (LXR) agonist, and GW4869 is a neutral sphingomyelinase inhibitor. They are small molecules that affect lipid metabolism but do not mimic apoE's structure.\n4. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3140,
    "user_query": "What are there sex differences in SAMHD1 activity?",
    "llama-2-7b-chat-hf_response": "SAMHD1 (Sperm-associated antigen 1) is an enzyme that plays a crucial role in the regulation of DNA damage response and immune function. There are sex differences in SAMHD1 activity, with studies suggesting that males and females have different levels of SAMHD1 expression and activity. Here are some of the sex differences in SAMHD1 activity that have been observed:\n1. Males have higher levels of SAMHD1 expression: Several studies have shown that males have higher levels of SAMHD1 expression compared to females, particularly in peripheral blood mononuclear cells (PBMCs) and other immune cells.\n2. Females are more susceptible to SAMHD1-mediated DNA damage: SAMHD1 has been shown to play a protective role in DNA damage response, but females are more susceptible to DNA damage and have a higher incidence of DNA damage-related disorders, such as cancer. This suggests that sex differences in SAMHD1 activity may play a role in these differences.\n3. SAMHD1 activity is regulated by sex hormones: Sex hormones, such as estrogen and testosterone, have been shown to regulate SAMHD1 expression and activity in various tissues, including the immune system. For example, estrogen has been shown to increase SAMHD1 expression in PBMCs, while testosterone has been shown to decrease SAMHD1 expression in the same cells.\n4. SAMHD1 activity is altered in sex-specific manner in response to toxins: Some studies have shown that sex-specific differences in SAMHD1 activity can be observed in response to exposure to certain toxins, such as dioxins and polycyclic aromatic hydrocarbons (PAHs). For example, dioxins have been shown to increase SAMHD1 activity in females, while PAHs have been shown to decrease SAMHD1 activity in both males and females.\n5. Sex differences in SAMHD1-mediated immune response: Sex differences in SAMHD1 activity have been observed in the context of immune responses, with males showing a more robust immune response to infection than females. This may be due in part to differences in SAMHD1 activity, which can influence the balance between pro",
    "llama-2-7b-chat-hf_fact_raw": "1. Males have higher levels of SAMHD1 expression compared to females, particularly in peripheral blood mononuclear cells (PBMCs) and other immune cells.\n2. Females are more susceptible to SAMHD1-mediated DNA damage and have a higher incidence of DNA damage-related disorders such as cancer.\n3. Sex hormones regulate SAMHD1 expression and activity, with estrogen increasing and testosterone decreasing SAMHD1 expression in PBMCs.\n4. Exposure to toxins like dioxins and polycyclic aromatic hydrocarbons (PAHs) alters SAMHD1 activity in a sex-specific manner, with dioxins increasing activity in females.\n5. There are observed sex differences in SAMHD1-mediated immune responses, with males exhibiting a more robust immune response to infection than females.",
    "llama-2-7b-chat-hf_fact": [
      "Males have higher levels of SAMHD1 expression compared to females, particularly in peripheral blood mononuclear cells (PBMCs) and other immune cells.",
      "Females are more susceptible to SAMHD1-mediated DNA damage and have a higher incidence of DNA damage-related disorders such as cancer.",
      "Sex hormones regulate SAMHD1 expression and activity, with estrogen increasing and testosterone decreasing SAMHD1 expression in PBMCs.",
      "Exposure to toxins like dioxins and polycyclic aromatic hydrocarbons (PAHs) alters SAMHD1 activity in a sex-specific manner, with dioxins increasing activity in females.",
      "There are observed sex differences in SAMHD1-mediated immune responses, with males exhibiting a more robust immune response to infection than females."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN \n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe provided statements require specific scientific data and research backing to verify their accuracy. Without access to current and relevant scientific studies directly addressing these claims about SAMHD1 expression, sex differences, and the effects of hormones and toxins, it is difficult to determine the truthfulness of these statements. They speak to precise biological mechanisms and would need to be corroborated with empirical evidence from the field of molecular biology or related disciplines.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3205,
    "user_query": "Does RUNX2 inhibit astrocyte differentiation?",
    "llama-2-7b-chat-hf_response": "Yes, RUNX2 (RUNX2 transcription factor 1) has been shown to inhibit astrocyte differentiation. RUNX2 is a transcription factor that plays a crucial role in the regulation of cell fate decisions, including the differentiation of neural progenitor cells into astrocytes. Studies have shown that RUNX2 can repress the expression of genes involved in astrocyte differentiation and inhibit the process of astrocyte maturation.",
    "llama-2-7b-chat-hf_fact_raw": "1. RUNX2 (RUNX2 transcription factor 1) inhibits astrocyte differentiation.\n2. RUNX2 is a transcription factor involved in the regulation of cell fate decisions.\n3. RUNX2 can repress the expression of genes involved in astrocyte differentiation.\n4. RUNX2 inhibits the process of astrocyte maturation.",
    "llama-2-7b-chat-hf_fact": [
      "RUNX2 (RUNX2 transcription factor 1) inhibits astrocyte differentiation.",
      "RUNX2 is a transcription factor involved in the regulation of cell fate decisions.",
      "RUNX2 can repress the expression of genes involved in astrocyte differentiation.",
      "RUNX2 inhibits the process of astrocyte maturation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n\nRUNX2, also known as Runt-related transcription factor 2, is known for its role in bone development and osteogenesis. It is also implicated in the regulation of cell fate decisions and can inhibit certain cellular differentiation pathways, including inhibiting astrocyte differentiation and maturation by repressing the expression of genes involved in these processes.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3209,
    "user_query": "Where, in the body, would the Cobb-Stainsby excision arthroplasty be performed?",
    "llama-2-7b-chat-hf_response": "The Cobb-Stansby excision arthroplasty is a surgical procedure that is typically performed on the knee joint. It involves removing a portion of the damaged or arthritic joint cartilage and bone, and replacing it with an implant or prosthesis. The procedure is usually performed through a surgical incision on the knee, and may involve other techniques such as bone reshaping or ligament reconstruction to restore proper joint function.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Cobb-Stainsby excision arthroplasty is a surgical procedure performed on the knee joint.\n2. This procedure involves removing part of the damaged or arthritic joint cartilage and bone.\n3. It includes replacing the removed section with an implant or prosthesis.\n4. The Cobb-Stainsby excision arthroplasty is usually performed through a surgical incision on the knee.",
    "llama-2-7b-chat-hf_fact": [
      "The Cobb-Stainsby excision arthroplasty is a surgical procedure performed on the knee joint.",
      "This procedure involves removing part of the damaged or arthritic joint cartilage and bone.",
      "It includes replacing the removed section with an implant or prosthesis.",
      "The Cobb-Stainsby excision arthroplasty is usually performed through a surgical incision on the knee."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Cobb-Stainsby excision arthroplasty is a surgical procedure performed on the hip joint, not the knee joint.\n2. TRUE\n3. FALSE [correction]: The Cobb-Stainsby excision arthroplasty involves excising the neck of the femur and the stabilization of the hip with capsular and muscle reconstruction. It does not traditionally include the replacement with an implant or prosthesis.\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3243,
    "user_query": "Does GRHL2 over-expression lead to EMT?",
    "llama-2-7b-chat-hf_response": "Yes, over-expression of GRHL2 has been shown to promote epithelial-to-mesenchymal transition (EMT) in various cell types, including cancer cells. EMT is a process by which epithelial cells lose their cell-cell adhesion and gain mesenchymal characteristics, such as increased migratory and invasive properties. GRHL2 has been shown to play a role in this process by modulating the expression of genes involved in EMT and by interacting with other transcription factors that promote EMT.",
    "llama-2-7b-chat-hf_fact_raw": "1. Over-expression of GRHL2 promotes epithelial-to-mesenchymal transition (EMT) in various cell types, including cancer cells.\n2. Epithelial-to-mesenchymal transition (EMT) is a process where epithelial cells lose cell-cell adhesion and gain mesenchymal characteristics.\n3. GRHL2 plays a role in EMT by modulating the expression of genes involved in the process.\n4. GRHL2 interacts with other transcription factors that promote EMT.",
    "llama-2-7b-chat-hf_fact": [
      "Over-expression of GRHL2 promotes epithelial-to-mesenchymal transition (EMT) in various cell types, including cancer cells.",
      "Epithelial-to-mesenchymal transition (EMT) is a process where epithelial cells lose cell-cell adhesion and gain mesenchymal characteristics.",
      "GRHL2 plays a role in EMT by modulating the expression of genes involved in the process.",
      "GRHL2 interacts with other transcription factors that promote EMT."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Over-expression of GRHL2 typically suppresses epithelial-to-mesenchymal transition (EMT) in various cell types, including cancer cells.\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3254,
    "user_query": "Which T-UCRs have been implicated in lung cancer?",
    "llama-2-7b-chat-hf_response": "T-UCRs (tumor-associated circular RNAs) have been implicated in lung cancer, including:\n1. Circular RNA 001 (circRNA001): upregulated in lung cancer tissues and cell lines, and promotes cell proliferation and migration.\n2. Circular RNA 1 (circRNA1): downregulated in lung cancer tissues and cell lines, and inhibits cell proliferation and migration.\n3. Circular RNA 2 (circRNA2): upregulated in lung cancer tissues and cell lines, and promotes cell proliferation and migration.\n4. Circular RNA 3 (circRNA3): upregulated in lung cancer tissues and cell lines, and inhibits cell proliferation and migration.\n5. Circular RNA 4 (circRNA4): downregulated in lung cancer tissues and cell lines, and inhibits cell proliferation and migration.\n6. Circular RNA 5 (circRNA5): upregulated in lung cancer tissues and cell lines, and promotes cell proliferation and migration.\n7. Circular RNA 6 (circRNA6): downregulated in lung cancer tissues and cell lines, and inhibits cell proliferation and migration.\n8. Circular RNA 7 (circRNA7): upregulated in lung cancer tissues and cell lines, and promotes cell proliferation and migration.\n9. Circular RNA 8 (circRNA8): downregulated in lung cancer tissues and cell lines, and inhibits cell proliferation and migration.\n10. Circular RNA 9 (circRNA9): upregulated in lung cancer tissues and cell lines, and promotes cell proliferation and migration.\n11. Circular RNA 10 (circRNA10): downregulated in lung cancer tissues and cell lines, and inhibits cell proliferation and migration.\nThese T-UCRs may serve as potential biomarkers or therapeutic targets for lung cancer diagnosis and treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. Circular RNA 001 (circRNA001) is upregulated in lung cancer tissues and cell lines and is said to promote cell proliferation and migration.\n2. Circular RNA 1 (circRNA1) is downregulated in lung cancer tissues and cell lines and supposedly inhibits cell proliferation and migration.\n3. Circular RNA 2 (circRNA2) is upregulated in lung cancer tissues and cell lines and is believed to promote cell proliferation and migration.\n4. Circular RNA 4 (circRNA4) is downregulated in lung cancer tissues and cell lines and is thought to inhibit cell proliferation and migration.\n5. T-UCRs may act as potential biomarkers or therapeutic targets for lung cancer diagnosis and treatment.",
    "llama-2-7b-chat-hf_fact": [
      "Circular RNA 001 (circRNA001) is upregulated in lung cancer tissues and cell lines and is said to promote cell proliferation and migration.",
      "Circular RNA 1 (circRNA1) is downregulated in lung cancer tissues and cell lines and supposedly inhibits cell proliferation and migration.",
      "Circular RNA 2 (circRNA2) is upregulated in lung cancer tissues and cell lines and is believed to promote cell proliferation and migration.",
      "Circular RNA 4 (circRNA4) is downregulated in lung cancer tissues and cell lines and is thought to inhibit cell proliferation and migration.",
      "T-UCRs may act as potential biomarkers or therapeutic targets for lung cancer diagnosis and treatment."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without specific research data or sources to confirm the statement about Circular RNA 001 (circRNA001), the claim cannot be verified.\n2. FALSE [correction]: This statement contradicts the first one. If circRNA001 is upregulated and promotes cell proliferation and migration, then it is unlikely that circRNA1, which seems to be another designation for the same molecule, would be downregulated and inhibit these processes. However, without specific details about \"circRNA1,\" a definitive correction cannot be provided.\n3. UNKNOWN: Similar to statement 1, without specific research data or sources to confirm the statement about Circular RNA 2 (circRNA2), the claim cannot be verified.\n4. UNKNOWN: Just like statements 1 and 3, without specific research data or sources to confirm the statement about Circular RNA 4 (circRNA4), the claim cannot be verified.\n5. TRUE: It is generally accepted in the scientific community that Transcribed Ultraconserved Regions (T-UCRs) can be important in cancer biology and have the potential to be used as biomarkers or therapeutic targets for diagnosis and treatment, including for lung cancer. However, this is a broad statement and specific T-UCRs would need to be identified to validate this claim in the context of lung cancer.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3268,
    "user_query": "What is known about the orphan receptor GPR151?",
    "llama-2-7b-chat-hf_response": "GPR151 (G protein-coupled receptor 151) is an orphan receptor, meaning that it does not have a well-defined endogenous ligand or a clear physiological function. However, research has shown that GPR151 is involved in various cellular processes, including:\n1. Inflammation: GPR151 has been shown to play a role in the regulation of inflammation, with studies suggesting that it may act as an anti-inflammatory receptor.\n2. Cardiovascular health: GPR151 has been implicated in the regulation of blood pressure and the maintenance of vascular tone.\n3. Metabolism: GPR151 has been linked to the regulation of glucose and lipid metabolism, with studies suggesting that it may play a role in the development of metabolic disorders such as insulin resistance and type 2 diabetes.\n4. Neuroprotection: GPR151 has been shown to have neuroprotective effects, with studies suggesting that it may play a role in the protection of neurons against damage caused by oxidative stress and excitotoxicity.\n5. Cancer: GPR151 has been implicated in the development and progression of certain types of cancer, including breast, lung, and colon cancer.\nOverall, GPR151 is a complex receptor with a multifaceted role in various cellular processes, and further research is needed to fully understand its function and potential as a therapeutic target.",
    "llama-2-7b-chat-hf_fact_raw": "1. GPR151 is classified as an orphan receptor without a well-defined endogenous ligand.\n2. GPR151 has been associated with the regulation of inflammation and may act as an anti-inflammatory receptor.\n3. Studies suggest that GPR151 is involved in the regulation of blood pressure and vascular tone maintenance.\n4. GPR151 has been linked to glucose and lipid metabolism regulation and may be relevant to metabolic disorders such as insulin resistance and type 2 diabetes.\n5. GPR151 has been implicated in cancer development and progression, with specific mention of breast, lung, and colon cancer.",
    "llama-2-7b-chat-hf_fact": [
      "GPR151 is classified as an orphan receptor without a well-defined endogenous ligand.",
      "GPR151 has been associated with the regulation of inflammation and may act as an anti-inflammatory receptor.",
      "Studies suggest that GPR151 is involved in the regulation of blood pressure and vascular tone maintenance.",
      "GPR151 has been linked to glucose and lipid metabolism regulation and may be relevant to metabolic disorders such as insulin resistance and type 2 diabetes.",
      "GPR151 has been implicated in cancer development and progression, with specific mention of breast, lung, and colon cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: GPR151 has not been specifically associated with the regulation of inflammation or described as an anti-inflammatory receptor. Its functions are not well-defined due to its classification as an orphan receptor.\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nFor statements 2, and 3-5, the roles of GPR151 in these specific biological processes are not well-established as of the last knowledge update I have. Further research may reveal more about GPR151's functions; however, without specific and current references to such research, the status of these statements cannot be accurately determined.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3285,
    "user_query": "List the attenuated live viruses contained in the Fluzone intradermal quadrivalent vaccine.",
    "llama-2-7b-chat-hf_response": "The Fluzone Intradermal Quadrivalent vaccine contains the following attenuated live viruses:\n1. H1N1\n2. H3N2\n3. B/Victoria\n4. B/Yamagata\nNote: The Fluzone Intradermal Quadrivalent vaccine is approved for use in individuals 18 through 64 years of age. It is not approved for use in children younger than 18 years of age.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Fluzone Intradermal Quadrivalent vaccine contains an attenuated live virus strain of H1N1.\n2. The Fluzone Intradermal Quadrivalent vaccine contains an attenuated live virus strain of H3N2.\n3. The Fluzone Intradermal Quadrivalent vaccine contains an attenuated live virus strain of B/Victoria.\n4. The Fluzone Intradermal Quadrivalent vaccine contains an attenuated live virus strain of B/Yamagata.\n5. The Fluzone Intradermal Quadrivalent vaccine is approved for use in individuals aged 18 through 64.",
    "llama-2-7b-chat-hf_fact": [
      "The Fluzone Intradermal Quadrivalent vaccine contains an attenuated live virus strain of H1N1.",
      "The Fluzone Intradermal Quadrivalent vaccine contains an attenuated live virus strain of H3N2.",
      "The Fluzone Intradermal Quadrivalent vaccine contains an attenuated live virus strain of B/Victoria.",
      "The Fluzone Intradermal Quadrivalent vaccine contains an attenuated live virus strain of B/Yamagata.",
      "The Fluzone Intradermal Quadrivalent vaccine is approved for use in individuals aged 18 through 64."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Fluzone Intradermal Quadrivalent vaccine contains killed virus strains, not live attenuated virus strains.\n2. FALSE [correction]: The Fluzone Intradermal Quadrivalent vaccine contains killed virus strains, not live attenuated virus strains.\n3. FALSE [correction]: The Fluzone Intradermal Quadrivalent vaccine contains killed virus strains, not live attenuated virus strains.\n4. FALSE [correction]: The Fluzone Intradermal Quadrivalent vaccine contains killed virus strains, not live attenuated virus strains.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 3345,
    "user_query": "Which part of the TNFR2 gene is genetically associated with Systemic Lupus Erythematosus?",
    "llama-2-7b-chat-hf_response": "The TNFR2 gene, also known as the Tumor Necrosis Factor Receptor 2 gene, has been genetically associated with Systemic Lupus Erythematosus (SLE). Specifically, mutations in the TNFR2 gene's promoter region have been identified as a risk factor for SLE.",
    "llama-2-7b-chat-hf_fact_raw": "1. The TNFR2 gene stands for Tumor Necrosis Factor Receptor 2 gene.\n2. The TNFR2 gene has a genetic association with Systemic Lupus Erythematosus (SLE).\n3. Mutations in the promoter region of the TNFR2 gene are identified as a risk factor for Systemic Lupus Erythematosus (SLE).",
    "llama-2-7b-chat-hf_fact": [
      "The TNFR2 gene stands for Tumor Necrosis Factor Receptor 2 gene.",
      "The TNFR2 gene has a genetic association with Systemic Lupus Erythematosus (SLE).",
      "Mutations in the promoter region of the TNFR2 gene are identified as a risk factor for Systemic Lupus Erythematosus (SLE)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3353,
    "user_query": "Is there a vaccine for peanut allergy?",
    "llama-2-7b-chat-hf_response": "There is currently no licensed vaccine available for the prevention of peanut allergy. However, researchers are actively working on developing a vaccine for peanut allergy, and several promising candidates are in various stages of clinical trials. These vaccines aim to stimulate the immune system to produce allergy-fighting antibodies and reduce the risk of an allergic reaction to peanuts. While the development of a peanut allergy vaccine is promising, it is important to note that it may take several years before a vaccine becomes available for widespread use.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is currently no licensed vaccine available for the prevention of peanut allergy.\n2. Researchers are developing a vaccine for peanut allergy.\n3. There are several candidates for a peanut allergy vaccine in various stages of clinical trials.\n4. Peanut allergy vaccine candidates aim to stimulate the immune system to produce allergy-fighting antibodies.\n5. It may take several years before a vaccine for peanut allergy becomes available for widespread use.",
    "llama-2-7b-chat-hf_fact": [
      "There is currently no licensed vaccine available for the prevention of peanut allergy.",
      "Researchers are developing a vaccine for peanut allergy.",
      "There are several candidates for a peanut allergy vaccine in various stages of clinical trials.",
      "Peanut allergy vaccine candidates aim to stimulate the immune system to produce allergy-fighting antibodies.",
      "It may take several years before a vaccine for peanut allergy becomes available for widespread use."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3365,
    "user_query": "What is particular about the mouse Fxy gene's chromosomal position?",
    "llama-2-7b-chat-hf_response": "The mouse Fxy gene is located on the X chromosome (Xp11.23).",
    "llama-2-7b-chat-hf_fact_raw": "1. The mouse Fxy gene is located on the X chromosome.\n2. The specific location of the mouse Fxy gene on the X chromosome is Xp11.23.",
    "llama-2-7b-chat-hf_fact": [
      "The mouse Fxy gene is located on the X chromosome.",
      "The specific location of the mouse Fxy gene on the X chromosome is Xp11.23."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The specific location of the mouse Fxy gene on the X chromosome is Xq13.3.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false"
    ]
  },
  {
    "id": 3397,
    "user_query": "What is the basis of the methidiumpropyl-EDTA sequencing (MPE-seq) method?",
    "llama-2-7b-chat-hf_response": "MPE-seq is a method for sequencing DNA that is based on the use of a modified base analogue called methidiumpropyl-EDTA (methidiumpropyl-ethylene diamine tetraacetic acid, or MPE). MPE is a fluorescently labeled base analogue that can be incorporated into DNA during replication or repair processes, allowing for the detection and sequencing of specific DNA sequences.\nThe basis of the MPE-seq method is to use MPE as a label to mark specific regions of DNA, such as gene promoters or repetitive sequences, and then use next-generation sequencing (NGS) technologies to detect and sequence the labeled DNA regions. The MPE label allows for the selective enrichment of labeled DNA regions, which can improve the accuracy and throughput of the sequencing process.\nThe MPE-seq method typically involves the following steps:\n1. MPE labeling: The target DNA sequence is labeled with MPE using a modified DNA polymerase enzyme that incorporates MPE at specific regions of the DNA.\n2. Sequencing: The labeled DNA is then subjected to NGS technologies, such as Illumina or PacBio sequencing, to detect and sequence the MPE-labeled regions.\n3. Data analysis: The sequencing data is analyzed to identify the MPE-labeled regions and determine the sequence of the target DNA.\nMPE-seq has several advantages over traditional sequencing methods, including improved resolution, increased sensitivity, and reduced bias. It can be used to analyze a wide range of DNA sequences, including repetitive regions and gene promoters, and can be applied to a variety of biological samples, including whole genomes, transcriptomes, and epigenomes.\nIn summary, the basis of the MPE-seq method is to use a modified base analogue called MPE to label specific regions of DNA and then use NGS technologies to detect and sequence the labeled DNA regions. This allows for the selective enrichment of labeled DNA regions, which can improve the accuracy and throughput of the sequencing process.",
    "llama-2-7b-chat-hf_fact_raw": "1. MPE-seq is a DNA sequencing method that uses a modified base analogue called methidiumpropyl-EDTA (MPE) for labeling DNA.\n2. The MPE label in MPE-seq is used to mark specific DNA regions such as gene promoters or repetitive sequences.\n3. Methidiumpropyl-EDTA is fluorescently labeled and can be incorporated into DNA during replication or repair processes.\n4. The MPE-seq method involves the use of next-generation sequencing (NGS) technologies to detect and sequence labeled DNA regions.\n5. The MPE-seq method has advantages over traditional sequencing methods, including improved resolution, increased sensitivity, and reduced bias.",
    "llama-2-7b-chat-hf_fact": [
      "MPE-seq is a DNA sequencing method that uses a modified base analogue called methidiumpropyl-EDTA (MPE) for labeling DNA.",
      "The MPE label in MPE-seq is used to mark specific DNA regions such as gene promoters or repetitive sequences.",
      "Methidiumpropyl-EDTA is fluorescently labeled and can be incorporated into DNA during replication or repair processes.",
      "The MPE-seq method involves the use of next-generation sequencing (NGS) technologies to detect and sequence labeled DNA regions.",
      "The MPE-seq method has advantages over traditional sequencing methods, including improved resolution, increased sensitivity, and reduced bias."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: There is no widely recognized DNA sequencing method known as MPE-seq in the scientific literature as of my last update. \n2. UNKNOWN: Since MPE-seq is not a widely established method, it is not possible to confirm if MPE labels are used to mark specific DNA regions such as gene promoters or repetitive sequences.\n3. FALSE [correction]: Methidiumpropyl-EDTA (MPE) is not a modified base analogue used for labeling DNA; it is actually a chemical compound used as a DNA cleaving agent. It is not fluorescently labeled nor incorporated into DNA during replication or repair processes as described in DNA sequencing methods.\n4. UNKNOWN: Given that MPE-seq is not an established method, it cannot be confirmed whether or not it involves the use of next-generation sequencing (NGS) technologies.\n5. UNKNOWN: Without any recognized research or information available about MPE-seq, it is not possible to ascertain the claimed advantages of this method over traditional sequencing methods.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3400,
    "user_query": "Which programming language has been used for implementing GWAR?",
    "llama-2-7b-chat-hf_response": "GWAR (Genome-Wide Association Study) is typically implemented using a variety of programming languages depending on the specific analysis and the research group involved. However, some common programming languages used for GWAR include:\n* R: R is a popular language for statistical computing and graphics, and is widely used in the field of genetics and genomics. Many GWAR studies use R for data analysis and visualization.\n* Python: Python is a versatile language that is widely used in bioinformatics and computational biology. Many GWAR studies use Python for data analysis, particularly for large-scale genomic data sets.\n* MATLAB: MATLAB is a high-level programming language that is commonly used in bioinformatics and computational biology for data analysis, visualization, and modeling. Some GWAR studies use MATLAB for data analysis and visualization.\n* SAS: SAS (Statistical Analysis System) is a software suite that is widely used in statistical analysis and data management. Some GWAR studies use SAS for data analysis and visualization.\nIt's worth noting that the choice of programming language may depend on the specific requirements of the study, the research question, and the availability of resources and expertise within the research group.",
    "llama-2-7b-chat-hf_fact_raw": "1. R is a programming language used in the field of genetics and genomics for GWAR studies.\n2. Python is a programming language used in bioinformatics and computational biology for GWAR studies.\n3. MATLAB is used in bioinformatics and computational biology for data analysis and visualization in some GWAR studies.\n4. SAS is a software suite used in statistical analysis and some GWAR studies utilize it for data analysis and visualization.\n5. The choice of programming language for implementing GWAR depends on the specific requirements of the study and the resources and expertise available within the research group.",
    "llama-2-7b-chat-hf_fact": [
      "R is a programming language used in the field of genetics and genomics for GWAR studies.",
      "Python is a programming language used in bioinformatics and computational biology for GWAR studies.",
      "MATLAB is used in bioinformatics and computational biology for data analysis and visualization in some GWAR studies.",
      "SAS is a software suite used in statistical analysis and some GWAR studies utilize it for data analysis and visualization.",
      "The choice of programming language for implementing GWAR depends on the specific requirements of the study and the resources and expertise available within the research group."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3406,
    "user_query": "Does xaliproden improve prognosis of amyotrophic lateral sclerosis?",
    "llama-2-7b-chat-hf_response": "Xaliproden (also known as verubecestat) is an oral small molecule inhibitor of the enzyme bromodomain-containing protein 4 (BRD4). There is currently limited evidence to suggest that xaliproden improves the prognosis of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.\nA phase 2 clinical trial conducted by the pharmaceutical company Biogen found that xaliproden did not meet the primary endpoint of slowing the progression of ALS in patients with early-stage disease. Specifically, the trial did not show a significant difference in the rate of decline in the ALS Functional Rating Scale (ALSFRS-R) between the xaliproden and placebo groups over a 24-week treatment period.\nHowever, the trial did reveal some interesting findings on the potential mechanisms of action of xaliproden in ALS. The study found that xaliproden increased the levels of a protein called TARDBP (tumor-associated protein 130kDa brain-specific) in the cerebrospinal fluid of ALS patients, which suggests that the drug may be targeting the underlying disease mechanisms.\nWhile the results of this trial were disappointing in terms of the primary endpoint, they provide valuable insights into the potential therapeutic effects of xaliproden in ALS and suggest that further research is warranted to fully understand its mechanism of action and potential as a treatment for this devastating disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. Xaliproden is an inhibitor of the enzyme bromodomain-containing protein 4 (BRD4).\n2. There is limited evidence that xaliproden improves the prognosis of amyotrophic lateral sclerosis.\n3. A phase 2 clinical trial by Biogen found that xaliproden did not meet the primary endpoint of slowing the progression of ALS.\n4. The trial did not show a significant difference in the ALS Functional Rating Scale (ALSFRS-R) decline rate between xaliproden and placebo groups over 24 weeks.\n5. Xaliproden increased the levels of TARDBP in the cerebrospinal fluid of ALS patients according to the trial.",
    "llama-2-7b-chat-hf_fact": [
      "Xaliproden is an inhibitor of the enzyme bromodomain-containing protein 4 (BRD4).",
      "There is limited evidence that xaliproden improves the prognosis of amyotrophic lateral sclerosis.",
      "A phase 2 clinical trial by Biogen found that xaliproden did not meet the primary endpoint of slowing the progression of ALS.",
      "The trial did not show a significant difference in the ALS Functional Rating Scale (ALSFRS-R) decline rate between xaliproden and placebo groups over 24 weeks.",
      "Xaliproden increased the levels of TARDBP in the cerebrospinal fluid of ALS patients according to the trial."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Xaliproden is not an inhibitor of BRD4. Xaliproden is an investigational drug that has been studied for its potential neuroprotective and neurotrophic effects, not for inhibiting BRD4.\n2. TRUE: There have been studies and limited evidence suggesting potential benefits of xaliproden for amyotrophic lateral sclerosis (ALS), although the evidence is not conclusive.\n3. UNKNOWN: Without specific details of the phase 2 clinical trial by Biogen, such as the name of the trial or its publication, it's impossible to confirm or refute this statement.\n4. UNKNOWN: Similarly, without access to the specific trial results, the statement regarding the ALSFRS-R decline rate cannot be confirmed as true or false.\n5. UNKNOWN: The results about TARDBP levels following the xaliproden trial cannot be determined as true or false without additional context or citation of the specific study findings.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3410,
    "user_query": "In which chromosome are transgenes inserted in the case of the LiPS-A3S line?",
    "llama-2-7b-chat-hf_response": "The LiPS-A3S line is a transgenic line in which the transgene is inserted into chromosome 16.",
    "llama-2-7b-chat-hf_fact_raw": "1. The transgene in the LiPS-A3S line is inserted into chromosome 16.",
    "llama-2-7b-chat-hf_fact": [
      "The transgene in the LiPS-A3S line is inserted into chromosome 16."
    ],
    "llama-2-7b-chat-hf_judge_raw": "UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown"
    ]
  },
  {
    "id": 3430,
    "user_query": "Which tool exist for predicting drug synergy with deep learning?",
    "llama-2-7b-chat-hf_response": "There are several deep learning tools and models that can be used for predicting drug synergy, including:\n1. DeepDrug: This is a deep learning model that predicts drug synergy by analyzing the molecular structures of drugs and their targets. It uses a convolutional neural network (CNN) architecture to predict the binding affinity and synergy between drugs.\n2. Drug2gene: This is a deep learning model that predicts drug synergy by analyzing the gene expression profiles of drugs. It uses a random forest algorithm to identify the genes that are co-regulated by different drugs and predicts the synergy between them.\n3. DrugSynth: This is a deep learning model that predicts drug synergy by analyzing the chemical structures of drugs. It uses a graph convolutional neural network (GCNN) architecture to predict the molecular interactions between drugs and their targets.\n4. Synergizer: This is a deep learning model that predicts drug synergy by analyzing the genomic and transcriptomic profiles of drugs. It uses a combination of CNN and recurrent neural network (RNN) architectures to predict the synergy between drugs.\n5. DrugCombinator: This is a deep learning model that predicts drug synergy by analyzing the chemical structures of drugs and their targets. It uses a combination of CNN and RNN architectures to predict the interactions between drugs and their targets and predict the synergy between them.\n6. DrugNet: This is a deep learning model that predicts drug synergy by analyzing the protein-protein interaction networks of drugs. It uses a graph convolutional neural network (GCNN) architecture to predict the interactions between drugs and their targets and predict the synergy between them.\n7. DrugSynergyNet: This is a deep learning model that predicts drug synergy by analyzing the genomic and transcriptomic profiles of drugs. It uses a combination of CNN and RNN architectures to predict the synergy between drugs.\n8. DeepSynergy: This is a deep learning model that predicts drug synergy by analyzing the molecular structures of drugs and their targets. It uses a combination of CNN and RNN architectures to predict the interactions between drugs and their targets",
    "llama-2-7b-chat-hf_fact_raw": "1. DeepDrug is a deep learning model that predicts drug synergy using a convolutional neural network architecture.\n2. Drug2gene predicts drug synergy by analyzing gene expression profiles through a random forest algorithm.\n3. DrugSynth uses a graph convolutional neural network to analyze the chemical structures of drugs for predicting drug synergy.\n4. Synergizer predicts drug synergy by utilizing both convolutional neural network and recurrent neural network architectures.\n5. DeepSynergy is a deep learning model that combines CNN and RNN architectures to predict drug synergy.",
    "llama-2-7b-chat-hf_fact": [
      "DeepDrug is a deep learning model that predicts drug synergy using a convolutional neural network architecture.",
      "Drug2gene predicts drug synergy by analyzing gene expression profiles through a random forest algorithm.",
      "DrugSynth uses a graph convolutional neural network to analyze the chemical structures of drugs for predicting drug synergy.",
      "Synergizer predicts drug synergy by utilizing both convolutional neural network and recurrent neural network architectures.",
      "DeepSynergy is a deep learning model that combines CNN and RNN architectures to predict drug synergy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nFor the statements where I've responded with \"UNKNOWN,\" there's not enough provided context to determine the truthfulness of the claims about each specific deep learning model and its architecture or methodology. Without additional information or references, I cannot verify these statements.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3433,
    "user_query": "Which cloud-based platform has been developed for comparing GWAS?",
    "llama-2-7b-chat-hf_response": "The cloud-based platform that has been developed for comparing GWAS is called \"GWAS Central\". It is a web-based platform that allows researchers to upload and compare genome-wide association study (GWAS) data from different populations, and to identify genetic variants that are associated with the same trait or disease across different studies. GWAS Central was developed by the National Center for Biotechnology Information (NCBI) and is available for free use by researchers.",
    "llama-2-7b-chat-hf_fact_raw": "1. GWAS Central is a cloud-based platform developed for comparing GWAS.\n2. GWAS Central allows researchers to upload and compare genome-wide association study data.\n3. The platform is used to identify genetic variants associated with the same trait or disease across different studies.\n4. The National Center for Biotechnology Information (NCBI) developed GWAS Central.\n5. GWAS Central is available for free use by researchers.",
    "llama-2-7b-chat-hf_fact": [
      "GWAS Central is a cloud-based platform developed for comparing GWAS.",
      "GWAS Central allows researchers to upload and compare genome-wide association study data.",
      "The platform is used to identify genetic variants associated with the same trait or disease across different studies.",
      "The National Center for Biotechnology Information (NCBI) developed GWAS Central.",
      "GWAS Central is available for free use by researchers."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: GWAS Central is a database and online resource for genome-wide association studies, but not specifically described as cloud-based.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: GWAS Central is developed and maintained by the University of Leicester in collaboration with the European Bioinformatics Institute (EBI), not the NCBI.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3434,
    "user_query": "Can CMB305 be used against sarcomas?",
    "llama-2-7b-chat-hf_response": "Yes, CMB305 has been shown to be effective in treating sarcomas. CMB305 is a bispecific antibody that targets both CD3 and CD19, which are proteins found on the surface of T cells and B cells, respectively. By binding to these proteins, CMB305 can stimulate the immune system to attack cancer cells, including sarcomas.\nSarcomas are a type of cancer that originates in the connective tissue of the body, such as bone, cartilage, and fat. They can be difficult to treat and often have a poor prognosis, especially if they are aggressive or have spread to other parts of the body.\nStudies have shown that CMB305 can be effective in treating various types of sarcomas, including osteosarcoma, chondrosarcoma, and soft tissue sarcoma. For example, a phase 1 clinical trial published in the journal Cancer Research in 2017 found that CMB305 was well-tolerated and showed signs of anti-tumor activity in patients with advanced sarcomas.\nOverall, CMB305 is a promising immunotherapy approach for treating sarcomas, and further research is needed to fully understand its potential in this context.",
    "llama-2-7b-chat-hf_fact_raw": "1. CMB305 is a bispecific antibody that targets CD3 and CD19 on T cells and B cells.\n2. Sarcomas are cancers originating in the connective tissue of the body such as bone, cartilage, and fat.\n3. CMB305 has been found to stimulate the immune system to attack cancer cells, including sarcomas.\n4. A phase 1 clinical trial published in the journal Cancer Research in 2017 reported that CMB305 was well-tolerated and exhibited anti-tumor activity in patients with advanced sarcomas.\n5. CMB305 is considered a promising immunotherapy for treating various types of sarcomas.",
    "llama-2-7b-chat-hf_fact": [
      "CMB305 is a bispecific antibody that targets CD3 and CD19 on T cells and B cells.",
      "Sarcomas are cancers originating in the connective tissue of the body such as bone, cartilage, and fat.",
      "CMB305 has been found to stimulate the immune system to attack cancer cells, including sarcomas.",
      "A phase 1 clinical trial published in the journal Cancer Research in 2017 reported that CMB305 was well-tolerated and exhibited anti-tumor activity in patients with advanced sarcomas.",
      "CMB305 is considered a promising immunotherapy for treating various types of sarcomas."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: CMB305 is a bispecific vaccine that targets NY-ESO-1-expressing cancers and has been tested in sarcoma patients. It is not a bispecific antibody nor does it target CD3 and CD19 on T cells and B cells.\n2. TRUE\n3. TRUE\n4. TRUE – However, without direct access to the specific article and details, I can't confirm the exact findings reported. This assessment is based on typical language used in scientific literature.\n5. TRUE – While the specific efficacy and promise can only be accurately assessed by reviewing scientific data and ongoing research, CMB305 is considered a candidate for immunotherapy in sarcomas, particularly in those expressing the NY-ESO-1 antigen.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3461,
    "user_query": "What are manifestations of the Saint's Triad?",
    "llama-2-7b-chat-hf_response": "The Saint's Triad, also known as the Behçet's triad, is a set of three symptoms that are commonly seen in patients with Behçet's disease, a chronic inflammatory disorder that affects the blood vessels. The three manifestations of the Saint's Triad are:\n1. Uveitis: Inflammation of the uvea (the middle layer of the eye) is a common symptom of Behçet's disease. It can cause eye pain, redness, sensitivity to light, and blurred vision.\n2. Mucous membrane ulceration: Behçet's disease can cause ulcers to develop on the mucous membranes, including the mouth, nose, and genitals. These ulcers can be painful and can cause difficulty swallowing, breathing, or urinating.\n3. Arthritis: Behçet's disease can cause joint pain, swelling, and stiffness, similar to rheumatoid arthritis. The joints most commonly affected are those in the hands and feet.\nTogether, these three symptoms make up the Saint's Triad, which is often used to diagnose Behçet's disease. However, not everyone with Behçet's disease will develop all three symptoms, and some people may have additional symptoms not included in the triad.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Saint's Triad is a set of symptoms associated with Behçet's disease.\n2. Uveitis is a manifestation of the Saint's Triad and involves inflammation of the uvea.\n3. Ulcers on mucous membranes, including the mouth, nose, and genitals, are part of the manifestations of the Saint's Triad.\n4. Arthritis, particularly in the hands and feet, is a symptom of Behçet's disease included in the Saint's Triad.\n5. The Saint's Triad is used to diagnose Behçet's disease.",
    "llama-2-7b-chat-hf_fact": [
      "The Saint's Triad is a set of symptoms associated with Behçet's disease.",
      "Uveitis is a manifestation of the Saint's Triad and involves inflammation of the uvea.",
      "Ulcers on mucous membranes, including the mouth, nose, and genitals, are part of the manifestations of the Saint's Triad.",
      "Arthritis, particularly in the hands and feet, is a symptom of Behçet's disease included in the Saint's Triad.",
      "The Saint's Triad is used to diagnose Behçet's disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The phrase \"Saint's Triad\" is not typically associated with Behçet's disease. However, Behçet's disease does have a set of symptoms known as a \"triad,\" consisting of recurrent oral ulcers, genital ulcers, and uveitis.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: While arthritis can be a symptom of Behçet's disease, it is not specifically part of the classic triad used to describe the main symptoms of the disease. The classic triad includes recurrent oral ulcers, genital ulcers, and uveitis.\n5. FALSE [correction]: The triad of symptoms—oral ulcers, genital ulcers, and uveitis—is characteristic of Behçet's disease and can be used to support the diagnosis, but Behçet's disease is diagnosed based on a broader set of criteria that includes these symptoms and others, as well as exclusion of other diseases. There is no established entity known as the \"Saint's Triad\" used to diagnose Behçet's disease.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 3470,
    "user_query": "Is overexpression of LY6K associated with better prognosis for non-small cell lung cancer patients?",
    "llama-2-7b-chat-hf_response": "Yes, overexpression of LY6K has been associated with better prognosis for non-small cell lung cancer (NSCLC) patients. Studies have shown that high levels of LY6K expression are associated with improved overall survival, disease-free survival, and response to chemotherapy in NSCLC patients.",
    "llama-2-7b-chat-hf_fact_raw": "1. Overexpression of LY6K is associated with better prognosis for non-small cell lung cancer patients.\n2. High levels of LY6K expression are associated with improved overall survival in NSCLC patients.\n3. High levels of LY6K expression are associated with improved disease-free survival in NSCLC patients.\n4. High levels of LY6K expression are associated with a better response to chemotherapy in NSCLC patients.",
    "llama-2-7b-chat-hf_fact": [
      "Overexpression of LY6K is associated with better prognosis for non-small cell lung cancer patients.",
      "High levels of LY6K expression are associated with improved overall survival in NSCLC patients.",
      "High levels of LY6K expression are associated with improved disease-free survival in NSCLC patients.",
      "High levels of LY6K expression are associated with a better response to chemotherapy in NSCLC patients."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Overexpression of LY6K is associated with worse prognosis for non-small cell lung cancer (NSCLC) patients.\n2. FALSE [correction]: High levels of LY6K expression are typically associated with poorer overall survival in NSCLC patients.\n3. FALSE [correction]: High levels of LY6K expression are generally associated with poorer disease-free survival in NSCLC patients.\n4. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3473,
    "user_query": "List Cdk targets that are dephosphorylated during cytokinesis",
    "llama-2-7b-chat-hf_response": "Certainly! Here are some Cdk targets that are dephosphorylated during cytokinesis:\n1. Cyclin-dependent kinase 1 (Cdk1): Cdk1 is dephosphorylated at threonine 14 by the protein phosphatase Cdc25A during cytokinesis.\n2. Cyclin-dependent kinase 2 (Cdk2): Cdk2 is dephosphorylated at threonine 16 by the protein phosphatase Cdc25A during cytokinesis.\n3. Cyclin-dependent kinase 4 (Cdk4): Cdk4 is dephosphorylated at threonine 16 by the protein phosphatase Cdc25A during cytokinesis.\n4. Cyclin-dependent kinase 6 (Cdk6): Cdk6 is dephosphorylated at threonine 30 by the protein phosphatase Cdc25A during cytokinesis.\n5. Cyclin-dependent kinase 9 (Cdk9): Cdk9 is dephosphorylated at threonine 20 by the protein phosphatase Cdc25A during cytokinesis.\nThese dephosphorylation events are important for the proper progression of cytokinesis, as they allow the Cdks to interact with and activate their downstream targets, such as the microtubule-severing enzyme Ect2, and the actin-organizing protein APC.",
    "llama-2-7b-chat-hf_fact_raw": "1. Cyclin-dependent kinase 1 (Cdk1) is dephosphorylated at threonine 14 by the protein phosphatase Cdc25A during cytokinesis.\n2. Cyclin-dependent kinase 2 (Cdk2) is dephosphorylated at threonine 16 by the protein phosphatase Cdc25A during cytokinesis.\n3. Cyclin-dependent kinase 4 (Cdk4) is dephosphorylated at threonine 16 by the protein phosphatase Cdc25A during cytokinesis.\n4. Cyclin-dependent kinase 6 (Cdk6) is dephosphorylated at threonine 30 by the protein phosphatase Cdc25A during cytokinesis.\n5. Cyclin-dependent kinase 9 (Cdk9) is dephosphorylated at threonine 20 by the protein phosphatase Cdc25A during cytokinesis.",
    "llama-2-7b-chat-hf_fact": [
      "Cyclin-dependent kinase 1 (Cdk1) is dephosphorylated at threonine 14 by the protein phosphatase Cdc25A during cytokinesis.",
      "Cyclin-dependent kinase 2 (Cdk2) is dephosphorylated at threonine 16 by the protein phosphatase Cdc25A during cytokinesis.",
      "Cyclin-dependent kinase 4 (Cdk4) is dephosphorylated at threonine 16 by the protein phosphatase Cdc25A during cytokinesis.",
      "Cyclin-dependent kinase 6 (Cdk6) is dephosphorylated at threonine 30 by the protein phosphatase Cdc25A during cytokinesis.",
      "Cyclin-dependent kinase 9 (Cdk9) is dephosphorylated at threonine 20 by the protein phosphatase Cdc25A during cytokinesis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Cyclin-dependent kinase 1 (Cdk1) is dephosphorylated at threonine 14 by the protein phosphatase Cdc25, not Cdc25A, during the process that leads up to mitosis, not cytokinesis.\n2. FALSE [correction]: Cyclin-dependent kinase 2 (Cdk2) is primarily activated by the removal of phosphate groups from threonine 14 and tyrosine 15 by Cdc25A, among other Cdc25 phosphatases, but this happens during the cell cycle progression prior to mitosis, not specifically during cytokinesis.\n3. UNKNOWN: The specific dephosphorylation site and timing during cell cycle for Cdk4 by Cdc25A is not commonly referred to in basic cell biology, making the specificity of this statement difficult to confirm without more detailed biochemical context.\n4. UNKNOWN: The specific dephosphorylation site and function of Cdk6 in relation to Cdc25A and cytokinesis is not universally agreed upon in scientific literature, rendering this statement difficult to confirm without more detailed information.\n5. UNKNOWN: Threonine 20 dephosphorylation of Cdk9 by Cdc25A during cytokinesis is not an established fact in cell biology literature, and the role of Cdk9 is more typically associated with transcription control rather than direct regulation of cytokinesis.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3508,
    "user_query": "What is Xanamem?",
    "llama-2-7b-chat-hf_response": "Xanamem is a drug that inhibits the activity of the enzyme glycogen synthase kinase-3 (GSK-3).",
    "llama-2-7b-chat-hf_fact_raw": "1. Xanamem is a drug.\n2. Xanamem inhibits the activity of the enzyme glycogen synthase kinase-3 (GSK-3).",
    "llama-2-7b-chat-hf_fact": [
      "Xanamem is a drug.",
      "Xanamem inhibits the activity of the enzyme glycogen synthase kinase-3 (GSK-3)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Xanamem is designed to inhibit the activity of the enzyme 11β-HSD1 (11 beta-hydroxysteroid dehydrogenase type 1), not GSK-3 (glycogen synthase kinase-3).",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false"
    ]
  },
  {
    "id": 3520,
    "user_query": "What is the role of the Hof1-Cyk3 interaction in yeast?",
    "llama-2-7b-chat-hf_response": "In yeast, the interaction between Hof1 and Cyk3 plays a crucial role in regulating the cellular response to oxidative stress. Hof1 is a transmembrane protein that functions as a sensor of oxidative stress, while Cyk3 is a protein kinase that regulates various cellular processes, including the DNA damage response. The interaction between Hof1 and Cyk3 leads to the activation of Cyk3 and the induction of genes involved in DNA repair and other stress-response pathways. This interaction helps to protect the cell against oxidative stress and maintain genome stability.",
    "llama-2-7b-chat-hf_fact_raw": "1. The interaction between Hof1 and Cyk3 in yeast regulates the cellular response to oxidative stress.\n2. Hof1 is a transmembrane protein that functions as a sensor of oxidative stress in yeast.\n3. Cyk3 is a protein kinase that regulates various cellular processes, including the DNA damage response in yeast.\n4. Activation of Cyk3 occurs through its interaction with Hof1.\n5. The Hof1-Cyk3 interaction induces genes involved in DNA repair and other stress-response pathways in yeast.",
    "llama-2-7b-chat-hf_fact": [
      "The interaction between Hof1 and Cyk3 in yeast regulates the cellular response to oxidative stress.",
      "Hof1 is a transmembrane protein that functions as a sensor of oxidative stress in yeast.",
      "Cyk3 is a protein kinase that regulates various cellular processes, including the DNA damage response in yeast.",
      "Activation of Cyk3 occurs through its interaction with Hof1.",
      "The Hof1-Cyk3 interaction induces genes involved in DNA repair and other stress-response pathways in yeast."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[explanation]: Without specific information from a scientific study or a reliable source, it is not possible to verify the accuracy of the statements regarding the precise biological functions of Hof1, Cyk3, their interaction, and their role in stress responses or DNA repair in yeast. These are highly specialized claims that require direct knowledge of the specific scientific literature or data being referenced.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3598,
    "user_query": "Which T-UCRs have been implicated in gastric cancer?",
    "llama-2-7b-chat-hf_response": "T-bet (T-box transcription factor Eomesodermin) and Eomesodermin (Eomes) are T-UCRs that have been implicated in gastric cancer.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3607,
    "user_query": "What is the Lupus Severity Index (LSI)?",
    "llama-2-7b-chat-hf_response": "The Lupus Severity Index (LSI) is a tool used to assess the severity of systemic lupus erythematosus (SLE), a chronic autoimmune disease that affects multiple organ systems. The LSI is a composite score that takes into account various clinical and laboratory parameters, including:\n1. Serologic markers (such as anti-nuclear antibodies and complement levels)\n2. Organ involvement (such as kidney, skin, and joint involvement)\n3. Disease activity (such as fever, fatigue, and pain)\n4. Functional status (such as physical and cognitive impairment)\nThe LSI is calculated by assigning scores to each of these parameters based on their severity, and then adding up these scores to obtain a total LSI score. The higher the LSI score, the more severe the disease. The LSI has been shown to be a useful tool for evaluating the severity of SLE and monitoring the effectiveness of treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Lupus Severity Index (LSI) is a tool used to assess the severity of systemic lupus erythematosus (SLE).\n2. SLE is a chronic autoimmune disease that affects multiple organ systems.\n3. The LSI is a composite score that includes clinical and laboratory parameters.\n4. Serologic markers and organ involvement, such as kidney and skin, are considered in the LSI score.\n5. A higher LSI score indicates more severe disease severity in SLE patients.",
    "llama-2-7b-chat-hf_fact": [
      "The Lupus Severity Index (LSI) is a tool used to assess the severity of systemic lupus erythematosus (SLE).",
      "SLE is a chronic autoimmune disease that affects multiple organ systems.",
      "The LSI is a composite score that includes clinical and laboratory parameters.",
      "Serologic markers and organ involvement, such as kidney and skin, are considered in the LSI score.",
      "A higher LSI score indicates more severe disease severity in SLE patients."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The existence of a specific tool named \"Lupus Severity Index\" (LSI) for assessing the severity of systemic lupus erythematosus (SLE) cannot be confirmed or denied without further context, as there are various methods and indices used to evaluate SLE severity, such as the SLE Disease Activity Index (SLEDAI), but \"LSI\" is not a widely recognized standard acronym for these.\n2. TRUE: Systemic lupus erythematosus (SLE) is indeed a chronic autoimmune disease that can affect multiple organ systems.\n3. UNKNOWN: Without specific knowledge of the Lupus Severity Index, it is not possible to confirm the inclusion of clinical and laboratory parameters. However, most indices used to assess SLE, like SLEDAI, do include a combination of these parameters.\n4. TRUE: In the assessment of SLE severity using various indices, serologic markers (such as antibodies) and the level of organ involvement, including kidneys (nephritis) and skin (cutaneous manifestations), are certainly considered.\n5. TRUE: Generally, in indices that evaluate the severity of diseases like SLE, a higher score represents more severe disease activity or severity.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3615,
    "user_query": "Which disorders are caused by de novo mutations in ZSWIM6?",
    "llama-2-7b-chat-hf_response": "ZSWIM6 is a gene that has been associated with several human disorders caused by de novo mutations, including:\n1. Neuromyelitis optica (NMO): A rare autoimmune disease that affects the central nervous system (CNS), including the optic nerves and spinal cord.\n2. Acute flaccid paralysis (AFP): A sudden onset of weakness or paralysis in one or more limbs, often accompanied by loss of sensation in the affected area.\n3. Spastic paraplegia: A type of paralysis that affects one or both legs, characterized by stiffness and spasms.\n4. Spastic paresis: A condition where there is a loss of muscle tone and weakness in one or more limbs, often accompanied by spasms and stiffness.\n5. Spinal muscular atrophy (SMA): A genetic disorder that affects the nerve cells (motor neurons) responsible for controlling voluntary muscle movement, leading to muscle weakness and wasting.\nThese disorders are caused by mutations in the ZSWIM6 gene, which codes for a protein involved in the regulation of intracellular signaling pathways and cytoskeleton organization. The mutations lead to dysfunction of the ZSWIM6 protein, which in turn disrupts the normal functioning of the affected signaling pathways and leads to the development of the associated disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. Neuromyelitis optica (NMO) is associated with de novo mutations in the ZSWIM6 gene.\n2. Acute flaccid paralysis (AFP) can be caused by de novo mutations in the ZSWIM6 gene.\n3. Spastic paraplegia has been linked to de novo mutations in the ZSWIM6 gene.\n4. Spastic paresis can be a result of de novo mutations in the ZSWIM6 gene.\n5. Spinal muscular atrophy (SMA) is a genetic disorder associated with mutations in the ZSWIM6 gene.",
    "llama-2-7b-chat-hf_fact": [
      "Neuromyelitis optica (NMO) is associated with de novo mutations in the ZSWIM6 gene.",
      "Acute flaccid paralysis (AFP) can be caused by de novo mutations in the ZSWIM6 gene.",
      "Spastic paraplegia has been linked to de novo mutations in the ZSWIM6 gene.",
      "Spastic paresis can be a result of de novo mutations in the ZSWIM6 gene.",
      "Spinal muscular atrophy (SMA) is a genetic disorder associated with mutations in the ZSWIM6 gene."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Neuromyelitis optica (NMO) is associated with autoantibodies to aquaporin-4, but there's no established association with de novo mutations in the ZSWIM6 gene.\n2. UNKNOWN: Without more specific information, it's unclear whether acute flaccid paralysis (AFP) can be caused by de novo mutations in the ZSWIM6 gene. AFP can have various causes including poliovirus and non-poliovirus causes.\n3. FALSE [correction]: Spastic paraplegia has been linked to mutations in various genes, primarily the SPG genes, but there is no evidence directly linking de novo mutations in the ZSWIM6 gene with hereditary spastic paraplegia as of my knowledge cutoff date.\n4. UNKNOWN: Spastic paresis can be a symptom in various conditions, and while it could theoretically be a result of genetic mutations, without explicit evidence linking ZSWIM6 gene mutations to spastic paresis, a definitive statement cannot be made.\n5. FALSE [correction]: Spinal muscular atrophy (SMA) is a genetic disorder associated with mutations in the SMN1 gene, not the ZSWIM6 gene.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3626,
    "user_query": "Which disease can be classified using the Koos Classification?",
    "llama-2-7b-chat-hf_response": "The Koos Classification is used to classify diseases related to the nervous system, particularly those that affect the brain and spinal cord. Examples of diseases that can be classified using the Koos Classification include:\n1. Brain tumors\n2. Neurodegenerative disorders (e.g. Alzheimer's disease, Parkinson's disease, Huntington's disease)\n3. Stroke and cerebrovascular diseases\n4. Traumatic brain injuries\n5. Infections of the brain and meninges (e.g. meningitis, encephalitis)\n6. Demyelinating diseases (e.g. multiple sclerosis, neuromyelitis optica)\n7. Movement disorders (e.g. Parkinson's disease, dystonia)\n8. Seizure disorders (e.g. epilepsy)\n9. Sleep disorders (e.g. narcolepsy, insomnia)\n10. Psychiatric disorders (e.g. depression, anxiety)\nEach of these diseases is classified based on the specific symptoms and characteristics they exhibit, and the Koos Classification provides a standardized framework for organizing and understanding these conditions.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Koos Classification is used to classify diseases of the nervous system.\n2. It includes the classification of brain tumors.\n3. Neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease, can be classified using the Koos Classification.\n4. The Koos Classification is applicable to stroke and cerebrovascular diseases.\n5. Multiple sclerosis, a demyelinating disease, falls under the diseases that can be classified by the Koos Classification.",
    "llama-2-7b-chat-hf_fact": [
      "The Koos Classification is used to classify diseases of the nervous system.",
      "It includes the classification of brain tumors.",
      "Neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease, can be classified using the Koos Classification.",
      "The Koos Classification is applicable to stroke and cerebrovascular diseases.",
      "Multiple sclerosis, a demyelinating disease, falls under the diseases that can be classified by the Koos Classification."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Koos Classification is used to classify vestibular schwannomas (acoustic neuromas), not all diseases of the nervous system.\n2. FALSE [correction]: The Koos Classification specifically classifies vestibular schwannomas rather than all brain tumors.\n3. FALSE [correction]: Neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease are not classified using the Koos Classification, which is specific to vestibular schwannomas.\n4. FALSE [correction]: The Koos Classification is not applicable to stroke and cerebrovascular diseases, as it is intended for grading vestibular schwannomas.\n5. FALSE [correction]: Multiple sclerosis, a demyelinating disease, is not classified by the Koos Classification, which is used for vestibular schwannomas.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3628,
    "user_query": "What are the in vivo effects of AZD8601?",
    "llama-2-7b-chat-hf_response": "AZD8601 is a potent and selective inhibitor of the enzyme PI3K (phosphatidylinositol 3-kinase). In vivo, AZD8601 has been shown to have a variety of effects, including:\n1. Inhibition of tumor growth: AZD8601 has been shown to inhibit the growth of various types of tumors, including breast, lung, and colon cancer, both in vitro and in vivo.\n2. Inhibition of angiogenesis: AZD8601 has been shown to inhibit the formation of new blood vessels, a process known as angiogenesis, which is necessary for tumor growth and metastasis.\n3. Enhancement of chemotherapy: AZD8601 has been shown to enhance the effectiveness of certain chemotherapeutic agents, such as paclitaxel, in treating cancer.\n4. Immune modulation: AZD8601 has been shown to modulate the immune response, including the activation of immune cells and the production of cytokines.\n5. Anti-inflammatory effects: AZD8601 has been shown to have anti-inflammatory effects in various models of inflammation, including colitis and arthritis.\n6. Neuroprotection: AZD8601 has been shown to have neuroprotective effects in various models of neurodegeneration, including Alzheimer's disease and Parkinson's disease.\n7. Cardiovascular protection: AZD8601 has been shown to have cardiovascular protective effects in various models of cardiovascular disease, including hypertension and atherosclerosis.\n8. Anti-aging effects: AZD8601 has been shown to have anti-aging effects in various models of aging, including delayed aging in mice.\nIt is important to note that these effects are based on studies in cell cultures and animal models, and more research is needed to determine the efficacy and safety of AZD8601 in humans.",
    "llama-2-7b-chat-hf_fact_raw": "1. AZD8601 is an inhibitor of the enzyme phosphatidylinositol 3-kinase (PI3K).\n2. AZD8601 has been shown to inhibit the growth of various types of tumors, including breast, lung, and colon cancer in vitro and in vivo.\n3. AZD8601 has been shown to inhibit angiogenesis, the formation of new blood vessels.\n4. AZD8601 has been shown to enhance the effectiveness of the chemotherapeutic agent paclitaxel in treating cancer.\n5. AZD8601 has been reported to have neuroprotective effects in models of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.",
    "llama-2-7b-chat-hf_fact": [
      "AZD8601 is an inhibitor of the enzyme phosphatidylinositol 3-kinase (PI3K).",
      "AZD8601 has been shown to inhibit the growth of various types of tumors, including breast, lung, and colon cancer in vitro and in vivo.",
      "AZD8601 has been shown to inhibit angiogenesis, the formation of new blood vessels.",
      "AZD8601 has been shown to enhance the effectiveness of the chemotherapeutic agent paclitaxel in treating cancer.",
      "AZD8601 has been reported to have neuroprotective effects in models of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: AZD8601 is not an inhibitor of the enzyme phosphatidylinositol 3-kinase (PI3K). AZD8601 is actually a modified mRNA therapy designed to encode for the protein VEGF-A, which is involved in the restoration of blood vessels and cardiac tissue.\n2. FALSE [correction]: Since AZD8601 is not a PI3K inhibitor and is actually a therapy based on modified mRNA for VEGF-A, it has not been shown to inhibit the growth of various types of tumors. The statement is false as it pertains to AZD8601; PI3K inhibitors might inhibit tumor growth, but that is not the function of AZD8601.\n3. TRUE: AZD8601 has been shown to promote angiogenesis, the formation of new blood vessels, through the expression of VEGF-A, which is the intended therapeutic function. While the statement says \"inhibit\", in the context of angiogenesis, AZD8601 does the opposite: it encourages new blood vessel growth.\n4. UNKNOWN: Without specific evidence or studies detailing the combination of AZD8601 and paclitaxel in treating cancer, it's difficult to verify this claim.\n5. FALSE [correction]: AZD8601 has been reported to promote angiogenesis and improve cardiac tissue repair due to its role in promoting VEGF-A expression. The claim of neuroprotective effects in models of neurodegenerative diseases like Alzheimer's and Parkinson's is incorrect for AZD8601; this might be confused with different compounds or therapeutics.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3640,
    "user_query": "How are SAHFS created?",
    "llama-2-7b-chat-hf_response": "SAHFs (Sperm Associated Histone Fragments) are created through a process called histone fragmentation, which involves the degradation of histone proteins in the sperm nucleus during the process of spermatogenesis. This process is mediated by enzymes called histone-specific proteases, which break down the histone proteins into smaller fragments. The resulting fragments are then packaged into the sperm nucleus, where they play a role in the regulation of gene expression during fertilization.",
    "llama-2-7b-chat-hf_fact_raw": "1. SAHFs stand for Sperm Associated Histone Fragments.\n2. SAHFs are created through a process called histone fragmentation.\n3. Histone fragmentation involves the degradation of histone proteins in the sperm nucleus.\n4. The process occurs during spermatogenesis.\n5. Histone-specific proteases are enzymes that mediate the breakdown of histone proteins into SAHFs.",
    "llama-2-7b-chat-hf_fact": [
      "SAHFs stand for Sperm Associated Histone Fragments.",
      "SAHFs are created through a process called histone fragmentation.",
      "Histone fragmentation involves the degradation of histone proteins in the sperm nucleus.",
      "The process occurs during spermatogenesis.",
      "Histone-specific proteases are enzymes that mediate the breakdown of histone proteins into SAHFs."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: SAHFs stand for Senescence-Associated Heterochromatin Foci.\n2. FALSE [correction]: SAHFs are not created through histone fragmentation; they represent a cellular structure associated with the onset of senescence in cells, not a component derived from the fragmentation of histones.\n3. UNKNOWN: The statement is based on the incorrect premise that SAHFs involve the degradation of histone proteins in the sperm nucleus, but since SAHFs are not Sperm Associated Histone Fragments, the statement cannot be accurately addressed as true or false.\n4. UNKNOWN: Since SAHFs pertain to Senescence-Associated Heterochromatin Foci and not to histone fragmentation during spermatogenesis, there is no direct relevance to the process of spermatogenesis.\n5. UNKNOWN: The statement proposes a role for histone-specific proteases related to the incorrect definition of SAHFs. Since SAHFs do not result from the breakdown of histone proteins into fragments, the statement about histone-specific proteases mediating this process is based on an incorrect premise and cannot be definitively addressed as true or false.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3672,
    "user_query": "What is the function of the PDZ domain in SATB1?",
    "llama-2-7b-chat-hf_response": "The PDZ (PSD-95/Discs-large/ZO-1) domain is a protein-binding module found in the SATB1 protein. The PDZ domain of SATB1 plays a crucial role in the regulation of its localization and function by interacting with other proteins and cytoskeletal elements. In particular, the PDZ domain of SATB1 can bind to the cytoplasmic tail of the Notch receptor and other transmembrane proteins, which helps to regulate the activity of the Notch signaling pathway.",
    "llama-2-7b-chat-hf_fact_raw": "1. The PDZ domain is a protein-binding module found in the SATB1 protein.\n2. The PDZ domain of SATB1 is involved in regulating the localization and function of SATB1.\n3. The PDZ domain of SATB1 interacts with other proteins and cytoskeletal elements.\n4. The PDZ domain of SATB1 can bind to the cytoplasmic tail of the Notch receptor.\n5. The PDZ domain of SATB1 helps to regulate the activity of the Notch signaling pathway.",
    "llama-2-7b-chat-hf_fact": [
      "The PDZ domain is a protein-binding module found in the SATB1 protein.",
      "The PDZ domain of SATB1 is involved in regulating the localization and function of SATB1.",
      "The PDZ domain of SATB1 interacts with other proteins and cytoskeletal elements.",
      "The PDZ domain of SATB1 can bind to the cytoplasmic tail of the Notch receptor.",
      "The PDZ domain of SATB1 helps to regulate the activity of the Notch signaling pathway."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. FALSE [correction]: The PDZ domain is known to mediate protein-protein interactions, but there is no specific evidence that the PDZ domain of SATB1 can bind to the cytoplasmic tail of the Notch receptor. This type of interaction has not been established for SATB1.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3678,
    "user_query": "What is the basis of the BLISS technique?",
    "llama-2-7b-chat-hf_response": "BLISS (Block, Lift, Increment, Shrink, and Shift) is a statistical technique used to estimate the effect of a treatment or intervention on an outcome variable in the presence of confounding variables. It is based on the idea of creating a comparison group that is similar to the treatment group in all observed characteristics except for the treatment itself.\nThe BLISS technique involves the following steps:\n1. Block: Divide the data into blocks based on the confounding variables.\n2. Lift: Create a lift sample for each block, which is a sample of observations that are similar to the treatment group in all observed characteristics except for the treatment.\n3. Increment: Increment the lift sample by a small amount to create a comparison group.\n4. Shrink: Shrink the lift sample back to the original sample size.\n5. Shift: Shift the comparison group by the amount of the treatment effect.\nThe BLISS technique can be used to estimate the effect of a treatment on an outcome variable in the presence of confounding variables, while also accounting for the correlation between the confounding variables and the treatment. It is a useful technique in causal inference and can be used in a variety of applications, including observational studies and randomized controlled trials.",
    "llama-2-7b-chat-hf_fact_raw": "1. The BLISS technique is used to estimate the effect of a treatment or intervention on an outcome variable while considering confounding variables.\n2. BLISS stands for Block, Lift, Increment, Shrink, and Shift.\n3. The BLISS technique includes creating a comparison group that is similar to the treatment group in all observed characteristics except for the treatment.\n4. The BLISS technique involves dividing the data into blocks based on confounding variables.\n5. The BLISS technique can be applied in observational studies and randomized controlled trials.",
    "llama-2-7b-chat-hf_fact": [
      "The BLISS technique is used to estimate the effect of a treatment or intervention on an outcome variable while considering confounding variables.",
      "BLISS stands for Block, Lift, Increment, Shrink, and Shift.",
      "The BLISS technique includes creating a comparison group that is similar to the treatment group in all observed characteristics except for the treatment.",
      "The BLISS technique involves dividing the data into blocks based on confounding variables.",
      "The BLISS technique can be applied in observational studies and randomized controlled trials."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The term BLISS technique is not a standard term recognized in statistics or epidemiology for estimating the effects of a treatment or intervention. Instead, techniques like propensity score matching, instrumental variable analysis, and regression adjustment are commonly used to address confounding variables.\n2. FALSE [correction]: Since BLISS is not a recognized technique for the stated purpose, there is no accepted acronym that stands for Block, Lift, Increment, Shrink, and Shift in this context.\n3. UNKNOWN: Without an established technique called BLISS, the specifics of creating comparison groups can't be confirmed as true or false.\n4. UNKNOWN: Since BLISS is not established or recognized, whether it involves dividing data into blocks based on confounding variables is not ascertainable.\n5. UNKNOWN: Without a recognized BLISS technique, we cannot determine its applicability in observational studies and randomized controlled trials.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3679,
    "user_query": "List 3 NK3R antagonists.",
    "llama-2-7b-chat-hf_response": "Here are three known NK3R (neurokinin receptor 3) antagonists:\n1. A-83-01: A potent and selective NK3R antagonist that has been shown to have anti-inflammatory effects in various animal models.\n2. GR 127935: A highly selective and potent NK3R antagonist that has been shown to have potential in the treatment of inflammatory disorders such as asthma and allergic rhinitis.\n3. MK-0599: A novel, orally available NK3R antagonist that has been shown to have anti-inflammatory effects in various animal models, including models of asthma and atopic dermatitis.",
    "llama-2-7b-chat-hf_fact_raw": "1. A-83-01 is a selective NK3R antagonist with anti-inflammatory effects in various animal models.\n2. GR 127935 is a selective and potent NK3R antagonist with potential in treating inflammatory disorders such as asthma and allergic rhinitis.\n3. MK-0599 is an orally available NK3R antagonist with anti-inflammatory effects in animal models, including those for asthma and atopic dermatitis.",
    "llama-2-7b-chat-hf_fact": [
      "A-83-01 is a selective NK3R antagonist with anti-inflammatory effects in various animal models.",
      "GR 127935 is a selective and potent NK3R antagonist with potential in treating inflammatory disorders such as asthma and allergic rhinitis.",
      "MK-0599 is an orally available NK3R antagonist with anti-inflammatory effects in animal models, including those for asthma and atopic dermatitis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without specific scientific literature or context confirming the properties of A-83-01, it's not possible to determine the truthfulness of this statement.\n2. FALSE [correction]: GR 127935 is actually a selective antagonist for the serotonin 5-HT1B and 5-HT1D receptors, not NK3R.\n3. UNKNOWN: There isn't enough information provided about MK-0599 to verify if it is an NK3R antagonist with anti-inflammatory effects in animal models for asthma and atopic dermatitis.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3691,
    "user_query": "Which drug is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects?",
    "llama-2-7b-chat-hf_response": "The first oral ghrelin receptor inverse agonist to be profiled in healthy subjects is called BMS-986177.",
    "llama-2-7b-chat-hf_fact_raw": "1. BMS-986177 is an oral ghrelin receptor inverse agonist.\n2. BMS-986177 has been profiled in healthy subjects.",
    "llama-2-7b-chat-hf_fact": [
      "BMS-986177 is an oral ghrelin receptor inverse agonist.",
      "BMS-986177 has been profiled in healthy subjects."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: BMS-986177 is an oral factor XIa inhibitor, not a ghrelin receptor inverse agonist.\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true"
    ]
  },
  {
    "id": 3693,
    "user_query": "What is the protective efficacy of vaxchora against moderate to severe cholera?",
    "llama-2-7b-chat-hf_response": "Vaxchora, a cholera vaccine, has been shown to provide protection against moderate to severe cholera in clinical trials. The protective efficacy of Vaxchora against moderate to severe cholera has been estimated to be around 80-90% in adults and 60-70% in children, based on the results of clinical trials conducted in endemic areas. However, it's important to note that no vaccine can provide 100% protection against cholera, and the duration of protection may vary depending on several factors, including the strain of the bacteria, the individual's immune response, and the overall health of the individual.",
    "llama-2-7b-chat-hf_fact_raw": "1. Vaxchora is a cholera vaccine.\n2. Clinical trials have shown that Vaxchora provides protection against moderate to severe cholera.\n3. The protective efficacy of Vaxchora is estimated to be around 80-90% in adults.\n4. The protective efficacy of Vaxchora is estimated to be around 60-70% in children.\n5. No vaccine can provide 100% protection against cholera.",
    "llama-2-7b-chat-hf_fact": [
      "Vaxchora is a cholera vaccine.",
      "Clinical trials have shown that Vaxchora provides protection against moderate to severe cholera.",
      "The protective efficacy of Vaxchora is estimated to be around 80-90% in adults.",
      "The protective efficacy of Vaxchora is estimated to be around 60-70% in children.",
      "No vaccine can provide 100% protection against cholera."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The protective efficacy of Vaxchora in children under 18 has not been established, as the vaccine is only FDA-approved for adults aged 18 to 64.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3716,
    "user_query": "Which was the first cholera vaccine approved in the US?",
    "llama-2-7b-chat-hf_response": "The first cholera vaccine approved in the US was the oral cholera vaccine, also known as the \"Live, Attenuated, Oral Cholera Vaccine\" (LAV), which was approved by the US Food and Drug Administration (FDA) in 1989.",
    "llama-2-7b-chat-hf_fact_raw": "1. The first cholera vaccine approved in the US was an oral cholera vaccine.\n2. The oral cholera vaccine is also known as the \"Live, Attenuated, Oral Cholera Vaccine\" (LAV).\n3. The US Food and Drug Administration (FDA) approved the first cholera vaccine in 1989.",
    "llama-2-7b-chat-hf_fact": [
      "The first cholera vaccine approved in the US was an oral cholera vaccine.",
      "The oral cholera vaccine is also known as the \"Live, Attenuated, Oral Cholera Vaccine\" (LAV).",
      "The US Food and Drug Administration (FDA) approved the first cholera vaccine in 1989."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. FALSE [correction]: The US Food and Drug Administration (FDA) approved the first cholera vaccine for adults aged 18 to 64 who are traveling to cholera-affected areas in June 2016; it was called Vaxchora.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3737,
    "user_query": "Which is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans?",
    "llama-2-7b-chat-hf_response": "The most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is mutations in the X-linked gene encoding the protein CD40 ligand (CD40L). CD40L is a co-stimulatory molecule that plays a critical role in the activation and differentiation of B cells, and mutations in the CD40L gene can lead to a range of immunological defects, including CVID.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutations in the X-linked gene encoding the protein CD40 ligand (CD40L) is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans.\n2. CD40 ligand (CD40L) is a co-stimulatory molecule that is involved in the activation and differentiation of B cells.\n3. Mutations in the CD40L gene can lead to a range of immunological defects, including common variable immunodeficiency (CVID).",
    "llama-2-7b-chat-hf_fact": [
      "Mutations in the X-linked gene encoding the protein CD40 ligand (CD40L) is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans.",
      "CD40 ligand (CD40L) is a co-stimulatory molecule that is involved in the activation and differentiation of B cells.",
      "Mutations in the CD40L gene can lead to a range of immunological defects, including common variable immunodeficiency (CVID)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Mutations in the X-linked gene encoding the protein CD40 ligand (CD40L) can lead to X-linked Hyper-IgM syndrome, not common variable immunodeficiency (CVID). Genetic causes of CVID are more heterogeneous and can involve a number of different genes.\n2. TRUE\n3. FALSE [correction]: While mutations in the CD40L gene can lead to immunological defects, such as X-linked Hyper-IgM syndrome, it is not the most common genetic cause of common variable immunodeficiency (CVID). CVID has a more complex etiology with different genetic contributions.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 3743,
    "user_query": "Which is the role of the IFIT1 gene in Systemic Lupus Erythematosus (SLE)?",
    "llama-2-7b-chat-hf_response": "The IFIT1 gene has been shown to play a role in the development and progression of Systemic Lupus Erythematosus (SLE), an autoimmune disease characterized by the production of autoantibodies and inflammation in multiple organ systems. Studies have found that IFIT1 is a negative regulator of type I interferons (IFN-α/β), which are key players in the immune response to infection and inflammation. In SLE patients, the IFIT1 gene is often mutated or downregulated, leading to an imbalance in the immune response and the production of excessive amounts of IFN-α/β. This can contribute to the development of autoantibodies and the progression of SLE flares.",
    "llama-2-7b-chat-hf_fact_raw": "1. The IFIT1 gene plays a role in the development and progression of Systemic Lupus Erythematosus (SLE).\n2. Systemic Lupus Erythematosus is an autoimmune disease that produces autoantibodies and causes inflammation in multiple organ systems.\n3. IFIT1 is a negative regulator of type I interferons (IFN-α/β).\n4. In Systemic Lupus Erythematosus patients, the IFIT1 gene is often mutated or downregulated.\n5. An imbalance in the immune response due to malfunctioning of the IFIT1 gene can lead to the production of excessive amounts of IFN-α/β in SLE patients.",
    "llama-2-7b-chat-hf_fact": [
      "The IFIT1 gene plays a role in the development and progression of Systemic Lupus Erythematosus (SLE).",
      "Systemic Lupus Erythematosus is an autoimmune disease that produces autoantibodies and causes inflammation in multiple organ systems.",
      "IFIT1 is a negative regulator of type I interferons (IFN-α/β).",
      "In Systemic Lupus Erythematosus patients, the IFIT1 gene is often mutated or downregulated.",
      "An imbalance in the immune response due to malfunctioning of the IFIT1 gene can lead to the production of excessive amounts of IFN-α/β in SLE patients."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The IFIT1 gene is known to be involved in the immune response, and variations in this gene have been studied in connection with autoimmune diseases like Systemic Lupus Erythematosus (SLE), though the exact role may vary and is an area of ongoing research.\n2. TRUE: Systemic Lupus Erythematosus is indeed an autoimmune disease characterized by the production of autoantibodies leading to inflammation affecting multiple organ systems.\n3. FALSE [correction]: IFIT1 is typically considered an interferon-induced protein with antiviral properties. It is usually associated with the positive regulation of the body's response to viral infections, including the promotion of type I interferon signaling, not its negative regulation.\n4. UNKNOWN: Without specific data or a source confirming the mutation or regulation status of the IFIT1 gene in SLE patients, the claim that IFIT1 is often mutated or downregulated in SLE patients cannot be confirmed or denied with certainty.\n5. UNKNOWN: While an imbalance in the immune response and the role of type I interferons (IFN-α/β) in SLE are areas of research, the specific connection to the malfunctioning of the IFIT1 gene leading to the excessive production of these interferons in SLE patients is not clear without specific reference to research findings confirming such a relationship.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3752,
    "user_query": "What is the use of the Liverpool Elbow Score?",
    "llama-2-7b-chat-hf_response": "The Liverpool Elbow Score (LES) is a patient-reported outcome measure used to assess the severity of elbow symptoms and disability in patients with elbow problems, such as tennis elbow (lateral epicondylitis) or golfer's elbow (medial epicondylitis). The score is used to evaluate the effectiveness of treatments for these conditions and to monitor progress over time. The LES consists of 10 questions that assess the severity of symptoms such as pain, stiffness, and weakness in the elbow, as well as the impact of these symptoms on daily activities. The score ranges from 0 to 100, with higher scores indicating greater severity of symptoms and disability.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Liverpool Elbow Score (LES) is used to assess the severity of elbow symptoms and disability in patients with elbow problems.\n2. LES is employed to evaluate the effectiveness of treatments for conditions like tennis elbow and golfer's elbow.\n3. The LES is used to monitor the progress of patients with elbow problems over time.\n4. The Liverpool Elbow Score consists of 10 questions.\n5. The LES scoring range is from 0 to 100, with higher scores indicating greater severity of symptoms and disability.",
    "llama-2-7b-chat-hf_fact": [
      "The Liverpool Elbow Score (LES) is used to assess the severity of elbow symptoms and disability in patients with elbow problems.",
      "LES is employed to evaluate the effectiveness of treatments for conditions like tennis elbow and golfer's elbow.",
      "The LES is used to monitor the progress of patients with elbow problems over time.",
      "The Liverpool Elbow Score consists of 10 questions.",
      "The LES scoring range is from 0 to 100, with higher scores indicating greater severity of symptoms and disability."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The Liverpool Elbow Score consists of 10 sections, not necessarily 10 questions, as each section contains multiple items or questions.\n5. FALSE [correction]: The LES scoring range is from 0 to 100, with lower scores indicating greater severity of symptoms and disability.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 3763,
    "user_query": "Describe efforts on Sarcoma from the 100,000 Genomes Project",
    "llama-2-7b-chat-hf_response": "The 100,000 Genomes Project is a large-scale genomics initiative launched in the UK in 2012 to accelerate the understanding of genetic variation and its role in disease. As part of this project, efforts have been made to investigate the genomics of sarcoma, a rare and complex cancer type that affects connective tissue. Here are some key findings and insights from the 100,000 Genomes Project related to sarcoma:\n1. High genomic diversity: Sarcomas are known to be genetically heterogeneous, and the 100,000 Genomes Project has confirmed this by identifying a high level of genomic diversity among sarcoma tumors. This diversity is thought to be due to the complex genetic mutations that occur in these tumors.\n2. Frequent mutations in genes involved in DNA damage response: The 100,000 Genomes Project has identified a number of genes that are frequently mutated in sarcomas, including genes involved in the DNA damage response pathway, such as ATM, ATR, and BRCA1. These mutations may contribute to the development and progression of sarcomas.\n3. Mutations in KRAS and other RTK signaling pathway genes: The 100,000 Genomes Project has also identified mutations in genes involved in the RTK (receptor tyrosine kinase) signaling pathway, such as KRAS, in a subset of sarcomas. These mutations are thought to play a role in the development and progression of these tumors.\n4. Identification of new sarcoma subtypes: The 100,000 Genomes Project has helped to identify new subtypes of sarcomas based on the genomic alterations present in these tumors. For example, the project has identified a subtype of sarcoma called \"clear cell sarcoma of soft tissue,\" which is characterized by a specific set of genomic alterations.\n5. Improved understanding of the molecular mechanisms underlying sarcoma development and progression: The 100,000 Genomes Project has provided valuable insights into the molecular mechanisms underlying the development",
    "llama-2-7b-chat-hf_fact_raw": "1. The 100,000 Genomes Project was launched in the UK in 2012.\n2. The project has investigated the genomics of sarcoma.\n3. The 100,000 Genomes Project identified a high level of genomic diversity among sarcoma tumors.\n4. Frequent mutations have been found in sarcoma genes involved in the DNA damage response pathway, such as ATM, ATR, and BRCA1, according to the project's findings.\n5. The 100,000 Genomes Project has identified mutations in genes in the RTK signaling pathway, like KRAS, in a subset of sarcomas.",
    "llama-2-7b-chat-hf_fact": [
      "The 100,000 Genomes Project was launched in the UK in 2012.",
      "The project has investigated the genomics of sarcoma.",
      "The 100,000 Genomes Project identified a high level of genomic diversity among sarcoma tumors.",
      "Frequent mutations have been found in sarcoma genes involved in the DNA damage response pathway, such as ATM, ATR, and BRCA1, according to the project's findings.",
      "The 100,000 Genomes Project has identified mutations in genes in the RTK signaling pathway, like KRAS, in a subset of sarcomas."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The 100,000 Genomes Project was launched in the UK in 2013.\n2. TRUE - While the project's main aim was rare diseases and cancer, sarcomas, which are a type of cancer, would have been within its scope.\n3. TRUE - It is expected that the 100,000 Genomes Project would identify a high level of genomic diversity among sarcoma tumors given the diversity observed in cancer genomes.\n4. UNKNOWN - Without specific data or outcomes from the project, we cannot confirm whether mutations were found in DNA damage response genes like ATM, ATR, and BRCA1 in sarcoma tumors.\n5. UNKNOWN - Similar to the previous statement, without specific results from the project, it is not possible to confirm the identification of mutations in the RTK signaling pathway, such as in the KRAS gene, in a subset of sarcomas.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3777,
    "user_query": "Does protein ALEX1 contain armadillo repeats?",
    "llama-2-7b-chat-hf_response": "Yes, protein ALEX1 contains multiple armadillo (ARM) repeats.",
    "llama-2-7b-chat-hf_fact_raw": "1. Protein ALEX1 contains multiple armadillo (ARM) repeats.",
    "llama-2-7b-chat-hf_fact": [
      "Protein ALEX1 contains multiple armadillo (ARM) repeats."
    ],
    "llama-2-7b-chat-hf_judge_raw": "UNKNOWN\n\nGiven the specificity of the statement regarding Protein ALEX1, it would require accessing a detailed bioinformatics database or scientific literature to confirm the exact structure and characteristics of this protein. Without access to the current scientific knowledge or databases to verify the composition of Protein ALEX1, the veracity of this statement cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "unknown"
    ]
  },
  {
    "id": 3789,
    "user_query": "List enzymes that removes histone modifications.",
    "llama-2-7b-chat-hf_response": "There are several enzymes that remove histone modifications. Here are some examples:\n1. Histone demethylases: These enzymes remove methyl groups from histone proteins, leading to changes in chromatin structure and gene expression. Examples of histone demethylases include KDM4B, KDM5, and KDM1A.\n2. Histone acetyltransferases: These enzymes add acetyl groups to histone proteins, leading to changes in chromatin structure and gene expression. Examples of histone acetyltransferases include CBP (CREB-binding protein) and p300.\n3. Histone deacetylases: These enzymes remove acetyl groups from histone proteins, leading to changes in chromatin structure and gene expression. Examples of histone deacetylases include HDAC1, HDAC2, and HDAC3.\n4. Histone ubiquitin ligases: These enzymes remove histone proteins from chromatin, leading to changes in chromatin structure and gene expression. Examples of histone ubiquitin ligases include RNF2 and RNF4.\n5. Histone phosphatases: These enzymes remove phosphate groups from histone proteins, leading to changes in chromatin structure and gene expression. Examples of histone phosphatases include PP1 and PP2A.\nThese enzymes play important roles in regulating chromatin structure and gene expression, and their dysregulation has been implicated in various diseases, including cancer and neurological disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. Histone demethylases, such as KDM4B, KDM5, and KDM1A, remove methyl groups from histone proteins.\n2. Histone acetyltransferases, such as CBP (CREB-binding protein) and p300, add acetyl groups to histone proteins.\n3. Histone deacetylases, such as HDAC1, HDAC2, and HDAC3, remove acetyl groups from histone proteins.\n4. Histone ubiquitin ligases, such as RNF2 and RNF4, remove histone proteins from chromatin.\n5. Histone phosphatases, such as PP1 and PP2A, remove phosphate groups from histone proteins.",
    "llama-2-7b-chat-hf_fact": [
      "Histone demethylases, such as KDM4B, KDM5, and KDM1A, remove methyl groups from histone proteins.",
      "Histone acetyltransferases, such as CBP (CREB-binding protein) and p300, add acetyl groups to histone proteins.",
      "Histone deacetylases, such as HDAC1, HDAC2, and HDAC3, remove acetyl groups from histone proteins.",
      "Histone ubiquitin ligases, such as RNF2 and RNF4, remove histone proteins from chromatin.",
      "Histone phosphatases, such as PP1 and PP2A, remove phosphate groups from histone proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Histone ubiquitin ligases, such as RNF2 (also known as RING1B) and RNF4, do not remove histone proteins from chromatin. Instead, they are involved in adding ubiquitin to histones which can signal for different downstream processes, including altering chromatin structure or signaling for histone removal by other mechanisms.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3806,
    "user_query": "Does head ct increase brain tumor risk?",
    "llama-2-7b-chat-hf_response": "Head CT scans do not increase the risk of brain tumors. While there is some concern that repeated exposure to radiation from CT scans may increase the risk of cancer, the risk associated with a single head CT scan is considered to be very low.\nThe American College of Radiology recommends that patients receive a CT scan only when the potential benefit of the scan outweighs the small risk of radiation exposure. Additionally, the use of advanced imaging techniques, such as MRI or PET scans, may reduce the need for repeated CT scans and further minimize the risk of radiation exposure.\nIt is important to note that while head CT scans do not increase the risk of brain tumors, they can help identify potential brain abnormalities, such as tumors or cerebral edema, which can be treated to improve outcomes.",
    "llama-2-7b-chat-hf_fact_raw": "1. Head CT scans do not increase the risk of brain tumors.\n2. Repeated exposure to radiation from CT scans may increase the risk of cancer.\n3. The American College of Radiology recommends CT scans only when the benefit outweighs the small risk of radiation exposure.\n4. Advanced imaging techniques, such as MRI or PET scans, may reduce the need for repeated CT scans.\n5. Head CT scans can help identify brain abnormalities such as tumors or cerebral edema.",
    "llama-2-7b-chat-hf_fact": [
      "Head CT scans do not increase the risk of brain tumors.",
      "Repeated exposure to radiation from CT scans may increase the risk of cancer.",
      "The American College of Radiology recommends CT scans only when the benefit outweighs the small risk of radiation exposure.",
      "Advanced imaging techniques, such as MRI or PET scans, may reduce the need for repeated CT scans.",
      "Head CT scans can help identify brain abnormalities such as tumors or cerebral edema."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Head CT scans involve exposure to radiation, which can potentially increase the risk of brain tumors, particularly with repeated exposure.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3809,
    "user_query": "Which type of pluripotency is Otx2 associated with?",
    "llama-2-7b-chat-hf_response": "Otx2 is associated with neural pluripotency.",
    "llama-2-7b-chat-hf_fact_raw": "1. Otx2 is associated with neural pluripotency.",
    "llama-2-7b-chat-hf_fact": [
      "Otx2 is associated with neural pluripotency."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Otx2 is not directly associated with neural pluripotency. Instead, Otx2 is a homeobox transcription factor that plays a crucial role in the development of the brain and sensory organs. Neural pluripotency is more commonly associated with factors such as Sox2, Oct4, and Nanog.",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 3815,
    "user_query": "How many DNaseI hypersensitive sites (DHS) mark the murine beta globin locus region?",
    "llama-2-7b-chat-hf_response": "The murine beta globin locus region has 11 DNaseI hypersensitive sites (DHS).",
    "llama-2-7b-chat-hf_fact_raw": "1. The murine beta globin locus region contains 11 DNaseI hypersensitive sites (DHS).",
    "llama-2-7b-chat-hf_fact": [
      "The murine beta globin locus region contains 11 DNaseI hypersensitive sites (DHS)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "UNKNOWN\n\nWithout additional context or a reference to a specific scientific study or resource that details the count of DNaseI hypersensitive sites within the murine beta globin locus region, I cannot confirm the accuracy of this statement. In genetics and molecular biology, the number of such sites can be determined through experimental data, which may vary by study or by the specific techniques used to analyze the locus.",
    "llama-2-7b-chat-hf_judge": [
      "unknown"
    ]
  },
  {
    "id": 3822,
    "user_query": "List as many European influenza vaccines as possible.",
    "llama-2-7b-chat-hf_response": "Here are some European influenza vaccines that are currently available or have been approved in the past:\n1. Fluarix Tetra (GlaxoSmithKline): This is a quadrivalent vaccine that protects against four strains of the influenza virus (two A strains and two B strains).\n2. Fluvirin (Novartis): This is a trivalent vaccine that protects against three strains of the influenza virus (two A strains and one B strain).\n3. Aggripulse (GlaxoSmithKline): This is a quadrivalent vaccine that protects against four strains of the influenza virus (two A strains and two B strains).\n4. Fluad (GlaxoSmithKline): This is a quadrivalent vaccine that protects against four strains of the influenza virus (two A strains and two B strains). It is specifically designed for adults aged 65 years and older.\n5. Focetria (Sanofi Pasteur): This is a trivalent vaccine that protects against three strains of the influenza virus (two A strains and one B strain).\n6. Flublok (Protein Sciences): This is a trivalent vaccine that protects against three strains of the influenza virus (two A strains and one B strain). It is made using an insect cell-based production process.\n7. FluMist (AstraZeneca): This is a quadrivalent vaccine that protects against four strains of the influenza virus (two A strains and two B strains). It is administered as a nasal spray.\n8. Agrippal (Novartis): This is a quadrivalent vaccine that protects against four strains of the influenza virus (two A strains and two B strains). It is specifically designed for children and adolescents.\n9. Fluarix (GlaxoSmithKline): This is a trivalent vaccine that protects against three strains of the influenza virus (two A strains and one B strain). It is specifically designed for children and adolescents.\n10. Vaxigrip (Sanofi",
    "llama-2-7b-chat-hf_fact_raw": "1. Fluarix Tetra is a quadrivalent influenza vaccine.\n2. Fluvirin is a trivalent influenza vaccine.\n3. Fluad is specifically designed for adults aged 65 years and older.\n4. Flublok is made using an insect cell-based production process.\n5. FluMist is administered as a nasal spray.",
    "llama-2-7b-chat-hf_fact": [
      "Fluarix Tetra is a quadrivalent influenza vaccine.",
      "Fluvirin is a trivalent influenza vaccine.",
      "Fluad is specifically designed for adults aged 65 years and older.",
      "Flublok is made using an insect cell-based production process.",
      "FluMist is administered as a nasal spray."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3832,
    "user_query": "Is the Paramyxovirus geneome segmented, negative-sense RNA?",
    "llama-2-7b-chat-hf_response": "Yes, the Paramyxovirus geneome is segmented, negative-sense RNA. Paramyxoviruses are a family of viruses that include the viruses that cause measles, mumps, and respiratory diseases, among others. Their genome consists of several segments of negative-sense RNA, which are transcribed in the opposite direction to the direction of transcription, resulting in a complementary RNA molecule.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Paramyxovirus genome is segmented.\n2. The Paramyxovirus genome is negative-sense RNA.\n3. Paramyxoviruses are a family of viruses that cause diseases such as measles and mumps.\n4. The Paramyxovirus genome consists of several segments of RNA that are transcribed in the opposite direction to produce a complementary RNA molecule.",
    "llama-2-7b-chat-hf_fact": [
      "The Paramyxovirus genome is segmented.",
      "The Paramyxovirus genome is negative-sense RNA.",
      "Paramyxoviruses are a family of viruses that cause diseases such as measles and mumps.",
      "The Paramyxovirus genome consists of several segments of RNA that are transcribed in the opposite direction to produce a complementary RNA molecule."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Paramyxovirus genome is non-segmented.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The Paramyxovirus genome consists of a single strand of negative-sense RNA, but it is non-segmented and does not consist of several segments. The RNA is transcribed in the opposite direction to produce a complementary RNA molecule, which is then used to produce messenger RNA and viral proteins.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3869,
    "user_query": "Roflumilast Cream is effective for which disease?",
    "llama-2-7b-chat-hf_response": "Roflumilast cream is effective for the treatment of plaque psoriasis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Roflumilast cream is used for the treatment of plaque psoriasis.",
    "llama-2-7b-chat-hf_fact": [
      "Roflumilast cream is used for the treatment of plaque psoriasis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Roflumilast is known to be formulated as a pill for oral use in the treatment of chronic obstructive pulmonary disease (COPD). There are creams that have been developed using roflumilast for the treatment of psoriasis, but the cream formulation specifically would not be accurate if only referred to as \"roflumilast cream\" without additional context indicating it's a topical formulation for psoriasis, as the original roflumilast formulation is an oral one for COPD.",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 3885,
    "user_query": "Which tools have been developed for identifying and visualising ncRNA promoters?",
    "llama-2-7b-chat-hf_response": "Several tools have been developed for identifying and visualizing non-coding RNA (ncRNA) promoters. Here are some of the commonly used tools:\n1. PROMoter Finder: This tool uses a Bayesian approach to predict the location of ncRNA promoters in the genome. It can be used to identify both known and novel ncRNAs.\n2. CpG Island Finder: This tool identifies regions of the genome that are enriched in the dinucleotide CpG, which is often associated with ncRNA promoters.\n3. RNApromoter: This tool uses a combination of sequence and functional data to predict the location of ncRNA promoters. It can also be used to predict the expression level of ncRNAs.\n4. NCRNApromoter: This tool uses a machine learning approach to predict the location of ncRNA promoters in the genome. It can be used to identify both known and novel ncRNAs.\n5. DeepSEA: This tool uses a deep learning approach to predict the location of ncRNA promoters in the genome. It can be used to identify both known and novel ncRNAs.\n6. RNAPro: This tool uses a combination of sequence and functional data to predict the location of ncRNA promoters. It can also be used to predict the expression level of ncRNAs.\n7. NCRNApromoter2: This tool is an updated version of the NCRNApromoter tool, which uses a more advanced machine learning algorithm to predict the location of ncRNA promoters.\n8. RNApromoter2: This tool is an updated version of the RNApromoter tool, which uses a more advanced machine learning algorithm to predict the location of ncRNA promoters.\nThese are some of the commonly used tools for identifying and visualizing ncRNA promoters. Each tool has its own strengths and limitations, and the choice of tool will depend on the specific research question and experimental design.",
    "llama-2-7b-chat-hf_fact_raw": "1. PROMoter Finder is a tool that predicts the location of ncRNA promoters using a Bayesian approach.\n2. CpG Island Finder is a tool that identifies regions in the genome enriched with the dinucleotide CpG, often associated with ncRNA promoters.\n3. RNApromoter is a tool combining sequence and functional data to predict the location and expression level of ncRNA promoters.\n4. DeepSEA uses a deep learning approach to predict the location of ncRNA promoters in the genome.\n5. NCRNApromoter2 is an updated tool that uses a more advanced machine learning algorithm to predict the location of ncRNA promoters.",
    "llama-2-7b-chat-hf_fact": [
      "PROMoter Finder is a tool that predicts the location of ncRNA promoters using a Bayesian approach.",
      "CpG Island Finder is a tool that identifies regions in the genome enriched with the dinucleotide CpG, often associated with ncRNA promoters.",
      "RNApromoter is a tool combining sequence and functional data to predict the location and expression level of ncRNA promoters.",
      "DeepSEA uses a deep learning approach to predict the location of ncRNA promoters in the genome.",
      "NCRNApromoter2 is an updated tool that uses a more advanced machine learning algorithm to predict the location of ncRNA promoters."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The correctness of this statement depends on whether a tool named \"PROMoter Finder\" actually exists and uses a Bayesian approach to predict ncRNA promoters. Without context to verify the existence of such a tool and its method, the truth of this statement cannot be established.\n\n2. FALSE [correction]: CpG Island Finder is indeed a tool that identifies regions in the genome that are enriched with the dinucleotide CpG, but these regions are generally associated with the promoters of protein-coding genes, not specifically non-coding RNA (ncRNA) promoters.\n\n3. UNKNOWN: Similar to statement 1, the existence of a tool named \"RNApromoter\" that combines sequence and functional data to predict ncRNA promoters' location and expression levels needs context for verification.\n\n4. UNKNOWN: DeepSEA is a real computational framework that predicts the impact of noncoding variants on chromatin, but the statement is focused on ncRNA promoters' prediction which is not the primary scope of DeepSEA. Therefore, without additional context regarding an extension or a specific application of DeepSEA for ncRNA promoters, the statement's accuracy is unknown.\n\n5. UNKNOWN: Without context to verify the existence of a tool named \"NCRNApromoter2\" and its use of an updated machine learning algorithm for predicting non-coding RNA promoter locations, the truth of this statement cannot be established.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3918,
    "user_query": "List example genes that SWIM tool has identified and which are down-regulated in glioblastoma",
    "llama-2-7b-chat-hf_response": "SWIM (Splicing Workbench for Integrative Modeling) is a tool that can be used to identify genes that are differentially spliced between two or more sample groups, such as healthy tissue and glioblastoma. Here are some examples of genes that SWIM has identified as down-regulated in glioblastoma:\n1. KRAS (Kirsten rat sarcoma viral oncogene homolog): KRAS is a gene that encodes a protein involved in cell signaling pathways. SWIM analysis has identified several splicing variants of KRAS that are down-regulated in glioblastoma.\n2. BRAF (v-raf murine sarcoma viral oncogene homolog 1): BRAF is a gene that encodes a protein involved in cell signaling pathways. SWIM analysis has identified several splicing variants of BRAF that are down-regulated in glioblastoma.\n3. PTEN (phosphatase and tensin homolog): PTEN is a gene that encodes a protein involved in cell signaling pathways. SWIM analysis has identified several splicing variants of PTEN that are down-regulated in glioblastoma.\n4. TP53 (tumor protein p53): TP53 is a gene that encodes a protein involved in cell cycle regulation and DNA repair. SWIM analysis has identified several splicing variants of TP53 that are down-regulated in glioblastoma.\n5. CDKN2A (cyclin-dependent kinase inhibitor 2A): CDKN2A is a gene that encodes a protein involved in cell cycle regulation. SWIM analysis has identified several splicing variants of CDKN2A that are down-regulated in glioblastoma.\n6. SLC9A2 (solute carrier family 9, subfamily A, member 2): SLC9A2 is a gene that encodes a protein involved in drug transport. SWIM analysis has identified several splicing variants of SLC9A2 that are down-regulated in glioblastoma.\n7. GSTP1 (glutathione S-transferase P1): GSTP1 is a gene that encodes a",
    "llama-2-7b-chat-hf_fact_raw": "1. SWIM has identified several splicing variants of the KRAS gene that are down-regulated in glioblastoma.\n2. SWIM has identified several splicing variants of the BRAF gene that are down-regulated in glioblastoma.\n3. SWIM has identified several splicing variants of the PTEN gene that are down-regulated in glioblastoma.\n4. SWIM has identified several splicing variants of the TP53 gene that are down-regulated in glioblastoma.\n5. SWIM has identified several splicing variants of the CDKN2A gene that are down-regulated in glioblastoma.",
    "llama-2-7b-chat-hf_fact": [
      "SWIM has identified several splicing variants of the KRAS gene that are down-regulated in glioblastoma.",
      "SWIM has identified several splicing variants of the BRAF gene that are down-regulated in glioblastoma.",
      "SWIM has identified several splicing variants of the PTEN gene that are down-regulated in glioblastoma.",
      "SWIM has identified several splicing variants of the TP53 gene that are down-regulated in glioblastoma.",
      "SWIM has identified several splicing variants of the CDKN2A gene that are down-regulated in glioblastoma."
    ],
    "llama-2-7b-chat-hf_judge_raw": "UNKNOWN\n\nThe statements provided refer to specific findings related to splicing variants of genes down-regulated in glioblastoma, presumably identified by an entity or software named SWIM. Without access to the specific research or publication from SWIM, it is not possible to verify the accuracy of the statements regarding the identification of splicing variants of KRAS, BRAF, PTEN, TP53, and CDKN2A genes and their regulation in glioblastoma. More detailed information or a reference to the study results would be required to determine the truthfulness of these statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3926,
    "user_query": "Which R packages have been developed for studying TADs?",
    "llama-2-7b-chat-hf_response": "Several R packages have been developed for studying Topological Associated Domains (TADs), including:\n1. TADb: This package provides a comprehensive framework for the analysis of TADs, including the ability to identify TADs from ChIP-seq data, and to quantify the degree of association between TADs and various genomic features.\n2. TADtrack: This package provides a tool for identifying TADs in ChIP-seq data, as well as for visualizing the spatial organization of TADs in the genome.\n3. TADfinder: This package provides a comprehensive toolkit for identifying and characterizing TADs, including the ability to integrate TAD information with other genomic data, such as gene expression and histone modification data.\n4. TopoTool: This package provides a set of tools for the analysis of topological associating domains (TADs) in 3D chromatin structures.\n5. ChromHMM: This package provides a probabilistic model for the organization of chromatin into TADs, and can be used to infer the 3D structure of chromatin from ChIP-seq data.\n6. TADtrackR: This package provides a tool for identifying TADs in ChIP-seq data, as well as for visualizing the spatial organization of TADs in the genome.\n7. TAD-seq: This package provides a tool for identifying TADs in ChIP-seq data, as well as for quantifying the degree of association between TADs and various genomic features.\n8. TAD-genome: This package provides a tool for identifying TADs in ChIP-seq data, as well as for visualizing the spatial organization of TADs in the genome.\n9. TAD-seq-2: This package provides a tool for identifying TADs in ChIP-seq data, as well as for quantifying the degree of association between TADs and various genomic features.\n10. TAD-seq-3: This package provides a tool for identifying TADs in ChIP-seq data, as well as for visualizing the spatial organization of TADs in the genome.\nThese packages provide a range of tools and methods for studying TADs, including the ability to identify TADs from ChIP-seq",
    "llama-2-7b-chat-hf_fact_raw": "1. TADb is an R package developed for analyzing Topological Associated Domains (TADs), capable of identifying TADs from ChIP-seq data.\n2. TADtrack is an R package that offers tools for identifying TADs in ChIP-seq data as well as for visualizing their spatial organization.\n3. TADfinder is an R package that provides tools for identifying and characterizing TADs, including integration with other genomic data like gene expression.\n4. TopoTool is an R package that offers a set of tools for analyzing TADs in 3D chromatin structures.\n5. ChromHMM is an R package that provides a probabilistic model to study the organization of chromatin into TADs and infer the 3D structure from ChIP-seq data.",
    "llama-2-7b-chat-hf_fact": [
      "TADb is an R package developed for analyzing Topological Associated Domains (TADs), capable of identifying TADs from ChIP-seq data.",
      "TADtrack is an R package that offers tools for identifying TADs in ChIP-seq data as well as for visualizing their spatial organization.",
      "TADfinder is an R package that provides tools for identifying and characterizing TADs, including integration with other genomic data like gene expression.",
      "TopoTool is an R package that offers a set of tools for analyzing TADs in 3D chromatin structures.",
      "ChromHMM is an R package that provides a probabilistic model to study the organization of chromatin into TADs and infer the 3D structure from ChIP-seq data."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: ChromHMM is not an R package; it is a computational tool developed for characterizing the chromatin states of a cell. It uses a Hidden Markov Model to systematically detect chromatin state signatures from histone modification data, but it's not specifically designed to infer the 3D structure from ChIP-seq data nor is it exclusively for studying the organization of chromatin into TADs.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3927,
    "user_query": "Which bioconductor tool has been developed for accessing bacterial regulatory networks?",
    "llama-2-7b-chat-hf_response": "The BioConductor tool developed for accessing bacterial regulatory networks is called \"BioCyc\".",
    "llama-2-7b-chat-hf_fact_raw": "1. BioCyc is a tool developed within the BioConductor project for accessing bacterial regulatory networks.",
    "llama-2-7b-chat-hf_fact": [
      "BioCyc is a tool developed within the BioConductor project for accessing bacterial regulatory networks."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: BioCyc is a collection of pathway/genome databases for thousands of organisms, but it is not developed as part of the Bioconductor project which focuses on tools for the analysis of genomic data in the R programming language. BioCyc is instead developed by SRI International.",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 3933,
    "user_query": "What are the end products of the shikimate pathway?",
    "llama-2-7b-chat-hf_response": "The end products of the shikimate pathway are:\n1. Aromatic amino acids: phenylalanine, tyrosine, and tryptophan\n2. Quinones: ubiquinone (coenzyme Q) and menaquinone (vitamin K2)\n3. Chlorophyll: chlorophyll a and chlorophyll b\n4. Flavonoids: anthocyanins, flavonols, and isoflavonoids\n5. Carotenoids: beta-carotene, lycopene, and lutein\n6. Alkaloids: nicotine, caffeine, and morphine\n7. Tannins: ellagic acid and gallic acid\nThese end products are important for various physiological processes, including photosynthesis, antioxidant defense, and signal transduction.",
    "llama-2-7b-chat-hf_fact_raw": "1. The shikimate pathway produces aromatic amino acids: phenylalanine, tyrosine, and tryptophan.\n2. Ubiquinone (coenzyme Q) and menaquinone (vitamin K2) are end products of the shikimate pathway.\n3. Chlorophyll a and chlorophyll b are synthesized through the shikimate pathway.\n4. The shikimate pathway results in the production of flavonoids such as anthocyanins, flavonols, and isoflavonoids.\n5. Alkaloids like nicotine, caffeine, and morphine are end products derived from the shikimate pathway.",
    "llama-2-7b-chat-hf_fact": [
      "The shikimate pathway produces aromatic amino acids: phenylalanine, tyrosine, and tryptophan.",
      "Ubiquinone (coenzyme Q) and menaquinone (vitamin K2) are end products of the shikimate pathway.",
      "Chlorophyll a and chlorophyll b are synthesized through the shikimate pathway.",
      "The shikimate pathway results in the production of flavonoids such as anthocyanins, flavonols, and isoflavonoids.",
      "Alkaloids like nicotine, caffeine, and morphine are end products derived from the shikimate pathway."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Ubiquinone (coenzyme Q) is not an end product of the shikimate pathway; it is part of the electron transport chain. Menaquinone (vitamin K2) is also not a direct product of the shikimate pathway; it is synthesized from other pathways.\n3. FALSE [correction]: Chlorophyll a and chlorophyll b are not synthesized through the shikimate pathway; they are synthesized through a different pathway called the porphyrin and chlorophyll metabolism pathway.\n4. TRUE\n5. FALSE [correction]: Alkaloids like nicotine, caffeine, and morphine are not end products derived from the shikimate pathway; they are synthesized from different precursor pathways. Nicotine is synthesized from ornithine and nicotinic acid, caffeine from xanthosine, and morphine from tyrosine, but tyrosine is a product of the shikimate pathway.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 3936,
    "user_query": "Is cabergoline used for treatment of the Nelson's syndrome ?",
    "llama-2-7b-chat-hf_response": "Yes, cabergoline is sometimes used to treat Nelson's syndrome, which is a rare condition that occurs after surgical removal of a pituitary tumor. Cabergoline is a dopamine receptor agonist that can help to reduce the growth of the remaining pituitary tissue and alleviate symptoms such as excessive growth hormone secretion, prolactin secretion, and visual disturbances. However, it is important to note that cabergoline is not a cure for Nelson's syndrome, and other treatments such as radiation therapy may also be necessary to control the growth of the remaining pituitary tissue.",
    "llama-2-7b-chat-hf_fact_raw": "1. Cabergoline is used to treat Nelson's syndrome.\n2. Nelson's syndrome is a rare condition that can occur after the surgical removal of a pituitary tumor.\n3. Cabergoline works as a dopamine receptor agonist.\n4. Cabergoline can help reduce the growth of remaining pituitary tissue and alleviate symptoms associated with Nelson's Syndrome.\n5. Cabergoline is not a cure for Nelson's syndrome and may be used alongside other treatments, such as radiation therapy.",
    "llama-2-7b-chat-hf_fact": [
      "Cabergoline is used to treat Nelson's syndrome.",
      "Nelson's syndrome is a rare condition that can occur after the surgical removal of a pituitary tumor.",
      "Cabergoline works as a dopamine receptor agonist.",
      "Cabergoline can help reduce the growth of remaining pituitary tissue and alleviate symptoms associated with Nelson's Syndrome.",
      "Cabergoline is not a cure for Nelson's syndrome and may be used alongside other treatments, such as radiation therapy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Cabergoline is not typically used to treat Nelson's syndrome; it is used to treat conditions associated with hyperprolactinemia such as prolactinomas.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: While cabergoline is a dopamine receptor agonist and can reduce the growth of pituitary tumors such as prolactinomas, its use in Nelson's syndrome specifically for reducing the growth of remaining pituitary tissue or alleviating symptoms is not established.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3939,
    "user_query": "What is the main manifestation of Liebenberg syndrome?",
    "llama-2-7b-chat-hf_response": "Liebenberg syndrome is a rare genetic disorder that affects the nervous system and is characterized by the following main manifestations:\n1. Progressive weakness and wasting of the muscles, particularly those of the face, arms, and legs.\n2. Impaired coordination and balance, leading to difficulty with walking and maintaining posture.\n3. Gradual loss of vision, including loss of peripheral vision and eventual blindness.\n4. Cognitive decline and impaired memory.\n5. Seizures, which can be severe and frequent.\n6. Sleep disturbances, including excessive daytime sleepiness and difficulty initiating sleep.\n7. Hearing loss, particularly high-frequency hearing loss.\n8. Abnormalities in the structure and function of the heart, including abnormal heart rhythms and decreased heart function.\nThese manifestations typically appear in infancy or early childhood and can have a significant impact on an individual's quality of life.",
    "llama-2-7b-chat-hf_fact_raw": "1. Liebenberg syndrome is a rare genetic disorder that affects the nervous system.\n2. Progressive weakness and wasting of the muscles, particularly those of the face, arms, and legs, is a manifestation of Liebenberg syndrome.\n3. Impaired coordination and balance associated with Liebenberg syndrome can lead to difficulty with walking and maintaining posture.\n4. Gradual loss of vision, including loss of peripheral vision and eventual blindness, can occur in individuals with Liebenberg syndrome.\n5. Individuals with Liebenberg syndrome may experience seizures.",
    "llama-2-7b-chat-hf_fact": [
      "Liebenberg syndrome is a rare genetic disorder that affects the nervous system.",
      "Progressive weakness and wasting of the muscles, particularly those of the face, arms, and legs, is a manifestation of Liebenberg syndrome.",
      "Impaired coordination and balance associated with Liebenberg syndrome can lead to difficulty with walking and maintaining posture.",
      "Gradual loss of vision, including loss of peripheral vision and eventual blindness, can occur in individuals with Liebenberg syndrome.",
      "Individuals with Liebenberg syndrome may experience seizures."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Justification]: Liebenberg syndrome is not a well-documented or recognized genetic disorder regarding its effects on the nervous system. Without a reliable source of information to confirm the details of these statements, their veracity cannot be established. It's possible that Liebenberg syndrome may not be an actual medical condition, or it might be known by a different name in medical literature, which is why the details cannot be confirmed.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3977,
    "user_query": "List orally bioavailable MPS1 kinase inhibitors",
    "llama-2-7b-chat-hf_response": "There are several orally bioavailable MPS1 kinase inhibitors that have been identified and developed for the treatment of various diseases, including cancer. Here are some examples:\n1. Vorinostat (Zolinza): Vorinostat is an oral histone deacetylase (HDAC) inhibitor that has been shown to inhibit MPS1 kinase activity and is approved for the treatment of cutaneous T-cell lymphoma.\n2. Romidepsin (Istodax): Romidepsin is an oral HDAC inhibitor that has been shown to inhibit MPS1 kinase activity and is approved for the treatment of cutaneous T-cell lymphoma.\n3. Panobinostat (Farydak): Panobinostat is an oral inhibitor of the enzyme PI3K (phosphatidylinositol 3-kinase), which is downstream of MPS1 kinase. It is approved for the treatment of multiple myeloma.\n4. GDC-0980 (GDC-0980): GDC-0980 is an oral inhibitor of the PI3K/Akt signaling pathway, which is downstream of MPS1 kinase. It is being developed for the treatment of various cancers, including breast, lung, and ovarian cancer.\n5. BAY 80-6946: BAY 80-6946 is an oral inhibitor of the PI3K/Akt signaling pathway, which is downstream of MPS1 kinase. It is being developed for the treatment of various cancers, including breast, lung, and ovarian cancer.\n6. AZD-2850: AZD-2850 is an oral inhibitor of the PI3K/Akt signaling pathway, which is downstream of MPS1 kinase. It is being developed for the treatment of various cancers, including breast, lung, and ovarian cancer.\n7. PF-04490153: PF-04490153 is an oral inhibitor of the PI3K/A",
    "llama-2-7b-chat-hf_fact_raw": "1. Vorinostat (Zolinza) is an oral histone deacetylase inhibitor approved for the treatment of cutaneous T-cell lymphoma and has been shown to inhibit MPS1 kinase activity.\n2. Romidepsin (Istodax) is an oral histone deacetylase inhibitor approved for the treatment of cutaneous T-cell lymphoma and has been shown to inhibit MPS1 kinase activity.\n3. Panobinostat (Farydak) is an oral inhibitor of phosphatidylinositol 3-kinase (PI3K) and is approved for the treatment of multiple myeloma.\n4. GDC-0980 is an oral inhibitor of the PI3K/Akt signaling pathway and is being developed for the treatment of various cancers, including breast, lung, and ovarian cancer.\n5. BAY 80-6946 is an oral inhibitor of the PI3K/Akt signaling pathway and is being developed for the treatment of various cancers.",
    "llama-2-7b-chat-hf_fact": [
      "Vorinostat (Zolinza) is an oral histone deacetylase inhibitor approved for the treatment of cutaneous T-cell lymphoma and has been shown to inhibit MPS1 kinase activity.",
      "Romidepsin (Istodax) is an oral histone deacetylase inhibitor approved for the treatment of cutaneous T-cell lymphoma and has been shown to inhibit MPS1 kinase activity.",
      "Panobinostat (Farydak) is an oral inhibitor of phosphatidylinositol 3-kinase (PI3K) and is approved for the treatment of multiple myeloma.",
      "GDC-0980 is an oral inhibitor of the PI3K/Akt signaling pathway and is being developed for the treatment of various cancers, including breast, lung, and ovarian cancer.",
      "BAY 80-6946 is an oral inhibitor of the PI3K/Akt signaling pathway and is being developed for the treatment of various cancers."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Romidepsin (Istodax) is not an oral medication; it is administered intravenously.\n3. FALSE [correction]: Panobinostat (Farydak) is not a PI3K inhibitor; it is a pan-deacetylase (pan-DAC) inhibitor.\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 4031,
    "user_query": "Was golimumab tested for diabetes?",
    "llama-2-7b-chat-hf_response": "Yes, golimumab, a tumor necrosis factor-alpha (TNF-alpha) inhibitor, has been studied for the treatment of diabetes. Golimumab has been shown to improve glycemic control and reduce the frequency of severe hypoglycemic events in patients with type 1 diabetes and type 2 diabetes. However, it is not FDA-approved for the treatment of diabetes.",
    "llama-2-7b-chat-hf_fact_raw": "1. Golimumab is a tumor necrosis factor-alpha (TNF-alpha) inhibitor.\n2. Golimumab has been studied for the treatment of diabetes.\n3. Studies have shown that golimumab can improve glycemic control in patients with diabetes.\n4. Golimumab has been demonstrated to reduce the frequency of severe hypoglycemic events in patients with diabetes.\n5. Golimumab is not FDA-approved for the treatment of diabetes.",
    "llama-2-7b-chat-hf_fact": [
      "Golimumab is a tumor necrosis factor-alpha (TNF-alpha) inhibitor.",
      "Golimumab has been studied for the treatment of diabetes.",
      "Studies have shown that golimumab can improve glycemic control in patients with diabetes.",
      "Golimumab has been demonstrated to reduce the frequency of severe hypoglycemic events in patients with diabetes.",
      "Golimumab is not FDA-approved for the treatment of diabetes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Golimumab has been studied for the treatment of various autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, but not specifically for the treatment of diabetes.\n3. FALSE [correction]: There is no well-established evidence that golimumab improves glycemic control in patients with diabetes, as it is not approved or primarily studied for this condition.\n4. FALSE [correction]: There is no well-established evidence to suggest that golimumab reduces the frequency of severe hypoglycemic events in patients with diabetes.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 4055,
    "user_query": "Is progeria caused by an autosomal recessive gene?",
    "llama-2-7b-chat-hf_response": "Yes, progeria, also known as Hutchinson-Gilford progeria syndrome (HGPS), is caused by an autosomal recessive mutation in the LMNA gene. This gene encodes for the protein lamin A, which is involved in the structure and function of the nuclear lamina, a network of filaments that provides mechanical support to the nucleus and regulates various cellular processes. Mutations in the LMNA gene lead to a deficiency of functional lamin A, which results in the characteristic features of progeria, including accelerated aging and a shortened lifespan.",
    "llama-2-7b-chat-hf_fact_raw": "1. Progeria, also known as Hutchinson-Gilford progeria syndrome (HGPS), is caused by a mutation in the LMNA gene.\n2. The LMNA gene mutation related to progeria is autosomal recessive.\n3. The LMNA gene encodes for the protein lamin A.\n4. Lamin A is involved in the structure and function of the nuclear lamina.\n5. Mutations in the LMNA gene can lead to a deficiency of functional lamin A, which results in accelerated aging and a shortened lifespan in progeria patients.",
    "llama-2-7b-chat-hf_fact": [
      "Progeria, also known as Hutchinson-Gilford progeria syndrome (HGPS), is caused by a mutation in the LMNA gene.",
      "The LMNA gene mutation related to progeria is autosomal recessive.",
      "The LMNA gene encodes for the protein lamin A.",
      "Lamin A is involved in the structure and function of the nuclear lamina.",
      "Mutations in the LMNA gene can lead to a deficiency of functional lamin A, which results in accelerated aging and a shortened lifespan in progeria patients."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The LMNA gene mutation related to progeria is generally a de novo (new) autosomal dominant mutation.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 4082,
    "user_query": "What are common variants at 12q14 and 12q24 associated with?",
    "llama-2-7b-chat-hf_response": "Variants at 12q14 and 12q24 have been associated with several common diseases and conditions, including:\n12q14:\n* Bipolar disorder: Several genetic variants at 12q14 have been associated with an increased risk of developing bipolar disorder.\n* Schizophrenia: Some studies have found an increased risk of schizophrenia in individuals with genetic variants at 12q14.\n* Major depressive disorder: Variants at 12q14 have been linked to an increased risk of major depressive disorder.\n* Autism spectrum disorder: Some studies have found an increased risk of autism spectrum disorder in individuals with genetic variants at 12q14.\n12q24:\n* Prostate cancer: Variants at 12q24 have been associated with an increased risk of developing prostate cancer.\n* Breast cancer: Some studies have found an increased risk of breast cancer in individuals with genetic variants at 12q24.\n* Ovarian cancer: Variants at 12q24 have been linked to an increased risk of ovarian cancer.\n* Colorectal cancer: Some studies have found an increased risk of colorectal cancer in individuals with genetic variants at 12q24.\nIt's important to note that the association between these variants and these diseases is complex and not fully understood, and more research is needed to determine the exact mechanisms by which these variants contribute to disease risk.",
    "llama-2-7b-chat-hf_fact_raw": "1. Genetic variants at 12q14 have been associated with an increased risk of developing bipolar disorder.\n2. An increased risk of schizophrenia has been observed in individuals with genetic variants at 12q14.\n3. Variants at 12q14 have been linked to an increased risk of major depressive disorder.\n4. Genetic variants at 12q24 have been associated with an increased risk of developing prostate cancer.\n5. Some studies have identified an increased risk of breast cancer in individuals with genetic variants at 12q24.",
    "llama-2-7b-chat-hf_fact": [
      "Genetic variants at 12q14 have been associated with an increased risk of developing bipolar disorder.",
      "An increased risk of schizophrenia has been observed in individuals with genetic variants at 12q14.",
      "Variants at 12q14 have been linked to an increased risk of major depressive disorder.",
      "Genetic variants at 12q24 have been associated with an increased risk of developing prostate cancer.",
      "Some studies have identified an increased risk of breast cancer in individuals with genetic variants at 12q24."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nGenetic associations can be complex and vary between studies. However, there have been studies showing associations between specific genetic loci, such as 12q14 and 12q24, with various diseases, including psychiatric disorders and cancers. For this task, without contradicting or confirming literature, the general associations are assumed to be true as the statements are plausible and align with types of findings that are often reported in genetic research. Further detail would be needed for a more precise validation of each statement.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 4096,
    "user_query": "Which are the ligands of the Roundabout (Robo) receptors?",
    "llama-2-7b-chat-hf_response": "The ligands of the Roundabout (Robo) receptors are the Robo ligands, which are a family of secreted proteins that bind to and activate Robo receptors. The specific Robo ligands include:\n* Robo1 ligand (RALBP1)\n* Robo2 ligand (RALBP2)\n* Robo3 ligand (RALBP3)\n* Robo4 ligand (RALBP4)\nThese ligands are involved in regulating the migration and axon guidance of neurons during development and in the maintenance of neural circuits.",
    "llama-2-7b-chat-hf_fact_raw": "1. The ligands of the Roundabout (Robo) receptors are a family of secreted proteins.\n2. These secreted proteins bind to and activate Robo receptors.\n3. Robo receptors have specific ligands such as Robo1 ligand (RALBP1), Robo2 ligand (RALBP2), Robo3 ligand (RALBP3), and Robo4 ligand (RALBP4).\n4. The Robo ligands are involved in regulating the migration of neurons.\n5. The Robo ligands play a role in axon guidance during development and in the maintenance of neural circuits.",
    "llama-2-7b-chat-hf_fact": [
      "The ligands of the Roundabout (Robo) receptors are a family of secreted proteins.",
      "These secreted proteins bind to and activate Robo receptors.",
      "Robo receptors have specific ligands such as Robo1 ligand (RALBP1), Robo2 ligand (RALBP2), Robo3 ligand (RALBP3), and Robo4 ligand (RALBP4).",
      "The Robo ligands are involved in regulating the migration of neurons.",
      "The Robo ligands play a role in axon guidance during development and in the maintenance of neural circuits."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE - The ligands of Roundabout (Robo) receptors are indeed a family of secreted proteins, specifically the Slit proteins.\n2. TRUE - These secreted Slit proteins bind to and activate Robo receptors.\n3. FALSE [correction]: The known specific ligands for Robo receptors are Slit proteins, not the ones named RALBP1, RALBP2, RALBP3, and RALBP4. These ligands are referred to as Slit1, Slit2, Slit3, etc.\n4. TRUE - The Robo ligands (Slit proteins) are involved in regulating the migration of neurons and are important for neuronal network formation.\n5. TRUE - The Robo/Slit signaling pathway is crucial for axon guidance during development and maintenance of neural circuits.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 4112,
    "user_query": "Is there a role for TFII-I in megakaryopoiesis?",
    "llama-2-7b-chat-hf_response": "Yes, TFII-I has been shown to play a role in megakaryopoiesis, the process of developing megakaryocytes (blood cells that give rise to platelets) from hematopoietic stem cells. TFII-I is a transcription factor that is involved in the regulation of gene expression, particularly in the context of hematopoiesis. Studies have shown that TFII-I is required for the proper differentiation of megakaryocytes and the maintenance of platelet function. Specifically, TFII-I regulates the expression of genes involved in platelet-specific functions such as platelet membrane protein expression and secretion.",
    "llama-2-7b-chat-hf_fact_raw": "1. TFII-I plays a role in megakaryopoiesis, which is the development of megakaryocytes from hematopoietic stem cells.\n2. TFII-I is a transcription factor involved in the regulation of gene expression in hematopoiesis.\n3. TFII-I is required for proper differentiation of megakaryocytes.\n4. TFII-I is necessary for the maintenance of platelet function.\n5. TFII-I regulates the expression of genes involved in platelet-specific functions, including membrane protein expression and secretion.",
    "llama-2-7b-chat-hf_fact": [
      "TFII-I plays a role in megakaryopoiesis, which is the development of megakaryocytes from hematopoietic stem cells.",
      "TFII-I is a transcription factor involved in the regulation of gene expression in hematopoiesis.",
      "TFII-I is required for proper differentiation of megakaryocytes.",
      "TFII-I is necessary for the maintenance of platelet function.",
      "TFII-I regulates the expression of genes involved in platelet-specific functions, including membrane protein expression and secretion."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: TFII-I, as a transcription factor, is involved in the regulation of gene expression during megakaryocyte development but its necessity for the maintenance of platelet function specifically is not well-established.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 4145,
    "user_query": "Is atenolol metabolized by CYP2D6?",
    "llama-2-7b-chat-hf_response": "Yes, atenolol is metabolized by the cytochrome P450 enzyme CYP2D6. CYP2D6 is responsible for the metabolism of approximately 20-30% of atenolol, and the metabolism of the drug is a major determinant of its pharmacokinetics and pharmacodynamics. Individuals with a functional CYP2D6 gene tend to have higher levels of atenolol in their bodies and may experience greater side effects compared to those with a non-functional CYP2D6 gene.",
    "llama-2-7b-chat-hf_fact_raw": "1. Atenolol is metabolized by the cytochrome P450 enzyme CYP2D6.\n2. CYP2D6 is responsible for the metabolism of approximately 20-30% of atenolol.\n3. The metabolism of atenolol by CYP2D6 is a major determinant of the drug's pharmacokinetics and pharmacodynamics.\n4. Individuals with a functional CYP2D6 gene may have higher levels of atenolol in their bodies.\n5. Those with a functional CYP2D6 gene might experience greater side effects from atenolol compared to those with a non-functional CYP2D6 gene.",
    "llama-2-7b-chat-hf_fact": [
      "Atenolol is metabolized by the cytochrome P450 enzyme CYP2D6.",
      "CYP2D6 is responsible for the metabolism of approximately 20-30% of atenolol.",
      "The metabolism of atenolol by CYP2D6 is a major determinant of the drug's pharmacokinetics and pharmacodynamics.",
      "Individuals with a functional CYP2D6 gene may have higher levels of atenolol in their bodies.",
      "Those with a functional CYP2D6 gene might experience greater side effects from atenolol compared to those with a non-functional CYP2D6 gene."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Atenolol is not primarily metabolized by the cytochrome P450 enzyme system; it is largely excreted unchanged in urine.\n2. FALSE [correction]: Since atenolol is not significantly metabolized by CYP2D6, this enzyme is not responsible for the metabolism of a significant percentage of atenolol.\n3. FALSE [correction]: The metabolism of atenolol is not a major determinant of the drug's pharmacokinetics and pharmacodynamics due to its minimal metabolism by the liver enzymes such as CYP2D6.\n4. UNKNOWN: Because atenolol is not extensively metabolized by CYP2D6, the impact of a functional CYP2D6 gene on atenolol levels isn't well-established.\n5. UNKNOWN: Given that atenolol is excreted largely unchanged and not significantly metabolized by CYP2D6, the relationship between CYP2D6 gene functionality and the experience of side effects from atenolol is not clear.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4158,
    "user_query": "List versions of ExpansionHunter",
    "llama-2-7b-chat-hf_response": "ExpansionHunter is a tool used for the detection of gene fusion events in cancer genomes. Here are some versions of ExpansionHunter:\n1. ExpansionHunter 1.0: This was the initial release of the tool, which could detect gene fusions in RNA-seq data.\n2. ExpansionHunter 2.0: This version improved the accuracy of gene fusion detection and introduced a new algorithm for identifying fusions in DNA sequencing data.\n3. ExpansionHunter 2.1: This update added new features, including the ability to detect gene fusions in single-cell RNA-seq data and improved performance in detecting fusions in low-coverage data.\n4. ExpansionHunter 3.0: This version introduced a new algorithm for detecting gene fusions in DNA sequencing data, which improved the accuracy and speed of the analysis.\n5. ExpansionHunter 3.1: This update added new features, including the ability to detect gene fusions in circular RNA transcripts and improved performance in detecting fusions in RNA-seq data with high levels of repetitive sequences.\n6. ExpansionHunter 4.0: This version introduced a new algorithm for detecting gene fusions in DNA sequencing data, which improved the accuracy and speed of the analysis.\n7. ExpansionHunter 4.1: This update added new features, including the ability to detect gene fusions in single-molecule real-time sequencing data and improved performance in detecting fusions in RNA-seq data with high levels of repetitive sequences.\n8. ExpansionHunter 5.0: This version introduced a new algorithm for detecting gene fusions in DNA sequencing data, which improved the accuracy and speed of the analysis.\n9. ExpansionHunter 5.1: This update added new features, including the ability to detect gene fusions in single-cell RNA-seq data and improved performance in detecting fusions in RNA-seq data with high levels of repetitive sequences.\n10. ExpansionHunter 6.0: This version introduced a new algorithm for detecting gene fusions in DNA sequencing data, which improved the accuracy and speed of the analysis.\nNote that the versions of ExpansionHunter may have different features, improvements, and bug fixes, so it's worth",
    "llama-2-7b-chat-hf_fact_raw": "1. ExpansionHunter is a tool used for the detection of gene fusion events in cancer genomes.\n2. ExpansionHunter 1.0 was the initial release that could detect gene fusions in RNA-seq data.\n3. ExpansionHunter 2.0 improved the accuracy of gene fusion detection and was able to identify fusions in DNA sequencing data.\n4. ExpansionHunter 3.0 introduced a new algorithm for detecting gene fusions in DNA sequencing data.\n5. ExpansionHunter 4.1 added the ability to detect gene fusions in single-molecule real-time sequencing data.",
    "llama-2-7b-chat-hf_fact": [
      "ExpansionHunter is a tool used for the detection of gene fusion events in cancer genomes.",
      "ExpansionHunter 1.0 was the initial release that could detect gene fusions in RNA-seq data.",
      "ExpansionHunter 2.0 improved the accuracy of gene fusion detection and was able to identify fusions in DNA sequencing data.",
      "ExpansionHunter 3.0 introduced a new algorithm for detecting gene fusions in DNA sequencing data.",
      "ExpansionHunter 4.1 added the ability to detect gene fusions in single-molecule real-time sequencing data."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: ExpansionHunter is a tool used for the detection of repeat expansions and contractions in genomic sequences, not gene fusion events in cancer genomes.\n2. FALSE [correction]: Since ExpansionHunter is not a tool for detecting gene fusions, the assertion about what the initial release could do in terms of gene fusion detection is incorrect.\n3. FALSE [correction]: Version 2.0 of ExpansionHunter may have improved the accuracy of repeat expansion detection, not the detection of gene fusions, and it was designed for DNA sequencing data.\n4. TRUE: ExpansionHunter 3.0 did introduce new algorithms to improve detection, but these relate to repeat expansions and contractions, not gene fusions.\n5. FALSE [correction]: ExpansionHunter 4.1 did introduce new features, but the tool is designed for repeat expansions, not for detecting gene fusions in single-molecule real-time sequencing data.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 4164,
    "user_query": "What is the role of Adamts18 in hormone receptor signaling?",
    "llama-2-7b-chat-hf_response": "Adamts18 (a disintegrin and metalloproteinase domain-containing protein 18) plays a role in regulating hormone receptor signaling by modulating the activity of hormone receptors and their downstream signaling pathways. Specifically, Adamts18 has been shown to interact with and inhibit the activity of estrogen receptors (ERs), leading to reduced activation of downstream signaling pathways in response to estrogen. This suggests that Adamts18 may play a role in regulating hormone-sensitive processes, such as cell proliferation, differentiation, and survival, in response to hormone signaling.",
    "llama-2-7b-chat-hf_fact_raw": "1. Adamts18 is involved in regulating hormone receptor signaling.\n2. Adamts18 modulates the activity of hormone receptors along with their downstream signaling pathways.\n3. Adamts18 has been shown to interact with and inhibit the activity of estrogen receptors (ERs).\n4. The interaction of Adamts18 with estrogen receptors leads to the reduced activation of downstream signaling pathways in response to estrogen.\n5. Adamts18 plays a role in regulating hormone-sensitive processes such as cell proliferation, differentiation, and survival.",
    "llama-2-7b-chat-hf_fact": [
      "Adamts18 is involved in regulating hormone receptor signaling.",
      "Adamts18 modulates the activity of hormone receptors along with their downstream signaling pathways.",
      "Adamts18 has been shown to interact with and inhibit the activity of estrogen receptors (ERs).",
      "The interaction of Adamts18 with estrogen receptors leads to the reduced activation of downstream signaling pathways in response to estrogen.",
      "Adamts18 plays a role in regulating hormone-sensitive processes such as cell proliferation, differentiation, and survival."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: ADAMTS18 is a metalloproteinase involved in the processing of extracellular matrix components and angiogenesis; it is not prominently known for regulating hormone receptor signaling.\n2. FALSE [correction]: As for statement 1, ADAMTS18's known functions relate to the extracellular matrix rather than modulating the activity of hormone receptors and their signaling pathways.\n3. UNKNOWN: Without specific scientific evidence provided, it's unclear whether ADAMTS18 interacts with and inhibits the activity of estrogen receptors (ERs).\n4. UNKNOWN: Since the interaction of ADAMTS18 with estrogen receptors is not established, the effect on downstream signaling pathways in response to estrogen is also unknown.\n5. UNKNOWN: The role of ADAMTS18 in regulating hormone-sensitive processes like cell proliferation, differentiation, and survival is not clearly established and is generally unknown without confirming studies or evidence.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4208,
    "user_query": "What is the mode of action of Thiazovivin?",
    "llama-2-7b-chat-hf_response": "Thiazovivin is a small molecule inhibitor of the enzyme p300/CBP-associated factor (PCAF), which is involved in the regulation of various cellular processes, including gene expression, cell proliferation, and differentiation. Thiazovivin works by binding to the active site of PCAF and preventing it from catalyzing the acetylation of histones and other proteins, leading to changes in chromatin structure and gene expression. This can result in the inhibition of the expression of genes involved in cell proliferation and survival, leading to the death of cancer cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. Thiazovivin is an inhibitor of the enzyme p300/CBP-associated factor (PCAF).\n2. PCAF is involved in the regulation of cellular processes such as gene expression, cell proliferation, and differentiation.\n3. Thiazovivin binds to the active site of PCAF, inhibiting its function.\n4. PCAF catalyzes the acetylation of histones and other proteins.\n5. The inhibition of PCAF by Thiazovivin can lead to changes in gene expression and may result in the death of cancer cells.",
    "llama-2-7b-chat-hf_fact": [
      "Thiazovivin is an inhibitor of the enzyme p300/CBP-associated factor (PCAF).",
      "PCAF is involved in the regulation of cellular processes such as gene expression, cell proliferation, and differentiation.",
      "Thiazovivin binds to the active site of PCAF, inhibiting its function.",
      "PCAF catalyzes the acetylation of histones and other proteins.",
      "The inhibition of PCAF by Thiazovivin can lead to changes in gene expression and may result in the death of cancer cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Thiazovivin is not an inhibitor of PCAF; it is a small molecule known to act as a potent inhibitor of Rho-associated protein kinase (ROCK).\n2. TRUE\n3. FALSE [correction]: Since Thiazovivin is not an inhibitor of PCAF but rather an inhibitor of ROCK, it does not bind to the active site of PCAF. \n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "unknown"
    ]
  }
]